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According to Virchow’s triad, venous thrombosis can occur as a result of one or 
more of three factors: changes in the dynamics of the blood flow, endothelial injury/
dysfunction of the blood vessel and hypercoagulability. The blood in the veins is 
constantly forming microscopic thrombi that are routinely broken down by the body, 
and significant clotting can occur only when the balance of thrombus formation and 
resolution is altered. This book is a fresh synthesis of venous thromboembolism care 
and considers the opinions and studies from different fields of medicine. As venous 
thrombosis spectrum is wide and can affect many organ systems, from deep veins 
of the leg to the cerebral venous system, our intent is for this to be a comprehensive, 
up-to-date and readable book. We tried to present a synthesis of existing material 
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The venous thrombosis care and profession has evolved considerably over the past 20 
years. This book reflects the current practice, both technical and professional, of 
physicians from different fields. Venous thromboembolism became treatable with the 
discovery of heparin at the beginning of the 20th century. The presence of an effective 
therapy increased the importance of diagnosing venous thromboembolism, fueling a 
plethora of medical research and technological developments over the next century. 
Despite the advances made, venous thromboembolism remains an elusive entity 
because of its atypical presentations and associated diagnostic challenges.  
This book is a fresh synthesis of venous thromboembolism care and considers the 
opinions and studies from different fields of medicine. As venous thrombosis 
spectrum is wide and can affect many organ systems, from deep veins of the leg to the 
cerebral venous system, our intent is for this to be a comprehensive, up-to-date and 
readable book. Section 1 covers the etiology of venous thrombosis and specific disease 
conditions that are largely associated with venous thrombosis. Section 2 is a review of 
the current catheter-based therapy and late complications of the venous thrombosis. 
Section 3 covers all aspects of assessment of the patients with cerebral venous 
thrombosis and venous thrombosis of the eye. Section 4 focuses on venous thrombosis 
in general surgery patients and catheter-related venous thrombosis in cancer patients. 
Section 5 covers special issues about venous thrombosis, clinical experiences and 
perspectives of the authors about the special topics. 
We sought the best contributing authors to write these chapters. Many of them are not 
only experts in their assigned topics, but also have extensive teaching experience. We 
encouraged all contributors to present a new synthesis of the existing material infused 
with new ideas and perspectives, their own clinical studies and even case-reports.  
So, we present to you the fruits of our efforts. We all hope that this book will be a 
significant contribution to the scientific knowledge about venous thrombosis. 
 
Dr. Ertugrul Okuyan 
Istanbul Bagcilar Education and  











Aetiology of Venous Thrombosis 




Blood is a fluid tissue that circulates in the body inside intact blood vessels (veins, arteries 
and capillaries) to perform several vital functions. For perfect performance, blood should 
flow smoothly inside blood vessels without interruption. If a blood vessel gets injured or 
perforated, blood will flow out and be lost, which may be fatal. To prevent this, several 
natural physiological processes occur to form a “plug”, usually called “blood clot”, to block 
the puncture and prevent blood loss. These processes are called “Haemostasis”, which 
involves the blood vessels themselves, specialized blood cells called platelets, as well as 
specific blood proteins called clotting factors.  Haemostasis functions to prevent blood loss 
from injured blood vessels and ensure the fluidity of blood inside intact (uninjured) blood 
vessels (Hoffbrand et al., 2001; Escobar et al., 2002; Laffan & Manning, 2002a).  
Like any other physiological process in the body, haemostasis may get abnormal due to many 
reasons. It may not be able to function well and therefore the blood becomes unable to clot, 
which leads to bleeding problems (haemophilia). On the other hand, haemostasis may happen 
abnormally inside intact blood vessels, without any injury, forming a blood clot (thrombus) 
inside the vessel (intravascular thrombosis), which may lead to partial or complete blockage of 
blood flow through this vessel. This mostly occurs in the deep veins of the lower extremities, 
and to a less extent in the upper extremities, and this pathological condition is called deep vein 
thrombosis (DVT). If a thrombus detaches (called embolus), it usually goes up through the 
circulation and settles in an arterial branch in the lungs causing pulmonary embolism (PE). 
DVT and PE together are called venous thromboembolic disorders (VTE). VTE are serious 
vascular conditions that account for high morbidity and mortality rates in many countries with 
an annual incidence of 1/1000 (Dahlbäck, 1995; Ridker et al., 1997).  
Several “genetic” and “acquired” risk factors were identified to cause VTE, and this is why 
the WHO expert group described VTE in 1996 as being genetically determined, acquired or 
both (Lane et al., 1996). This chapter describes the different genetic and acquired risk factors 
for VTE. The chapter is divided into two main sections: genetic factors and acquired factors, 
and it is concluded by a third section on intersections of risk factors. In order to better 
understand how these factors cause VTE, a preliminary section is given to explain the major 
processes of haemostasis, namely the Coagulation and Fibrinolysis processes, and how 
abnormalities may lead to VTE.   
2. Coagulation and Fibrinolysis 
As explained above, haemostasis is the normal physiological process by which an injured 
blood vessel is sealed by a blood clot to prevent blood loss. Haemostasis involves many 
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processes, two of which are “The Coagulation Process” and “The Fibrinolysis Process”. In 
both processes, blood clotting factors are the crucial constituents. Clotting factors are 
enzymatic proteins that are synthesised mostly in the liver and circulate in the blood in an 
inactive form. When a blood vessel gets injured, these factors get activated and start a 
cascade of chemical reactions leading to the formation of a fibrin “clot” which blocks the site 
of injury and therefore prevents blood loss and allows for wound healing. Although the 
clotting factors have specific names, they are usually given Roman numerals. Figure 1 gives 




Fig. 1. The Coagulation process and its control elements. Solid arrows indicate activation; 
dotted arrows indicate inactivation (prepared and drawn by the author).  
The Coagulation process maybe virtually divided into three pathways: Extrinsic, Intrinsic 
and Common pathways. When a blood vessel is injured, the components of the blood 
vessels start to activate the clotting factors by two methods. Firstly, the injured tissues 
release a membrane protein called thromboplastin (tissue factor [TF] or clotting factor III) 
which is capable of activating clotting factor VII in the Extrinsic pathway. Activated clotting 
factor VII (VIIa) forms a complex with TF, and this tends to activate clotting factor X in the 
Common pathway. On the other hand, the subendothelial layers of blood vessels have 
abundant amounts of collagen embedded inside them. This collagen gets exposed in injured 
vessels, and collagen is capable of activating clotting factor XII in the Intrinsic pathway. 
Activated factor XII (XIIa) in turn activates clotting factor XI, which in turn activates clotting 
 
Aetiology of Venous Thrombosis 
 
5 
factor IX. Activated clotting factor IX, with the help of clotting co-factor VIII, is capable of 
activating clotting factor X in the Common pathway. So, both the Extrinsic and Intrinsic 
pathways team up to activate the Common pathway. In the Common pathway, activated 
clotting factor X, with the help of clotting co-factor V, continues the process by activating 
clotting factor II (prothrombin) into thrombin. The main function of thrombin is the 
conversion of fibrinogen (clotting factor I) into fibrin. Fibrin molecules then polymerize to 
form thread-like structures which form a mesh that gives the basis of blood clot. Finally, 
clotting factor XIII crosslinks fibrin polymers to form a stable fibrin mesh which traps 
activated platelets and other blood cells to form the final blood clot which eventually blocks 
the injured blood vessel. In addition to co-factors V and VIII, phospholipids and calcium 
ions (factor IV) act as co-factors in the process of Coagulation (Kane & Davie, 1988; Furie & 
Furie, 1988; Walker & Fay, 1992; Davie, 1995; Hoffbrand et al., 2001; Escobar et al., 2002; 
Laffan & Manning, 2002a).   
After clot formation, wound healing starts and the injured blood vessel regenerates and 
becomes intact again. When the healing process is complete, the fibrin clot will no longer be 
needed and therefore it has to be removed. This occurs by the process of Fibrinolysis (figure 
2). The key enzyme in this process is plasmin, which normally circulates in the blood in an 
inactive form called plasminogen. Plasminogen is usually activated into plasmin by tissue 
plasminogen activator (tPA) produced by the endothelial cells in the healing blood vessels. 
Plasmin breaks down fibrin threads into smaller pieces called fibrin degradation products 
(FDP) which are excreted from the circulation, and therefore the clot dissolves and the blood 
flow recovers normally (Rock & Wells, 1997; Hoffbrand et al., 2001; Escobar et al., 2002; 
Laffan & Manning, 2002a).   
 
 
Fig. 2. Fibrinolysis process and its control elements. Solid arrows indicate activation; dotted 
arrows indicate inactivation (prepared and drawn by the author). 
The processes of Coagulation and Fibrinolysis are carefully monitored and supervised by 
several control systems. This is important to prevent excessive or unnecessary coagulation 
or fibrinolysis. In the Coagulation process, thrombin is a very robust enzyme which exerts 
many coagulation functions. It can activate other clotting factors and form many positive 
feedback loops in the Coagulation process. Therefore, the clotting process may continue 
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forever and the clot may enlarge until it blocks the whole lumen of the blood vessel. 
Therefore, the Coagulation process should be limited to the area of blood vessel injury and 
should be prevented from extending abroad. This is achieved by three main proteins that 
circulate normally in the blood, namely protein C (PC), protein S (PS) and antithrombin 
(AT). Together they are called “natural anticoagulants” since they function as antagonists to 
clotting. They exert their function after a blood clot is formed to prevent excessive clotting. 
They also interfere with the Coagulation process if it starts working accidently inside intact 
blood vessels. To explain more, AT, as its name indicates, inactivates thrombin, and 
therefore stops the process of Coagulation. PC, which is first activated into activated protein 
C (APC), tends to breakdown co-factors V and VIII and therefore slows down the 
Coagulation process. For APC to function normally, PS is involved as a cofactor. 
Phospholipids and calcium ions also assist in this process. Another inhibitor specific for the 
Extrinsic pathway, namely Tissue Factor Pathway Inhibitor (TFPI), limits the action of TF in 
activating factor VII (Kalafatis et al., 1994; Novotny, 1994; Davie, 1995; Esmon et al., 1997; 
Rosing & Tans, 1997; Cella et al., 1997; Hoffbrand et al., 2001; Escobar et al., 2002; Laffan & 
Manning, 2002a). 
Regarding the control of the Fibrinolysis process, there are many proteins involved. For 
example, plasminogen activator inhibitors (PAI) prevent tPA from activating plasminogen 
and therefore stop the initiation of fibrinolysis. This is important to avoid early removal of 
blood clot before the completion of blood vessel healing. Another anti-fibrinolysis protein is 
α2-antiplasmin (AP) which is a major inhibitor of plasmin. Thrombin-Activatable 
Fibrinolysis Inhibitor (TAFI) is a protein that is activated by thrombin to prevent the binding 
of plasmin to fibrin and therefore stops plasmin from breaking down the clot. The control 
actions of these fibrinolysis antagonists are illustrated in figure 2 (Hoffbrand et al., 2001; 
Escobar et al., 2002; Laffan & Manning, 2002a).  
For normal healthy clotting/anticlotting results, the Coagulation and Fibrinolysis processes, 
with their control systems, should work in a highly balanced manner. Any abnormalities 
may disturb this balance leading to serious consequences. Abnormalities can be quantitative 
(deficiency or increase in quantity) or qualitative (abnormal structure or function [loss, 
lowering or gain]) that may affect any of the proteins involved. For example, abnormalities 
in clotting factors may lead to bleeding problems (termed haemophilia), while abnormalities 
in the natural anticoagulants may lead to increased clotting tendency (termed 
hypercoagulability) leading to thrombosis, with certain exceptions in both (figure 3).  
In the following sections, different genetic and acquired abnormalities affecting the 
Coagulation and Fibrinolysis processes are discussed. Only those leading to thrombosis are 
included in accordance with the scope of this chapter. These abnormalities are usually 
referred to as “risk factors” since they put forth clinical manifestations in patients suffering 
from these abnormalities. 
3. Genetic risk factors for venous thrombosis 
Like all proteins produced in the body, clotting factors and other proteins of the Coagulation 
and Fibrinolysis processes are encoded by genes in the DNA of human cells. Any genetic 
abnormalities may lead to lower or no production of these proteins, or the production of 
molecules with abnormal structure and/or functions, although the quantity of which may 
be normal. Many of these abnormalities were found to cause venous thrombosis. For 
example, genetic defects in the genes of the natural anticoagulants may lead to lower  
 




Fig. 3. Balance between the Coagulation and Fibrinolysis processes, in health and disease 
(prepared and drawn by the author).  
production of these proteins and therefore lower control over the Coagulation process. This 
usually leads to an increase in the rate of coagulation, a phenomenon called 
“hypercoagulability”, which is usually manifested clinically in patients as VTE. On the other 
hand, the natural anticoagulants may be produced normally, but they can not exert their 
function normally on their targets, and therefore hypercoagulability and VTE are expected 
too. Also, certain genetic defect may affect the clotting factors themselves leading to 
overproduction of such factors causing hypercoagulability. Moreover, abnormalities in the 
Fibrinolysis process may lower the efficiency of removal of clot, which leads to 
accumulation of clots and formation of thrombosis. In the following lines, several genetic 
abnormalities (risk factors) leading to venous thrombosis are discussed. These usually cause 
VTE at relatively earlier ages (less than 40 years-old) and may be referred to as "familial or 
hereditary thrombophilia". Although the condition known as “Activated Protein C 
Resistance” is the most common genetic defect associated with VTE, this defect will be left 
till the end because it was discovered relatively more recently and it was found to be the 
most common and important genetic risk factor for VTE.  
3.1 Antithrombin (AT) deficiency 
Historically, Egeberg (1965) was the first to associate cases of venous thrombosis with a 
hereditary defect in the Coagulation system; namely AT deficiency. AT is an inhibitor for 
thrombin, and its inhibition action is largely enhanced by heparin as a co-factor. AT 
deficiency causes lower control over thrombin, and therefore the Coagulation process 
becomes overactive (hypercoagulability) leading to VTE. Also, decreased control over 
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Fig. 3. Balance between the Coagulation and Fibrinolysis processes, in health and disease 
(prepared and drawn by the author).  
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abnormalities (risk factors) leading to venous thrombosis are discussed. These usually cause 
VTE at relatively earlier ages (less than 40 years-old) and may be referred to as "familial or 
hereditary thrombophilia". Although the condition known as “Activated Protein C 
Resistance” is the most common genetic defect associated with VTE, this defect will be left 
till the end because it was discovered relatively more recently and it was found to be the 
most common and important genetic risk factor for VTE.  
3.1 Antithrombin (AT) deficiency 
Historically, Egeberg (1965) was the first to associate cases of venous thrombosis with a 
hereditary defect in the Coagulation system; namely AT deficiency. AT is an inhibitor for 
thrombin, and its inhibition action is largely enhanced by heparin as a co-factor. AT 
deficiency causes lower control over thrombin, and therefore the Coagulation process 
becomes overactive (hypercoagulability) leading to VTE. Also, decreased control over 
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thrombin in cases with AT deficiency may have a positive effect on an inhibitor of 
fibrinolysis called thrombin-activatable fibrinolysis inhibitor (TAFI), which may add to the 
hypercoagulable status in these patients, as will be explained later.  
Hereditary AT deficiency has been found in 1-5 % of thrombotic cases, with a prevalence of 
one in 500-5000 in different populations (Tait et al., 1991; Koster et al., 1995a; Koeleman et 
al., 1997; Bertina, 1997; Laffan & Manning, 2002b; Ehsan & Plumbley, 2002; Dahlbäck, 2008; 
Patnaik & Moll, 2008). It has an autosomal dominant mode of inheritance, and it accounts 
for a 10-fold increased risk of developing VTE (Dahlbäck, 2008). AT deficiency maybe 
divided into two types: Type I (quantitative; lower amount) and Type II (qualitative; 
abnormal function). Type II AT deficiency is also subdivided into three subtypes based on 
the kind of abnormality in function it has: affecting inhibition of thrombin, affecting the 
binding to heparin, or affecting both. More than 80 genetic abnormalities (missense, 
nonsense, deletions) were reported to cause AT deficiency (Bertina, 1997; Hoffbrand et al., 
2001; Ehsan & Plumbley, 2002; Dahlbäck, 2008). More than half of the patients with 
hereditary AT deficiency have been reported to suffer from VTE at an age less than 40 years 
(Finazzi et al., 1987; van Boven et al., 1996). No reports are present on cases of homozygous 
AT deficiency, suggesting it is incompatible with life to have complete absence of AT in the 
blood (Dahlbäck, 2008). 
3.2 Protein C (PC) deficiency 
PC and its active form APC inactivate clotting co-factors V and VIII and therefore down-
regulates the Coagulation process. Hence, any abnormality in PC may lead to continuous 
running of co-factors V and VIII causing VTE. Another method by which PC deficiency may 
cause VTE is through its interaction with the Fibrinolysis process. PC usually inhibits 
plasminogen activator inhibitor-1 (PAI-1), which is an inhibitor of tissue plasminogen activator 
(tPA) responsible for the presence of active plasmin (figure 2). Therefore, PC deficiency causes 
an impaired control over PAI-1, and this interferes with the normal function of the Fibrinolysis 
process, and hence may lead to accumulation of clots and eventually VTE. 
Several cases of VTE were reported to have genetic deficiency of PC, which was first 
described in 1981 (Griffin et al, 1981). Hereditary PC deficiency has an autosomal dominant 
mode of inheritance, but many reports also claimed autosomal recessive mode (Mohanty et 
al., 1995; Ehsan & Plumbley, 2002; Bereczky et al., 2010). Almost 250 different genetic defects 
have been reported so far to be associated with PC deficiency (Bertina, 1997; D’Ursi et al., 
2007; Bereczky et al., 2010). The prevalence of PC deficiency has been reported to be one in 
200 to 16,000 normal individuals in different studies (Miletich et al., 1987; Tait et al., 1995; 
Mohanty et al., 1995; Koster et al., 1995b; Ehsan & Plumbley, 2002). The prevalence in 
patients with first episode of VTE is 2-5% (Bertina, 1997; Laffan & Manning, 2002b; 
Dahlbäck, 2008;). Heterozygous carriers of PC deficiency have 50% reduction in PC level, 
and they have an increased risk of developing thrombosis (Svensson & Dahlbäck, 1994; 
Hoffbrand et al., 2001). Homozygotes for PC deficiency may suffer from recurrent VTE 
episodes and from skin necrosis especially when treated with Warfarin, which is a vitamin 
K antagonist  commonly used for treatment of VTE (Heeb et al., 1989;  Svensson & 
Dahlbäck, 1994; Bennett, 1997; Hoffbrand et al., 2001; Dahlbäck, 2008). Infants with 
homozygous PC deficiency usually have fatal multiple microvascular thrombosis known as 
neonatal purpura fulminans (Ehsan & Plumbley, 2002; Dahlbäck, 2008). Two types of PC 
deficiency are present: Type I PC deficiency in which the level and function of PC are 
abnormal; and type II deficiency in which the level of PC is normal but the function is 
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defective. Type I is more common and has been found to be present in 1 to 14 % of cases 
having recurrent thrombosis. Type II is present in 10-15% of PC deficiency cases (Mohanty 
et al., 1995, Ehsan & Plumbley, 2002; Bereczky et al., 2010).  
3.3 Protein S (PS) deficiency 
PS acts as a co-factor in the process of inactivation of clotting co-factors V and VIII by APC, 
enhancing the process by 10-fold (ten Kate & van der Meer, 2008). PS has a very high affinity 
towards complement 4b binding protein (C4bBP). PS bound to C4bBP becomes inactive, and 
only free PS is active. Normally, the concentration of PS is more than C4bBP, and therefore 
only 60% of PS is present in an inactive form bound to C4bBP, while 40% remain as free 
active PS (Simmonds et al, 1998; Ehsan & Plumbley, 2002; Laffan & Manning, 2002b; 
Dahlbäck, 2008). First cases with hereditary PS deficiency were reported in 1984 (Comp & 
Esmon, 1984; Comp et al, 1984). Hereditary PS deficiency is an autosomal dominant 
disorder that has been associated with a 3- to 11-fold increased risk of venous thrombosis 
(Svensson and Dahlbäck, 1994; Hoffbrand et al, 2001; Ehsan & Plumbley, 2002; ten Kate & 
van der Meer, 2008; Bereczky et al., 2010). Similar to PC deficiency, homozygous cases with 
PS deficiency have tendency towards developing neonatal purpura fulminans and 
Warfarin-associated skin necrosis (Hoffbrand et al, 2001; Ehsan & Plumbley, 2002). In 
addition, PS deficiency has been linked to foetal loss (ten Kate & van der Meer, 2008). More 
than 200 genetic abnormalities in the PS gene were identified to cause PS deficiency, half of 
which were missense mutations and one-fifth were deletions or insertions (Bertina, 1997; ten 
Kate & van der Meer, 2008; Bereczky et al., 2010). The prevalence of PS deficiency is 0.03-2% 
in the general population and 1-13% in patients with VTE (Lane et al., 1996; Bertina, 1997; 
Seligsohn & Lubetsky, 2001; Dykes et al., 2001; Ehsan & Plumbley, 2002; Beauchamp et al., 
2004; ten Kate & van der Meer, 2008; Bereczky et al., 2010). There are three types of 
hereditary PS deficiency. In Type I, total and free PS levels are lower than normal. Type II PS 
deficiency is the dysfunctional type of PS deficiency, in which the level of PS remains 
normal. A third type (Type III) is characterized by a mild deficiency in PS, and this is 
reflected in lower free PS level (Ehsan & Plumbley, 2002; ten Kate & van der Meer, 2008; 
Bereczky et al., 2010). Type I and III are the quantitative types of PS deficiency while Type II 
is the qualitative type. Certain sources refer to Type II as Type IIb and Type III as Type IIa 
(Ehsan & Plumbley, 2002). The majority of hereditary PS deficiency are Type I while 5-15% 
of cases are Type II (Bertina, 1997; Bereczky et al., 2010).  
3.4 Tissue Factor Pathway Inhibitor (TFPI) deficiency 
TFPI is a protease that inhibits TF-VIIa complex in the presence of factor Xa, thereby 
regulating the Extrinsic pathway of coagulation. Only 10% of TFPI is present as a free active 
form in the blood while the majority is in combination with lipoproteins. Deficiency in TFPI 
may lead to a hypercoagulable state and hence VTE (Novotny et al., 1989; Novotny, 1994; 
Samama et al, 1996; Cella et al, 1997; Ehsan & Plumbley, 2002). TFPI decreased activity was 
noticed to contribute in developing thrombosis in women using oral contraceptives, and in 
patients with paroxysmal nocturnal haemoglobinuria (Maroney & Mast; 2008). Experiments 
on genetically modified mice with TFPI gene disruption showed that they die prematurely 
in embryonic stage and before birth due to haemorrhagic and intravascular thrombi. 
Human embryos with TFPI deficiency may suffer a similar problem and this may explain 
why no cases with TFPI deficiency has been identified so far (Broze, 1998; Chan, 2001; 
Maroney & Mast; 2008).  
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Human embryos with TFPI deficiency may suffer a similar problem and this may explain 
why no cases with TFPI deficiency has been identified so far (Broze, 1998; Chan, 2001; 
Maroney & Mast; 2008).  
 
Venous Thrombosis – Principles and Practice 
 
10
3.5 Heparin Cofactor II (HCII) deficiency 
HCII was first detected and isolated in the early 80s (Tollefsen & Blank, 1981, Tollefsen et al., 
1982). It specifically inhibits thrombin with less affinity than AT and therefore it may be 
considered as a second line inhibitor of thrombin (Ehsan & Plumbley, 2002). A number of 
cases with HCII deficiency were reported to have VTE, but many cases remained 
asymptomatic (Ehsan & Plumbley, 2002; Laffan & Manning, 2002b). More studies are 
needed on larger number of cases to determine any significant effect of this defect in causing 
VTE.  
3.6 Dysfibrinogenaemia 
As explained earlier, the main aim of the Coagulation system is to convert fibrinogen 
(clotting factor I) into fibrin clot. Fibrinogen is encoded by three genes on chromosome 4 
(Acharya & Dimichele, 2008; Miesbach et al., 2010). Genetic abnormalities in the fibrinogen 
genes may lead to lower or no production of fibrinogen (quantitative defects), causing 
bleeding problems in patients. On the other hand, other genetic abnormalities may lead to 
the production of fibrinogen molecules with abnormal structure and/or function 
(qualitative defects). Such abnormalities may negatively affect the binding of fibrinogen 
with thrombin, the polymerization of fibrin molecules, or the fibrinolytic inactivation by 
plasmin. This is the condition known as “Dysfibrinogenaemia”, which has an autosomal 
dominant or recessive mode of inheritance (Dahlbäck, 1995; Koeleman et al, 1997; Ehsan & 
Plumbley, 2002; Laffan & Manning, 2002b; Acharya & Dimichele; 2008). Dysfibrinogenaemia 
was first reported in 1965 (Beck et al., 1965). Around 60% of cases show no clinical 
manifestations, while 20% show bleeding problems and 20% show thrombosis (Ehsan & 
Plumbley, 2002; Miesbach et al., 2010). There are at least 15 different genetic defects affecting 
the fibrinogen gene that were associated with Dysfibrinogenaemia (Bertina, 1997; Miesbach 
et al., 2010;). Still, Dysfibrinogenaemia remains a very rare disorder (1% of VTE cases) and 
more cases should be studied to fully understand the disease (Manucci, 2000; Acharya & 
Dimichele; 2008).   
3.7 Elevated clotting factors 
Several cases with VTE were found to be associated with elevated levels of clotting factors 
such as VIII, IX, XI, XII, fibrinogen and prothrombin. Elevated prothrombin is mostly 
associated with a genetic mutation in the prothrombin gene, which will be discussed in the 
next section. Elevated fibrinogen (hyperfibrinogenaemia) was found to promote faster fibrin 
formation and increased thrombus fibrin content, density, strength and stability. 
Hyperfibrinogenaemia was also found to have increased thrombolysis resistance, which 
explains more the association with VTE (Koster et al., 1995a; Poort et al, 1996; O'Donnell et 
al., 1997; Meijers et al., 2000; Kamphuisen et al., 2001; de Visser et al., 2001; Bertina et al., 
2005; Machlus et al., 2011).  
3.8 Prothrombin G20210A mutation 
In 1996, Poort et al performed extensive DNA sequencing on the prothrombin gene located 
on chromosome 11 for patients with unexplained VTE. They discovered a single missense 
mutation (guanine to adenine; GA) at nucleotide position 20210 in the 3′ untranslated 
region of the prothrombin gene. Since the mutation is present outside the coding region for 
prothrombin, it does not affect the structure of the prothrombin molecule. However, the 
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Prothrombin G20210A mutation was found to be associated with elevated levels of plasma 
prothrombin (elevation by one-third  above normal; 133%), and therefore accounts for 
hypercoagulability and an increased risk of developing VTE (2 to 4-fold) (Poort et al, 1996; 
Bertina, 1997; Koeleman et al, 1997; Hillarp et al, 1997; Alhenc-Gelas et al. 1997; Hoffbrand et 
al., 2001; Ehsan & Plumbley, 2002; Laffan & Manning, 2002b; Dahlbäck, 2008). In fact, it has 
been demonstrated that prothrombin levels more than 115% have 2-fold increased risk of 
developing VTE (Poort et al, 1996). A study by Ceelie et al (2004) has proven that 
Prothrombin G20210A mutation leads to increased mRNA and protein expression. Another 
point worth mentioning here is that increased prothrombin levels may lead to an increase in 
the inhibitor of fibrinolysis called TAFI. This increase in TAFI disturbs the Fibrinolysis 
process and therefore may add to the hypercoagulable status in these patients, as will be 
explained later (Ehsan & Plumbley, 2002).  
Several studies reported the prevalence of Prothrombin G20210A mutation to be 1-4% in 
healthy populations and 6-8% in patients with VTE. However, that was true when 
populations of Caucasian origin were studied. The Prothrombin G20210A mutation was 
very rare or absent in populations of East Asia and Africa, and in native populations of 
America and Australia (Franco et al., 1998; Dilley et al., 1998; Lin et al., 1998; Isshiki et al., 
1998; Ruiz-Argüelles et al., 1999; Angelopoulou et al, 2000; Ghosh et al., 2001; Ruiz-
Argüelles, 2001; Bennett et al, 2001; Lee, 2002; El-Karaksy et al, 2004; Eid & Rihani, 2004; 
Erber et al, 2004; Gibson et al., 2005; Dahlbäck, 2008). This brought speculations that 
Prothrombin G20210A mutation might have occurred as a single event in a single Caucasian 
ancestor. This hypothesis was strengthened by a molecular study that estimated the 
occurrence of the mutation around 24 thousand years ago (Zivelin et al., 2006). 
Another mutation in the prothrombin gene was later discovered in 2002 at a neighbour 
position to the Prothrombin G20210A mutation, namely Prothrombin C20209T mutation. 
Unlike the Prothrombin G20210A mutation, this newer mutation was found in non-
Caucasians in addition to Caucasians (Warshawsky et al, 2002; Arya, 2005; Danckwardt et 
al, 2006). Still, clear-cut association with VTE has to be established.  
3.9 Defects of fibrinolysis 
Fibrinolysis is the process responsible for the removal of intravascular clots. Therefore, one 
may expect that defects in this process can provide an environment suitable for the 
development of thrombosis. However, there is yet no final or definite proof of that in spite of 
the fact that reduced fibrinolysis efficacy (hypofibrinolysis) was observed in many patients 
with VTE with higher risk values (Laffan & Manning, 2002b; Lisman et al., 2005; Meltzer et al., 
2008). For example, defects in plasminogen may cause defective fibrinolysis and impaired 
removal of fibrin clots, and hence might lead to accumulation of thrombi. There are two types 
of hereditary plasminogen deficiency: Type I hypoplasminogenaemia (quantitative) and Type 
II dysplasminogenaemia (qualitative), which are caused by many mutations and thought to be 
inherited as autosomal dominant defects. Hypoplasminogenaemia is associated with 
abnormal fibrin removal during wound healing, leading to pseudomembrane diseases in the 
mucous membranes, while dysplasminogenaemia is probably only a silent polymorphism 
without clinical manifestations (Aoki et al., 1978; Song et al., 2003; Schuster et al., 2007; Mehta 
& Shapiro, 2008; Klammt et al., 2011). At the same time, hereditary plasminogen deficiency 
was found in 2-8% of patients with thrombosis (Aoki et al., 1978; Dolan et al., 1988; Heijboer et 
al., 1990; Brandt, 2002; Song et al., 2003). Thus, more studied maybe needed before definitely 
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Prothrombin G20210A mutation was found to be associated with elevated levels of plasma 
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inherited as autosomal dominant defects. Hypoplasminogenaemia is associated with 
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linking plasminogen deficiency with VTE, and establishing Plasminogen Deficiency Registry 
databases may help to determine the prevalence and risk of this defect.  
Another member of the Fibrinolysis process is tissue plasminogen activator (tPA) which is 
the main activator of plasmin in the Fibrinolysis process. Therefore, tPA deficiency may also 
lead to thrombosis. However, there is paucity in reports on cases with hereditary tPA 
deficiency to justify that (Patrassi et al., 1991; Brandt, 2002). The main inhibitor of tPA is the 
plasminogen activator inhibitor-1 (PAI-1). In this context, one should expect thrombosis to 
develop in cases having higher levels of PAI-1, rather than PAI-1 deficiency. This has been 
shown in different human cases and in transgenic mouse models. At least 5 polymorphisms 
were found in the PAI-1 gene, two of which were associated with thrombosis. In fact, this 
encouraged trials to use inhibitors of PAI-1 as anti-thrombotic treatments (Carmeliet et al., 
1993; Huber, 2001; Wu & Zhao, 2002; Meltzer et al., 2010a; Jankun & Skrzypczak-Jankun, 
2011). Trials were also conducted on inhibitors of another regulator of the Fibrinolysis 
process, namely Thrombin-Activatable Fibrinolysis Inhibitor (TAFI). TAFI, which was 
discovered in 1988, circulates as an inactive form, and is activated into its active form 
(TAFIa) by thrombin. TAFIa inhibits binding of plasmin to fibrinogen and therefore down-
regulates the Fibrinolysis process. AT deficiency, previously described, causes elevated 
levels of thrombin, and therefore elevated levels of TAFIa are also expected leading to 
lowering in the efficiency of fibrinolysis in removing clots. This is thought to be another 
pathophysiological pathway by which AT deficiency causes VTE. In addition, this may be 
an additive factor in increasing hypercoagulability in cases with Prothrombin G20210A 
mutation in which there is an elevated level of plasma prothrombin. However, studies on 
association between TAFI level and VTE gave inconsistent results. At least three genetic 
variations in the TAFI gene were identified, but linkage with risk of developing VTE is not 
very evident. Focus is now on developing inhibitors of TAFI as a possible anticoagulant 
therapy (Mosnier & Bouma, 2006; Bunnage & Owen, 2008; Meltzer et al., 2010a & b; Miljić et 
al., 2010).  
3.10 Activated Protein C Resistance (APC-R) and Factor V Leiden Mutation (FVL) 
In 1993, Dahlbäck and his colleagues in Sweden were involved in studying patients with 
VTE. They added external APC to plasma of patients with VTE and recorded the effect of 
that on the Coagulation process. As explained earlier, APC inactivates co-factors V and VIII 
and therefore down-regulates the Coagulation process. Therefore, the addition of external 
APC should prolong the clotting time of the plasma under test. When they tried that on the 
plasma samples of VTE patients, they noticed that the expected prolongation effect did not 
happen in all cases (Figure 4). They discussed that there is a “resistance” to the action of 
APC, and therefore they called it “APC resistance or APC-R”, a name which persisted until 
now. The team originally though that there must have been a yet unknown clotting co-factor 
that co-helps APC in inactivating factors V and VIII, and these patients showing APC-R 
should have had a deficiency in this yet-to-find co-factor. However, they could not  find 
such a proposed co-factor. One year later, Bertina and his research team in the Netherlands 
could identify a missense point mutation in the factor V gene (guanine to adenine; GA) at 
nucleotide number 1691 of exon 10 of the factor V gene, only eleven nucleotides upstream to 
intron 10. This new mutation was termed Factor V Leiden mutation (FVL) after the Dutch 
city where they made their discovery in. This nucleotide change causes a change in the 
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translated factor V molecule at amino acid residue number 506 (arginine to glutamine; 
CGACAA). Arginine 506 is an important cleavage site for APC. In other words, APC has 
to recognise arginine at position 506 of the factor V molecule in order to be able to inactivate 
factor V. This change in amino acid residue at position 506 of the mutant FVL molecule 
makes the FVL molecule “resistant” to the action of APC, and therefore the mutant FVL 
remains active. Mutant FVL was found to retain its coagulation function, and therefore the 
Coagulation process is not down-regulated by APC in regards to factor V. This explains 
why FVL leads to hypercoagulability and henceforth VTE (figure 5). Since then, the terms 
APC-R and FVL were linked together and used interchangeably. Several studies quickly 
followed that discovery and proved a positive association between FVL and VTE, showing 
that heterozygous carriers of the mutation are at higher risk of developing VTE by 10-fold 
while homozygous carriers have a much higher risk ratio reaching 140-fold (Dahlbäck et al., 
1993; Zöller et al., 1994; Bertina et al., 1994; Hoagland et al., 1996; Dahlbäck, 1997; Faioni et 
al., 1997; Alderborn et al., 1997; Bontempo et al., 1997). Moreover, most homozygous cases 
were found to get at least one VTE event in their life time, and at an earlier time of their life 








































Fig. 4. APC-R test as developed originally by Dahlbäck et al., 1993 (prepared and drawn by 
the author). 
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Fig. 4. APC-R test as developed originally by Dahlbäck et al., 1993 (prepared and drawn by 
the author). 
 




Fig. 5. Factor V molecule showing the site of amino acid 506 where FVL is present and how 
this leads to APC-R and VTE (prepared and drawn by the author). 
The identification of APC-R/FVL and its high risk value have exploded a massive rush in 
researches to study this new disease, its prevalence and its relationship with VTE in almost 
every part of the world. First researches were conducted in Europe which concentrated on 
Caucasian populations. Results showed that FVL was present in a quite high percentage of 
patients with VTE (15-65%) and healthy subjects (1-15%). Other studies on Caucasians living in 
non-European countries, like the USA, Australia and Israel, revealed similar numbers (table 1). 
However, when studies started to appear in other ethnic groups and in other countries, FVL 
was astonishingly found to be very rare and in most occasions absent, like in Africans, South-
East Asians, Chinese, Japanese, American Indians (native nations of America), Greenland Inuit 





Fig. 6. Prevalence of FVL worldwide in different ethnic groups (prepared and drawn by the 
author).  
 








European UK ---- 1.74-5.6 Beauchamp et al., 1994;  
Bengtsson et al., 1996
Sweden 41.5-50 7.5-11.4 Zöller et al., 1994; Bengtsson et al.,  
1996; Alderborn et al., 1997  
Poland ---- 5 Herrmann et al, 1997
Netherlands 21 2 Bertina et al., 1994; Beauchamp et al., 
1994
Germany 30 7.1-12 Aschka et al, 1996; Schröder et al., 
1996
Belgium 22 3.3 Hainaut et al., 1997
Slovakia 29.5-37.0 4 Hudecek et al., 2003; Simkova et al., 
2004 
Austria 26 ---- Melichart et al., 1996
Hungary 44 6.9 Nagy et al., 1997; 
Stankovics et al., 1998 
Serbia 29.9 5.8 Djordjevic et al., 2004
Azerbaijan ---- 14 Gurgey & Mesci, 1997 
 
Spain 9.2-26.3 1.6-5.8 Olave et al., 1998; González Ordóñez 
et al., 1999; Vargas et al., 1999; Aznar 
et al., 2000; Ricart et al., 2006; García-
Hernández et al., 2007 
France 9-18 3.5-5.0 Leroyer et al., 1997; Mansourati et 






Bauder et al., 1997; Zabalegui et al., 
1998 
Italy 9.0-42.8 2-13.1 Faioni et al., 1997; Simioni  et al., 
1997; Martinelli et al., 2004; Sottilotta 
et al., 2009; Gessoni  et al., 2010 
Yugoslavia 15.5 4.0 Mikovic et al., 2000
Slovenia 12.9 6.3 Bedencic et al., 2008
Croatia 21.0-28.2 2.4-4.0 Coen et al., 2001; Cikes et al., 2004; 
Jukic et al., 2009
Albania/
Kosovo
---- 3.4 Mekaj et al., 2009
Greece 16.2-31.9 2.5-7.0 Rees et al., 1995; Lambropoulos et 
al., 1997; Antoniadi et al., 1999; 





USA 8.6 3.2-6.0 Ridker et al., 1997; Bontempo et al., 
1997; Limdi et al., 2006 
Australia ---- 4-10.2 Aboud & Ma, 1997; Bennett et al., 
2001; Gibson et al., 2005;  
Israel ---- 4.3 Rosen et al., 1999
Brazil 20 2 Arruda et al., 1995
Table 1. Prevalence of FVL in Caucasian patients with VTE and healthy populations living 
in European and non-European countries.  
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Asians Japan 0 0 Fujimura et al., 1995; Zama et al., 
1996;  
Kodaira et al., 1997; Ro et al., 1999 
 Korea 0 ---- Kim et al., 1998 
 China 0 0 Pepe et al., 1997; Ho et al., 1999 
 Indonesia ---- 0 Pepe et al., 1997 
 Malaysia 0.5 ---- Lim et al., 1999 
 Singapore 5 ---- Lim et al., 1999; Lee, 2002 
 India 3 1.3 Herrmann et al., 1997; Ghosh et al.,  
2001; Mishra & Bedi, 2010 
 Pakistan 1.25 ---- Nasiruddin et al., 2005 
 USA ---- 0  Gregg et al., 1997 
Africans/ 
Black 
Ethiopia ---- 0 Pepe et al., 1997;  
Abdulkadir et al., 1997 
 USA 1.4 0.9 Gregg et al., 1997;  
Limdi et al., 2006  
 Sub- 
Sahara  
---- 0 Pepe et al., 1997 
 Ecuador ---- 0 Pepe et al., 1997 
 Venezuela ---- 4.4 Vizcaino et al., 2000 
Amerindians Ecuador ---- 0 Pepe et al., 1997 
 Venezuela ---- 1.25 Vizcaino et al., 2000 
 USA ---- 0 Gregg et al., 1997 
Eskimos Greenland  ---- 0 De Maat et al., 1996 
Indigenous 
Australians 
Australia ---- 0 Bennett et al., 2001;  
Erber et al., 2004 
Table 2. Prevalence of FVL in non-Caucasian patients with VTE and healthy populations in 
different parts of the world.  
Finding FVL to be mostly confined to Caucasian populations have brought speculations that 
FVL might have occurred as a single event in one European Caucasian ancestor, and the 
current carriers of the mutation descended from that ancestor. To prove a single origin of 
FVL, several molecular studies were conducted on different single nucleotides 
polymorphisms (SNPs) in the factor V gene trying to identify any association of FVL with 
such SNPs. At least 9 SNPs were found to be always associated with FVL. These studies 
included carriers and non-carriers of FVL, as well factor V gene in chimpanzees to elucidate 
when FVL might have first appeared (figure 7). These studies, combined with the 
distribution of FVL worldwide and the anthropological knowledge on movement of 
Mankind in the far past suggested that FVL should have occurred after the separation 
between Caucasoid (who settled in Europe) and Mongoloid (who moved to East Asia) 
populations, which is estimated to occur around 32,000 years ago (figure 8). This means that 
FVL is less than 32 thousand years old and this is why it is present in Caucasians only. The 
next question is: where in Europe has it happened? Since 1997 Castoldi et al suggested that 
FVL probably occurred outside Europe. It was observed that FVL was very rare in the 
 








Fig. 7. Molecular studies exploring the origin of FVL (prepared and drawn by the author).  
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Fig. 7. Molecular studies exploring the origin of FVL (prepared and drawn by the author).  
 




Fig. 8. Map showing movement of humans in the far past from Africa to the Middle East 
(March out-of-Africa), then to Europe and Asia. FVL event is thought to occur earlier than 
32,000 years ago after the divergence of Caucasoid and Mongoloid populations (prepared 
and drawn by the author). 
French and Spanish Basque populations, who are thought to be the oldest ethnic groups in 
Europe. This suggested FVL to occur outside Europe first (Bauder et al., 1997; Zabalegui et 
al., 1998). The prevalence of FVL in Eastern Mediterranean countries have shown the highest 
numbers in the world (table 3), bringing speculations that FVL might have occurred 
somewhere there and then spread to Europe (Castoldi  et al., 1997; Bauder et al., 1997; 
Zabalegui et al., 1998; Irani-Hakime et al., 2000; Taher et al., 2001; Lucotte & Mercier et al., 
2001, Dashti & Jadaon, 2011). Lucotte & Mercier (2001) proposed that FVL expanded in 
Europe during the Neolithic period, from a probable Anatolian center of origin in Turkey, 
which has occurred around 10,000 years ago. This may explain the highest prevalence of 
FVL in East Mediterranean countries, with noticeable gradual decrease in prevalence when 
radiating away from this region towards Europe and other parts of the world (Figure 9). 
Our research team in Kuwait has found that Arabs from Eastern Mediterranean countries 
who carry FVL also carried the same SNPs found to be associated with FVL in European 
carriers of the mutation (Jadaon et al., 2011). This gives another confirmation that FVL had 
most probably occurred as a single event in the past in the Eastern Mediterranean region. 
The large number of cases having FVL in our days suggests that FVL should have an 
evolutionary survival advantage explaining its persistence until now. For example, Man had 
faced many challenges since long time in the past, like fighting wild animals, diseases or each 
other which should have caused a lot of injuries and fatal bleeding incidences. Increased 
clotting tendency due to FVL might have an advantageous effect in such occasions giving 
carriers of FVL some privilege. Women with FVL have higher clotting tendency which may be 
advantageous in preventing fatal blood loss during menstruation and childbirth. Less blood 
loss also improves the haemoglobin level in these women creating better life expectancy 
(Lindqvist et al., 2001; Lindqvist & Dahlbäck, 2008; Franchini & Lippi, 2011). This is also true in 
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cases having both FVL and haemophilia, in which increased clotting due to FVL compensates 
for the bleeding tendency due to haemophilia, and hence better survival chances (Yan & 
Nelson, 2004; Franchini & Lippi, 2010). In addition, recent studies showed that FVL decreased 
risk of developing severe sepsis from infections to some extent, again another privilege to 
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Other mutations in the factor V gene were later identified, including Factor V Cambridge 
(Arg306Thr) (Williamson et al., 1998), Factor V Hong Kong (Arg306Gly) (Chan et al., 1998), 
Factor V Liverpool (Ile359Thr) (Mumford et al, 2003), and Factor V Kuwait (His1254Arg) 
(Jadaon et al., 2006). The number of cases reported to have these mutations were small and 
the relationship with VTE could not be well established like FVL, although many of these 
cases were reported in patients with VTE. Another mutation in the factor V gene called HR2 
Haplotype (His1299Arg) was identified in 1996, which is discussed separately in the 
following section. 
3.11 HR2 haplotype 
In 1996, a new missense mutation in exon 13 of factor V gene (A4070G) was identified 
(Lunghi et al., 1996). This mutation leads to an amino acid change, replacing histidine with 
arginine at amino acid residue position 1299 (His1299Arg). The new mutation was first 
assigned the name R2 polymorphism because of the use of the restriction enzyme Rsa I in 
the test used to detect it. Later on, R2 polymorphism was found to be in tight association 
with at least 12 polymorphisms in the factor V gene. Therefore, these SNPs were collectively 
called HR2 (Haplotype R2) (Bernardi et al., 1997; Castoldi et al., 2000). Several studies in 
different parts of the world gave the prevalence of HR2 to be 9.5%–15.2% in VTE cases and 
5.8%–10.4% in healthy controls, with an increased risk by at least 2.5-fold (Bernardi et al., 
1997; Alhenc-Gelas et al., 1999; Castoldi et al., 2000; Pecheniuk et al., 2001; Margaglione et 
al., 2002; Castaman et al., 2003; Faioni et al., 2004; Jadaon & Dashti, 2005a). The exact 
mechanism by which HR2 haplotype increases the risk for development of VTE is still not 
that clear. However, Castoldi et al (2000) have studied the two isoforms of factor V, V1 and 
V2, in cases with or without HR2. V1 is 7-fold more thrombogenic than V2. They showed 
that V1 was present in cases with HR2 more than in cases without the haplotype. This may 
give a possible explanation for the hypercoagulation and increased risk of developing VTE 
in carriers of HR2. However, more studies may be needed before understanding the real 
mechanism involved in that.  
4. Acquired risk factors for venous thrombosis 
VTE due to genetic risk factors (familial or hereditary thrombophilia), discussed above, 
mostly occur at ages less than 40 years, and they often recurrent. However, there are several 
acquired risk factors that are usually associated with VTE at above 40 years of age (Florell & 
Rodgers, 1997).  
4.1 Lupus Anticoagulants (LA) 
LA is a member of a group of autoantibodies (immunoglobulins) against phospholipids, 
including anticardiolipin and anti-β2-glycoprotein, which are produced in different 
autoimmune conditions. They often cause clinical manifestations like thrombosis, pregnancy 
loss and others, and the clinical condition is termed Antiphospholipid Syndrome 
(Hoffbrand et al., 2001; Laffan & Manning, 2002b; Ehsan & Plumbley, 2002). LA were given 
this name in 1972 because they were recognized initially in a patient with systemic lupus 
erythematosus (SLE) who had bleeding problems. However, later studies confirmed the 
association of LA with VTE, and not bleeding, but the name persisted (Greaves & Preston, 
1991; Bengtsson et al, 1996; Ehsan & Plumbley, 2002). Although the mechanism of causing 
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VTE is still not clear, the involvement of phospholipids in the Coagulation process and its 
regulators may give a possible explanation. In fact, there are in vitro evidences that LA lead 
to inhibition of APC, AT and fibrinolysis, and increase in expression of TF. In addition, LA 
were shown to directly contribute to hypercoagulability in animal models (Roubey, 1994; 
Kinev & Roubey, 2008; Farmer-Boatwright & Roubey, 2009). The prevalence of LA was 
reported to be up to 20% of VTE cases, with up to 10-fold increased risk of developing VTE 
(Ghosh et al., 2001; Galli et al., 2002; Ehsan & Plumbley, 2002; Jadaon & Dashti, 2005b; 
Farmer-Boatwright & Roubey, 2009; Anderson & Weitz, 2010). 
4.2 Pregnancy, childbirth and hormone therapy 
Pregnancy and delivery (and post-delivery up to 6 weeks after childbirth) account for more 
than 6-fold increased risk of developing VTE. This may be due to changes in the 
Coagulation and Fibrinolysis processes happening during these events, which include 
increased levels of most clotting factors and their activators, with reduced fibrinolysis and 
PS level. Women taking oral contraceptives or receiving hormone replacement therapy were 
also found to have higher risk of developing VTE, which may again be attributed to 
increased clotting factors and decreased AT and tPA (Rosing et al., 1997; Hoffbrand et al., 
2001; Ehsan & Plumbley, 2002; Chan, 2010; Anderson & Weitz, 2010).  
4.3 Other acquired risk factors 
VTE are common complications of major trauma like in surgery, fractures and blood 
transfusion, especially in elder and obese patients. VTE was also noticed to be secondary to 
other diseases like liver and kidney diseases, myeloproliferative disorders, disseminated 
intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP) and 
haemolytic uraemic syndrome (HUS) (Hoffbrand et al., 2001; Ehsan & Plumbley, 2002). 
Furthermore, patients with cancers of the gastrointestinal and urogenital tracts and the 
lungs were reported to have higher risk of VTE. This may be due to activation of clotting 
factors by the cancerous cells themselves or the chemotherapy these patients usually receive 
which affects the liver and vitamin K metabolism, or predisposes to DIC (Dahlbäck, 1995; 
Florell & Rodgers, 1997; Hoffbrand et al., 2001; Ehsan & Plumbley, 2002; Anderson & Weitz, 
2010; Vossen et al., 2011). Therefore, such diseases affect the Coagulation and Fibrinolysis 
processes in favour of developing VTE. Also, VTE in such diseases, especially those 
involving chronic inflammation, maybe due to increased C4bBP which captures more PS 
and lowers the availability of the active free PS and therefore may cause hypercoagulation. 
VTE was also present in many cases challenged with prolonged immobilization like being 
confined to bed due to major illnesses or post-operation, or after long airplane journey. The 
latter attracted a lot of public attention and was referred to in the media as “traveller’s 
thrombosis” or “economy-class syndrome” (Hoffbrand et al., 2001; O'Keeffe & Baglin, 2003; 
DeHart, 2003; Bhatia et al., 2009).  
5. Combined genetic and acquired risk factors for VTE 
All genetic and acquired risk factors discussed above are usually present as a “single” defect 
in a patient. However, many cases with VTE were reported to have more than one 
genetic/acquired risk factor at the same time, which may account for a higher risk of 
developing VTE (Jadaon & Dashti, 2005a & b). For example, several studies reported a 
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Other mutations in the factor V gene were later identified, including Factor V Cambridge 
(Arg306Thr) (Williamson et al., 1998), Factor V Hong Kong (Arg306Gly) (Chan et al., 1998), 
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(Jadaon et al., 2006). The number of cases reported to have these mutations were small and 
the relationship with VTE could not be well established like FVL, although many of these 
cases were reported in patients with VTE. Another mutation in the factor V gene called HR2 
Haplotype (His1299Arg) was identified in 1996, which is discussed separately in the 
following section. 
3.11 HR2 haplotype 
In 1996, a new missense mutation in exon 13 of factor V gene (A4070G) was identified 
(Lunghi et al., 1996). This mutation leads to an amino acid change, replacing histidine with 
arginine at amino acid residue position 1299 (His1299Arg). The new mutation was first 
assigned the name R2 polymorphism because of the use of the restriction enzyme Rsa I in 
the test used to detect it. Later on, R2 polymorphism was found to be in tight association 
with at least 12 polymorphisms in the factor V gene. Therefore, these SNPs were collectively 
called HR2 (Haplotype R2) (Bernardi et al., 1997; Castoldi et al., 2000). Several studies in 
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V2, in cases with or without HR2. V1 is 7-fold more thrombogenic than V2. They showed 
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this name in 1972 because they were recognized initially in a patient with systemic lupus 
erythematosus (SLE) who had bleeding problems. However, later studies confirmed the 
association of LA with VTE, and not bleeding, but the name persisted (Greaves & Preston, 
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VTE is still not clear, the involvement of phospholipids in the Coagulation process and its 
regulators may give a possible explanation. In fact, there are in vitro evidences that LA lead 
to inhibition of APC, AT and fibrinolysis, and increase in expression of TF. In addition, LA 
were shown to directly contribute to hypercoagulability in animal models (Roubey, 1994; 
Kinev & Roubey, 2008; Farmer-Boatwright & Roubey, 2009). The prevalence of LA was 
reported to be up to 20% of VTE cases, with up to 10-fold increased risk of developing VTE 
(Ghosh et al., 2001; Galli et al., 2002; Ehsan & Plumbley, 2002; Jadaon & Dashti, 2005b; 
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Pregnancy and delivery (and post-delivery up to 6 weeks after childbirth) account for more 
than 6-fold increased risk of developing VTE. This may be due to changes in the 
Coagulation and Fibrinolysis processes happening during these events, which include 
increased levels of most clotting factors and their activators, with reduced fibrinolysis and 
PS level. Women taking oral contraceptives or receiving hormone replacement therapy were 
also found to have higher risk of developing VTE, which may again be attributed to 
increased clotting factors and decreased AT and tPA (Rosing et al., 1997; Hoffbrand et al., 
2001; Ehsan & Plumbley, 2002; Chan, 2010; Anderson & Weitz, 2010).  
4.3 Other acquired risk factors 
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which affects the liver and vitamin K metabolism, or predisposes to DIC (Dahlbäck, 1995; 
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2010; Vossen et al., 2011). Therefore, such diseases affect the Coagulation and Fibrinolysis 
processes in favour of developing VTE. Also, VTE in such diseases, especially those 
involving chronic inflammation, maybe due to increased C4bBP which captures more PS 
and lowers the availability of the active free PS and therefore may cause hypercoagulation. 
VTE was also present in many cases challenged with prolonged immobilization like being 
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latter attracted a lot of public attention and was referred to in the media as “traveller’s 
thrombosis” or “economy-class syndrome” (Hoffbrand et al., 2001; O'Keeffe & Baglin, 2003; 
DeHart, 2003; Bhatia et al., 2009).  
5. Combined genetic and acquired risk factors for VTE 
All genetic and acquired risk factors discussed above are usually present as a “single” defect 
in a patient. However, many cases with VTE were reported to have more than one 
genetic/acquired risk factor at the same time, which may account for a higher risk of 
developing VTE (Jadaon & Dashti, 2005a & b). For example, several studies reported a 
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number of individuals who had FVL in addition to other accompanying genetic defect(s) 
like hereditary AT, PC or PS deficiency. Both FV and AT genes are located on chromosome 
1. As a result, a segregated inheritance pattern of APC-R and AT deficiency can persist in 
families for several generations (Ireland et al, 1995; Koeleman et al, 1997). In fact, van Boven 
et al (1996) found that the incidence of VTE in individuals having both FVL and AT 
deficiency was significantly higher than the incidence in individuals having only one of 
these two genetic defects. Similarly, coexistence of FVL and PC deficiency has 3 to 7-fold 
more risk of VTE than either of the two defects alone (Hallam et al, 1995; Zama et al, 1996; 
Koeleman et al, 1997, Jadaon & Dashti, 2005b). Moreover, more than half of patients with 
both APC-R and genetic PS deficiency were found to have thrombosis (Garcia de Frutos & 
Dahlbäck, 1995; Koeleman et al, 1997). It is interesting to mention here that a few isolated 
cases were reported to be double heterozygous for FVL and factor V deficiency, the 
mutations being present on opposite chromosomes. Plasma of such patients contain mutant 
FVL molecules only, similar to what is present in the plasma of people homozygous for the 
FVL mutation, resulting in what is called "Pseudohomozygous APC-R". Such cases have 
similar risk value to develop VTE as homozygous APC-R/FVL cases (Greengard et al, 1995; 
Simioni et al, 1996; Guasch et al, 1997).  
Acquired risk factors, including trauma, surgery, immobilization, pregnancy, use of oral 
contraceptives and LA have been reported to greatly increase the risk of developing VTE in 
individuals who have FVL. This may explain why in women who have FVL mutation there 
is an increased incidence of VTE during pregnancy especially in the last trimester and 
during delivery (Samama et al, 1996; Florell & Rodgers, 1997; Perry & Pasi, 1997; Rotmensch 
et al, 1997; Hallak et al, 1997). Further, women who are heterozygous for the FVL and take 
oral contraceptives are at 34-fold increased risk for developing VTE (Melichart et al, 1996; 
Rosing et al., 1997). LA present in a patient's plasma may create a status similar to APC-R 
(acquired APC-R). FVL was found in more than half of the LA positive patients who had 
one thrombotic event, and in more than 90% of the LA positive patients who had recurrent 
thrombosis (Griffin et al, 1995; Bengtsson et al, 1996; Alarcon-Segovia et al, 1996).  
Generally, there is a perception that familial thrombosis may be better considered as a 
complex genetic disorder caused by segregation of two (or more) genetic defects (known or 
yet unknown) in a family. Moreover, combination of these genetic defects with other 
acquired or circumstantial risk factors (like pregnancy, surgery, immobilization, etc.) or 
disorders (like LA) may greatly increase the risk for development of thrombosis in this 
group of patients. For example, it has been perceived that APC-R/FVL alone may be only a 
mild risk factor for developing VTE, especially when it is in heterozygous state. This may be 
partially explained by the fact that only FVL resists inactivation by APC, but the inactivation 
function of APC on FVIII is not affected by the FVL mutation. Thus, additional genetic or 
acquired factors may significantly enhance the risk of developing VTE in patients with FVL. 
The same may be said about the other genetic/acquired risk factors for VTE.   
6. Conclusions 
VTE are serious disorders with high morbidity and mortality rates. Several different genetic 
abnormalities were found to cause VTE, with different prevalence and risk ratios in different 
populations and ethnic groups. Also, several acquired risk factors were found to cause VTE 
by different methods. Combination of more than one risk factor (genetic or acquired) in the 
same patient is not uncommon and it leads to higher risk of developing VTE.  
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these two genetic defects. Similarly, coexistence of FVL and PC deficiency has 3 to 7-fold 
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similar risk value to develop VTE as homozygous APC-R/FVL cases (Greengard et al, 1995; 
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Acquired risk factors, including trauma, surgery, immobilization, pregnancy, use of oral 
contraceptives and LA have been reported to greatly increase the risk of developing VTE in 
individuals who have FVL. This may explain why in women who have FVL mutation there 
is an increased incidence of VTE during pregnancy especially in the last trimester and 
during delivery (Samama et al, 1996; Florell & Rodgers, 1997; Perry & Pasi, 1997; Rotmensch 
et al, 1997; Hallak et al, 1997). Further, women who are heterozygous for the FVL and take 
oral contraceptives are at 34-fold increased risk for developing VTE (Melichart et al, 1996; 
Rosing et al., 1997). LA present in a patient's plasma may create a status similar to APC-R 
(acquired APC-R). FVL was found in more than half of the LA positive patients who had 
one thrombotic event, and in more than 90% of the LA positive patients who had recurrent 
thrombosis (Griffin et al, 1995; Bengtsson et al, 1996; Alarcon-Segovia et al, 1996).  
Generally, there is a perception that familial thrombosis may be better considered as a 
complex genetic disorder caused by segregation of two (or more) genetic defects (known or 
yet unknown) in a family. Moreover, combination of these genetic defects with other 
acquired or circumstantial risk factors (like pregnancy, surgery, immobilization, etc.) or 
disorders (like LA) may greatly increase the risk for development of thrombosis in this 
group of patients. For example, it has been perceived that APC-R/FVL alone may be only a 
mild risk factor for developing VTE, especially when it is in heterozygous state. This may be 
partially explained by the fact that only FVL resists inactivation by APC, but the inactivation 
function of APC on FVIII is not affected by the FVL mutation. Thus, additional genetic or 
acquired factors may significantly enhance the risk of developing VTE in patients with FVL. 
The same may be said about the other genetic/acquired risk factors for VTE.   
6. Conclusions 
VTE are serious disorders with high morbidity and mortality rates. Several different genetic 
abnormalities were found to cause VTE, with different prevalence and risk ratios in different 
populations and ethnic groups. Also, several acquired risk factors were found to cause VTE 
by different methods. Combination of more than one risk factor (genetic or acquired) in the 
same patient is not uncommon and it leads to higher risk of developing VTE.  
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1. Introduction 
Behcet’s Disease (BD) is manifested by a triad of relapsing hypopyon uveitis, aphthous 
stomatitis and genital ulcers. The disease initially described by a Turkish dermatologist 
Hulusi Behcet in 1937. The etiology and pathogenesis of Behçet’s disease have not been fully 
clarified yet. However, it is now recognized as a multisystemic, immunoinflammatory 
disorder involving vessels of all sizes. The disease is most prevalent in the Mediterranean 
countries, Middle East, and Japan but has a worldwide distribution (Durmazlar et al., 2009; 
Kartal Durmazlar et al., 2008a).  
2. History and diagnosis 
The disease, currently known all over the world as “Behçet disease”, “Behçet syndrome”, 
“Behçet’s triad”, “Morbus Behçet” or “Tri-symptom Behçet” was first recognized by Dr. 
Hulusi Behçet (1889-1948) with a patient in 1924 (Tuzun, 2006; Ustun, 2002; Kartal 
Durmazlar & Kandi, 2011). This patient, who had been examined because of eye 
disturbances, recurrent oral and genital ulcers both in Istanbul and Vienna for 40 years, was 
given several diagnoses. Some doctors thought of tuberculosis or syphilis while some other 
doctors said a microorganism which was not present in Europe might have caused the 
disease. Hulusi Behçet, who continued to examine the patient after his loss of vision, 
thought that the causative agent was a virus. In the next several years he met two more 
patients with similar to that was seen in the previous patient. Hulusi Behçet thought the 
symptoms of these three patients were the symptoms of a new disease and reported his 
ideas on this topic firstly in 1936, in the Journal of Skin and Venereal Diseases (Tuzun, 2006; 
Ustun, 2002; Kartal Durmazlar & Kandi, 2011; Saylan, 1997). Later, in 1937 he wrote clear 
examples of symptomatic triad, which are still used as criterias worlwide for diagnosis of 
Behçet’s disease, in Dermatologische Wochenschrift. In the same year at the meeting of the 
Society of Paris Dermatology he declared that several factors may cause the etiology of the 
disease, which still can be an acceptable statement. Later he diagnosed further patients and 
published in German as “Tri-Symptomenkomplex” in 1939, and in English as “Triple 
symptom complex” in 1940 (Tuzun, 2006; Ustun, 2002; Kartal Durmazlar & Kandi, 2011; 
Saylan, 1997; Evereklioglu, 2006). In subsequent years, this unique disorder drew the 
attention, and the term “Behçet syndrome” was first used by Jensen in 1941 (Jensen, 1941). 
The term “Behçet disease” was first used by Fiegenbaum and Kornblueth in 1946 (Kartal 
Durmazlar & Kandi, 2011; Figenbaum, 1946; Dilsen, 1996; Alpsoy, 2009).  On 13 September 
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1947, international dermatologic societies came together in Zurich and named the disease as 
“Morbus Behçet”, which honored the first describer of “triple symptom complex” after 
Zurich Medical Faculty Professor Mischner’s proposal. In fact, several authors before Hulusi 
Behçet described one or several individual findings of this disorder. Among these 
physicians, for example, Hippocrates in the fifth century BC reported some individual 
symptoms attributed to an originally endemic and epidemic disease. But, due to sporadic 
appereance of the disease in the course of time, the disease became less significant and was 
forgotten. There were also other physicians who described one or several individual 
findings of this disorder, for example, Janin (1772), Reis (1906), Blüthe (1908), Gilbert (1920, 
1921, 1923), Planner and Remenowsky (1922), Weve (1923), Shigeta (1924), Adamantiades 
(1930), Dascalopoulos (1932), Whitwell (1934), Nishimura (1936), Blobner (1937) reported 
several individual findings of this disorder.  However, all these papers ascribed the findings 
either to another disease, such as tuberculosis, syphilis, sepsis or allergy, or to a coincidence 
and none of them indicated a new or a single syndrome with “classical triad” (Kartal 
Durmazlar & Kandi, 2011; Alpsoy 2009; Evereklioglu, 2006, 2007a, 2007b, 2007c; 
Freigenbaum, 1956). The disease is sometimes named as Adamantiades-Behcet’s disease, 
however, Behcet’s disease should be preferred as suggested by International Associations 
and Societies of “Behcet” (Mendes et al., 2009).  
Several diagnostic criteria have been developed during the years, all have in common the 3 
major features of oral ulceration, genital ulceration and eye lesion (16). Today, International 
Study Group criteria for the diagnosis of Behcet’s disease is used worldwide (Table 1) 




Minor aphthous, major aphthous, or herpetiform ulceration 
observed by physician or patient recurring at least three times 
in one 12-month period 
Plus any two of the following: 
Recurrent genital 
ulceration 
Aphthous ulceration or scarring, observed by physician or 
patient 
Eye lesions Anterior uveitis, posterior uveitis, cells in the vitreous on slit-
lamp examination; or retinal vasculitis observed by 
ophthalmologist 
Skin lesions Erythema nodosum observed by the physician or patient, 
pseudofolliculitis, papulopustular lesions; or acneiform 
nodules observed by physician in post adolescent patients not 
on corticosteroids treatment 
Pathergy Read by physician at 24-48 hours (The test is performed by 
introducing a 20-gauge or smaller sterile needle 5 mm 
obliquely into the patient’s flexor aspect of the avascular 
forearm skin without injection of saline under sterile 
conditions. The test is considered positive if there is an 
indurated erythematous small papule or pustule formation of 
more than 2 mm in diameter. 
*Findings applicable only in the absence of other clinical explanations 
Table 1. International Study Group diagnostic criteria, 1990. 
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As a systemic disease, Behcet’s disease involves visceral organs also such as the 
gastrointestinal tract, pulmonary, musculoskeletal, and neurological systems (Table 2) 
(Evereklioglu, 2005).  
 
Manifestations  Characteristics 
Articular 
manifestations 
Non-migratory monoarthritis or oligoarthritis, rarely polyarthritis, 
characterized by non-specific inflammatory-type synovitis. Favors 
large joints such as the knee (most commonly), ankle, wrist, and elbow 
as well as proximal interphalangeal and metacarpophalangeal joints. 
Spinal and sacroiliac involvements are uncommon. Symptoms and 
signs: arthralgia, tenderness, swelling, limitation of joint movement, 




Inner ear involvement cochlear and peripheral vestibular 
disturbances, tinnitus, deafness, dizziness, unilateral or bilateral 
sensorineural hearing, orthostatic disequilibrium 
Thoracic 
involvement 
Aorta and pulmonary artery aneurysms, infarct and hemorrhage, 
pleural effusion, pulmonary thromboembolism, tracheobronchial 
ulcerations, pneumonitis, mediastinitis, paranchymal fibrosis, 
arteriobronchial fistula, cor pulmonale, hilar and mediastinal 
lymphadenopathy, and lobular perfusion defects. Symptoms: 




Ulcerative lesions especially terminal ileum, cecum, occasionally in 
esophagus and stomach.  
Symptoms: anorexia, dysphagia, dyspepsia, vomiting, flatulence, vague 
abdominal discomfort, distention and pain, bloating, and diarrhea. 
Perforation can occur and malabsorbtion is common 
Vascular 
involvement 
Superficial and deep obliterative thrombophlebitis in lower extremity, 
varices, embolization, infarction, bleeding ulcers. Veins are affected 
more frequently than arteries. Large vessel thromboses in superior 
and inferior vena cava with a caput medusa, deep femoral and 
subclavian veins can occur. Occasionally, aorta, carotid, and popliteal 
aneurysms, radial artery occlusion, and thromboses of the hepatic 
(Budd-Chiari syndrome), mesenteric, pulmonary, iliac and renal veins 
with intracranial hypertension, mesenteric artery aneurysm 
Cardiac 
involvement 
Coronary artery disease, myocardial infarction, endocarditis, 
myocarditis, pericarditis, aortitis, valvular disease (aortic/mitral 




Microscopic hematuria and proteinuria (microalbuminuria) with 
normal renal functions, or rapidly progressive anti-neutrophylic 
antibody-associated vasculitis, cresentic or proliferative 
glomerulonephritis (focal segmental or sclerosing, diffuse or 
mesangial), IgA nephritis, renal vein thrombosis, amyloidosis, 
nephrotic syndrome, renal failure 
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Inflammation of the testis, typically epididymitis with painful 




5–10% of patients are affected. Focal or multifocal parenchymal , 
peripheral or CNS involvement with both motor and sensory 
manifestations, migraine-like headache (most frequent initial sign), 
hemiparesis, behavioral changes, stiff neck, pyramidal and 
extrapyramidal signs, cerebellar ataxia, cerebral vein thrombosis, 
isolated cerebral sinus thrombosis, cranial nerve palsies, peripheral 
neuropathy, seizures, benign intracranial hypertension, life-
threatening brainstem and spinal cord lesions, aseptic meningitis, 
chronic meningoencephalitis, multiple sclerosis-like illness, organic 
confusional syndrome, acute myelitis, aneurysms, stroke, and pseudo-
tumor cerebri.  
Psychosomatic 
status 
Character disorders, aggressiveness, anxiety, depression, dementia, 
cognitive deficits, memory disturbances, impairment in 
acquisition/information storage, personality change, attention deficit, 
bipolar disorder, and chorea 
CNS _ central nervous system; GIS _ gastrointestinal system. 
Table 2. Additional Systemic Features of Behcet Disease (From Evereklioglu, 2005).  
3. Vascular involvement in Behcet’s disease 
Vasculo-Behcet Disease (VBD), which involves the arterial and venous system, is found in 
15-38% of patients with BD. Three major manifestations of VBD have been identified: 
venous occlusion, arterial occlusion and aneurysm formation, with a clear preponderance 
of the venous lesions compared to arterial involvement. The coexistence of arterial and 
venous involvement is not frequent and is one of the major causes of morbidity and 
mortality. Venous involvement, including superficial thromboflebitis and deep venous 
thrombosis, is a characteristic manifestation. Thrombosis of superficial and deep vein is 
more frequent than arterial aneurism and thrombotic occlusions (Kartal Durmazlar et al., 
2008a, 2009; Houman et al., 2001; Aksoy et al., 2010). Venous thrombosis appeared to be 
the major vascular involvement reported in 7 to 33% of cases with BD with a male 
predominance, and representing 85 to 93% of VBD (Houman et al., 2001). Deep vein 
thrombosis is seen in about one-fifth of Turkish patients with BD (Gul et al., 1999). Lower 
extremities is the most frequent site of thromboses but thromboses of other venous sites 
such as superior and inferior vena cava, coronary, portal, renal and pulmonary veins have 
been identified (Houman et al., 2001; La Regina et al., 2010). Leg ulcers in BD, which may 
be caused by vasculitis or deep vein thrombosis, have a chronic recurrent course and are 
refractory to treatment (Jung et al., 2008; Kartal Durmazlar et al, 2008b; Akgul & Kartal 
Durmazlar, 2008). 
4. Pathogenesis of Behcet’s disease and thrombosis 
The main pathology in BD is an inflammatory process of small arteries and veins and 
thrombosis as a result of vasculitis of the vaso vasorum (Evereklioglu et al., 2002). 
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Histopathological studies revealed cellular infiltrations consisting of lymphocytes, 
plasmocytes, monocytes and PMN in varying degrees, depending on the stage of lesion in 
BD. Since cytokines are involved in the regulation of functions of lymphocytes and 
phagocytes, they are playing important role in the pathogenesis of the disease (Durmazlar et 
al, 2009). Chemotactic and phagocytic activity of neutrophils in patients with BD has been 
reported to be high (19). Increased spontaneous secretion of Tumor necrotizing factor (TNF-
α), Interleukin-6 (IL-6) and Interleukin-8 (IL-8) in monocyte cultures obtained from BD 
patients have been reported (Mege et al., 1993). IL-8 secretion after incubation of human 
dermal microvascular endothelial cells with serum of BD patients indicates that chemotaxis is 
an initial process of inflammation. IL-8 upregulates neutrophil chemotaxis as mRNA 
expression have been reported to be more prominent in patients with active BD than in 
patients with inactive disease (Evereklioglu, 2005). IL-8, a major chemokine known as neutrofil 
activating factor, attract and activate leukocytes has been assumed to represent such a notable 
link between immune system activation and endothelial alterations in BD (Durmazlar et al., 
2009; Evereklioglu, 2005; Tursen, 2009). It has been suggested that Th1 type cytokines and 
chemokines including IL-17, largely produced by activated CD4+ and CD8+ T cells, are 
involved in the recruitment of neutrophils to the site of inflammation. Activated neutrophils in 
BD patients produce significant quantities of IL-12 and IL-18 (Pay et al., 2007).  
The pathogenesis of thrombotic events in BD is not fully understood. The primary 
abnormalities of the coagulation, anticoagulation, or fibrinolytic systems have not been 
confirmed yet in BD. The main factor responsible for the increased frequency of thrombosis 
in BD is thought to be endothelial dysfunction caused by vascular inflammation 
(Evereklioglu, 2005). There is accumulating evidence for inflammation markers as a result of 
thrombosis. Deep vein thrombosis significantly associates with the male gender and a 
positive pathergy test (Houman et al., 2001). A number of studies have explored the 
pathogenesis of thrombophilia in Behçet’s disease. Neither deficiency in protein C, in 
protein S, in factor V Leiden and in antithrombin III nor resistance to activated protein C 
and anticardiolipin antibody levels seem to be correlated with vascular thrombosis in 
Behçet’s disease (Houman et al., 2001; Espinosa et al., 2002; Hirohata & Kikuchi, 2003). In 
BD, there is an occlusive inflammatory thrombus formation, strictly adherent to inflamed 
vessel wall, which is typically not complicated with thromboembolism (Lakhanpal et al., 1985; 
Kobayashi et al., 2000; Matsumoto et al., 1991). There are increased thrombin generation, 
fibrinolysis, and thrombomodulin in Behçet’s disease, but these abnormalities are not related 
to thrombosis (Espinosa et al., 2002). These results therefore suggest that thrombophilia in 
Behçet’s disease may be related more to inflammation than to clotting disorder (Hirohata & 
Kikuchi, 2003). Studies have disclosed the occurrence of antiendothelial cell antibodies, 
increased E-selectin and myeloperoxydase expression in Behçet’s disease (Houman et al., 2001; 
Espinosa et al., 2002; Hirohata & Kikuchi, 2003). As neutrophils from active Behçet’s disease 
release increased amounts of myeloperoxydase, it is probable that neutrophil activation as well 
as the expression of antiendothelial cell antibodies may play an important role in the 
development of endothelial inflammatory damages, leading to thrombophilia (Houman et al., 
2001; Espinosa et al., 2002; Hirohata & Kikuchi, 2003). Figure 1 summarizes the 
immunopathogenesis of Behcet’s disease (Pay et al., 2007). 
Homocysteine (Hcy) is an intermediary sulphydryl-containing aminoacid formed during 
the conversion of methionine to cysteine. Its sulphydryl group can cause direct endothelial 
cytotoxicity, inhibition of glutathione peroxidase and nitric oxide, interference with clotting 
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Fig. 1. Immunopathogenesis of Behcet’s disease  (From Pay et al., 2007). 
factor, and LDL oxidation (Kartal Durmazlar et al., 2008a, 2009). The association between 
Hcy levels and endothelial dysfunction and its correlation to the degree of endothelial 
damage have been shown in patients with BD. Hcy is thought to induce proinflammatory 
cytokines.  Suggested mechanisms of Hcy in promoting such a clotting cascade are the 
inactivation of protein C, activation of coagulation factor V, and inhibition of 
thrombomodulin (Kartal Durmazlar et al., 2008a, 2009). The increase in Hcy concentration in 
patients at risk for vascular disease is expressed as odds ratio and for venous thrombosis, 
this odds ratio is approximately 1.6. In a study, a change of 1 µmol/l in Hcy concentration 
was found to correspond to a risk ratio of 1.01 (Willems et al., 2006). A study reported that 5 
µmol/l increase of Hcy was associated with a 60% and 27% increased risk of venous 
thrombosis in retrospective and prospective studies, respectively (Omar et al., 2007). The 
association between Hcy levels and endothelial dysfunction and its correlation to the degree 
of endothelial damage has been shown in patients with BD (Ozdemir et al., 2004). Hcy 
generates superoxide and hydrogen peroxide, both of which have been linked to endothelial 
damage (Er et al., 2002). Hcy-induced vascular problems are thought to be multifactorial, 
including direct Hcy damage to the endothelium, enhanced lipid peroxidation and 
increased platelet aggregation by the effects on the coagulation system (Er et al., 2002; 
Sarican et al., 2007). Hcy has been shown in vivo and in vitro to promote inflammatory 
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process such as the adhesion of neutrophils to endothelial cells as well as the release of the 
inflammatory cytokine IL-8 and monocyte chemoattractant protein-1 (MPC-1) (Koga et al., 
2002). Hcy was shown to enhance the cytokine-stimulated expression of endothelial cell 
adhesion molecules and monocyte and T-cell adhesion to endothelial cells (Koga et al., 
2002). Hcy was shown to promote TNF-α mediated induction of vascular cell adhesion 
molecule-1 (VCAM-1) in endothelial cells (Silverman et al., 2002). Some studies have shown 
hyperhomocysteinemia as a correctable risk factor for thrombosis in BD (Kartal Durmazlar 
et al., 2008a, 2009; Omar et al., 2007; Ozdemir et al., 2004; Er et al., 2002; Sarican et al., 2007). 
In a recent work, thrombogenesis in BD is discussed through the concept of Virchow’s triad 
of venous thrombosis (La Regina et al., 2010). Based on this concept; abnormal blood flow, 





Enhanced erythrocyte aggregation, increased fibrinogen, high blood 
viscosity 
Impaired microcirculation 
Turbulent blood flow at sites of venous varices and arterial aneurysms 










Endothelial factors such as  vWF, t-PA, thrombomodulin, NO, VEGF, 
endothelin-1 
Procoagulant factors  such as factor V Leiden and prothrombin 
mutations, 
hyperhomocystenemia, factors VIII, IX, lipoprotein a 
Factors of fibrinolysis such as PAI-1, t-PA 
Anticoagulant factors (protein C, S, Z,  antithrombin) 
vWF: von Willebrand factor, t-PA: tissue plasminogen activator, NO: nitric oxide, VEGF: vascular 
endothelial growth factor, PAI-1: the type-1 inhibitor of plasminogen activators, t-PA: tissue 
plasminogen activator 
Table 3. Thrombogenesis in Behcet’s Disease according to Virchow’s triad of venous 
thrombosis (From La Regina et al., 2010). 
5. Medical management of Behcet’s disease 
The choice of treatment is generally based on the clinical presentation and the site affected. 
Although the treatment has become much more effective in recent years, BD still associates 
with severe morbidity and considerable mortality. Therefore, the main aim of the treatment 
should be the prevention of irreversible organ damage, especially, during the early, active 
phase of the disease. Male sex and a younger age of onset have been reported to be 
associated with severe disease, which in case may require aggressive treatment (Alpsoy & 
Akman, 2009).Recently, a group of experts developed recommendations for the 
management of BD by combining the current evidence from controlled trials (Hatemi et al., 
2008). The European League against Rheumatism (EULAR) recommendations are 
summarized in Table 4. 
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Eye disease  Affecting the posterior segment: Azathioprine and 
local and systemic corticosteroids 
 If refractory eye involvement (retinal vasculitis or 
macular involvement):  Cyclosporine A or 
infliximab in combination with azathioprine and 
corticosteroids or  IFN-a alone or with 
corticosteroids 
Major vessel disease* 
 
 Acute deep vein thrombosis: Corticosteroids, 
azathioprine, cyclophosphamide or cyclosporine A 
 Thrombosis of the vena cava and Budd–Chiari 
syndrome: Cyclophosphamide 
 Pulmonary and peripheral arterial aneurysms: 
Cyclophosphamide and corticosteroids; surgery  
 Anticoagulants, antiplatelet and antifibrinolytic 
agents are not recommended ( there are no controlled 
data on, or evidence of benefit from uncontrolled 
experience with anticoagulants, antiplatelet or 
antifibrinolytic agents in the management of deep 
vein thrombosis pulmonary embolism is rare and 
there is the risk of major bleeding in case there are 
concomitant pulmonary aneurysms) 
Gastrointestinal involvement** 
 
Sulfasalazine, corticosteroids, azathioprine, TNF-a 
antagonists or thalidomide; surgery 
Articular involvement 
 




 Parenchymal disease: Corticosteroids, IFN-a, 
azathioprine, cyclophosphamide, methotrexate, 
TNF-a antagonists 
 Dural sinus thrombosis: Corticosteroids 
 Cyclosporine should be avoided in case of 
neurological involvement due to neurotoxicity, 
unless necessary for intraocular inflammation. 
Mucocutaneous involvement 
(oral, genital and skin lesions) 
 Isolated lesions: Topical measures such as 
corticosteroids preparations, lidocaine gel, 
chlorhexidine, sucralfate suspension 
 Acne-like lesions:  Topical measures as used in acne 
vulgaris  
 Erythema nodosum: Colchicines 
 Resistant cases: Azathioprine, IFNa and TNFa 
antagonists may be considered in resistant cases. 
CNS: Central nervous system; IFN: Interferon; TNF: Tumour necrosis factor. 
* There is no firm evidence to guide the management of major vessel disease in BD 
** There is no evidence-based treatment that can be recommended for the management of 
gastrointestinal involvement of BD 
*** There are no controlled data to guide the management of CNS involvement in BD 
Table 4. EULAR recommendations for treatment of Behcet’s disease (Hatemi et al., 2008) 
 




The pathogenesis of thrombotic events in BD is not fully understood. The primary 
abnormalities of the coagulation, anticoagulation, or fibrinolytic systems have not been 
confirmed yet in BD. In this review current knowledge of venous thrombosis in BD are 
summarized. There is no agreement on the treatment of thrombosis in BD. However, in 
general immunosuppressive agents such as corticosteroids, azathioprine, cyclophosphamide 
or cyclosporine  are recommended for the treatment of venous thrombosis in BD. There is 
no enough evidence of benefit with anticoagulants or fibrinolytic agents in the management 
of thrombosis of BD (La Regina et al., 2010). Further studies are needed to clarify the safety 
and effectiveness of antithrombotic therapy in BD. However, owing to the complications of 
established thrombus, it would be reasonable to target different steps of the coagulation 
cascade for the prophylaxis and treatment of thrombosis in BD.  
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1. Introducton 
Antiphospholipid syndrome(APLS) is a prothrombotic state characterized by recurrent 
venous thrombotic events including deep venous thrombosis, as well as pulmonary 
embolism, arterial thrombosis, recurrent fatal loss due to placental thrombosis and the 
presence of circulating antiphospholipid antibodies(APA) (Roubey RAS, 2001). As both 
thrombosis and pregnancy morbidity have a large number of other origins, the diagnosis of 
APLS relies on the quality and reliability of the laboratory investigations, on the persistent 
positivity of the APA assays, and sometimes on the lack of any other cause. Although a 
broad spectrum of APA exists, the universally accepted diagnostic APA tests are lupus 
anticoagulant(LA) functional coagulation assay; anticardiolipin antibody(ACA) enzyme-
linked immunosorbent assay(ELISA); and anti-β2-glycoprotein I antibody(aβ2GPI) ELISA.  
Antiphospholipid antibodies were first described in 1906 in patients with syphilis. These 
complement-fixing antibodies reacting with extracts from bovine hearts(mitochondrial 
phospholipid cardiolipin) formed the basis for the serologic syphilis test(Venereal Disease 
Research Laboratory-VDRL assay). Mass population screening for syphilis demonstrated 
that patients with systemic lupus erythematosus(SLE) without clinical syphilis had 
persistently false-positive VDRL tests(Haserick J,et al 1952, Baker WF, et al 2008). As false-
positive VDRL tests in patients with SLE were also found to be associated with prolonged in 
vitro coagulation, the term ‘lupus anticoagulant’ was introduced.  
The lupus anticoagulant is an antibody that prolongs phospholipid dependent coagulation 
tests in vitro. It was given this name in 1972 because clear proof of its site of action was 
lacking, and because the anticoagulant had been recognized in patients with systemic lupus 
erythematosus(Donald I Feinstein 2009 ). It is a misnomer because the lupus anticoagulant is 
more frequently encountered in patients without lupus and is associated with thrombosis 
rather than with bleeding. Immunoglobulins reacting with other hemostatic factors, such as 
von Willebrand factor (VWF), factor VIII, factor IX, and factor XI, inhibitors of thrombin and 
fibrin polymerization, and factor XIII have also been described in patients with SLE(Donald 
I Feinstein 2009), but they are rare compared with the lupus anticoagulant. 
Patients with the lupus anticoagulant who do not have established SLE fall into several 
different categories: (1) patients with “lupus-like”chronic autoimmune disorders but 
without findings that fit the criteria for the diagnosis of SLE; (2) patients with other chronic 
systemic autoimmune disorders; (3) patients presenting with a venous or arterial thrombotic 
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event for which no underlying cause may be apparent; (4) patients receiving certain drugs, 
including procainamide and phenothiazines(a high prevalence of the lupus anticoagulant 
and a positive antinuclear antibody test are observed in psychotic patients receiving long-
term chlorpromazine therapy); other drugs or biologics that can induce the lupus 
anticoagulant include hydralazine, quinidine, and possibly α-interferon; (5) patients with a 
recent acute viral infection, in whom the antibody is usually transient; (6) patients with 
human immunodeficiency virus infection; (7) women with recurrent fetal wastage;(8) 
occasionally in older patients with malignancies and (9) patients seeking medical attention 
for a variety of disorders in whom the lupus anticoagulant is discovered as an incidental 
finding, usually discovered because of a prolonged partial thromboplastin time (PTT) 
performed as a routine preoperative evaluation. 
2. Epidemiology 
APA can be detected in the absence of thrombosis or pregnancy morbidity or other systemic 
autoimmune diseases. During ongoing infectious disease, during treatments with a variety of 
drugs and even in healthy individuals, APA positivity may occur. The prevalence of APA 
ranges from 1% to 10% in the general population, 16% in patients with rheumatoid arthritis, 
and 30% to 40% in patients with SLE(Petri M 2000, Lim W et al 2006). The prevalence of 
positive tests for lupus anticoagulant and anticardiolipin antibody in a normal population has 
been reported in several studies. Because of the non-Gaussian distribution of anticardiolipin 
antibody levels in normal subjects, the cut-off points between normal and abnormal results is 
difficult to determine. One study reported IgG and IgM anticardiolipin antibodies in 
approximately 5% of normal individuals, although only 2% had persistently elevated levels on 
repeat testing. Shi and colleagues detected anticardiolipin antibodies in 6% of normal blood 
donors, respectively, and detected lupus anticoagulant activity by kaolin clotting time in 
4%Shi W 1993). The prevalence of anticardiolipin antibody appears to increase with age. 
The prevalences of elevated levels of IgG and IgM anticardiolipin antibody in healthy 
pregnant women were 2% to 3% and 4%, respectively(Harris EN 1991, Aoki K 1994, 
Lockshin MD 1997). Most of these were low titer; only 0.2% were high titer. In other studies, 
the incidence of anticardiolipin antibodies in pregnant individuals ranged from 1% to 2% 
and lupus anticoagulant 1% to 4%(Petri M 2000). 
When the patient does not exhibit any other symptom that would allow the diagnosis of 
another associated autoimmune disease, the antiphospholipid syndrome is considered 
primary, or isolated. The term ‘secondary’ APLS is sometimes used for patients suffering 
from another autoimmune or inflammatory disease.  
3. Etiopathogenesis 
Lupus anticoagulants and anticardiolipin antibodies are immunoglobulins that were 
originally thought to react only with phospholipid. However, it is now well established that 
these antibodies react directly with epitopes on β2-GPI(McNeil HP 1990, Galli M 1990) or 
prothrombin(Rao LVM 1996, Bevers EM 1991 ), that subsequently bind to anionic 
phospholipid. Anticardiolipin antibodies are low-affinity monovalent antibodies to β2-GPI 
when in solution, and the monovalent complexes bind weakly to anionic phospholipids. 
However, when the antigen density is high, bivalent complexes are formed that have a high 
affinity for phospholipid surfaces. The fact that β2-GPI antibodies are polyclonal reacting 
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with different epitopes on the β2-GPI molecule and the increased affinity of the divalent 
antigen-antibody complexes for phospholipid surfaces explains why some anticardiolipin 
antibodies have anticoagulant activity and some do not(Arnout J 2003). This anticoagulant 
activity correlates best with the incidence of thrombosis(Galli M 2003), and a subset of lupus 
anticoagulants caused by anti–β2-GPI antibodies with specificity for an epitope on domain I. 
In some patients the anticardiolipin antibody will react with immobilized cardiolipin in 
vitro but not prolong phospholipid-dependent coagulation tests. Similarly, some of the 
antiprothrombin antibodies can prolong coagulation tests and some will not. 
As with most autoimmune conditions, the etiology of APLS is not understood. It has been 
demonstrated that normal healthy individuals without APS have memory B cells that 
produce aPL antibodies; in a study of patients with infectious mononucleosis, 10 to 60 
percent of immunoglobulin M aCL-producing cells expressed CD 27, the marker of memory 
B cells(Lieby P 2003).  
Although antibodies against anionic phospholipid moieties arise during the course of 
infections such as syphilis and lyme disease, those are distinct from antibodies generated by 
patients with the syndrome because they generally recognize phospholipid epitopes directly 
and are not associated with the clinical manifestations of the syndrome. 
Reports of familial clustering of raised aPL antibody levels indicate that genetic 
susceptibility can play a role in their development(Donald I. Feinstein 2007). In one study of 
84 APLS patients, more than 35% had at least one relative, and more than 20% had two or 
more relatives, with evidence of at least one clinical feature of APS, such as thrombosis or 
recurrent fetal loss(Weber M 2000). 
Many different mechanisms have been described for thrombosis during APLS, mainly after 
in-vitro experiments: (1) activation of endothelial cells by complexes of β2 GPI and anti-β2 
GPI, these complexes could bind to annexin 2 or even Toll-like receptors on the surface of 
endothelial cells(Zhang J 2005, Fischetti F 2005); (2) platelet activation after direct binding of 
the β2 GPI, which targets the autoantibodies on the surface of these cells, the β2 GPI is 
selectively bound by the activator receptor apo ER 2(Lutters BC 2003); (3) functional 
dysregulation of hemostasis by the presence of autoantibodies against natural anticoagulant 
proteins like annexin 5 and activated protein C; (4) abnormal fibrinolysis directly linked to 
the presence of APL(Cesarman-Maus G 2006). 
APL can stimulate platelet aggregation(Lin YL 1992), an effect that might be promoted via 
signalling through apolipoprotein E receptor 2(apoER2) receptors; the beta2GPI binding site 
for apo ER2 on platelets was localized to its domain V. Beta2GPI also has a dampening effect 
on platelet adhesion by interfering with the platelet-von Willebrand factor interaction, and 
consequently aPL antibodies, by interfering with this dampening, can increase platelet 
adhesion in flow systems(Hullstein JJ 2007). 
Normal endothelial function includes control over thrombosis and thrombolysis, platelets 
and leukocyte interaction with the vessel wall, and regulation of vascular tone and smooth 
muscle proliferation. Several in vitro studies and studies on animal models have shown that 
incubation of endothelial cells with aPL from APLS patients generates different effects on 
endothelial function via β2 GPI. As a whole this might cooperate in sustaining endothelial 
perturbation that has been suggested to have a pivotal pathogenetic role in APS associated 
thrombosis(Stalc  M 2006).  
Because high-level aPLs may persist for years in asymptomatic persons, it is likely that 
vascular injury, endothelial cell activation, or both immediately precede the occurrence of 
thrombosis in those bearing the antibody (second-hit hypothesis). Of note, at least 50% of 
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APLS patients with vascular factors possess other acquired thrombosis risk factors at the 
time of their events(Kaul M 2006, Erkan D 2002). 
Both persons congenitally lacking ß2GPI39 and ß2GPI knockout mice appear normal(Sheng 
Y 2001).  ß2GPI polymorphisms influence the generation of aPLs in individuals, but they 
have only a weak relationship to the occurrence of APLS. A cluster of 50 upregulated genes 
may have an effect on the occurrence of thrombosis in aPL-positive individuals(Potti A 
2006). 
4. Diagnostic criteria of the antiphospholipid syndrome 
The international preliminary classification criteria for APLS was published in 1999 after a 
workshop in Sapporo, Japan(Wilson WA 1999)-the so-called Sapporo criteria-. It was 




1. Vascular thrombosis 
One or more clinical episodes of arterial,venous or small vessel thrombosis, in any tissue 
or organ. 
2. Pregnancy morbidity 
a. One or more unexplained deaths of a morphologically normal fetus at or beyond 
the 10th week of gestation, or 
b. One or more premature births of a morphologically normal neonate before the 
34th week of gestation because of eclampsia, severe preeclampsia, or recognized 
features of placental insufficiency, or 
c. Three or more unexplained consecutive spontaneous abortions before the 10th 
week of gestation, with maternal anatomic or hormonal abnormalities and 
paternal and maternal chromosomal causes excluded. 
Laboratory criteria 
 
1. Lupus anticoagulant present in plasma, on 2 or more occasions at least 12 weeks 
apart, detected according to the guidelines of the International Society on 
Thrombosis and Hemostasis 
2. Anticardiolipin antibody of IgG and/or IgM isotype in serum or plasma, present in 
medium or high titer(ie, >40 GPL or MPL, or greater than the 99th percentile),on 2 or 
more occasions at least 12 week apart, measured by a standardized ELISA. 
3. Anti-β2-glycoprotein I antibody of IgG and/or IgM isotype in serum or plasma(in 
titer greater than the 99th percentile) present one or more occasions, at least 12 week 
apart, measured by a standardized ELISA. 
***Definite APLS is present if at least one of the clinical criteria and one of the laboratory criteria are 
met. Classification of APLS should be avoided if less than 12 weeks or more than 5 years seperate the 
positive APL test and the clinical manifestation. 
Table 1. Updated Sapporo classification criteria for the antiphospholipid syndrome 
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The first clinical aspect of the APLS is thrombosis, which can affect arterial or venous 
vessels, as well as small vessels, and must be confirmed by means of imaging studies 
and/or histopathology. Arterial thrombosis mainly occurs in the central nervous system. 
But all arteries can be effected and myocardial infarction, peripheral gangrene, aseptic 
osteonecrosis and adrenal insufficency can develop with respect to effected arterial site. The 
venous thrombosis commonly localizes to the deep veins of the limbs and can be 
complicated by pulmonary embolism. As in arterial thrombosis, any segment of the venous 
vasculature can be effected, which will induce different manifestations. 
A definitive diagnosis of APLS is based on fulfilling at least one of the Updated Sapporo 
Clinical criteria(vascular thrombotic event or pregnancy morbidity) and at least one of the 
laboratory criteria(Table 1). In general, medium titer aCL is considered 40 U or more and 
high titer, more than 80 U; titers between 20 and 40 U should be evaluated cautiously. 
Transient APL positivity is common during infections; thus documentation of the 
persistence(at least 12 weeks apart) of autoimmune APL is crucial for both diagnostic and 
therapeutic purposes.  
The choice of initial APL tests remains a subject of debate. In general, the LA test is more 
specific for APL-related clinical events. The specificity of aCL for APL-related clinical events 
increases with higher titers. The IgG isotype is more strongly associated with APL-related 
clinical events than the IgM isotype. In a patient with suspected APS, testing for LA and 
IgG/IgM aCL should be ordered initially. If these tests are negative or low-titer and there is 
still a high level of suspicion for APS, then testing for antiβ2GPI antibodies and IgA 
aCL/antiβ2GPI can be pursued(George D 2009). Antiphospholipid antibody tests developed 
based on other phospholipids such as phosphatidylserine, phosphatidylinositol, or 
phosphatidylethanolamine or phospholipid-binding plasma proteins(such as prothrombin) 
are not yet well standardized and accepted. 
5. Clinical features 
Although any vasculature can be affected by thrombosis, stroke and transient ischemic 
attack are the most common presentations of arterial thrombosis, whereas deep vein 
thrombosis with or without pulmonary embolism is the most common presentation of 
venous thrombosis in APLS(George D 2009). Antiphospholipid antibodies can cause both 
arterial and venous thrombosis in the same patient. Reccurent thromboses tend to occur in 
the same vascular distribution(venous followed by venous and arterial followed by arterial). 
in some studies the incidence of venous thrombosis (70%) is greater than the incidence of 
arterial thrombosis.(Galli M 1997, Triplett DA 1995). 
Superficial thrombophlebitis, superior vena cava syndrome, renal vein thrombosis, Budd 
Chiari syndrome, central retinal vein occlusion, pulmonary hypertension due to recurrent 
pulmonary embolism, and diffuse pulmonary hemorrhage due to microthrombosis are 
some of the thrombotic manifestations of APLS. 
Of unselected patients with antiphospholipid antibody, 1% to 2.5% per year will develop 
thromboembolism(Galli M 2003, Finazzi G 1996),and 10% to 25% of patients with deep 
venous thrombosis will be found to have antiphospholipid antibodies(Ginsburg KS 
1992).However, in a prospective population based study of 66140 individuals in 
Norway(Naess IA 2005), elevated anticardiolipin antibody levels were not a risk factor for 
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time of their events(Kaul M 2006, Erkan D 2002). 
Both persons congenitally lacking ß2GPI39 and ß2GPI knockout mice appear normal(Sheng 
Y 2001).  ß2GPI polymorphisms influence the generation of aPLs in individuals, but they 
have only a weak relationship to the occurrence of APLS. A cluster of 50 upregulated genes 
may have an effect on the occurrence of thrombosis in aPL-positive individuals(Potti A 
2006). 
4. Diagnostic criteria of the antiphospholipid syndrome 
The international preliminary classification criteria for APLS was published in 1999 after a 
workshop in Sapporo, Japan(Wilson WA 1999)-the so-called Sapporo criteria-. It was 




1. Vascular thrombosis 
One or more clinical episodes of arterial,venous or small vessel thrombosis, in any tissue 
or organ. 
2. Pregnancy morbidity 
a. One or more unexplained deaths of a morphologically normal fetus at or beyond 
the 10th week of gestation, or 
b. One or more premature births of a morphologically normal neonate before the 
34th week of gestation because of eclampsia, severe preeclampsia, or recognized 
features of placental insufficiency, or 
c. Three or more unexplained consecutive spontaneous abortions before the 10th 
week of gestation, with maternal anatomic or hormonal abnormalities and 
paternal and maternal chromosomal causes excluded. 
Laboratory criteria 
 
1. Lupus anticoagulant present in plasma, on 2 or more occasions at least 12 weeks 
apart, detected according to the guidelines of the International Society on 
Thrombosis and Hemostasis 
2. Anticardiolipin antibody of IgG and/or IgM isotype in serum or plasma, present in 
medium or high titer(ie, >40 GPL or MPL, or greater than the 99th percentile),on 2 or 
more occasions at least 12 week apart, measured by a standardized ELISA. 
3. Anti-β2-glycoprotein I antibody of IgG and/or IgM isotype in serum or plasma(in 
titer greater than the 99th percentile) present one or more occasions, at least 12 week 
apart, measured by a standardized ELISA. 
***Definite APLS is present if at least one of the clinical criteria and one of the laboratory criteria are 
met. Classification of APLS should be avoided if less than 12 weeks or more than 5 years seperate the 
positive APL test and the clinical manifestation. 
Table 1. Updated Sapporo classification criteria for the antiphospholipid syndrome 
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The first clinical aspect of the APLS is thrombosis, which can affect arterial or venous 
vessels, as well as small vessels, and must be confirmed by means of imaging studies 
and/or histopathology. Arterial thrombosis mainly occurs in the central nervous system. 
But all arteries can be effected and myocardial infarction, peripheral gangrene, aseptic 
osteonecrosis and adrenal insufficency can develop with respect to effected arterial site. The 
venous thrombosis commonly localizes to the deep veins of the limbs and can be 
complicated by pulmonary embolism. As in arterial thrombosis, any segment of the venous 
vasculature can be effected, which will induce different manifestations. 
A definitive diagnosis of APLS is based on fulfilling at least one of the Updated Sapporo 
Clinical criteria(vascular thrombotic event or pregnancy morbidity) and at least one of the 
laboratory criteria(Table 1). In general, medium titer aCL is considered 40 U or more and 
high titer, more than 80 U; titers between 20 and 40 U should be evaluated cautiously. 
Transient APL positivity is common during infections; thus documentation of the 
persistence(at least 12 weeks apart) of autoimmune APL is crucial for both diagnostic and 
therapeutic purposes.  
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specific for APL-related clinical events. The specificity of aCL for APL-related clinical events 
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based on other phospholipids such as phosphatidylserine, phosphatidylinositol, or 
phosphatidylethanolamine or phospholipid-binding plasma proteins(such as prothrombin) 
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some of the thrombotic manifestations of APLS. 
Of unselected patients with antiphospholipid antibody, 1% to 2.5% per year will develop 
thromboembolism(Galli M 2003, Finazzi G 1996),and 10% to 25% of patients with deep 
venous thrombosis will be found to have antiphospholipid antibodies(Ginsburg KS 
1992).However, in a prospective population based study of 66140 individuals in 
Norway(Naess IA 2005), elevated anticardiolipin antibody levels were not a risk factor for 
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predicting an initial venous thrombosis. Thrombosis is more frequent as the level of 
anticardiolipin antibody increases, and medium and high titers (>40 GPL and/or MPL 
units) are more frequently associated with thrombotic events. Although some investigators 
believe that elevated levels of IgG or IgA isotypes are more common than IgM in patients 
with thrombotic complications, this has not been clearly established. The lupus 
anticoagulant or increased levels of anticardiolipin antibody must be persistently present on 
more than one occasion at least 12 weeks apart because the incidence of thrombotic 
complications is almost the same in patients with transiently positive tests as in patients 
with negative tests at two different time intervals. The persistent presence of elevated levels 
of anticardiolipin antibody has been shown to be associated with indices of in-vivo 
coagulation activation. In a study of patients with SLE(Ginsberg JS 1993) who were 
persistently anticardiolipin antibody– positive versus patients who were transiently positive 
or persistently negative, anticardiolipin antibody–positive patients had a higher mean level 
of F1+2 and fibrinopeptide A than patients who were transiently positive, persistently 
negative, or on warfarin therapy. The differences remained significant even if patients with 
prior thromboembolism were excluded from the analysis. These results suggest that the 
presence of persistently elevated levels of anticardiolipin antibody in SLE patients is 
associated with an ongoing prothrombotic state. 
Patients who are persistently positive for the lupus anticoagulant or who have persistently 
elevated levels of anticardiolipin antibody and suffer a thromboembolic event have a 
recurrence rate of approximately 50% within 2 years(Rosove MH 1992, Khamashta MA 
1995). Recurrences tend to occur in most of the patients on the same side of the circulation as 
the initial event—venous recurrences after an initial venous event and arterial recurrences 
after an initial arterial event. 
6. Treatment of venous thrombosis in APLS  
6.1 General treatment 
The standard of care for venous thromboembolism is continous infusion of intravenously 
delivered unfractionated heparin(UFH) and, more recently, subcutaneous low-molecular 
weight heparins(LMWH). DVT is associated with several possible complications, including 
recurrent nonfatal venous thromboembolism, postthrombotic chronic venous insufficiency, 
and nonfatal/fatal pulmonary embolism. The goals of therapy for DVT include the 
prevention of thrombus propagation, embolization, and early and late thrombus recurrence. 
Proper anticoagulation is the first critical step in the effective treatment of DVT. 
Complications can develop soon after thrombus detection, presenting a narrow window of 
opportunity for a safe and effective intervention. The secondary stage of treatment involves 
the maintenance of adequate anticoagulation to prevent the development of recurrent 
thromboembolism. 
LMWH or fondaparinux is preferred for the initial anticoagulation of patients with deep 
vein thrombosis(Table 2). LMWH and fondaparinux are as safe and as effective as 
continuous unfractionated heparin (UFH). Suitable patients can be safely treated with 
LMWH and fondaparinux in the outpatient setting. Heparin/fondaparinux should be 
continued for at least five days after the initiation of warfarin therapy and until 
International Normalized Ratio (INR) is > 2.0 for two consecutive days. Warfarin should be 
initiated 5 mg on day 1. 
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Treatment for venous thromboembolism with LMWH provides reliable anticoagulation 
levels when given subcutaneously on a weight-based dosing schedule. No laboratory 
monitoring of the intensity of anticoagulation is required for LMWH, except in special 
circumstances. Recent randomized controlled trials of the treatment of pulmonary 
embolism (PE) have shown LMWH to be as effective and safe as UFH. One randomized 
controlled trial of the treatment of venous thromboembolism (VTE) in 1,021 patients 
included 271 patients presenting with PE. In this study, there were no significant 
differences in outcomes following  treatment with UFH versus LMWH. These studies 
used reviparin and tinzaparin. Two reviews agreed that LMWH may be efficacious in the 
treatment of PE, but cautioned that the LMWH products may not be equivalent to each 
other (Raskob 1999 ; Charland, 1998; Columbus Investigators, 1997; Simonneau, 1997). 
LMWH may not be appropriate for patients with renal insufficiency (creatinine clearance 
less than 30 mL/min). Studies have shown modestly delayed clearance in patients with 
chronic renal failure. The clinician should weigh this evidence when considering outpatient 
therapy. 
A high-loading dose of warfarin (greater than 10 mg) is of no clinical use and should be 
discouraged.  A 10 mg initial dose of warfarin has been associated with early over-
anticoagulation and, when compared to a 5 mg initial dose, was no more effective in 
achieving a therapeutic international normalized ratio (INR) by day four or five of therapy. 
A therapeutic range of anticoagulation to keep the INR at 2.5 (range 2.0-3.0) is 
recommended for patients with venous thromboembolism. Heparin and warfarin may be 
started at the same time. The anticoagulant effect of warfarin is delayed until clotting factors 
already circulating are cleared. Although Factor VII has a shorter half-life in the blood (six to 
seven hours), peak anticoagulant activity is delayed for up to 96 hours until factors with 
longer plasma half-lives (II, IX and X) have cleared . Heparin (UFH or LMWH) and warfarin 
may be started at the same time. Heparin (UFH or LMWH) and/or fondaparinux should be 
given for a minimum of five days. Patient should continue heparin until INR >=2.0 for two 
consecutive days. In patients with suspected hypercoagulable state (Protein C or Protein S 
deficiency), the patient should be adequately anticoagulated with heparin (UFH or LMWH) 
and/or fondaparinux before warfarin is started at a low dose (2-5 mg). This is to avoid 
warfarin-induced skin necrosis or other transient hypercoagulable complications. 
Recommendations for the management of thrombosis in the APLS have been based largely 
on retrospective case series. Recently, several clinical trials have been published on the 
management of thrombosis in APLS.These new clinical trials have challenged the previous 
dogma of a target INR of 3 to 4(high-intensity warfarin). 
6.2 Primary prophylaxis of thrombosis in patients with APL antibodies 
The therapeutic approach in asymptomatic carriers of APL without prior thrombotic 
events is still controversial. Present evidence-based knowledge does not support the 
widespread use of aspirin in all these aPL-positive patients. Annual thrombosis risk in 
asymptomatic APL-positive patients range from 0% to 3.8%( Finazzi G 1996, Shah NM 
1998), being equivalent to that of major bleeding associated with the use of aspirin. The 
only randomized clinical trial (APLASA study) in which 98 asymptomatic persistently 
APL-positive individuals were randomized to recieve a daily dose of 81 mg of aspirin or 
placebo showed that these patients have a low overall annual incidence rate of acute 
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Complications can develop soon after thrombus detection, presenting a narrow window of 
opportunity for a safe and effective intervention. The secondary stage of treatment involves 
the maintenance of adequate anticoagulation to prevent the development of recurrent 
thromboembolism. 
LMWH or fondaparinux is preferred for the initial anticoagulation of patients with deep 
vein thrombosis(Table 2). LMWH and fondaparinux are as safe and as effective as 
continuous unfractionated heparin (UFH). Suitable patients can be safely treated with 
LMWH and fondaparinux in the outpatient setting. Heparin/fondaparinux should be 
continued for at least five days after the initiation of warfarin therapy and until 
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placebo showed that these patients have a low overall annual incidence rate of acute 
 
Venous Thrombosis – Principles and Practice 
 
62
thrombosis, and develop vascular events when additional risk factors are present(Erkan D 
2007). Therefore, according to the results of this trial, asymptomatic, persistently APL-
positive individuals seem not to benefit from low-dose aspirin for primary 
thromboprophylaxis.  
However, a more realistic approach with a lower degree of evidence  would be to stratify 
these individuals according to some clinical features such as the presence of traditional 
congenital or acquired procoagulant risk factors, the APL profile(persistently positive aCL 
and or anti-β2GPI antibodies at moderate/high titers), and the coexistence of an 
underlying autoimmune disease, to consider primary prophylactic therapy with low-dose 
75-100 mg aspirin daily. It is known that SLE represents a prothrombotic condition and 
acts as strong thrombophilic risk factor, primarily related to the chronic systemic 
inflammation and renal involvement. Furthermore, one study has shown that 
prophylactic aspirin should be given to all patients with SLE to prevent both arterial and 
venous thrombotic manifestations, especially in patients with APL(Wahl DG 2000). In the 
same study, the authors suggested that in selected patients with LA and a low bleeding 
risk, prophylactic oral anticoagulant therapy may provide higher utility. Therefore, there 
is currently consensus for primary thromboprophylaxis in these patients, mainly with 
low-dose aspirin. 
An alternative to aspirin in SLE patients may be hydroxychloroquine. There are many 
evidences for the protective role of this old drug against the development of both venous 
and arterial thrombosis(Ruiz-Irastorza G 2006, Erkan D 2002). 
All nonthrombotic APL-positive subjects should be encouraged to stop smoking. Cessation 
of  oestrogen –containg oral contraceptive use and treatment of other vascular risk factors if 
present are additional recommended therapeutic measures. 
At least half of patients with APLS with vascular events also have another reversible risk 
factors which are not related to APLS at time of thrombosis(Erkan D 2002). Therefore, 
identification and elimination of these risk factors and agressive prophylaxis during high-
risk periods, are crucial for the primary thrombosis prevention in asymptomatic persistently 
APL-positive individuals. Serious perioperative complications including catastrophic 
antiphospholipid syndrome(CAPS) may occur despite prophylaxis in APL-positive 
individuals as they are at additional risk for thrombosis when undergoing surgical 
procedures. Therefore, perioperative strategies should be clearly identified before any 
surgical procedure, pharmacological, and physical antithrombosis interventions should be 
vigorously used; periods without anticoagulation should be kept to an absolute 
minimum(George D 2009). 
6.3 Therapy for acute thrombosis and secondary propylaxis of thrombosis in patients 
with antiphospholipid syndrome 
Therapy for thrombosis associated with the  APLS should be guided by the knowledge that 
recurrence is common. In one study, patients who had discontinued oral anticoagulation 
had a 50% probability of recurrence in 2 years and a 78% recurrence in 8 years(Derksen 
RHWM 1993). Similar results have been published by others with a recurrence rate of 10% 
to 30% per year(Galli M 2003, Rosove MH 1992, Khamashta MA 1995). Three prospective 
studies reported that there was an increased risk of recurrence that varied from 10% to 
67% per year(Lim W 2006, Schulman S 1998, Kearon C 1999, Kearon C 2003, Ortel TL 
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2005). In most reports the incidence of recurrence is highest in the first 6 months after 
discontinuing anticoagulant therapy.  Although it was initially thought that prevention of 
venous recurrence required high-intensity warfarin with a target INR of 3.5, evidence has 
been accumulating from recent studies that standard intensity warfarin (INR 2 to 3) can 
almost completely abrogate recurrence of venous thromboembolic disease(Crowther MA 
2003, Finazzi G 2005). The pooled data from these two studies revealed no difference in 
recurrent thrombosis between moderate-intensity warfarin (INR 2 to 3) and high-intensity 
(INR 3 to 4), nor was there a greater bleeding risk. As the data from several studies have 
demonstrated that patients with antiphospholipid syndrome have a high risk for 
recurrent venous thromboembolic disease after anticoagulation is discontinued, many feel 
that anticoagulation should be continued indefinitely. The American College of Chest 
Physicians recommends treatment for 12 months and consideration of indefinite therapy 
after an initial event(Ortel TL 2005, Buller HR 2004). Because of the efficacy of warfarin 
therapy in preventing recurrences, the use of corticosteroids and other 
immunosuppressive agents to suppress antibody production in the absence of 
autoimmune disease is not recommended.  
 
- Objectively confirm DVT; provide short-term treatment with SC LMWH or IV UFH 
or SC UFH(1A) 
- High clinical suspicion for DVT: treat until diagnosis is confirmed(1C) 
- Initial treatment LMWH or UFH for ≥5 days 
- Warfarin should be started on the first day of treatment  
- IV UFH by weight based or standard dosing to achieve and maintain an aPTT 
prolongation that corresponds to plasma heparin levels of 0.3 to 0.7 IU/mL anti-Xa 
activity(1C) 
- UFH with large doses:measure anti-Xa to adjust dose(1B) 
- SC UFH at a dose of 17500 U,SC, Q 12 hours or 250 U/kg, sc, Q 12 hours with 
adjustment to achieve a therapeutic aPTT(1C). 
- SC fixed dose UFH at a dose of 333 U/kg, sc, Q 12 hours without monitoring for 
adjustment of dose(1C). 
- SC LMWH once or twice daily over UFH as an outpatient if possible(1C) or as an 
inpatient(1A). 
- Reccomend against monitoring with anti-Xa levels(1A). 
- Severe renal failure: suggest IV UFH over LMWH(2C). 
Table 2. Venous thromboembolism(VTE) treatment guidelines adapted from the American 
College of Chest Physicians  Evidence –based clinical practice guidelines-8th edition 
Monitoring anticoagulant therapy may be difficult in patients with lupus anticoagulants and 
a prolonged PTT. It is mandatory when using unfractionated heparin to monitor therapy 
using a specific heparin assay, such as the one dependent on factor Xa inhibition 
(therapeutic range, 0.3 to 0.7). In most instances, it is preferable to use low-molecular-weight 
heparin in therapeutic doses, which usually eliminates the need for monitoring. When using 
warfarin, the optimal INR for patients with lupus anticoagulants is controversial, because 
patients with lupus anticoagulants may have a variably prolonged prothrombin time,and 
various thromboplastins have a different sensitivity in the presence of a lupus 
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is currently consensus for primary thromboprophylaxis in these patients, mainly with 
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2005). In most reports the incidence of recurrence is highest in the first 6 months after 
discontinuing anticoagulant therapy.  Although it was initially thought that prevention of 
venous recurrence required high-intensity warfarin with a target INR of 3.5, evidence has 
been accumulating from recent studies that standard intensity warfarin (INR 2 to 3) can 
almost completely abrogate recurrence of venous thromboembolic disease(Crowther MA 
2003, Finazzi G 2005). The pooled data from these two studies revealed no difference in 
recurrent thrombosis between moderate-intensity warfarin (INR 2 to 3) and high-intensity 
(INR 3 to 4), nor was there a greater bleeding risk. As the data from several studies have 
demonstrated that patients with antiphospholipid syndrome have a high risk for 
recurrent venous thromboembolic disease after anticoagulation is discontinued, many feel 
that anticoagulation should be continued indefinitely. The American College of Chest 
Physicians recommends treatment for 12 months and consideration of indefinite therapy 
after an initial event(Ortel TL 2005, Buller HR 2004). Because of the efficacy of warfarin 
therapy in preventing recurrences, the use of corticosteroids and other 
immunosuppressive agents to suppress antibody production in the absence of 
autoimmune disease is not recommended.  
 
- Objectively confirm DVT; provide short-term treatment with SC LMWH or IV UFH 
or SC UFH(1A) 
- High clinical suspicion for DVT: treat until diagnosis is confirmed(1C) 
- Initial treatment LMWH or UFH for ≥5 days 
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inpatient(1A). 
- Reccomend against monitoring with anti-Xa levels(1A). 
- Severe renal failure: suggest IV UFH over LMWH(2C). 
Table 2. Venous thromboembolism(VTE) treatment guidelines adapted from the American 
College of Chest Physicians  Evidence –based clinical practice guidelines-8th edition 
Monitoring anticoagulant therapy may be difficult in patients with lupus anticoagulants and 
a prolonged PTT. It is mandatory when using unfractionated heparin to monitor therapy 
using a specific heparin assay, such as the one dependent on factor Xa inhibition 
(therapeutic range, 0.3 to 0.7). In most instances, it is preferable to use low-molecular-weight 
heparin in therapeutic doses, which usually eliminates the need for monitoring. When using 
warfarin, the optimal INR for patients with lupus anticoagulants is controversial, because 
patients with lupus anticoagulants may have a variably prolonged prothrombin time,and 
various thromboplastins have a different sensitivity in the presence of a lupus 
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anticoagulant.Therefore, it is possible that in various studies of therapy in patients with 
lupus anticoagulants that the degree of anticoagulation is overestimated, and the target INR 
of 3.0 noted earlier might be an overestimate because of the presence of the lupus 
anticoagulant(Donald I. Feinstein 2007). Rarely, patients may continue to have recurrent 
venous thromboembolic events despite INR values in the therapeutic range. Recurrent 
thrombotic events despite therapeutic anticoagulation require evaluation and modification 
of all non-APL thrombosis risk factors. Warfarin therapy is generally increased to high-
intensity(INR, 3.0-4.0). Other options include adding low-dose aspirin, hydroxychloroquine, 
and/or statins to warfarin or switching to low-molecular weight heparin. There are no 
randomized controlled studies investigating the effectiveness of any of these approaches. 
Based on many cohort studies ,subgroup analysis and two randomized controlled studies, a 
recent review(Ruiz-Irastorza G  2007) suggests that patients with definite APLS with a first 
venous thrombosis should be treated with prolonged oral anticoagulation at a target INR of 
2.0-3.0 and those with an arterial event at an 3.0-4.0.  
So, the best secondary thromboprophylaxis in patients with definite APLS  is long-term 
anticoagulation at a target INR of 2.0-3.0. Patients with recurrent venous thrombotic events 
despite optimal anticoagulation should be treated with warfarin at an INR of 3.0-4.0. 
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Deep Venous Thrombosis in  
Children with Musculoskeletal Infection 
Lawson A. B. Copley and Ngozi Okoro 
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USA 
1. Introduction 
Deep venous thrombosis (DVT) is rarely identified in children. However, there has been an 
increase in the reported association of DVT with pediatric musculoskeletal infection.1-13 The 
relationship appears to be tied to the rise of community-acquired, Methicillin-resistant 
Staphylococcus aureus (CA-MRSA).5-13 Children who are affected by musculoskeletal infection 
and deep venous thrombosis appear to share similar clinical features. They often require 
intensive care, surgical intervention, and prolonged hospitalization.5,6,9 Pulmonary 
involvement, including pneumonia and septic pulmonary emboli, is frequent.9,11 It is 
possible that the causative organisms have an underlying genetic makeup, such as Panton 
Valentine leukocidin, that potentiates the cascade of clinical features seen in these 
children.6,8,10 This chapter explores the relationship of DVT and pediatric musculoskeletal 
infection through meta-analysis of the medical literature from the past forty years. To the 
extent possible, risk factors and clinical characteristics are evaluated and evaluation and 
treatment strategies are discussed. 
2. Review of literature 
The earliest case report of DVT associated with osteomyelitis was by Horvath et al. in 1971.14 
Including that original case, 58 cases of pediatric DVT associated with musculoskeletal 
infection have surfaced in the medical literature (see table 1).1-19 A decade by decade review 
of the case occurrence reveals an exponential increase in the number of cases reported since 
2000, during which time 51 new cases have been identified. This is compared to one case 
from the 1970s and 3 cases from each decade of the 1980s and 1990s. The largest series, to the 
present, was reported at a single institution, Children’s Medical Center of Dallas, compiled 
from two separate reports with overlapping study periods and included 15 unique cases of 
children with DVT.5,9  Of the four studies that report the incidence of DVT within a series of 
children with musculoskeletal infection, the total number of children with DVT is 32 among 
a total of 430 children reviewed giving an estimated incidence of DVT associated with 
musculoskeletal infection of 7.4%.3,6,8,9 
3. Gender, age, type, and site of infection  
Several trends can be derived from the reported cases in a descriptive manner. Children 
with DVT were noted to be male 34 times out of the 46 cases in which gender was identified 
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Source Year Series DVT Age (y) Sex Type Location Organism DVT Site Pulmonary Findings Features 
Horvath14 1971  1 9 m Osteo. R proximal 
tibia 
MSSA R femoral; popliteal L lower lobe 
infiltrate 
 
Jupiter15 1982  2 12 m Osteo. L humerus MSSA L arm deep Multiple 
infiltrates 
 
    12 f Osteo. L femur,  
R tibia 
MSSA L femoral; popliteal Diffuse infiltrates  
Muhlendahl16 1988  1 12 f Osteo. R distal 
femur 
MSSA R femoral Multiple lung 
emboli 
 
Smith17 1997  2 4 f Osteo. L femur S aureus IVC and femoral Pneumatoceles Death 
    2.5 f Osteo. L ilium S aureus IVC and common iliac Pneumonia  
Letts18 1999  1 11.5 m Osteo. Sacrum MSSA R popliteal; R femoral; 
R atrium 
R middle lobe SPE 
Gorenstein19 2000  3 11 m Osteo. L proximal 
femur 
MSSA L femoral Pneumatoceles Death 
    10 m Osteo. L femoral 
head 
MSSA L femoral Pneumonia, 
empyema 
PneumoT. 
    10 m Osteo. L femoral 
neck 
S aureus L iliac Multiple 
infiltrates 
 
Walsh2 2002  4 11 m Osteo. L distal 
fibula 
MSSA L femoral; popliteal Bil. patchy 
infiltrates 
ICU 
    4 f Osteo. L femur,  
R tibia 
S aureus IVC; L common 
femoral 
patchy infiltrates Death 
    2.5 f Osteo. L ilium S aureus IVC; common iliac Pneumonia ICU 
    6 f Pyom. L soleus GABHS L popliteal; peroneal Unknown Comp. sy. 
Newgard1 2002  1 12 m Osteo. Sacroiliac MSSA R common iliac SPE  
Martinez-
Aguilar3 
2004 59 5 U U Osteo. Unkown MRSA Unkown Unknown PVL 
    U U Osteo. Unkown MRSA Unkown Unknown PVL 
    U U Osteo. Unkown MRSA Unkown Unknown PVL 
    U U Osteo. Unkown MRSA Unkown Unknown PVL 
    U U Osteo. Unkown MSSA Unkown Unknown PVL 
Yuksel4 2004  1 3 m Osteo. R distal 
fibula 
S aureus R external iliac Bil. Densities; 
cavities 
 
Gonzalez6 2006 116 9 12 m Osteo. R ilium MSSA R deep pelvic Clear  
    3 m Osteo. R femur MRSA R common femoral; 
external iliac 
Clear PVL 
    3 m Osteo. R tibia MSSA R femoral; popliteal Clear  
    10 m Osteo. L ischium, 
pubis  
& ilium 
MRSA L common iliac Bilateral infiltrates PVL; CVC 
    14 m Osteo. R femur  
and tibia 
MRSA R femoral; popliteal SPE PVL; CVC 
    13 m Osteo. L femur  
and tibia 
MRSA L saphenous Pleural effusions PVL; CVC 
    14 m Osteo. L tibia MRSA L popliteal; saphenous SPE PVL 
    11 m Osteo. L femur MRSA L femoral vein SPE PVL; CVC 
    14 m Osteo. R femur MRSA R common femoral; 
popliteal 
SPE PVL; CVC 
Crary5; 
Hollmig9 
2006/7 352 15 13 m Osteo. R distal 
femur 
MRSA SVC Clear CVC 
    13 m Osteo. R proximal 
fibula 
MRSA R femoral; popliteal Clear CVC 
    9 m Osteo. R proximal 
tibia 
MRSA R femoral; popliteal SPE CVC 
    11 f Osteo. L distal 
femur 
MRSA L femoral; popliteal SPE CVC 
    12 m Osteo. R proximal 
tibia 
MRSA SVC; L internal jugular; 
subclavian 
Clear CVC 





    13 m Osteo. R distal 
femur 
MSSA R femoral; popliteal Unknown CVC 
    7 m Osteo. Thoracic 
spine 
MRSA Azygous; IVC SPE CVC 
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Source Year Series DVT Age (y) Sex Type Location Organism DVT Site Pulmonary Findings Features 
    10 m Osteo. R proximal 
femur 
MRSA R femoral SPE CVC 
    2 m Osteo. R proximal 
tibia 
MRSA R femoral; external 
iliac; saphenous 
SPE CVC 
    14 m Osteo. L distal 
femur 
MSSA L popliteal SPE CVC 
    4 m Osteo. L proximal 
tibia 
C. Tropicalis L popliteal Unknown CVC 
    6 f Osteo. L distal tibia, 
L distal 
femur 
MRSA IVC and SVC Unknown CVC 
    8 f Pyom. L calf Strep. MilleriL posterior tibial Clear  
    6 f Sep. 
Art. 
L hip GABHS R IJ; Sigmoid; 
transverse sinues 
Clear  
Castaldo7 2007  1 U U Sep. 
Art. 
Hip MRSA Unkown Necrotizing 
pneumonia 
 
Dohin8 2007 39 3 U U U Unknown S aureus Unkown Unknown PVL 
    U U U Unknown S aureus Unkown Unknown PVL 
    U U U Unknown S aureus Unkown Unknown PVL 
Mitchell10 2007  3 9 m Osteo. R proximal 
femur 
MSSA L femoral; bilateral IJs; 
R brachial 
Unknown ICU; PVL  
    9 m Osteo. R proximal 
femur 
S aureus R femoral Bilateral infiltrates ICU; PVL  
    13 m Osteo. R femur  
and tibia 
S aureus Unkown SPE PVL 
Nourse11 2007  2 1 m Osteo. L femur MRSA L superficial/common 
femoral; iliac 
SPE PVL 
    13 m Osteo. L proximal 
femur 
MRSA L superficial/common 
femoral 
SPE PVL 
Gite12 2008  3 8 U Osteo. R femur No growth Unkown Unknown  
    6 U Osteo. L femur EnterococcusUnkown Unknown  
    13 U Osteo. L femur S aureus Unkown Unknown  
McDonald13 2010  1 5 m Osteo. R proximal 
humerus 
MRSA R subclavian; brachial; 
cephalic 
SPE ICU 
DVT-Deep vein thrombosis; y-years; m-Male; f-Female; U-Unknown; Osteo.-Osteomyelitis; R-Right; L-
Left; MSSA-Methicillin Senstive Staph Aureus; Bil.-Bilateral; 
MRSA-Methicillin Resistant Staph Aureus; S-staphyloccocus; GABHS-Group A beta hemolytic 
streptoccocci; IVC-Inferior vena cava; SVC-Superior vena cava; 
SPE-Septic pulmonary emboli; PneumoT-Pneumothorax; ICU-Intensive care unit; Comp. sy.-
Compartment syndrome; PVL-Panton-Valentine Leukocidin; C. Candida;  
CVC-Central venous catheters; Sep. Art.- Septic Arthritis; Strep.- Streptoccocus; IJ-Internal jugular 
Table 1. Summary of Published Cases of DVT in Patients with Musculoskeletal Infection 
(73.9%).1-19  The average age of the children with DVT in the reviewed studies was 9 years with 
only six children under the age of 4 years among the 49 children with a recorded age (12.2%).1-
19  The type of infection was found to be osteomyelitis in 51 out of the 55 cases (92.7%) in which 
the musculoskeletal infection type was delineated. 1-19 However, two cases of septic arthritis 
and two cases of pyomyositis were also noted.2,7,9 The location of the infection was reported in 
46 out of the 54 children with osteomyelitis and noted to be unifocal in 40 children and 
multifocal in the remaining six (see table 2). The site of osteomyelitis was most commonly 
reported in the femur (26 occurrences), and specifically reported in the proximal femur on 7 
occasions and the distal femur on 6 occasions. The tibia was the second most common location 
of osteomyelitis (13 occurrences) with the proximal tibia specified in 5 cases and the distal tibia 
specified in one case. Overall, the location of the musculoskeletal infection was found to be in 
the pelvis (ilium, ischium, pubis, or sacrum) or lower extremities in 48 out of the 51 cases in 
which the site of infection was reported (94.1%), with the three remaining cases identified in 
the upper extremities (humerus in two children) and thoracic spine.  
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Horvath14 1971  1 9 m Osteo. R proximal 
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Source Year Series DVT Age (y) Sex Type Location Organism DVT Site Pulmonary Findings Features 
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Gite12 2008  3 8 U Osteo. R femur No growth Unkown Unknown  
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DVT-Deep vein thrombosis; y-years; m-Male; f-Female; U-Unknown; Osteo.-Osteomyelitis; R-Right; L-
Left; MSSA-Methicillin Senstive Staph Aureus; Bil.-Bilateral; 
MRSA-Methicillin Resistant Staph Aureus; S-staphyloccocus; GABHS-Group A beta hemolytic 
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Table 1. Summary of Published Cases of DVT in Patients with Musculoskeletal Infection 
(73.9%).1-19  The average age of the children with DVT in the reviewed studies was 9 years with 
only six children under the age of 4 years among the 49 children with a recorded age (12.2%).1-
19  The type of infection was found to be osteomyelitis in 51 out of the 55 cases (92.7%) in which 
the musculoskeletal infection type was delineated. 1-19 However, two cases of septic arthritis 
and two cases of pyomyositis were also noted.2,7,9 The location of the infection was reported in 
46 out of the 54 children with osteomyelitis and noted to be unifocal in 40 children and 
multifocal in the remaining six (see table 2). The site of osteomyelitis was most commonly 
reported in the femur (26 occurrences), and specifically reported in the proximal femur on 7 
occasions and the distal femur on 6 occasions. The tibia was the second most common location 
of osteomyelitis (13 occurrences) with the proximal tibia specified in 5 cases and the distal tibia 
specified in one case. Overall, the location of the musculoskeletal infection was found to be in 
the pelvis (ilium, ischium, pubis, or sacrum) or lower extremities in 48 out of the 51 cases in 
which the site of infection was reported (94.1%), with the three remaining cases identified in 
the upper extremities (humerus in two children) and thoracic spine.  
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Location Recorded occurrence Percent 
Thoracic spine 1 2% 
Pelvis 
Ilium 5 9% 
Ischium 1 2% 
Pubis 1 2% 
Sacrum 3 6% 
Total 10 
Femur Unspecified 13 25% 
Proximal 7 13% 
Distal 6 11% 
Total 26 
Tibia Unspecified 7 13% 
Proximal 5 9% 
Distal 1 2% 
Total 13 
Fibula 
Proximal 1 2% 
Distal 2 4% 
Total 3 
Total 53 100% 
Multifocal 6 12% 
Table 2. Frequency Distribution of Osteomyelitis Site 
4. Causative organism 
Staphylococcus aureus was found to be the causative organism in 38 of 43 culture positive 
cases (88.4%) and, of those isolates, 18 (47.4%) were identified as Methicillin-resistant 
Staphylococcus aureus. In one series, the rise in recognition of DVT in their practice appeared 
to coincide with the establishment of USA 300 ST8 as the predominant clone of CA-MRSA in 
their community.6   
5. Panton-Valentine leukocidin 
The identification of Panton-Valentine leukocidin (PVL) genes in the isolates of 
Staphylococcus aureus in children with DVT has been reported in several studies.3,6,8,10,11  
These reports suggest that PVL may be associated with enhanced inflammatory response in 
cases of musculoskeletal infection including pneumonia, multifocal osteomyelitis, 
bacteremia, and concurrent pyomyositis, subperiosteal abscesses or intra-osseous abscesses 
requiring surgical debridment.3,6,8,10,11 The advent of rapid PCR technology as a tool to 
identify the presence of PVL may prove valuable in identifying potentially “silent” cases of 
DVT that would otherwise go unrecognized. To this point, however, the technology to 
perform rapid testing to identify the bacterial genetics of the S. aureus isolates is not readily 
available at most institutions. Our meta-analysis identified 20 children out of the 58 reported 
cases with DVT who were found to be PVL positive (34.5%).3,6,8,10,11 
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6. Location of DVT 
Among the 58 children with DVT, the location of occurrence of the DVT was recorded in 45 
cases and was noted to be multi-focal in 22 (48.9%) children (see table 3). 79 specific 
locations of the DVT were recorded with the most common being femoral (25 or 32%); 
popliteal (14 or 18%); iliac (12 or 15%); and inferior vena cava (6 or 8%). Overall, the 
reported incidence of DVT involving a location inclusive of the inferior vena cava, pelvis, or 
lower extremities was 62 of the 79 occurrences (78.5%).  
 
Location of DVT Occurrence   
Sigmoid Sinus 1 1% 
Transverse Sinus 1 1% 
Internal Jugular 4 5% 
Superior Vena Cava 3 4% 
Subclavian 2 3% 
Arm 4 5% 
Atrium 1 1% 
Azygous 1 1% 
Inferior Vena Cava 6 8% 
Iliac 12 15% 
Femoral 25 32% 
Popliteal 14 18% 
Posterior Tibial 1 1% 
Peroneal 1 1% 
Saphenous 3 4% 
Total 79 100% 
Multiple locations reported 22   
Location not reported 13
Table 3. Frequency Distribution of DVT Location 
7. Clinical features 
Several studies have suggested that children with DVT- associated osteomyelitis 
demonstrate a more severe clinical course when compared to children who do not have 
deep venous thrombosis.3,5,6,8,9,10,11 Specifically, children with DVT are more likely to be 
admitted to the intensive care unit (ICU), require more surgical procedures, and have a 
longer hospitalization than their counterparts who do not have DVT but who do have 
similar forms of musculoskeletal infection.2,5,9,10,13,17,19 One study found that children with 
DVT required an average of 2.6 surgical procedures per child and had a mean duration of 
hospitalization of 30.6 days, compared to children without DVT who underwent an average 
of 0.9 surgical procedures per child and were hospitalized an average of 9.5 days.9  The same 
study determined that children with DVT presented with higher inflammatory indices in 
comparison to children who did not have DVT.9 The mean C-reactive protein (CRP) in 
children with DVT was 16.9 mg/dL , compared with only 6.8 mg/dL in children without 
DVT.9  While intuitively it might be thought that children with DVT would have a delay in 
clinical presentation to a healthcare facility, the authors found that there was in fact a 
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shorter duration between the onset of admission for children with DVT compared to those 
without. (5.6 days versus 14.4 days).9 This lends further support to the possibility that 
children with musculoskeletal infection and DVT have a more abrupt onset and rapid 
clinical decline to the point where medical attention is sought. Pulmonary involvement with 
a variety of manifestations including pneumonia, septic pulmonary emboli, cavitary 
pneumatoceles, empyema, and various infiltrates was recorded in 36 of the 58 children with 
DVT (62.1%).1,2,4-7,9-11,13-19 
8. Central venous catheters 
The use of central venous catheters (CVCs) in the treatment of children with 
musculoskeletal infection has raised the concern that these catheters may be associated with 
risk including DVT development. Our review noted the concurrent presence of CVLs in 
several children with DVT, but the conclusions were generally that there was no clear 
relationship.5,6,9 Hollmig et al. found that CVCs were used in all eleven children with 
osteomyelitis and DVT in their series.9 However, there did not appear to be a relationship 
between the location or temporal onset of the DVT to the CVC in their experience.9  
9. Statistical analysis 
We reviewed 19 articles (15 case reports1,2,4,5,7,10-19, three studies pertaining to musculoskeletal 
infection in general3,8,9, and one  study focused on an osteomyelitis population6). In estimating 
the heterogeneity of the three musculoskeletal infection papers (k = 3), we measured the I2 
index as our test of heterogeneity and found the I2 index to be 7.7%. The Cochran’s Q value 
was found to be 2.153 (p = 0.3407). This statistic signifies a degree of heterogeneity between the 
three papers which makes it difficult to derive meaningful conclusions from the summary data 
from these studies. However, this level of heterogeneity is expected considering several factors 
such as different study methodology, different timing of the onset of disease, different disease 
severity and different patient groups.  
The incidence rate of DVT was calculated to compare the difference between an incidence 
rate specific to osteomyelitis and the incidence related to musculoskeletal infection in 
general. From our results, the number of DVTs in the three musculoskeletal infection papers 
was 23 with a sample size of 450.3,8,9 Therefore the incidence of DVT in children with 
musculoskeletal infection was 5.1%. However, in the one paper in which osteomyelitis alone 
was considered, the number of DVTs was 9 with a sample size of 116.6  Hence, the incidence 
of DVT with osteomyelitis was 7.8%. Although the differences in incidence could be due to 
different populations being studied, there does appear to be a higher incidence of DVT 
specifically with pediatric osteomyelitis as compared to pediatric musculoskeletal infection 
in general. Further research is required in this area.  
10. Evaluation recommendations 
Any child with deep musculoskeletal infection, particularly osteomyelitis caused by 
Staphylococcus aureus should be considered at risk for DVT. However, in light of the medical 
literature, a higher index of suspicion should be held for those children with severe clinical 
presentation, including: intensive care unit admission, markedly elevated inflammatory 
indices, lower extremity location of the musculoskeletal infection, need for repeated surgical 
debridement, and pulmonary involvement with infiltrates or septic pulmonary emboli. These 
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children should undergo screening with non-invasive Doppler ultrasound evaluation of the 
extremities in the region of the musculoskeletal infection to look for DVT. If the ability to 
assess the PVL status of the organism is present within any institution, then this should be 
considered whenever Staphylococcus aureus is isolated from bone, joint, or muscle specimens.  
While stratification of the relative risk of DVT may increase the awareness of the treating 
physician of the child’s potential for DVT, it is important not to overlook the rare cases of 
DVT that might occur in children who fall outside of this risk profile, such as those with 
upper extremity locations of infection, infection types other than osteomyelitis, causative 
organisms other than Staphylococcus aureus, or age under 4 years. Whenever the clinical 
suspicion of DVT exists, supplemental imaging should be considered. 
11. Treatment 
Children with DVT and osteomyelitis can be effectively managed with low molecular 
weight heparin. Resolution of the DVT occurs at an average of ten to twelve weeks.5,9  
Follow-up imaging is helpful to ensure resolution of the DVT. In cases refractory to low 
molecular-weight heparin, consideration may be given to placement of an intravascular 
filter. Warfarin is also an option, but requires additional effort in managing the prothrombin 
time (PT) and international normalized ratio (INR) effectively.  
Because children with DVT and osteomyelitis may require repeat surgical procedures, care 
must be taken to appropriately withhold and resume the anticoagulant therapy around 
periods of surgery to avoid bleeding complications.  
12. Conclusions 
Pediatric musculoskleletal infection is associated with the risk for DVT. Risk factors include:  
osteomyelitis; lower extremity location of infection; Staphylococcus aureus, particularly 
MRSA, as the causative organism; age greater than 4 years; markedly elevated inflammatory 
indices; severe clinical illness often requiring intensive care unit admission, intubation, or 
inotrope support; and pulmonary involvement with infiltrates, pneumonia, or septic 
pulmonary emboli. A high index of suspicion should be maintained when risk factors are 
present and appropriate screening imaging should be obtained. One study demonstrated a 
40% rate of DVT when the child was greater than 8 years of age with positive cultures for 
MRSA and an initial CRP of greater than 6 mg/dL.9 Consideration may be given to 
evaluating for the presence of PVL within the bacterial genetics to help further stratify the 
risk of DVT. Whenever DVT is identified, appropriate treatment should be administered in a 
timely manner and the child should be monitored until the point of resolution. The 
anticipated outcome is good. 
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1. Introduction 
Venous disease continues to increase in number of patients throughout the 2000’s. With 
continued use of venous access devices, dialysis and cancer on the increase and overall 
patient sedentary life style, we will continue to see more and more venous disease in our 
population. Overall, venous disease is far more prevalent in the population than arterial 
disease. However, it is less diagnosed than arterial disease due in part too less acute 
symptomatology. Patients tend to present later in their disease process due to a multitude of 
factors including lack of debilitating symptoms, non-life threatening presentation and 
manageable discomfort until later stages.  
Symptoms like gradual leg swelling in DVT patients, arm swelling in Dialysis fistulas and 
facial edema in superior vena cava (SVC) syndrome are slowly progressive until symptoms 
become debilitating. Even pulmonary emboli can be sub clinical with only non-specific 
findings like dyspnea and chest discomfort. Coumadin and the other low molecular weight 
heparin products are used as outpatient therapies in oral or injection preparations. These are 
adequate therapies for further prevention of clot formation and help resolve clots outside 
the hospital setting. However, weekly blood draws and side effects of these drugs 
particularly in the elderly can be significant and are potential reasons for multiple 
readmissions to the hospitals related to complications from bleeding. 
2. Treatment options 
The standard treatment for deep venous thrombosis and pulmonary is anti-coagulation 
embolism. Intravenous heparin is used in the acute hospital setting. Coumadin and the other 
low molecular weight heparin products are used as outpatient therapies.  
For those patients with significant clot burden within peripheral or pulmonary embolism, 
endovenous therapies can be used if not candidates for anticoagulation. These patients 
present emergently with significant morbidity. In fact, acute extensive DVT of the lower 
extremity can cause severe peripheral vascular arterial emergency called Phlegmasia 
Cereulens Dolans. This disorder needs rapid clot lysis to dissolve the massive clot burden. 
Thus, only catheter directed thrombolysis could provide this direct form of endovenous 
therapy. Whether it is acute, semi acute or chronic venous occlusive process, endovenous 
therapies have become the first line of therapy. If left untreated or inadequately treated with 
conventional means, patients may develop post thrombotic syndrome.  
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Various areas may be treated within the venous distribution. The treatable areas include 
extremity veins, superior venacava, portal vein, inferior venacava, mesenteric veins, renal 
veins, and pulmonary veins. These cases present in various different clinical scenarios based 
on acuity and severity of symptoms. Extremity swelling, pain and positive Doppler duplex 
venous ultrasound are the typical presenting clinical picture. For other venous thromboses, 
more severe clinical sequela are evident in the setting of portal vein and mesenteric vein 
thromboses. If not treated quickly, these can present with severe bowel compromise 
requiring emergent surgery. Computed tomographic angiographic images usually confirm 
the findings. Massive pulmonary emboli can also present as cardiovascular collapse if not 
treated emergently. Various scenarios from life threatening entities to outpatient treatments 
can be approached with endovascular means.  
3. Available devices 
There are many devices now on the market to treat vascular thromboses and in particular 
venous thrombosis. Various types of endovascular devices are now on the market for venous 
thrombolysis. These include the Unifuse and Speed-Lyser infusion catheters (Angiodynamics, 
Queensbury, New York), Possis AngioJet Ultra thrombectomy system (Medrad, Minneapolis, 
Minnesota), EKOS endowave endovascular system (EKOS Corporation, Bothell, WA), Trellis 
peripheral infusion system (Bacchus Vascular, Santa Clara, CA), Spectranetics Turbo Elite 
Laser Ablation catheter (Spectranetics, Colorado Springs, CO) and a pure aspiration catheter 
called the Pronto Extraction catheter (Vascular Solutions, Minneapolis, MN). 
There are three different types of catheter systems. One catheter is just used for thrombolytic 
drug infusion (Speed-Lyser and Uni-Fuse). The second sets of catheter systems are combined 
devices using both mechanical and pharmacological thrombolysis (EKOS endowave, Possis 
angiojet, and Trellis thrombectomy) The third set of devices use only mechanical 
thrombectomy (Possis angiojet, Spectranectics laser ablation and Pronto extraction catheter). 
4. Thrombolysis/Infusion catheters 
These catheters systems are the original type for thrombolysis. The Uni fuse is a single 
catheter system with multiple side holes throughout its infusion length. (Fig 1) They infuse 
drug directly into the clot and allow the drug to act directly on the thrombus intraluminally. 
The catheters come in various sizes and lengths. The speed lyser catheter is unique short 
device with only 15 and 20cm lengths. This device is designed to be used during fistulalysis 
procedures for dialysis patients. Both catheter systems are excellent for clot dissolution due 
to their ease of use and ability to use any drug combination.  
5. Combination mechanical and pharmacological thrombolysis catheters 
These devices combine both mechanical dissolution and pharmacological thrombolysis to 
the clot. The devices include EKOS endowave system, Trellis peripheral infusion system and 
the Possis Angiojet system. The EKOS system is the newest of the devices. EKOS uses 
ultrasonic agitation of the clot with drug infusion to speed the clot lysis. This helps clear the 
large bulky clot typically seen in the venous system. (Fig 2) (Fig 3) The large clot burden in 
the legs and pulmonary arteries are ideal for this device. Theoretically, there is less drug 
used and less infusion time resulting in less intensive care monitoring and lessening the cost 
of the hospital stay. (Fig 4)  
 










Fig. 1. 64 y/o female with left leg swelling and pain and a positive U/S for DVT A) 
Extensive DVT Left SFV extending into iliac system B) EKOS Endowave combination 
thrombolysis catheter in place with TNK infusion overnight C) Widely patent ilio-femoral 
venous system following thrombolysis 
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Fig. 1. 64 y/o female with left leg swelling and pain and a positive U/S for DVT A) 
Extensive DVT Left SFV extending into iliac system B) EKOS Endowave combination 
thrombolysis catheter in place with TNK infusion overnight C) Widely patent ilio-femoral 
venous system following thrombolysis 
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Fig. 2. 39 y/o female with May-Thurner Syndrome presents with left leg swelling, pain and 
+ DVT A) Extensive DVT left leg B) Pure thrombolytic therapy performed with Unifuse 
catheter system and TNK for overnight infusion C) Uncovered irregular stenosis Left iliac 
vein D) Balloon venoplasty performed with improved appearance but residual stenosis 
remains E) Iliac venous stent placed now with widely patent venous flow through iliac veins 
 












Fig. 3. 54 y/o male with bilateral leg DVT and ilio-caval DVT  
A) Extensive ilio-caval thrombus B) and C) Kissing EKOS catheters placed simultaneously 
with TNK initiated for overnight infusion now with widely patent iliac veins and venacava 
on final images 
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Fig. 4. 71 y/o male with cardiopulmonary collapse/shock with bilateral pulmonary 
embolism A) and B) Bilateral extensive pulmonary embolism C) Bilateral simultaneous 
EKOS/TNK combination thrombolysis catheters in place D) Widely patent pulmonary 
arteries following 12 hour infusion  
The Trellis device also combines mechanical and pharmacological thrombolysis. This device 
comes in various lengths and uses balloon occlusion technique to focus on the segmental 
clot burden. The “whip like” mechanical disruption breaks up the clot allowing the drug to 
act more effectively. (Fig 5) This is a useful device for isolated clot and can be performed as 
an outpatient with need for hospital admission.  
The Possis AngioJet system can be both a pure mechanical and combination mechanical and 
pharmacological thrombolytic system. For combined systems, the Possis catheter is used in a 
“power pulse spray mode” where the thrombolytic drug is pulse sprayed directly into the 
clot. It is then allowed to sit in the vessel and dissolve the clot and then is removed by the 
standard angiojet thrombectomy fashion. This device can be used in many venous 
distributions with its various lengths and catheter treatment diameters. (Fig 6) 
 











Fig. 5. 59 y/o male with extensive DVT left leg swelling and pain  
A) Extensive DVT identified B) Trellis thrombectomy device in SFV with balloon occlusion 
and mixed mechanical and pharmacological thrombolysis C) Marked improvement 
following Trellis device  
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Fig. 6. 61 y/o male with chronic pancreatitis with portal vein thrombosis A) Extensive portal 
vein thrombosis as seen on this transhepatic portogram B) Power pulse spray possis angiojet 
and TPA thrombolysis of the portal vein C) Improved patency of portal vein  
6. Pure mechanical devices 
These devices require no thrombolytic agent to be infused into the vessel. The devices are 
the Possis angiojet catheter, Spectranectics laser catheter and Pronto extraction catheter. The 
Possis system uses saline jet through its distal side holes to create a Bernoulli effect thereby 
removing clot without need for drug therapy. (Fig 7) The Spectranectic device uses laser 
technology to vaporize the clot and thereby clear the vessel of clot quickly without chance of 
distal embolic phenomenon. They also come in various sizes for different vessel territories. 
This device can also be used as an outpatient without need for overnight stay.  
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The Pronto catheter (Pronto .035 extraction catheter, Vascular Solutions, Inc., Minneapolis, 
MN) is the newest pure mechanical device. Previously, developed from coronary 
interventions, it is now made for venous interventions. Pure aspiration catheters with large 
8 French end hole-guiding catheters are used for cases with large clot burden such as 
massive pulmonary embolism and extensive deep venous thrombosis.  
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Fig. 7. 31 y/o body building male with dominant right arm swelling and pain c/w Paget 
Schroetter syndrome A) Possis angiojet pure thrombectomy device cleared clot from 
subclavian vein B) Uncovered focal irregular stenosis in subclavian vein which is worse 
with adduction arm motion C) Balloon Venoplasty of right subclavian vein D) Patent right 
subclavian vein with all degrees of motion the right arm on final images  
7. Additional venous interventions  
Following mechanical or pharmacological thrombolysis for acute venous thrombolysis, 
additional endovascular interventions are usually necessary. Whether, there are focal 
stenoses uncovered following intervention as in Paget Schroetter syndrome, May -Thurner 
syndrome or fistula anastomoses in dialysis graft, there is typically some element of recoil in 
the vein, fixed stenosis or some chronic residual thrombus. Further interventions are 
required involving balloon venoplasty, stent placement or filter placement.  
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8. Balloon venoplasty  
Balloon venoplasty can be performed after the bulky thrombus has been removed 
uncovering an underlying venous stenosis. This can be treated with venoplasty to improve 
the diameter of the vessel thus improving its flow. It is the gold standard for venous stenosis 
in various distributions including subclavian, iliac or venacava corresponding to the various 
syndromes described previously. Typically, these interventions treat the underlying venous 
stenosis resulting in venous patency. The more central the venous stenosis, the better the 
result following venoplasty. Recurrent or residual venous stenosis following balloon 
venoplasty occurs frequently especially in those patients with chronic central venous 
catheters. Despite venoplasty, these venous lesions are very difficult to treat and recurrent 
venous stenosis may require stenting  
9. Venous stenting  
Stents can be used in any venous distribution from peripheral to central veins. Covered and 
uncovered metal stents can be used for recurrent stenosis. Central venous stenosis as in the 
SVC and IVC require the largest available stents. Covered stents and the newest Flair 
covered stent (CR Bard, Tempe, AZ) are now available for dialysis fistula anastomoses 
where by a smaller fistula graft enters into the larger native venous outflow resulting in a 
smooth transition and improve flow dynamics. Venous stenting can also be performed 
following suboptimal balloon venoplasty result. Venous stenting is not performed on 
thrombus alone but is used as an adjunct to suboptimal venoplasty and venous 
thrombolysis.   
10. Thrombolytic agents 
Activase (TPA) (Genenetech, South San Francisco, CA) and Tenecteplase (TNK) 
(Genenetech, South San Francisco, CA) are the most common thrombolytic agents currently 
available. These drugs are fibrinolytic agents which break down fibrin into split products 
thus allowing clot to lyse within the vascular system. In the veins, both work similarly but 
TNK seems to lyse clot faster with less bleeding complications due to its exquisite fibrin 
specificity. Tenecteplase is the newer of the two agents. It has a 14 fold higher fibrin binding 
specificity than TPA. Due to the larger volume of clot within veins, a larger dose of drug is 
necessary to lyse the clot burden. This is one of the reasons for combining mechanical with 
thrombolytic agents. With combination therapy, less drug can be used in these larger 
capacitance vessels if combined with one of the above-mentioned mechanical devices. 
11. Dialysis Interventions 
Dialysis fistulas grafts are increasing in number, as renal failure becomes an epidemic. 
Failure of these grafts is frequent and accounts for most of the morbidity associated with 
these grafts.  Immediate graft malfunction due to surgical causes is quickly identified during 
placement. Acute thrombosis within these grafts can occur at any time following placement. 
This is a constant problem for nephrologists due to the nature of hemodialysis itself. 
Chronic needle punctures within the graft 3-4 times a week results in numerous chances for 
thrombus formation. Also, heparinization during hemodialysis and then reversing the 
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coagulation during and after dialysis catheter removal results in thrombosis of the graft. If 
unable to open the graft within a reasonable time, then other means of vascular access are 
required. Typically, another central venous dialysis catheter is needed until a new graft is 
created or the present one is cleaned out.  
Interventional doctors are well adapted to lysis of dialysis graft using both pure 
pharmacological and mechanical thrombectomy. These grafts can be cleared of their 
thrombus burden in the interventional lab without requiring further surgery. Pure 
thrombolysis catheters like Speed Lyser delivers drug directly to the clot through multi-side 
holes via one micro catheter system. The drug is allowed to sit within the graft and dwell for 
a period of time called “lyse and wait” technique.  Over this period of time, the clot is lysed 
and the graft is cleared of thrombus. TPA is used for this purpose. It can be injected directly 
into a graft. TPA can be given as a 6mg bolus within the dialysis grafts for this treatment. 
Following lysis, other interventions may be necessary to alleviate the source of the 
underlying graft malfunction.  
12. Inferior venacava filter placement 
Caval thrombosis can be acute or chronic. Filters can be used for the treatment of acute caval 
thrombosis, prophylaxis of pulmonary embolism and also be the source of caval thrombosis. 
Both treatment and cause of caval thrombosis makes interruption filters a double-edged 
sword. Either way, endovenous means are used exclusively for caval thrombosis.  
Furthermore, most of the patients undergoing venous thrombolysis receive retrieval Inferior 
Vena Cava filter before the intervention. This is usually placed at the same setting. This idea 
is to reduce the risk of an iatrogenic fatal pulmonary embolism during the procedure. This 
filter can then be removed if indicated up to six months following implantation. Prior to 
removing the filter, a duplex venous ultrasound of the lower extremities is obtained to 
document clot resolution.  
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Late Complications of Deep Venous 
Thrombosis: Painful Swollen Extremities  
and Non Healing Ulcers 
Daniel Link  
Davis School of Medicine University of California,  
USA 
1. Introducton 
Patients with complications of deep vein thrombosis (DVT) experience a “life changing event” 
stemming from their DVT. Constant swelling, pain and discoloration of the involved lower 
extremity are common. These symptoms result from “venous hypertension secondary to 
reflux, obstruction, or insufficiency of muscle pumps” (Kearon 2003; Labropoulos 2004). 
Although the symptoms are well described, patients often have no plan for long term follow 
up after the acute DVT event.  The venous system adjusts to impaired valvular function and 
obstructed outflow venous channels in the first year following the DVT.  A life long 
commitment to compression hose therapy (Franks, Moffatt et al. 1995) with ambulation and 
extremity elevation at rest will minimize swelling and pain. Unfortunately, in the acute phase 
patients often cannot tolerate compression hose but they should be “coached” into 
compression hose as soon as possible. “60% of patients post DVT develop post thrombotic 
syndrome (Ashrani, Silverstein et al. 2009); fitted, graded compression hose reduce the rate in 
half” (Kahn ; Brandjes, Buller et al. 1997; Pirard, Bellens et al. 2008). Following a course of 
anticoagulation and advice for compression hose therapy, DVT patients usually are followed 
by their primary care provider. Recently there has been increasing interest in more closely 
following DVT patients. A duplex supervised by a vascular/vein specialist should be 
performed to assess the “pumping” capacity, available venous channels and valvular 
competence a few weeks to months after a DVT event (van Ramshorst, van Bemmelen et al. 
1994; Caps, Manzo et al. 1995; Salcuni, Fiorentino et al. 1996; Nicolaides 2000). This is 
especially indicated if patients experience persistent pain and swelling, or if a change occurs in 
the status of the limb swelling and pain after a long stable period, or if there is continued 
increase in pigmentation in the pressurized area. Chronic complications, post thrombotic 
syndrome (PTS), can present clinically depending on the initial severity of the deep venous 
abnormality, but may also develop abnormalities in the years following a DVT (Bradbury 
2010). The overwhelming goal of the treatment of complicated post DVT patients is to preserve 
skin integrity and to prevent or heal ulceration (Kearon 2004; Bradbury 2010). Pain, infection, 
and loss of function result in a significant cost to the patient and the community as a whole. 
2. Anatomy 
Veins are substantially different from arteries and exist as a network of thin channels with 
little intrinsic muscular wall. Large intramuscular veins like the gastrocnemius vein can 
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dilate with the muscle relaxed and empty with calf muscular contraction. The veins in the 
calf muscles (May 1975) and the plantar venous plexus (Corley, Broderick et al. 2010) are 
major components of the muscular pump but all muscular veins contribute as do the 
superficial systems to the return of extremity venous blood. Obstruction leads to dilation of 





Fig. 1. Diagram of muscular pump with and without obstructing venous thrombosis. Note, 
bulging sub dermal veins. 
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Veins that connect the subdermal veins and saphenous veins to the deep vein are called 
perforating veins. The muscular vascular pedicle usually enters the proximal portion of the 
muscle with the distal muscle and tendons are relatively less vascular. The perforating veins 
usually follow the cutaneous nerves in a neurovascular bundle. The increased volume and 
eventually pressure to the subdermal (reticular) veins leads to expansion of the 
subcutaneous vascular space. The actual distribution of venous blood and pressure is 
distributed through this system and related to the configuration of each pressurized 
subdermal vein complex. Three different complexities have been described as the 
perforating vein (P) exits the deep fascia to enter a sub dermal vein (Hern and Mortimer 
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veins and abnormal perforating veins are also visualized on venography (figure 4). The 
resultant dilation of the subdermal veins also can be documented in the clinic with duplex 
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pressurization can affect the viability of the overlying dermis. Plastic surgeons have 
recognized and studied this venous anatomy (Schaverien, Saint-Cyr et al. 2008). In this work 
there are excellent figures with the anatomy of the epidermal and subdermal venous 
anatomy and emphasizes the role of the perforating vein and the complex of subdermal 
veins in the outcome of “anterolateral thigh perforator flap”.  
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Fig. 3A. A foot veins has been injected with the patient at rest and the standing at 60 degree 
tilt. The extremity is non-weight bearing. The deep system fills preferentially. The great 
saphenous vein is small and perforating veins are demonstrated. 
Late Complications of Deep Venous Thrombosis:  
Painful Swollen Extremities and Non Healing Ulcers 95 
 
Fig. 3B. The deep veins of the calf fill and enlarge with the great saphenous vein remaining 
small. Normal perforating vein function. 
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Fig. 3B. The deep veins of the calf fill and enlarge with the great saphenous vein remaining 
small. Normal perforating vein function. 
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Fig. 3C. Following muscular contraction, the deep and superficial calf veins empty 
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Fig. 4. Patient with proximal venous obstruction. Demonstrating dilation of subdermal vein 
complexes. 
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Fig. 4. Patient with proximal venous obstruction. Demonstrating dilation of subdermal vein 
complexes. 
 




Fig. 5. Venous thrombosis left common femoral vein after 6 months, arrowhead. 
After a DVT, the clinician should be aware of the early signs of a post thrombotic syndrome. 
At every stage following DVT there is a role for follow up in a center for vascular care and 
DVT patients should be alerted to the symptoms of venous hypertension, so that 
progression of the disease can be minimized early. The progression from increased skin 
pigmentation to non-healing ulceration can be prevented. Most patients cannot wear graded 
compression hose acutely, but as the swelling and tenderness subside the patients should be 
encouraged to wear compression before skin changes develop. Local venous hypertension 
from distal reflux leads to the skin changes and are usually associated with pain and 
swelling. The venous hypertension can persist and develop increasing pain and skin 
abnormalities including ulceration despite optimum compression hose therapy (Felty and 
Rooke 2005). In addition to pressurization of the subdermal veins patient develop tense 
swelling of the affected lower extremity, lymph edema (Shrubb and Mason 2006). Figure 5 
shows thrombus in the femoral vein that is chronic and non-occluding. The patient, though 
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Fig. 6. Lymph edema 6 months following DVT in left femoral vein (figure 5). 
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Fig. 6. Lymph edema 6 months following DVT in left femoral vein (figure 5). 
 
Venous Thrombosis – Principles and Practice 100 
wearing compression dressings as much as possible showed tense swelling of the leg to the 
ankle. 4 months following her initial visit and 7 months following the DVT the femoral vein 
thrombus had resolved by duplex, the only residual thrombus was a partially occluding 
thrombus in the popliteal vein. The gastrocnemius veins cleared with exercise and no reflux 
could be demonstrated in the femoral or common femoral veins by duplex. Lymph edema 
can persist following DVT despite resolution of deep venous reflux and obstruction. This 
patient had skin thickening and pitting edema, which is classified as Stage II lymph edema. 
Evaluating these patients require a clinical examination and duplex. Occasionally, unusual 
conditions may arise compressing the venous return (Bekou, Galis et al. 2011). The value of 
an evaluation of patients with suspected DVT is emphasized by a group studied where DVT 
(the thrombosis in the outflow veins) was found in “213 (28.6%) of 745 suspected cased”. 
The clinical examination including sonography revealed, chronic vein thrombosis and 
superficial vein thrombosis, 122 patients (28%,  and  76 patients with lymph edema 
(13.3%)(Taute, Melnyk et al. 2010). In acute venous hypertension may obstruct the lymphatic 
in the acute phase leading to the lymph edema seen as a result of gynecologic surgery where 
rich protein fluid absorption from the interstitium results (Bollinger, Isenring et al. 1982; 
Shrubb and Mason 2006; Ohba, Todo et al. 2011) . “In severe CVI leading to tropical changes 
of the skin lymphatic microangiopathy was detected. Obliterations of parts of the superficial 
capillary network, phenomena of cutaneous reflux and increased permeability of capillary 
fragments occurred. These findings contrast to primary lymph edema where the rete 
remains intact..”(Bollinger, Isenring et al. 1982). Imbalances between extracellular matrix 
synthesis and degradation has been found associated with chronic non healing ulcers(Moor, 
Vachon et al. 2009). Compression therapy is often painful. Physical therapy with massage 
and mechanical lymph edema pumps may be helpful but remain controversial; level one 
efficacy studies are not available. The patient in the example responded to the lymph edema 
pump, Flexitouch, Tactile Systems Technology, Inc Minneapolis, MN, USA). 
Symptom severity and CEAP grade increase can be correlated to Perforating vein reflux. 
Perforating vein reflux is found in less than 10% of patients with CEAP grade 0 but there is 
an increase from 46% with Grade 2/3, 82% at with grade 4 and 90% with grade 5/6 
(healed/open ulcers) (Stuart, Lee et al. 2001; Raju and Neglen 2009) 
2.1 Ulcers with pain not responding to compression dressings 
Evaluation of such patients by duplex can reveal large venous complexes deep the ulcers 
that impede healing and contribute to the pain. Sclerotherapy and Ablation (Radiofrequency 
Ablation(Marsh, Price et al. 2010) and Endovascular Laser(Proebstle and Herdemann 2007)) 
procedure can enhance healing.  
Sclerotherapy has been used for many years, but targeting the subepidermal veins by 
ultrasound imaging can improve outcomes. Sodium Tetracyl sulfate (Sotradecol, 1 & 3 %, 
Angiodynamics, NJ) has been used. Other sclerosants included Pilodocanol, Asclera, and 
Aethoxysklerol approved only for small varicose veins, and hypertonic saline. Recently, 
steam has been used in a few patients with non healing ulcer. Steam would have the 
advantage of “percolating” into the target subepidermal vein complexes. Steam scalds the 
veins and coagulates the luminal contents. Further development studies are ongoing 
(Milleret 2011). 
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Fig. 7A. Patient with non healing ulcers years after DVT despite compression therapy. 
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Fig. 7A. Patient with non healing ulcers years after DVT despite compression therapy. 
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Fig. 7B. Pressuring perforating vein with incompetence by duplex.  
 
Fig. 7C. Intra procedural imaging of laser closure. 
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Fig. 8A. Diagram of foam sclerotherapy. 
 
 
Fig. 8B. Intra procedural imaging of foam sclerotherapy. 
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Fig. 8A. Diagram of foam sclerotherapy. 
 
 
Fig. 8B. Intra procedural imaging of foam sclerotherapy. 
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Fig. 9. Photograph of above patient after few weeks of foam and laser therapy. 
Figures 7, 8 and 9 demonstrates an obese patient that has been in compression dressings, 
una boot or dynaflex for the last several years. Large non healing ulcers Figure 7A, 
Pressurizing perforating vein demonstrated, not seen incompetent by duplex, Figure 7B, 
Closure of perforating vein with laser fiber, Figure 7C. Diagram of foam sclerotherapy, 
Figure 8A Foam seen in veins deep to ulcer Figure 8B. 
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2.2 Arteriovenous malformations post venous thrombosis 
Patients who start to develop lower extremity pain post DVT that is not controlled by 
compression therapy should be evaluated. Some patients will show arterial signals on duplex 
distal to venous occlusions. The high flow inflow from the AVM can be found with duplex. 
The natural history of the neovasularity in the thrombus in unknown but has been described 
in the cerebral sinus post thrombosis and in the peripheral veins (Link, Garza et al. ; 
Chikamatsu, Nagashima et al. 2001; Aboian, Daniels et al. 2009). Many of these patients have 
been found to be factor V Leiden positive (Link, Garza et al.).  There is evidence that the veins 
are not passive and may play a significant and dynamic role in revascularization through 
angiogenesis (Aboian, Daniels et al. 2009). It is unclear whether the AVF/AVM in thrombus is 
transitory or may remain permanent. Figure 10A shows a chronic occlusion of the left internal 
iliac vein (presumably May-Thurner Syndrome (May R 1957; Fazel, Froehlich et al. 2007) in a 
patient followed by her primary care physician for many years without a specific, etiologic 
diagnosis. She developed large open and painful ulcers. The large collateral veins on her 




Fig. 10A. Patient with chronic left iliac vein occlusion after more than 20 years. 
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Fig. 10A. Patient with chronic left iliac vein occlusion after more than 20 years. 
 






Fig. 10B. Non healing ulcers, extremely painful, patient’s main compliant. 
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Fig. 10C. Duplex of left common femoral vein showing high flow with arterial pulses. 
 
 
Fig. 11. Foam Sclerotherapy procedure in above patient (Figure 10). 
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Fig. 10C. Duplex of left common femoral vein showing high flow with arterial pulses. 
 
 
Fig. 11. Foam Sclerotherapy procedure in above patient (Figure 10). 
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Fig. 11B. Photograph showing complete healing of ulcers; patient now pain free.  
Duplex examination Figure 10C showed high velocity flow in the patient,s femoral vein 
distal to the occluded external iliac vein. An arteriogram showed a large pelvic AVM with 
outflow to the deep pelvic veins and to the distal veins in the left lower extremity.  
Occlusion of the AVM was performed with injectable ethyl vinyl alcohol polymer dissolved 
in DMSO (Onyx, EV3 Neurovascular, Irvine, CA) (Link 2011). The pain in the ulcerated 
areas improved but persisted despite compression dressings being applied weekly. 
Endovenous Laser Ablation (EVLT) of the veins deep to the ulcers and foam sclerotherapy 
(0.5% Sodium tetradecyl Sotradecol, angiodynamics, Queensbury, NY was then performed 
on this patient).  Following the procedures the ulcers healed and the patient was pain free. 
Interventions for this condition have included an outflow procedure to reduce the venous 
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hypertension with transcatheter embolization of the arteriovenous channels from the 
feeding arteries (Chikamatsu, Nagashima et al. 2001).  Successful treatment of the pain has 
been achieved in localized femoral vein AVM lesions by transcatheter injection of the 
feeding arteries with anhydrous alcohol combined with tissue adhesive (n-Butyl 
Cyanoacylate, nbca, Trufill, Cordis neurovascular, Miami Lakes, Florida)(Link, Garza et al.). 
Non healing painful ulcers can be seen in end stage renal disease patients as a result of 
venous hypertension from their arteriovenous access,(George, Jhawar et al. 2008). 
Patients who develop DVT should be followed for complications during and after the 
period of anticoagulation. Emphasis on compression and lymph edema treatment should 
lead to improved outcomes. Severe post thrombotic syndrome patients should be managed 
in a vascular group and some will respond to ablative and injection therapies. 
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1. Introduction 
Cerebral venous thrombosis is a relatively rare, however life-threatening condition. Current 
studies show that around 10% of the patients die. Earlier works proved that most of the 
thromboses originated secondarily, as a consequence of local or systemic infection, more 
than 30% of the cases were considered to be idiopathic. More recent studies also mention 
other risk factors, which may contribute to the onset of thrombosis. These include 
thrombophilic states or use of oral contraceptives. A number of hypercoagulation states or 
thrombophilic conditions, which contribute to the onset of thromboembolic disease, have 
been discovered and described in the recent years. 
Thrombophilia is a congenital or acquired disorder of the haemostatic mechanism, 
characterized with an increased tendency towards blood clotting and thrombotization. Typical 
manifestations of the condition include frequent occurrence of lower extremities thromboses in 
young age, with frequent recurrence, or localization in unusual places. Congenital forms of the 
disorder are characterized with family occurrence. The most frequent conditions associated 
with congenital form of the disease are mutation of genes coding VLeiden factor (Leiden 
mutation), prothrombin G20210A, hyperhomocysteinemia and furthermore also autosomal 
inheritance of antithrombin III (AT III), protein C and protein S deficit. 
The point mutation of the factor V gene usually occurs in the place of protein C binding, 
which results in its cleavage and inactivation. The changes are associated with substitution 
of guanine with adenine at the 1691st nucleotide of the factor V, this substitution results in 
further substitution of glutamine with arginine on the 506th position of the factor V chain 
(FV Q506). The mutation is also known as “Leiden mutation”, based on the place of its 
discovery (Leiden, Holland). Substitution of amino acids in the factor V chain causes 
resistance against the activated protein C, resulting in a higher tendency towards 
thrombosis. The mutation is considered to be autosomal dominant hereditary. It affects 5-9% 
of the European population. The mechanism of resistance against the activated protein C 
(APC resistance) was first described by Dahlbäck in 1993 in Sweden. 
Another possible predisposition factor of venous thrombosis is a mutation of gene for 
prothrombin - G20210A variant. It is present in about 2% of the population. The mutation 
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causes an increase of the prothrombin level and contributes to elevation of the risk of 
thrombosis up to threefold level.  
Deficit of the antithrombin III is a disorder with most prothrombotic effects. The risk of 
developing a thromboembolic disease during life is 70-80% in carriers in the heterozygous 
form (homozygous carriers suffer from a lethal thromboembolic event usually already 
during childhood). AT III is a polypeptide synthetized in hepatocytes with an increased 
half-time (65 hours). Apart from its effect on thrombin, AT III is also able to activate factors 
Xa, IXa, VIIa and plasmin. The activation of antithrombin III is increased up to 40 000 times 
with heparin binding. The deficit of AT III is caused by numerous point mutations, deletion 
and insertion, and the inheritance is mostly autosomally dominant.  
Homocysteine is contained in plasma at concentrations of 5 – 16 mol/l. Congenital 
hyperhomocysteinemia may be caused by a number of enzymatic defects. Clinical 
manifestations may be strengthened with a deficit of B6 and B12 vitamins, folic acid or 
during a treatment with methotrexate. Thrombophilia caused by hyperfibrinogenemia and 
dysfibrinogenemia is observed significantly less frequently. 
Large population studies aimed at the relations between hormonal contraceptives and deep 
vein thrombosis have been performed. The increased risk was described mainly in patients 
using third-generation gestagens. Moreover, the identified risk of thrombosis in patients 
using hormonal contraceptives with thrombophilia is higher than what would correspond 
with a simple addition of risks. This finding confirms the theory that the procoagulation 
mechanisms are mutually strengthened in these women. 
The problems of cerebral venous thrombosis in women in fertile age, who are the users of 
hormonal contraceptives have been studied in several trials including only a small number 
of patients. The results are in many cases misleading and inconsistent. 
The aim of our study was to analyse cases of CVT in relation to sex, age, use of hormonal 
contraceptives and thrombophilic states, in correlation with CT, MRI and DSA findings and 
with clinical neurological findings. 
2. Clinical study 
We present a set of eight cases of women with a diagnosed cerebral venous thrombosis. The 
age scope of the group was 18.7 – 39.3 years of age, with mean of 28.1 years. The patients 
were hospitalized between April 2004 and October 2005. All patients were referred to CT / 
MRI and DSA venography examinations. Five of the women were treated with a therapeutic 
dose of low-molecular heparins (LMWH) only, with a transfer to warfarin treatment, other 
three patients underwent an interventional treatment with local thrombolysis with 
Actilyse® (rt-PA), following an ineffective LMWH application. 
We have evaluated all medical records of the patients, the patients were examined 
physically and we have taken a detailed history record. Seven patients were using third-
generation hormonal contraceptives with gestagens, one patient was using purely gestagen 
contraceptives, none of the patients smoked. 
3. Laboratory examinations 
All patients were referred for blood tests in order to define the presence of thrombophilic 
states. The blood samples were collected and tested prior to the onset of an anticoagulation 
treatment, and 3-6 months following a thrombotic event. 
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APC resistance was tested with the use of factor V deficient plasma (Coatest® APC resistance 
Chromogenix). The test presents almost 100% sensitivity and specificity in detection of factor V 
mutations (Leiden). Patients with APC ratio below 1.86 were tested with PCR analysis for the 
presence of FV:Q506  allele. We have also chromatogenously determined the levels of protein C, 
antithrombin III (AT III), prothrombin, heparin II cofactor and plasminogen. Protein S was 
determined immunologically, as a free form of protein S. 
In order to determine the complex mutations of FV 1691 G-A, prothrombin 20210 G-A and 
MTHFR 677 C-T, we used specific, polymerase chain reaction (MS PCR), according to the 
works of Austrian authors Endler et al. This method is a single-tube PCR technique based 
upon the use of allele-specific primers, differing mutually in 8-10 pairs of bases (bp). The 
subsequent amplification was carried out in accordance with the protocol, which was 
optimised for thermocycler Perkin Elmer 2400. Following the initial 10-minute denaturation 
at 95°C, 34 cycles follow, consisting of separation of DNA chains for 1 min at 95°C , 
annealing primers for 2 min at 56°C and DNA synthesis for 1 min at 72°C. After completion, 
final elongation was carried out for 7 min at 72°C, followed with cooling to 4°C. To separate 
the PCR products we used electrophoresis on Spreadex 400 gel (Elchrom Scientific), which 
enables separation of products up to 400 pb, with high resolution. The results were 
reviewed on UV review table at 254 nm, the photo documentation was obtained using a 
yellow filter with Mitsubishi camera enabling digital recording. 
3.1 Case Report of CVT – Application of local fibrinolysis in 24-year patient using HAK 
24-year-old female patient with a negative history, including pregnancy or 
thromboembolism used third-generation gestagen as oral contraceptives. The patient was 
admitted to Neurology ICU, suffering from a strong headache, localized retroaurically, 
lasting for the period of one week. During the previous two days, the pain was associated 
with vomiting. Neurological findings included IV-degree somnolence, apathy, dysarthria, 
nuchal rigidity with 12 points on the GCS (Glasgow Coma Scale) on admission. A CT 
examination and conventional DSA were carried out in the evening. Angiography showed a 
partial thrombotic closure of the superior sagittal sinus and complete closure of right-hand 
lateral and sigmoid sinus, Galen’s vein and direct sinus with stagnation of venous drainage 
in thalamus and basal ganglia. CT examination confirmed hypodensity in the right side of 
the thalamus and basal ganglia, oedema in right-hand temporal-occipital area and a minor 
haemorrhage in the area of right lateral and sigmoid sinus. 
Neurological examination  
The examination showed left-hand hemiparesis, divergent strabismus, bilateral miosis, 
nuchal rigidity and tachycardia 120/min. Oedema of the papillae was not present. 
Considering the progreding disorder of consciousness gradating into coma, the patient was 
intubated and left on artificial ventilation. Consequently, the patient was taken to 
Anaesthesiology-Resuscitation Department. We introduced anticoagulation treatment with 
dalteparine 1000 IU/hr and antibiotic therapy with amoxyciline with clavulanic acid 1,2 g/ 
8 hrs and ciprofloxacine 100 ml/12 hrs. The ventilation was maintained with FiO2 0,3, tidal 
volume (Vt) 550 ml and positive end-expiratory pressure (PEEP) of 5 cm H20. ECG was 
normal, without any ischemic signs, frequency 120/min. Magnetic resonance and magnetic 
resonance venography (MRV) confirmed vasogenic inflation, blood hypovolemia of the 
right mesencephalum, right thalamus and basal ganglia, as well as thrombosis of deep 
cerebral veins and venous sinuses. 
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Laboratory examination  
Creatinine 63,6 umol/l, glucose 6,1 mmol/l, coagulation: INR 1,41, fibrinogen 4,69 g/l, D 
dimers elevated 6-fold, protein C 45%, free protein S 56%, APC resistance negative- 4,791, 
AT III- 74%, factor II 76%, factor VIII – 112% (% of the standard). 
Despite the use of conventional anticoagulation treatment and anti-oedematous therapy 
according to the protocol, the serious brain stem symptoms progreded on the 5th day after 
admission, associated with a loss of vertical and horizontal oculocephalic reflexes. The patient 
was referred to interventional centre for endovascular treatment of cerebral venous 
thrombosis. After admission, a control DSA examination with three-dimensional venography 
(3D-XRV) was carried out, with reconstruction of the venous phase. We found an incomplete 
thrombotic closure of both venae cerebri internae, Galen’s vein and direct sinus, as well as a 
complete thrombosis of the right transversal and sigmoid sinuses. On the basis of this imaging 
examination, we decided to proceed with a local thrombolysis with rt-PA. 
Technique of the procedur  
5F Terumo loader (Radiofocus, Tokyo) was inserted into the common femoral vein for the 
purpose of a venous approach, and another 5F Terumo loader was inserted retrogradely into 
common femoral artery for angiography imaging of the right-side carotid basin. Control 
position digital subtraction angiography was carried out with the 4F Vertebral Aqua - Tempo 
catheter (Cordis - Endovascular, JJ, Miami, FL), with 3D-Xra reconstruction of the venous 
phase, with the outcome of a complete thrombolysis of the basal Rosenthal’s and Galen’s 
veins, sinus rectus, sinus transversus, sinus sigmoideus and right jugular vein (Fig. 1). The 
patient received unfractionated Heparin in the dose of 5000 U i.a. Another 4F Vertebral Aqua – 
Tempo catheter was inserted into the right v. jugularis interna, using the Terumo 035´/260cm 
loader (Radiofocus, Tokyo, Japan), and subsequently smoothly through the thrombus up to 
the area of confluens sinuum (Fig. 2). We have initiated local continuous thrombolysis on the 
5th day after admission, using the application of rtPA in the dose of 0,6mg/hr, with continuous 
application of UF Heparin in the dose of 700 IU/hr, to reach the therapeutic levels of 
anticoagulation therapy. Fibrinogen, aPTT, blood count and the count of thrombocytes were 
monitored in 6-hour intervals. The thrombolytic treatment lasted for a total of 48 hours. 
Control angiography with 3D-XRA venography performed on the 7th day confirmed 
recanalization of both cerebri internae, basal Rosenthal’s vein, Galen’s vein, sinus rectus, 
transversal and sigmoid sinuses, as well as v. jugularis interna, with a rapid drainage into 
cortical collectors. Thrombolytic therapy was terminated after the restoration of venous flow. 
Control CT examination excluded bleeding complications, and subsequent MRI examination 
confirmed regression of hyperaemia in the area of thalamus and right basal ganglia. 
During the following two days, the patient wakes from the comatose state, with further 
diminishing of clinical symptomatology in the following period. The NIHSS scale was scored 
at 4 points on the 7th day after the interventional procedure. During a follow-up check after 
one month, the patient is fully self-sufficient, with mRs – 0 points. The examination aimed at 
thrombophilic states verified heterozygous form of MTHFR: A/V 223 and homozygous form 
of PAI-I 4G/5G genotype mutation. The patient was introduced to anticoagulation treatment 
with warfarin, with periodical monthly INR check-ups. Subsequent neuro-psychological 
examination confirmed an excellent outcome: WAIS-R:IQ global test 141, verbal 128 and non-
verbal 146 points, with Wechsler memory quotient MQ l0l, pointing towards high intellectual 
functions. The examination further confirmed a high psychomotor speed, optimal verbal 
expression and memory functions at three months after the treatment. 
 




A, B, DSA (day 1) closure of sinus transversus, vena magna cerebri  (Galen), vena cerebri interna and 
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G, Sagittal view on DSA (day 5) – thrombosis of sinus transversus and sigmoid. 
H, 3D-Xra digital rotational angiography, partial thrombosis, sinus rectus – “double railing” image, 
thrombosis of vena basalis Rosenthali. Closure of right sinus transversus and sigmoid. 
I,4F-Vertebral Tempo Cordis JJ catheter inserted into right-hand sinus transversus, into the area of 
confluens sinuum, through a soft thrombus for introduction of local thrombolysis.  
J, Sagittal view - DSA (day 7) – 48 hours of local thrombolysis - recanalization of the right-hand side 
sinus transversus and sigmoid.  
Fig. 2. Interventional procedure + 3D-Xra control angiography and MRI after thrombolysis 
 




K, L, 3D-Xra digital rotational angiography with a complete recanalization of sinus rectus, vena magna 
cerebri, vena basalis Rosenthali and venae cerebri internae. 
M, Control MRI – (1 month), with a minor venous infarction of pulvinar thalami on the right. 
Fig. 2. Continues.  
3.2 Case report – CVT with malignant course 
Thirty-three-year-old female patient with a negative history and negative allergic history, 
using third-generation hormonal contraceptives for a short period of one month was 
examined for a headache localised in the right-hand side occipital area, accompanied with 
repeated vomiting. After five days of cephalgias, the patient observed worsening of the 
visual acuity, namely in the right eye. The patient was admitted at Neurology department 
due to an epileptic seizure. The subsequent CT examination was described as negative. On 
admission, the patient complained about inappetence and overall sickness after using 
individual tablets of the contraceptive. On the 8th hospitalisation day, the patient suddenly 
lost consciousness, tonic stiffening of the limbs and jaw appeared, accompanied with 
sweating, and, having regained consciousness, the patient showed signs of overall 
confusion. Control CT examination was performed, with the image of squalid cortical areas 
and suspected subarachnoidal haemorrhage in the occipital area on the right, around 
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sinuses. Within further two hours, the patient lost consciousness, accompanied with 
meningeal symptomatology and left-side hemiparesis.  
The patient was referred for MRI examination, which revealed a massive cerebral venous 
thrombosis of all cerebral sinuses, with a closure of the deep vein system drainage in the 
diencephalic area and around basal ganglia (Fig. 3). After subsequently performed 
examinations, the patient was intubated in semi-comatose state and transferred to the 
interventional centre for an emergency endovascular procedure. 
Interventional procedure 
Under general anaesthesia, through a cannulation of right-hand side common femoral vein, 
we inserted 4F sheath Terumo and applied UF-Heparin 5000 U i.a.. Through the sheath we 
inserted 4F Vertebral Aqua - Tempo (Cordis - Endovascular, JJ, Miami, FL) diagnostic 
catheter and proceeded with diagnostic angiography of the cerebral arteries. The AG 
revealed a significantly delayed capillary filling, and venous drainage of both hemispheres, 
as well as a complete thrombosis of sinus sagitalis superior, sinus transversus and 
sigmoideus on the right side, a complete closure of deep venous drainage - v. basalis 
Rosenthali, v. cerebri internae, v. magna cerebri and sinus rectus. We inserted a second 5F 
Terumo loader into the common femoral vein, and through it a second diagnostic Vertebral 
catheter, on Terumo loader (Radiofocus, Tokyo, Japan) we penetrated into v. jugularis 
interna on the right, through foramen jugulare into sinus sigmoideus and transversus on the 
right, up to the confluens sinuum area. We initiated the application of local thrombolysis in 
the dose of 1mg rt-PA/hr per 24 hours. 
Therapy at the Anaesthesiology-Resuscitation Department 
Patient was left on controlled artificial lung ventilation, on antibiotics (amoxyciline with 
clavulanic acid i.v., at the dose of 1,2 g every 8 hours), parenteral infusion therapy with 
crystaloids, glucose, massive anti-oedematous therapy, continuous local thrombolysis.  
Laboratory examination 
Antithrombin III 88..67, Leukocytes 15,7; Erythrocytes 4,40; Haemoglobin 13,6, Haematocrit 
0,357; Thrombocytes 291; APTT 180 vt., Quick 19,4; INR l,62; Fibrinogen 3,0. 
Control CT on the following day  
Significant progression of the cerebral oedema, faded basal cisterns, clouded structures of 
the mesencephalon, smoothened gyrification, clouded structure of the right basal ganglia, 
medium line without deviation, faded lateral ventricles, high density in sinus sagitalis 
superior and sinus rectus with proven thrombosis. Conclusion – manifestation of a diffusive 
oedema, together with thrombosis of cerebral sinuses. 
Neurological examination 
Patient without attenuation, on artificial lung ventilation without any spontaneous activity, 
no reaction to painful stimuli, stem reflexes not manifested, generalized hypotonic state 
with C5-C8, L2-S2 areflexia. Conclusion: areactive coma, without manifestation of stem 
reflexes, corresponding to cerebral death. The patient dies on basal therapy after 11 days of 
hospitalization. 
Pathology-anatomic finding  
see Fig. 4. The image confirms extensive cerebral venous thrombosis, cerebral oedema, 
mainly in the area of brainstem, without manifestations of intracerebral haemorrhage. 
 




N, T1WI-MRI - axial scan with the image of hyperintense signal of sinus transversus thrombosis on the 
right and hyperaemia, or vasogenic dilatation of the right temporal lobe.  
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T,U Thrombosis of sinus sagitalis superior as seen after opening of the sinus and removal of the hard 
meninges 
V Thrombosis of confluens sinuum and sinus rectus orifice, thrombosis of Labe collector on the right 
and cortical veins parietally on the left 
W Thrombosis of perimesenphalic veins with hyperaemia in the area of medulla oblongata 
Fig. 4. Pathology-anatomic finding 
4. Results 
We present eight cases of cerebral venous thrombosis in a group of young women (aged 
between 18.7 and 39.3 years, mean age 28.1 years), who were hospitalized between April 
2004 and October 2005. 
The most frequently observed manifestations of CVT (see Table 1) were headache (100%) 
and vertigo (87,5%). The most frequently detected objective findings were movement 
disorders – central hemiparesis or quadruparesis (75%), the same percentage applies to 
spasms, behavioural disorders, altered consciousness, sensoric disorders and aphasias 
(25%). CT and MRI examinations (see Table 3, 4) showed venous infarction or vasogenic 
inflation in 62.5% and presence of petechial haemorrhage in 25%. Digital subtraction 3D-XR 
venography most frequently confirmed a combination of occlusions of sinus transversus 
and sigmoideus (75%), sinus sagitalis superior (62,5%), cortical veins (62,5%) and deep 
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The outcomes of the therapy were excellent in seven patients receiving the basic treatment. 
The treatment included administration of a combination of low weight molecular heparin in 
the treatment dose and subsequent coverage with warfarin. In three patients with 
insufficient effect of LMWH, we used local thrombolysis Actilyse ® (rt-PA). One of the 
women died, despite acute thrombolysis and complex therapy. The results of coagulation 
tests (see Table 6) showed the presence of several thrombophilic risk factors in all women in 
our group. Homozygous form of the MTHFR-C677T gene mutation was detected in three 
patients, two patients had a mutation of the gene for PAI-1 in homozygous form. A 
combination of both homozygous forms was detected in one patient, the combination was 
present in heterozygous forms in two patients. The tests further detected an elevated level of 
factor VIII in three patients, and five of the patients showed a deficit of protein S, always in 
combination with mutations of the gene responsible for MTHFR-C677T, three of these were 
present in homozygous form. 
5. Discussion 
The first clinical and pathological finding of cerebral venous thrombosis was described by 
Ribs in 1825 in a 45-year-old male patient with generalized malignant process. Without the 
possibility of angiography imaging, the diagnosis was determined on the basis of clinical 
findings – progreding headaches, oedema of the eye papilla, spasms, focal deficit, coma, and 
was most usually confirmed with pathology-anatomical findings of thrombosis in the area 
of dural sinuses, accompanied with haemorrhagic infarsation. In 2001, an important study 
“International Study of Cerebral Vein Thrombosis“ - ISCVT was published; the study 
prospectively monitored data of 624 patients with this diagnosis. (2)  
Deep vein system, including vv. cerebri internae, v. basalis Rosenthali, v. magna cerebri and 
sinus rectus, responsible for the drainage of diencephalon, basal ganglia and deep structures 
of the white matter of hemispheres, is usually affected in 10% of cerebral venous 
thromboses. More serious clinical cases, including hemipareses and quadrupareses are 
caused by compression of capsula interna, with unilateral of bilateral infliction of the 
thalami or basal ganglia, and can be diagnosed with non-invasive examinations, e.g. CT or 
MRI under the image of the oedema or haemorrhagic infarction. Limitations of venous 
outflow result in cerebral hyperaemia, mostly detected on MRI in patients with CVT (3,4,5). 
The diagnosis of CVT in our group of patients was confirmed with MRI imaging, MR 
venography and subsequently also with digital subtraction angiography. Liang et al. 
confirm the importance of three-dimensional imaging of magnetic resonance MP-RAGE 
venography, supported with the use of contrast, in the diagnostics of thromboses in the area 
of dural sinuses. This method was also very useful in our patient group. (6) As an 
alternative diagnostic procedure for CVT it is also possible to perform CT venography, 
together with the subtraction of bone structures “Mathed Mask Bone Elimination” (MMBE). 
(7) 3D-Xra-digital rotation venography provides an excellent alternative, with the possibility 
of imaging the speed and direction of the flow in a normal section of the venous system, as 
well as in partially thrombotized parts of dural sinuses and deep vein system. 
The treatment of patients with intracranial venous thrombosis depends on the timeliness of 
the clinical suspicion of CVT and subsequent confirmation of the diagnosis with imaging 
techniques. Purdon Martin and Sheehan (1941) were the first to recommend anticoagulation 
therapy for the treatment of CVT. The treatment with heparin is currently considered as a 
treatment of choice in patients with CVT. (2) However, the effect of heparin may be too 
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slow, especially in patients with rapidly progreding symptoms and involvement of most of 
the dural sinuses and deep venous system. This patient population should be referred for 
thrombolytic treatment, as the overall mortality of these patients reaches 10%. (8-11) Our 
current experiences also point towards the possibility of mechanical revascularization of the 
obstructed venous bed, using the techniques of rheolytic thrombectomy and mechanical 
disturbance of the thrombus with balloon catheters. (12,13) 
Thrombophilic states are commonly observed in 25-35% of patients with venous thrombosis. 
(14,15) Hormonal contraceptives are currently used by more than 100 million women. 
Shortly after their introduction in 1960s, an increased incidence of thrombotic vascular 
complications was observed (16-18), together with an interaction of hormonal contraceptives 
and haemocoagulation system. Increased activity of coagulation factors VII, VIII, X and 
fibrinogen is a common finding in most cases. (19) Martinelli et al. in their work define the 
risk of onset of cerebral venous thrombosis in users of hormonal contraceptives OR 6,1 95% 
CI (3,3 – 11,00). This potential risk may be further intensified by congenital haemostatic 
disorders. (20) 
Peroral contraceptives induce extensive changes in the fibrinolytic system. The levels of 
plasminogen and plazmin-alfa2-antiplazmin complex are elevated, also the activity of tissue 
activator of plasminogen (tPA) is increased, at the same time, the level of antigen inhibitor of 
the plasminogen-I activator (PAI-I) and the PAI-I activity are decreased, and many other 
changes occur. The fibrinolysis in the users of contraceptives is elevated, which is most 
probably caused by the response and compensation of the prothrombogenic state, caused by 
hormonal preparations. These changes are identical in preparations containing levonorgestrel, 
as well as third-generation gestagens. (21) Genetically conditioned thrombophilic states of the 
fibrinolytic system (PAI-I) increase the potential risk of the onset of thrombosis in HAK users. 
An increased activity and clustering of platelets was observed. (22) 
Hormonal contraceptives with third-generation gestagens are connected with an increased risk 
of venous thromboses, in comparison with previous generations of contraceptives. This risk is 
also present in women without V Leiden factor mutation or a positive family history. (23)   
6. Conclusion  
Our experience points towards the possibility of CVT onset in young women using 
hormonal contraceptives. This condition needs to be taken into account in cases of 
intracranial difficulties. CVT is most commonly manifested with headaches, vertigo and 
visual disorders. That is why the diagnosis should be considered when a sudden onset of 
such manifestations occurs in otherwise healthy young woman. The CT or MRI 
examinations should be directed towards the possibility of affection of the venous 
intracranial system. MRI and MR-venography or 3DX-RA venography significantly decrease 
the diagnostic process in patients with disorders of the deep venous cerebral system and a 
rapid development of symptoms. Direct endovascular thrombolysis, with the possibility of 
mechanical revascularization may dramatically improve the clinical course of patients with 
thrombosis of cerebral veins in patients with insufficient effect of anticoagulation therapy, 
associated with rapidly progreding disorders of consciousness. Thrombolytic therapy also 
decreases the occurrence of secondary complications following thrombolyses of cerebral 
veins, such as chronic intracranial hypertension with visual disorders or onset of arterio-
venous shunts. (24,25) Taking into account the incidence of these serious complications, we 
consider as essential, in compliance with recommendations of the Czech Society of 
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Gynaecology and Obstetrics JEP, prior to administration of HAK, to perform a detailed 
analysis of personal and family history, and in indicated cases also a detailed examination of 
the presence of thrombophilic states. The significance of individual thrombophile mutations is 
inconsistent. Absolute contraindications for HAK usage include deficit of the antithrombin III, 
protein C deficit, homozygous form of V Leiden factor and combination of other thrombophile 
mutations. Other thrombophile mutations present a relative contraindication only. Screening 
examination of women prior to administration of HAK is not indicated. (26) However, in our 
study group, although we performed a detailed retrospective analysis, the personal and family 
history were negative in all patients. Considering this fact there arises the question of a 
facultative possibility of thrombophile examination covered by the patient, based on the 
patient’s request, prior to administration of HAK. 
As a certain surprise we may mention the high incidence of homozygous form of C677T in 
out study group (37,5%), which may be in consistence with the findings of Martinelli et al., 
who proved the risk of CVT onset in users of hormonal contraceptives with 
hyperhomocysteinemia OR 19,5 95% CI (5,7 – 67,3). The levels of homocystein were not 
monitored in our patients. Other frequently observed findings included mutations of the 
plasminogen activator inhibitor gene  (PAI-1) and deficit of protein S, which may be also 
present in combinations strengthening the prothrombogenic effect. On the other hand, we 
did not observe an incidence of V Leiden factor in patients with CVT, however this factor is 
frequently mentioned in literature as a significant thrombophilic risk factor. 
7. Tables 
 
 1. 2. 3. 4. 5. 6. 7. 8. Mean 
Age 32.0 32.5 24.1 18.7 33.3 24.8 39.3 20.2 28.1 
Table 1. Age of patients included into the study 
 
Symptoms 1. 2. 3. 4. 5. 6. 7. 8. % 
Headache + + + + + + + + 100 
Vertigo  + + + + + + + 87.5 
Central hemiparesis 
and quadruparesis  + +  + + +  62,5 
Sight disorders    + +    25.0 
Sensitivity disorder  +    +   25.0 
Behavioural disorder       + + 25.0 
Aphasia  +     +  25.0 
Spasms     + +   25.0 
Coma   +  +    25.0 
Table 2. Subjective and objective manifestations on admission 
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CT/MR 1. 2. 3. 4. 5. 6. 7. 8. % 
Venous infarction, 
vasogenic inflation  + +  + + +  62,5 
Petechial 
haemorrhage     +  +  25,0 
 
Table 3. Parenchymatous lesions on CT/MRI 
 
 
 1. 2. 3. 4. 5. 6. 7. 8. % 
Sinus sagitalis 
superior +  + + +  +  62.5 
Sinus transversus,  
sigmoideus +  + + + + +  75,0 
Deep vein system   + + + +   50,0 
Cortical veins  + + + + +   62.5 
V.jugularis interna +  +     + 37.5 
Cerebellar veins      +   12.5 
 
Table 4. Occlusion of sinuses / cortical veins on DSA  3D- XR venography 
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Smoking - - - - - - - - 
LMWH – Low Molecular Weight Heparin, Wa – warfarin, LKT -  local continuous thrombolysis 
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 1. 2. 3. 4. 5. 6. 7. 8. 
Factor V  
Leiden - - - - - - - - 
MTHFR ++ ++ +- +- - ++ +- +- 
PAI-1 - - ++ - - ++ +- +- 
Factor VIII - - - + + + - - 
Hyperhomo-
cysteinemia + - - - - - - - 
Protein C 
deficit + - + - - - - - 
Protein S 
deficit + + - + - + - + 
Antithrombi
n deficit - - + - - - - - 
Legend:- negative, +- heterozygous, ++ homozygous 
-MTHFR- methylentetrahydrofolate reductase, PAI- plasminogen activator inhibitor  
Table 6. Results of thrombophilic parameters 
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1. Introduction  
In 1825, Ribes described a case of a 45-year old man who died after a 6-month history of 
epilepsy, seizures and delirium. The autopsy examination revealed thrombosis of the 
superior sagittal sinus, the left lateral sinus and a cortical vein in the parietal region. This 
was probably the first detailed description of extensive cerebral venous sinus thrombosis 
(CVST). Since then, the literature describing this disease has comprised of case reports, 
series and some newer prospective studies, including recent reviews and guidelines 
(statement) on the diagnosis and management of CVST (Siddiqui & Kamal, 2006; Stam, 2005; 
Saposnik et al, 2011; Brown & Thore, 2011).  
The cerebral venous sinus thrombosis is a challenging condition and it is most common than 
previously thought. CVST accounts for 0.5% to 1.0% of all strokes and usually affects young 
individuals. Important advances have been made in the understanding of the 
pathophysiology of this vascular disorder. The diagnosis of CVST is still frequently 
overlooked or delayed as a result of the wide spectrum of clinical symptoms and the often 
sub-acute or lingering onset. Patients with CVST commonly present with headache, 
although some develop a focal neurological deficit, decreased level of consciousness, 
seizures, or intracranial hypertension without focal neurological signs. Uncommonly, an 
insidious onset may create a diagnostic challenge. The main problem of this disorder is that 
it is very often unrecognised at initial presentation. In particular, a prothrombotic factor or a 
direct cause is identified in approximately 66% of the CVST patients (a list of most 
important causal and risk factors are listed in Table 1). 
Cerebral venous thrombosis is more common in women than men, with a female to male 
ratio of 3:1 (cited in Ferro & Canhao, 2011). The imbalance may be due to the increased risk 
of CVST associated with pregnancy and puerperium and with oral contraceptives. The 
female predominance in CVST is found in young adults, but not in children or older adults. 
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In the prospective International Study on Cerebral Vein and Dural Sinus Thrombosis 
(ISCVST) cohort of 624 adults with CVST, women comprised 465 (75%) of the patients. 
Compared with men, women had significantly lower mean age (42 vs 34 years). 
Furthermore, a gender specific risk factor — oral contraceptives, pregnancy, puerperium, 
and hormone replacement therapy — was identified in 65% of the women. CVST is more 
common in neonates than it is in infants, children or adults. In adults, CVST affects patients 
who are younger on average than those with arterial types of stroke. In the ISCVST, the 
mean age of patients with CVST was 39 years, and only 8% of them were older than 65 years 
(Ferro & Canhao, 2011). Topographically, the most frequent occurrence of CVST has been 
observed in the superior sagitral sinus (62%) followed by the transverse (lateral) sinus (41-
45%) (Figure 1). 
 





Fig. 1. MRI venogram of the cerebral venous system and most frequent location of CVST. 
Reproduced with the written permission from the paper by Saposnik et al. (2011) as derived from 
data on 624 patients in the International Study on Cerebral Venous and Dural Sinuses 
Thrombosis as reported by Manolidis & Kutz (2005). 
The pathogenesis of CVST remains incompletely understood because of the high variability 
in the anatomy of the venous system, and the paucity of experiments in animal models of 
CVST. However, there are at least two different mechanisms that may contribute to the 
clinical features of CVST: a) thrombosis of cerebral veins or dural sinus leading to cerebral 
parenchymal lesions or dysfunction; and b) occlusion of dural sinus resulting in decreased 
cerebrospinal fluid (CSF) absorption and elevated intracranial pressure. (Figure 2). Obstruction of 
the venous structures may result in increased venous pressure, decreased capillary 
perfusion pressure, and increased cerebral blood volume. Dilatation of cerebral veins and 
recruitment of collateral pathways play an important role in the early phases of CVST and 
may initially compensate for changes in pressure. The increase in venous and capillary 
pressure leads to blood-brain barrier disruption, causing vasogenic edema, with leakage of 
blood plasma into the interstitial space. As intravenous pressure continues to increase, mild 
parenchymal changes, severe cerebral edema, and venous hemorrhage may occur due to 
venous or capillary rupture. The increased intravenous pressure may lead to an increase in 
intravascular pressure and a lowering of cerebral perfusion pressure, resulting in decreased 
cerebral blood flow (CBF) and failure of energy metabolism. In turn, this allows intracellular 
entry of water from failure of the Na+/K+ ATPase pump, and consequent cytotoxic edema 
(Ferro & Canhao, 2011). 
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Fig. 2. Possible mechanisms of the development of CVST. Reproduced with the written 
permission from the paper by Ferro & Canhao (2011). 
Advances in our understanding of the venous occlusion pathophysiology have been 
achieved by the use of newer magnetic resonance imaging (MRI) methods, mainly diffusion-
weighted MRI (DWI) and perfusion-weighted MRI (PWI). These techniques have 
demonstrated the coexistence of both cytotoxic and vasogenic edema in patients with CVST. 
The other effect of venous thrombosis is impairment of CSF absorption. Normally, CSF 
absorption occurs in the arachnoid granulations (Leach et al, 2008), which drain CSF into the 
superior sagittal sinus. Thrombosis of the dural sinuses leads to increased venous pressure, 
impaired CSF absorption, and consequently elevated intracranial pressure. Elevated 
intracranial pressure is more frequent if superior sagittal sinus thrombosis is present, but it 
may also occur with thrombosis of the jugular or lateral sinus, producing a rise of pressure 
in the superior sagittal sinus. 
As shown in Table 1, many causes or predisposing conditions are associated with CVST. 
The major risk factors for CVST in adults can be grouped in two classes: transient or 
permanent (Table 2) . In more than 85% of the adult patients, at least one risk factor for CVST 
can be identified, most often a prothrombotic condition as mentioned above. In the ISCVST 
cohort, a prothrombotic condition was found in 34%, and a genetic prothrombotic condition 
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was found in 22% of all patients. Although infectious causes of CVST were frequently 
reported in the past, they are responsible for only 6 to 12 percent of cases in modern-era 
studies of adults with CVST. As with venous thrombosis in other parts of the body, multiple 
risk factors may be found in about half of adult patients with CVST. No underlying etiology 
or risk factor for CVST is found in approximately 13% of adult patients. However, it is 
important to continue searching for a cause even after the acute phase of CVST, as some 
patients may have a condition such as the antiphospholipid syndrome (APS), polycythemia, 
thrombocythemia, or malignancy that is discovered weeks or months after the acute phase. 
It should be noted that the risk for CVST is influenced by the individual's genetic background. 
In the presence of some prothrombotic conditions, patients are at an increased risk of 
developing CVST when exposed to a precipitant such a head trauma, lumbar puncture, 
jugular catheter placement, pregnancy, surgery, infection, and drugs. These prothrombotic 
conditions include the following: antithrombin deficiency, protein C deficiency or protein S 




Table 2. Classification of systemic and local conditions increasing the risk of cerebral venous 
thrombosis. Reproduced with the written permission from the paper by Ferro & Canhao (2011). 
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In particular, the most frequent risk factor in young women is the use of oral contraceptives. 
Two case-control studies have shown an increased risk of sinus thrombosis in women who use 
oral contraceptives. Furthermore, the risk for CVST in women using oral contraceptives is 
increased if they have a prothrombotic defect. In elderly CVST patients, the proportion of cases 
without identified risk factors is higher (37%) than it is in adults <65 years of age. The most 
common risk factors in those ≥65 years old are genetic or acquired thrombophilia, malignancy, 
and hematologic disorders such as polycythemia (Ferro & Canhao, 2011; Plata et al, 2002). 
2. Methods 
Search strategy. For the purpose of this review, a systematic search of the literature databases 
(e.g., PubMed) by the EndNote software as well as other reference and electronic databases 
(e.g., Cochrane Library) have been searched by specifically chosen MESH terms, back to 
1960. In total, while using the main four single terms (“cerebral”, “sinus”, “venous”, 
“thrombosis”) and combinations thereof, 4049 peer-reviewed titles have been initially found 
which have been later reduced down to 43 titles, among which 25 review papers have been 
also identified. Many references for this review came from the authors’ own archives. Two 
of us (PAA, BDD) independently reviewed all 43 titles for inclusion as retrieved as above 
and 35 of them were decided to be included. Additionally, through hand-searching the 
references of the selected articles and other relevant electronic sources (e.g., Google Scholar), 
several additional relevant titles were also reviewed for inclusion. Finally, out of the initially 
4049 identified titles and all other relevant titles, 39 articles were studied and included in 
this review. Any disagreements between the original reviewers have been resolved by a 
third, blinded reviewer (NTC); any further discrepancies have been solved by an open 
consensus among all of the reviewers. 
3. Results 
Most of the articles that were identified were case reports or limited case series. Others were 
original articles and reviews or overviews. We were able to initially identify 4049 peer-
reviewed titles in PubMed, including 25 review papers. To note, we were able to identify 
separately only 3 systematic reviews in the Cochrane Library (Ciccone et al, 2004; Kwan & 
Gunther, 2006; Stam et al, 2002 as cited in Stam, 2005). Finally, 39 articles were included for 
the purposes of this review. 
3.1 Early clinical detection and diagnostic strategies with imaging in CVST 
Clinical signs and symptoms and laboratory tests. The diagnosis of CVST is typically based 
on a clinical suspicion and imaging confirmation. Clinical findings in CVST usually fall into 
2 major categories: a) focal brain injury from venous ischemia/infarction or hemorrhage and b) 
increased intracranial pressure attributable to impaired venous drainage. Headache, generally 
indicative of an increase in intracranial pressure, is the most common symptom in CVST (in 
90% of the patients in the ISCVST). The headache of CVST is typically described as diffuse 
and often progresses in severity over days to weeks. A minority of patients may present 
with thunderclap headache (Saposnik et al, 2011), suggestive of subarachnoid hemorrhage 
(SAH) (Atanassova et al, 2006), and a migrainous type of headache has been described. 
Isolated headache without focal neurological findings or papilledema occurs in up to 25% of 
the patients with CVST and presents a significant diagnostic challenge. CVST is an 
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important diagnostic consideration in patients with headache and papilledema or diplopia 
(caused by sixth nerve palsy) even without other neurological focal signs. When a focal 
brain injury occurs, most common are hemiparesis and aphasia, but other cortical signs and 
sensory symptoms may be also observed, together with psychosis in such cases. The clinical 
manifestations of CVST may also depend on the location of the thrombosis as mentioned 
above (Figure 1). The superior sagittal sinus is most commonly involved. For the lateral 
sinus thromboses, as a second prevalent location, the symptoms related to an underlying 
condition (middle ear infection) may be noted, including constitutional symptoms, fever, 
and ear discharge. Pain in the ear or mastoid region and headache are typical. On 
examination, an increased intracranial pressure and distention of the scalp veins may be 
noted (hemianopia, contralateral weakness, and aphasia may sometimes be seen owing to 
cortical involvement). Approximately 16% of the patients with CVST have thrombosis of the 
deep cerebral venous system (internal cerebral vein, vein of Galen, and straight sinus), 
which can lead to thalamic or basal ganglial infarction (van der Bergh et al, 2005). Most 
patients present with rapid neurological deterioration (Saposnik et al, 2011). Importantly, 
several principal clinical features distinguish CVST from other cerebrovascular diseases 
(CVD). Notably, the focal or generalized seizures are frequent, occurring in about 40% of 
patients; and, secondly, as a clinical correlate to the anatomy of cerebral venous drainage, 
the bilateral brain involvement is not infrequent. The latter is particularly notable in cases 
that involve the deep venous drainage system, when bilateral thalamic involvement may 
occur, causing alterations in level of consciousness without focal neurological findings. 
Bilateral motor signs, including paraparesis, may also be present due to sagittal sinus 
thrombosis and bihemispheric injury. Finally, patients with CVST often present with slowly 
progressive symptoms. It has to be underlined that very frequently the delays in diagnosis 
of CVST are common and significant. In the ISCVST, symptom onset was acute (<48 hours) 
in 37% of patients, subacute (>48 hours to 30 days) in 56% of patients, and chronic (>30 
days) in 7% of the patients. The median delay from the onset of symptoms to the hospital 
admission was 4 days, and from symptom onset to the diagnosis - 7 days.  
Specific diagnostic cues. About 40% of the patients with CVST present with intracranial 
hemorrhage (ICH). The features suggestive of CVST as a cause of ICH include prodromal 
headache (which is highly unusual with other causes of ICH), bilateral parenchymal 
abnormalities, and clinical evidence of a hypercoagulable state. These features may not be 
present, however, and a high index of clinical suspicion is necessary. An isolated subarachnoid 
hemorrhage may also occur due to CVST, although this is rare (0.8% of patients in ISCVST). A 
second specific occurrence is isolated headache/idiopathic intracranial hypertension – for example, 
25% of the CVST patients may present with isolated headache, and another 25% - with 
headache in conjunction with papilledema or sixth nerve palsies suggestive of idiopathic 
intracranial hypertension. In a series of 131 patients who presented with papilledema and 
clinically suspected idiopathic intracranial hypertension, 10% had CVST at MRI/magnetic 
resonance venography (MRV). Imaging of the cerebral venous system has been recommended 
for all patients with the clinical picture of idiopathic intracranial hypertension. Regarding 
headache - it is an extremely common symptom, and most patients with isolated headache 
will not have CVST. The cost-effectiveness and yield of routine imaging are highly uncertain. 
Factors that may suggest the diagnosis, and thus prompt imaging evaluation, include a new, 
atypical headache; headache that progresses steadily over days to weeks despite conservative 
treatment; and thunderclap headache, especially if a hypercoagulable state is also present. A 
third difficult occurrence in CVST is when the patients present with somnolence or a confusional 
 
Venous Thrombosis – Principles and Practice 
 
134 
In particular, the most frequent risk factor in young women is the use of oral contraceptives. 
Two case-control studies have shown an increased risk of sinus thrombosis in women who use 
oral contraceptives. Furthermore, the risk for CVST in women using oral contraceptives is 
increased if they have a prothrombotic defect. In elderly CVST patients, the proportion of cases 
without identified risk factors is higher (37%) than it is in adults <65 years of age. The most 
common risk factors in those ≥65 years old are genetic or acquired thrombophilia, malignancy, 
and hematologic disorders such as polycythemia (Ferro & Canhao, 2011; Plata et al, 2002). 
2. Methods 
Search strategy. For the purpose of this review, a systematic search of the literature databases 
(e.g., PubMed) by the EndNote software as well as other reference and electronic databases 
(e.g., Cochrane Library) have been searched by specifically chosen MESH terms, back to 
1960. In total, while using the main four single terms (“cerebral”, “sinus”, “venous”, 
“thrombosis”) and combinations thereof, 4049 peer-reviewed titles have been initially found 
which have been later reduced down to 43 titles, among which 25 review papers have been 
also identified. Many references for this review came from the authors’ own archives. Two 
of us (PAA, BDD) independently reviewed all 43 titles for inclusion as retrieved as above 
and 35 of them were decided to be included. Additionally, through hand-searching the 
references of the selected articles and other relevant electronic sources (e.g., Google Scholar), 
several additional relevant titles were also reviewed for inclusion. Finally, out of the initially 
4049 identified titles and all other relevant titles, 39 articles were studied and included in 
this review. Any disagreements between the original reviewers have been resolved by a 
third, blinded reviewer (NTC); any further discrepancies have been solved by an open 
consensus among all of the reviewers. 
3. Results 
Most of the articles that were identified were case reports or limited case series. Others were 
original articles and reviews or overviews. We were able to initially identify 4049 peer-
reviewed titles in PubMed, including 25 review papers. To note, we were able to identify 
separately only 3 systematic reviews in the Cochrane Library (Ciccone et al, 2004; Kwan & 
Gunther, 2006; Stam et al, 2002 as cited in Stam, 2005). Finally, 39 articles were included for 
the purposes of this review. 
3.1 Early clinical detection and diagnostic strategies with imaging in CVST 
Clinical signs and symptoms and laboratory tests. The diagnosis of CVST is typically based 
on a clinical suspicion and imaging confirmation. Clinical findings in CVST usually fall into 
2 major categories: a) focal brain injury from venous ischemia/infarction or hemorrhage and b) 
increased intracranial pressure attributable to impaired venous drainage. Headache, generally 
indicative of an increase in intracranial pressure, is the most common symptom in CVST (in 
90% of the patients in the ISCVST). The headache of CVST is typically described as diffuse 
and often progresses in severity over days to weeks. A minority of patients may present 
with thunderclap headache (Saposnik et al, 2011), suggestive of subarachnoid hemorrhage 
(SAH) (Atanassova et al, 2006), and a migrainous type of headache has been described. 
Isolated headache without focal neurological findings or papilledema occurs in up to 25% of 
the patients with CVST and presents a significant diagnostic challenge. CVST is an 
 
Cerebral Venous Sinus Thrombosis - Diagnostic Strategies and Prognostic Models: A Review 
 
135 
important diagnostic consideration in patients with headache and papilledema or diplopia 
(caused by sixth nerve palsy) even without other neurological focal signs. When a focal 
brain injury occurs, most common are hemiparesis and aphasia, but other cortical signs and 
sensory symptoms may be also observed, together with psychosis in such cases. The clinical 
manifestations of CVST may also depend on the location of the thrombosis as mentioned 
above (Figure 1). The superior sagittal sinus is most commonly involved. For the lateral 
sinus thromboses, as a second prevalent location, the symptoms related to an underlying 
condition (middle ear infection) may be noted, including constitutional symptoms, fever, 
and ear discharge. Pain in the ear or mastoid region and headache are typical. On 
examination, an increased intracranial pressure and distention of the scalp veins may be 
noted (hemianopia, contralateral weakness, and aphasia may sometimes be seen owing to 
cortical involvement). Approximately 16% of the patients with CVST have thrombosis of the 
deep cerebral venous system (internal cerebral vein, vein of Galen, and straight sinus), 
which can lead to thalamic or basal ganglial infarction (van der Bergh et al, 2005). Most 
patients present with rapid neurological deterioration (Saposnik et al, 2011). Importantly, 
several principal clinical features distinguish CVST from other cerebrovascular diseases 
(CVD). Notably, the focal or generalized seizures are frequent, occurring in about 40% of 
patients; and, secondly, as a clinical correlate to the anatomy of cerebral venous drainage, 
the bilateral brain involvement is not infrequent. The latter is particularly notable in cases 
that involve the deep venous drainage system, when bilateral thalamic involvement may 
occur, causing alterations in level of consciousness without focal neurological findings. 
Bilateral motor signs, including paraparesis, may also be present due to sagittal sinus 
thrombosis and bihemispheric injury. Finally, patients with CVST often present with slowly 
progressive symptoms. It has to be underlined that very frequently the delays in diagnosis 
of CVST are common and significant. In the ISCVST, symptom onset was acute (<48 hours) 
in 37% of patients, subacute (>48 hours to 30 days) in 56% of patients, and chronic (>30 
days) in 7% of the patients. The median delay from the onset of symptoms to the hospital 
admission was 4 days, and from symptom onset to the diagnosis - 7 days.  
Specific diagnostic cues. About 40% of the patients with CVST present with intracranial 
hemorrhage (ICH). The features suggestive of CVST as a cause of ICH include prodromal 
headache (which is highly unusual with other causes of ICH), bilateral parenchymal 
abnormalities, and clinical evidence of a hypercoagulable state. These features may not be 
present, however, and a high index of clinical suspicion is necessary. An isolated subarachnoid 
hemorrhage may also occur due to CVST, although this is rare (0.8% of patients in ISCVST). A 
second specific occurrence is isolated headache/idiopathic intracranial hypertension – for example, 
25% of the CVST patients may present with isolated headache, and another 25% - with 
headache in conjunction with papilledema or sixth nerve palsies suggestive of idiopathic 
intracranial hypertension. In a series of 131 patients who presented with papilledema and 
clinically suspected idiopathic intracranial hypertension, 10% had CVST at MRI/magnetic 
resonance venography (MRV). Imaging of the cerebral venous system has been recommended 
for all patients with the clinical picture of idiopathic intracranial hypertension. Regarding 
headache - it is an extremely common symptom, and most patients with isolated headache 
will not have CVST. The cost-effectiveness and yield of routine imaging are highly uncertain. 
Factors that may suggest the diagnosis, and thus prompt imaging evaluation, include a new, 
atypical headache; headache that progresses steadily over days to weeks despite conservative 
treatment; and thunderclap headache, especially if a hypercoagulable state is also present. A 
third difficult occurrence in CVST is when the patients present with somnolence or a confusional 
 
Venous Thrombosis – Principles and Practice 
 
136 
state in the absence of obvious focal neurological abnormalities (more common in the elderly and 
with thrombosis of the deep venous system). Although a number of mechanisms may underlie 
this clinical presentation, an important cause is bilateral thalamic lesions due to involvement of 
the deep venous system. Early CT scanning may not be useful; MRI will usually demonstrate 
abnormalities in such cases (Saposnik et al, 2011).   
Laboratory and other biochemical tests. A complete blood count, chemistry panel, 
sedimentation rate, and measures of the prothrombin time and activated partial 
thromboplastin time are indicated for suspected CVST. These may be indicative of hidden 
hypercoagulable state, infectious process or inflammatory state as contributing factors to the 
CVST development. Further, the examination of the cerebrospinal fluid (CSF) is typically 
not helpful in cases with focal neurological abnormalities and radiographic confirmation of 
the diagnosis of CVST unless there might be a suspicion of meningitis. An elevated opening 
pressure may be a clue for diagnosing CVST in patients who present with headaches (i.e., 
such pressure may be present in >80% of the patients). Elevated cell counts may be present 
in about 50% of the patients and the increased protein levels - in about 35%, however, their 
absence should not exclude a consideration of CVST. Usually, there are no specific CSF 
abnormalities in CVST. Additionally to the above routine tests, the D-dimer, a product of 
fibrin degradation, has a diagnostic role in exclusion of DVT or pulmonary embolus when 
used with pre-test probability assessment. In a well-designed prospective, multicenter study 
of 343 patients presenting to the emergency department with symptoms that suggested 
CVST, a positive D-dimer level (defined as a level >500µg/l) was found in 34 of 35 patients 
with confirmed CVST and 27 of 308 patients without CVST (sensitivity >97% and specificity 
>90%). Having a negative predictive value of 99.6% a normal D-dimer level test may easily 
help identify patients with a low probability of CVST. Several factors may account for some 
of discrepant findings of the D-dimer test - first, D-dimer levels decline with time from onset 
of symptoms, which suggests that patients who present with subacute or chronic symptoms 
are more likely to have negative D-dimer levels; second, the anatomic extent of thrombosed 
sinuses may correlate with D-dimer levels, which suggests that patients with lesser clot 
burden may have false negative D-dimer testing results.  
In the view of the above evidence, the following specific recommendations may be 
summarised (Saposnik et al, 2011): 
 In patients with suspected CVST, routine blood studies consisting of a complete blood 
count, chemistry panel, prothrombin time, and activated partial thromboplastin time 
should be performed; screening for potential prothrombotic conditions that may 
predispose a person to CVST (eg, use of contraceptives, underlying inflammatory 
disease, infectious process) is recommended in the initial clinical assessment;  
 A normal D-dimer level according to a sensitive immunoassay or rapid enzyme-linked 
immunosorbent assay (ELISA) may be considered to help identify patients with low 
probability of CVST - if there is a strong clinical suspicion of CVST, a normal D-dimer 
level should not preclude further evaluation;  
 In patients with lobar ICH of otherwise unclear origin or with cerebral infarction that 
crosses typical arterial boundaries, imaging of the cerebral venous system should be 
performed; 
 In patients with the clinical features of idiopathic intracranial hypertension, imaging of 
the cerebral venous system is recommended to exclude CVST; in patients with 
headache associated with atypical features, imaging of the cerebral venous system is 
reasonable to exclude CVST.  
 




Fig. 3. MRI of Sinus Thrombosis.In Panel A, a T1-weighted MRI scan obtained with the 
spin–echo technique provides a sagittal view of a hyperintense signal in the thrombosed 
superior sagittal sinus (arrows). In Panel B, a magnetic resonance venogram obtained 
without the administration of contrast material reveals the absence of a signal in the 
superior sagittal sinus (upper arrows) and a normal flow signal in the transverse and 
sigmoid sinuses (lower arrow) as well as in a number of veins. Reproduced with the written 
permission from the paper by Stam (2005). 
Diagnostic imaging in CVST. The diagnostic imaging has played an increasing role in the 
better diagnosis and management of CVST. The aim is to determine vascular and 
parenchymal changes associated with this medical condition (possibly, the diagnosis is 
made only with cerebral digital subtraction angiography). 
Noninvasive diagnostic techniques: CT, MRI and ultrasound. Computed tomography (CT) is 
widely used as the initial neuroimaging test in patients who present with new-onset 
neurological symptoms such as headache, seizure, mental alteration, or focal neurological 
signs. CT without contrast is often normal but may demonstrate findings that suggest CVST. 
Anatomic variability of the venous sinuses makes CT diagnosis of CVST insensitive, with 
results on a plain CT being abnormal only in about 30% of CVST cases. The primary sign of 
acute CVST on a non-contrast CT is hyperdensity of a cortical vein or dural sinus. Acutely 
thrombosed cortical veins and dural sinuses appear as a homogenous hyperdensity that fills 
the vein or sinus and are most clearly visualized when CT slices are perpendicular to the 
dural sinus or vein. However, only approximately 30% of CVST demonstrates direct signs of 
hyperdense dural sinus. Thrombosis of the posterior portion of the superior sagittal sinus 
may appear as a dense triangle, the dense or filled delta sign. An ischemic infarction, 
sometimes with a hemorrhagic component, may be seen. An ischemic lesion that crosses 
usual arterial boundaries (with a hemorrhagic component) or in close proximity to a venous 
sinus is suggestive of CVST. Subarachnoid hemorrhage is not frequent – it is seen only in up 
to 0.8% of the CVST patients, and when present, it was localized in the convexity as opposed 
to the area of the circle of Willis usually observed in patients with aneurysmal rupture. 
Contrast-enhanced CT may show enhancement of the dural lining of the sinus with a filling 
defect within the vein or sinus. Contrast-enhanced CT may show the classic “empty delta” 
 
Venous Thrombosis – Principles and Practice 
 
136 
state in the absence of obvious focal neurological abnormalities (more common in the elderly and 
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spin–echo technique provides a sagittal view of a hyperintense signal in the thrombosed 
superior sagittal sinus (arrows). In Panel B, a magnetic resonance venogram obtained 
without the administration of contrast material reveals the absence of a signal in the 
superior sagittal sinus (upper arrows) and a normal flow signal in the transverse and 
sigmoid sinuses (lower arrow) as well as in a number of veins. Reproduced with the written 
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dural sinus or vein. However, only approximately 30% of CVST demonstrates direct signs of 
hyperdense dural sinus. Thrombosis of the posterior portion of the superior sagittal sinus 
may appear as a dense triangle, the dense or filled delta sign. An ischemic infarction, 
sometimes with a hemorrhagic component, may be seen. An ischemic lesion that crosses 
usual arterial boundaries (with a hemorrhagic component) or in close proximity to a venous 
sinus is suggestive of CVST. Subarachnoid hemorrhage is not frequent – it is seen only in up 
to 0.8% of the CVST patients, and when present, it was localized in the convexity as opposed 
to the area of the circle of Willis usually observed in patients with aneurysmal rupture. 
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sign, in which a central hypointensity due to absent or very slow flow within the sinus is 
surrounded by contrast enhancement in the surrounding triangular shape in the posterior 
aspect of the superior sagittal sinus. This finding may not appear for several days after onset 
of symptoms but does persist for several weeks. Due to delays or overlooking, CVST may be 
seen only during the subacute or chronic stage. Compared with the density of adjacent brain 
tissue, thrombus may be isodense, hypodense, or of mixed density. In this situation, contrast 
CT or CT venography (CTV) may assist the imaging diagnosis. In general, the magnetic 
resonance imaging (MRI) is more sensitive for the detection of CVST than CT at each stage 
after thrombosis (Figure 3). CVST is diagnosed on MRI with the detection of thrombus in a 
venous sinus. Findings are variable but may include a “hyperintense vein sign”. Isolated 
cortical venous thrombosis (Chang et al, 1995) is identified much less frequently than sinus 
thrombosis. The magnetic resonance signal intensity of venous thrombus varies according to 
the time of imaging from the onset of thrombus formation. Acute thrombus may be of low 
intensity. In the first week, venous thrombus frequently appears as isointense to brain tissue 
on T1-weighted images and hypointense on T2- weighted images owing to increased 
deoxyhemoglobin. By the second week, thrombus contains methemoglobin, which results in 
hyperintensity on T1- and T2-weighted images. With evolution of the thrombus, the 
paramagnetic products of deoxyhemoglobin and methemoglobin are present in the sinus. A 
thrombosed dural sinus or vein may then demonstrate low signal on gradient-echo and 
susceptibility-weighted images of magnetic resonance images. The principal early signs of 
CVST on non–contrast-enhanced MRI are the combination of absence of a flow void with 
alteration of signal intensity in the dural sinus. MRI of the brain is suggestive of CVST by 
the absence of a fluid void signal in the sinus, T2 hypointensity suggestive of a thrombus, or 
a central isodense lesion in a venous sinus with surrounding enhancement. This appearance 
is the MRI equivalent of the CT empty delta sign. An acute venous thrombus may have 
hypo-intense signal that mimics a normal flow void. The nature of the thrombus then 
evolves through a subacute and chronic phase. 
Thus, a contrast-enhanced MRI and either CTV or MRV may be necessary to establish a 
definite diagnosis. The secondary signs of MRI may show similar patterns to CT, including 
cerebral swelling, edema, and/or hemorrhage. Occasionally, diffusion-weighted imaging 
(DWI) and perfusion-weighted MRI may assist in making the diagnosis. DWI may show 
high signal intensity as restricted diffusion- and perfusion-weighted MRI with prolonged 
transit time. Brain parenchymal lesions of CVST are better visualized and depicted on MRI 
than at CT. Focal edema without hemorrhage is visualized on CT in about 8% of cases and 
on MRI in 25% of cases. Focal parenchymal changes with edema and hemorrhage may be 
identified in up to 40% of patients. Petechial or confluent hemorrhage may also represent an 
underlying hemorrhagic venous infarction. This may include DWI abnormalities consistent 
with acute infarction, but the degree of DWI findings may be reduced in venous infarction 
compared with arterial infarction. An altered enhancement pattern suggestive of collateral 
flow or of venous congestion may be seen. There are some characteristic patterns of brain 
parenchymal changes that distinguish CVST from other entities. Also, to some extent, 
lesions related to specific sinuses are regionally distributed. Brain parenchymal changes in 
frontal, parietal, and occipital lobes usually correspond to superior sagittal sinus 
thrombosis. Temporal lobe parenchymal changes correspond to lateral (transverse) and 
sigmoid sinus thrombosis. Deep parenchymal abnormalities, including thalamic 
hemorrhage, edema, or intraventricular hemorrhage, correspond to thrombosis of the vein 
of Galen or straight sinus. MRI signal can also predict radiographic outcome to some extent, 
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because DWI abnormality within veins or sinus predicts poor recanalization. The CT 
venography (CTV) can provide a rapid and reliable modality for detecting CVST. CTV is 
much more useful in subacute or chronic situations because of the varied density in 
thrombosed sinus. Because of the dense cortical bone adjacent to dural sinus, bone artifact 
may interfere with the visualization of enhanced dural sinus. CTV is at least equivalent to 
MRV in the diagnosis of CVST. However, drawbacks to CTV include concerns about 
radiation exposure, potential for iodine contrast material allergy, and issues related to use of 
contrast in the setting of poor renal function. In some settings, MRV is preferable to CTV 
because of these concerns. The most commonly used magnetic resonance venography 
(MRV) techniques are time-of-flight (TOF) MRV and contrast-enhanced magnetic resonance. 
Phase-contrast MRI is used less frequently, because defining the velocity of the encoding 
parameter is both difficult and operator-dependent. T2-weighted magnetic resonance image 
showing mixed hypointensity (white arrow) and isointensity (black arrow) signals 
representing an acute hemorrhage at left parietal lobe.  
The 2D TOF technique is the most commonly used method currently for the diagnosis of 
CVST, because 2-dimensional TOF has excellent sensitivity to slow flow compared with 3-
dimensional TOF. It does have several potential pitfalls in imaging interpretation Despite 
the challenges, other sequences such as gradient echo, susceptibility/weighted imaging, and 
contrast MRI/MRV may assist in these situations. Nonthrombosed hypoplastic sinus will 
not have abnormal low signal in the sinus on gradient echo or susceptibility-weighted 
images. The chronic thrombosed hypoplastic sinus will have marked enhanced sinus and no 
flow on 2-dimensional TOF venography. Contrast-enhanced MRI offers improved 
visualization of cerebral venous structures (Figure 4).  
 
 
Fig. 4. CVST diagnosis: CT, MRI and venography. MR venography with limited spatial 
resolution, saturation of flow signal; CT venography; IA venography with hypoplasia vs. 
occlusion; high anatomical variability. Reproduced with the written permission from the 
presentation by Ferro (2010).  
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CVST on non–contrast-enhanced MRI are the combination of absence of a flow void with 
alteration of signal intensity in the dural sinus. MRI of the brain is suggestive of CVST by 
the absence of a fluid void signal in the sinus, T2 hypointensity suggestive of a thrombus, or 
a central isodense lesion in a venous sinus with surrounding enhancement. This appearance 
is the MRI equivalent of the CT empty delta sign. An acute venous thrombus may have 
hypo-intense signal that mimics a normal flow void. The nature of the thrombus then 
evolves through a subacute and chronic phase. 
Thus, a contrast-enhanced MRI and either CTV or MRV may be necessary to establish a 
definite diagnosis. The secondary signs of MRI may show similar patterns to CT, including 
cerebral swelling, edema, and/or hemorrhage. Occasionally, diffusion-weighted imaging 
(DWI) and perfusion-weighted MRI may assist in making the diagnosis. DWI may show 
high signal intensity as restricted diffusion- and perfusion-weighted MRI with prolonged 
transit time. Brain parenchymal lesions of CVST are better visualized and depicted on MRI 
than at CT. Focal edema without hemorrhage is visualized on CT in about 8% of cases and 
on MRI in 25% of cases. Focal parenchymal changes with edema and hemorrhage may be 
identified in up to 40% of patients. Petechial or confluent hemorrhage may also represent an 
underlying hemorrhagic venous infarction. This may include DWI abnormalities consistent 
with acute infarction, but the degree of DWI findings may be reduced in venous infarction 
compared with arterial infarction. An altered enhancement pattern suggestive of collateral 
flow or of venous congestion may be seen. There are some characteristic patterns of brain 
parenchymal changes that distinguish CVST from other entities. Also, to some extent, 
lesions related to specific sinuses are regionally distributed. Brain parenchymal changes in 
frontal, parietal, and occipital lobes usually correspond to superior sagittal sinus 
thrombosis. Temporal lobe parenchymal changes correspond to lateral (transverse) and 
sigmoid sinus thrombosis. Deep parenchymal abnormalities, including thalamic 
hemorrhage, edema, or intraventricular hemorrhage, correspond to thrombosis of the vein 
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because DWI abnormality within veins or sinus predicts poor recanalization. The CT 
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much more useful in subacute or chronic situations because of the varied density in 
thrombosed sinus. Because of the dense cortical bone adjacent to dural sinus, bone artifact 
may interfere with the visualization of enhanced dural sinus. CTV is at least equivalent to 
MRV in the diagnosis of CVST. However, drawbacks to CTV include concerns about 
radiation exposure, potential for iodine contrast material allergy, and issues related to use of 
contrast in the setting of poor renal function. In some settings, MRV is preferable to CTV 
because of these concerns. The most commonly used magnetic resonance venography 
(MRV) techniques are time-of-flight (TOF) MRV and contrast-enhanced magnetic resonance. 
Phase-contrast MRI is used less frequently, because defining the velocity of the encoding 
parameter is both difficult and operator-dependent. T2-weighted magnetic resonance image 
showing mixed hypointensity (white arrow) and isointensity (black arrow) signals 
representing an acute hemorrhage at left parietal lobe.  
The 2D TOF technique is the most commonly used method currently for the diagnosis of 
CVST, because 2-dimensional TOF has excellent sensitivity to slow flow compared with 3-
dimensional TOF. It does have several potential pitfalls in imaging interpretation Despite 
the challenges, other sequences such as gradient echo, susceptibility/weighted imaging, and 
contrast MRI/MRV may assist in these situations. Nonthrombosed hypoplastic sinus will 
not have abnormal low signal in the sinus on gradient echo or susceptibility-weighted 
images. The chronic thrombosed hypoplastic sinus will have marked enhanced sinus and no 
flow on 2-dimensional TOF venography. Contrast-enhanced MRI offers improved 
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In patients with persistent or progressive symptoms despite medical treatment, repeated 
neuroimaging (including a CTV or MRV) may help identify the development of a new 
ischemic lesion, ICH, edema, propagation of the thrombus, or other brain parenchymal 
lesions. The deep venous system is readily seen on CT and MRI and may be less impacted 
by artifact because of the separation from bony structures. A potential pitfall at the junction 
of the straight sinus and vein of Galen on TOF MRI is the appearance of absence of flow if 
image acquisition is in an axial plane to the skull. This pitfall may be overcome with 
contrast-enhanced MRI and DWI.   
Invasive diagnostic angiographic procedures. The cerebral angiographic procedures are less 
commonly needed to establish the diagnosis of CVST given the availability of MRV and 
CTV. These techniques are reserved for situations in which the MRV or CTV results are 
inconclusive or if an endovascular procedure is being considered. Cerebral angiography 
(arteriographic) findings include the failure of sinus appearance due to the occlusion; 
venous congestion with dilated cortical, scalp, or facial veins; enlargement of typically 
diminutive veins from collateral drainage; and reversal of venous flow. The venous phase of 
cerebral angiography will show a filling defect in the thrombosed cerebral vein/sinus. 
Because of the highly variable cerebral venous structures and inadequate resolution, CT or 
MRI may not provide adequate visualization of selected veins, especially cortical veins and 
in some situations the deep venous structures. Hypoplasia or atresia of cerebral veins or 
dural sinuses may lead to inconclusive results on MRV or CTV and can be clarified on the 
venous phase of cerebral angiography. Acute dural sinus and cortical vein thrombosis 
typically causes a delay in cerebral venous circulation, and cerebral angiography will 
demonstrate delayed and slow visualization of cerebral venous structures. Normally, the 
early veins begin to opacify at 4 to 5 seconds after injection of contrast material into the 
carotid artery, and the complete cerebral venous system is opacified in 7 to 8 seconds. If 
cerebral veins or dural sinuses are not visualized in the normal sequences of cerebral 
angiography, the possibility of acute thrombosis is suspected. This finding accounts for the 
observed delayed cerebral perfusion seen with perfusion/weighted MRI with prolonged 
transit time. The direct cerebral venography (DCV) is performed by direct injection of contrast 
material into a dural sinus or cerebral vein from microcatheter insertion via the internal 
jugular vein. DCV is usually performed during endovascular therapeutic procedures. In 
direct cerebral venography, intraluminal thrombus is seen either as a filling defect within 
the lumen in the setting of nonocclusive thrombosis or as complete nonfilling in occlusive 
thrombosis. Complete thrombosis may also demonstrate a “cupping appearance” within the 
sinus. Venous pressure measurements may be performed during direct cerebral venography 
to identify venous hypertension. Normal venous sinus pressure is <10 mm H2O. The extent 
of parenchymal change correlates with increased venous pressure and with the stage of 
thrombosis, with changes being maximal in acute thrombosis. Transfontanellar ultrasound 
may be used to evaluate pediatric patients, including newborn or young infants with open 
anterior or posterior fontanels. Ultrasound, along with transcranial Doppler, may be useful 
to support the diagnosis of CVST and for ongoing monitoring. Evidence on perfusion imaging 
methods (PIM) using positron emission tomography, although scarce, showed a reduction of 
the cerebral blood flow after ligation of the superior sagittal sinus with a concomitant 
venous infarction. An increased regional cerebral blood volume was also observed in a 
young adult with sagittal sinus thrombosis. A prolonged mean transit time and increased 
cerebral blood volume have been suggested as venous congestion, contrary to the pattern 
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observed in patients with an ischemic arterial stroke (prolonged mean transit time with 
reduction in cerebral blood volume).  
Of note, some common pitfalls in the diagnostic imaging should be also mentioned. The 
positive findings of intraluminal thrombus are the most important feature to a confident 
diagnosis of CVST by CT or MRI. Unfortunately, these findings are not always evident, and 
the diagnosis rests on nonfilling of a venous sinus or cortical vein. Given the variation in 
venous anatomy, it is sometimes impossible to exclude CVST on noninvasive imaging 
studies. Anatomic variants of normal venous anatomy may mimic sinus thrombosis, 
including sinus atresia/hypoplasia, asymmetrical sinus drainage, and normal sinus filling 
defects related to prominent arachnoid granulations or intrasinus septa. Angiographic 
examination of 100 patients with no venous pathology showed a high prevalence of 
asymmetrical lateral (transverse) sinuses (49%) and partial or complete absence of one 
lateral sinus (20%). Flow gaps are commonly seen on TOF MRV images, which sometimes 
affects their interpretation. The hypoplastic dural sinus may have a more tapering 
appearance than an abrupt defect in contrast-enhanced images of the sinus. The lack of 
identification of a thrombus within the venous sinus on MRI or contrast-enhanced MRV or 
CTV is helpful to clarify the diagnosis. As mentioned, sinus signal-intensity variations may 
also affect the interpretation of imaging in the diagnosis of CVST. The direct cerebral 
venography may be difficult to interpret owing to retrograde flow of contrast from the point 
of injection, and the venous pressure may not be accurate because of relative 
compartmentalization within the system.  
The following specific recommendations for diagnostic imaging in CVST may be 
summarised (Saposnik et al, 2011): 
 Plain CT or MRI is useful in the initial evaluation of patients with suspected CVST, 
however, a negative plain CT or MRI does not rule out CVST. A venographic study 
(either CTV or MRV) should be performed in suspected CVST if the plain CT or MRI is 
negative or to define the extent of CVST if the plain CT or MRI suggests CVST;  
 Early follow-up CTV or MRV is recommended in CVST patients with persistent or 
evolving symptoms despite medical treatment or with symptoms suggestive of 
propagation of thrombus; 
 For patients who present with recurrent symptoms suggestive of CVST and had had a 
previous CVST, a repeat CTV or MRV is recommended; 
 Gradient echo T2 susceptibility-weighted images combined with magnetic resonance 
can be useful to improve the accuracy of CVST diagnosis; 
 Catheter cerebral angiography can be useful in patients with inconclusive CTV or MRV 
in whom a clinical suspicion for CVST remains high; 
 A follow-up CTV or MRV at 3 to 6 months after diagnosis is reasonable to assess for 
recanalization of the occluded cortical vein/sinuses in stable patients. 
3.2 Management of CVST - Technological advances and treatment options 
Acute management and treatment of CVST. A summary algorithm for the diagnosis and 
management of patients with CVST is provided (Figure 5). The initial anticoagulation 
therapy (AT) has 3 aims in CVST: a) to prevent thrombus growth, b) to facilitate 
recanalization, and c) to prevent DVT or pulmonary embolism (PE). There is a controversy 
in the consideration for recommendations regarding AT, because a cerebral infarction with 
hemorrhagic transformation or ICH is commonly present at the time of diagnosis of CVST, 
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Fig. 5. Algorithm for initial management of CVST. Symbols and abbreviations:  CVST indicates 
cerebral venous and sinus thrombosis; LMWH, low molecular weight heparin; Tx, therapy; 
ICH, intracerebral hemorrhage; CTV, CT venogram; MRV, MR venogram. †Intracranial 
hemorrhage that occurred as the consequence of CVST is not a contraindication for 
anticoagulation. ‡Endovascular therapy may be considered in patients with absolute 
contraindications for anticoagulation therapy or failure of initial therapeutic doses of 
anticoagulant therapy. Note: Anticoagulation remains the principal therapy and is aimed at 
preventing thrombus propagation and increasing recanalization. This algorithm is not 
comprehensive, nor applicable to all clinical scenarios and patient management must be 
individualized. Limited evidence is available on the benefits of decompressive 
hemicraniectomy and endovascular therapy for the management of CVST as reflected by the 
low grade and level of recommendations. Anticipated future advances in imaging 
techniques, new pharmacological agents and endovascular procedures may provide other 
therapeutic alternatives to be considered in patients with CVST. Reproduced with the written 
permission from the paper by Saposnik et al (2011). 
and it may also complicate treatment. A number of observational studies, both prospective 
and retrospective, are available, primarily from single centers. Not all studies reported 
specifically on outcomes of anticoagulation treatment, because the majority of patients in most 
studies were treated with intravenous UFH or low-molecular-weight heparin (LMWH) at the 
time of diagnosis, with eventual use of vitamin K antagonists. Mortality rates were low, 
typically less than 10%, often due to the underlying disease (eg, cancer, etc (Knopp, 1995)) 
rather than CVST and rarely due to ICH. The majority of patients fully recovered neurological 
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function, and few became disabled. In a retrospective study of 102 patients with CVST, 43 had 
an ICH. Among 27 (63%) who were treated with doseadjusted intravenous heparin after the 
ICH, 4 died (15%), and 14 patients (52%) recovered completely. Of the 13 patients who did not 
receive heparin, mortality was higher (69%) with lower improvement in functional outcomes 
(only 3 patients completely recovered). The largest study by far was the ISCVST, which 
included 624 patients at 89 centers in 21 countries. Nearly all patients were treated with 
anticoagulation initially, and mortality was 8.3% over 16 months; 79% had complete recovery 
(modified Rankin scale [mRS] score of 0 to 1), 10.4% had mild to moderate disability (mRS 
score 2-3) and 2.2% remained severely disabled (mRS score 4-5).10 Few studies had sufficient 
numbers of patients not treated with anticoagulation to adequately address the role of 
anticoagulation in relation to outcome. Data from observational studies suggest a range of 
risks for ICH after anticoagulation for CVST from zero to 5.4%.  
There are two available randomized controlled trials comparing anticoagulant therapy with 
placebo or open control in patients with CVST confirmed by contrast imaging (cited in 
Saposnik et al, 2011). Taken together, these trials included only 79 patients. Meta-analysis of 
these 2 trials revealed a non-statistically significant relative risk of death or dependency 
with anticoagulation (relative risk 0.46, 95%CI 0.16 to 1.31), with a risk difference in favor of 
anticoagulation of -13% (95%CI -30% to 3%). The relative risk of death was 0.33 (95%CI 0.08 
to 1.21), with a risk difference of -13% (95%CI -27% to 1%). A third randomized trial with 57 
women (with puerperal CVST confirmed only by CT imaging) excluded those with 
hemorrhage on CT. Treatment was with subcutaneous heparin 5000 IU every 6 hours, dose 
adjusted to an activated partial thromboplastin time 1.5 times baseline for at least 30 days after 
delivery. Outcome assessment was not blinded. Three patients in the control group either died 
or had residual paresis compared with none in the heparin group. In the special situation of 
CVST with cerebral hemorrhage on presentation, even in the absence of anticoagulation, 
hemorrhage is associated with adverse outcomes. Highlighting this, in 1 trial of nadroparin, all 
6 deaths in the trial overall occurred in the group of 29 patients with hemorrhage on their 
pretreatment CT scan. None of the deaths were attributed to new or enlarged hemorrhage. 
These 29 patients were equally divided between treatment groups. Thus, cerebral hemorrhage 
was strongly associated with mortality but not with cerebral bleeding on treatment. Other 
studies suggested low rates of cerebral hemorrhage after anticoagulation for CVST. In the 
special situation of a patient with a major contraindication for anticoagulation (such as recent 
major hemorrhage), the risks and benefits of anticoagulation must be balanced. In these 
settings, as for venous thrombosis in general, consultation with an expert in anticoagulation 
management may be appropriate, and low-intensity anticoagulation may be considered if 
possible in favor of no anticoagulation until such time as it might be safe to use full-intensity 
anticoagulation. In conclusion, limited data from randomized controlled clinical trials in 
combination with observational data on outcomes and bleeding complications of 
anticoagulation support a role for anticoagulation in treatment of CVST, regardless of the 
presence of pretreatment ICH. On the basis of the available data, it is unlikely that researchers 
will have equipoise on this question, so a new randomized trial may not be feasible. 
Anticoagulation appears safe and effective. There was consensus in the writing group to 
support anticoagulation therapy in the management of patients with CVST. If anticoagulation 
is given, there are no data supporting differences in outcome with the use of UFH in adjusted 
doses or LMWH in CVST patients. However, in the setting of DVT or PE, a recent systematic 
review and meta-analysis of 22 studies showed a lower risk of major hemorrhage (1.2% vs. 
2.1%), thrombotic complications (3.6% vs. 5.4%), and death (4.5% vs. 6.0%) with LMWH.  
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Fibrinolytic therapy (FT) Although patients with CVST may recover with anticoagulation 
therapy, 9% to 13% have poor outcomes despite anticoagulation. Anticoagulation alone may 
not dissolve a large and extensive thrombus, and the clinical condition may worsen even 
during heparin treatment. Incomplete recanalization or persistent thrombosis may explain 
this phenomenon. Partial or complete recanalization rates for CVST ranged from 47% to 
100% with anticoagulation alone. Unfortunately, most studies reporting partial or complete 
recanalization at 3 to 6 months have a small sample size. When 4 studies that included 114 
CVST patients were combined, partial or complete recanalization at 3 to 6 months was 
observed in 94 (82.5%). Recanalization rates may be higher for patients who receive 
thrombolytic therapy (Stolz et al, 2004). In general, thrombolytic therapy is used if clinical 
deterioration continues despite anticoagulation or if a patient has elevated intracranial 
pressure that evolves despite other management approaches (Smith et alm 1997). Many 
invasive therapeutic procedures have been reported to treat CVST. These include direct 
catheter chemical thrombolysis and direct mechanical thrombectomy with or without 
thrombolysis. There are no randomized controlled trials to support these interventions 
compared with anticoagulation or with each other. Most evidence is based on small case 
series or anecdotal reports. Here, we review the studied interventions.  
In direct catheter thrombolysis (DCT), a standard microcatheter and microguidewire are 
delivered to the thrombosed dural sinus through a sheath or guiding catheter from the 
jugular bulb. Mechanical manipulation of the thrombus with the guidewire increases the 
amount of clot that might be impacted by the thrombolytic agent, potentially reducing the 
amount of fibrinolytic agent used. In a retrospective multicenter study of CVST in the 
United States, 27 (15%) of 182 patients received endovascular thrombolysis. Ten patients 
were receiving concomitant anticoagulation therapy. Recanalization was achieved in 26 
patients (96%), 4 developed an intracranial hemorrhage, and 1 patient (4%) died. A 
systematic review that included 169 patients with CVST treated with local thrombolysis 
showed a possible benefit for those with severe CVST, which indicates that fibrinolytics may 
reduce case fatality in critically ill patients. ICH occurred in 17% of patients after 
thrombolysis and was associated with clinical worsening in 5%.  
The other available options include mechanical thrombectomy/thrombolysis (MTT) 
techniques. The balloon-assisted thrombectomy and thrombolysis (BATT) may be more efficient 
in cases where (despite above approaches) the sinus thrombosis may still persist the inflated 
balloon may reduce washout of fibrinolytic agents, potentially lessening the dose of 
fibrinolytic agents required, the occurrence of hemorrhage,  and procedure time. The 
balloon may be used to perform partial thrombectomy before thrombolysis. A rheolytic 
catheter thrombectomy may be considered in patients with extensive thrombus that persists 
despite local administration of a fibrinolytic agent. One such device is the AngioJet 
(MEDRAD, Inc, Warrendale, PA), which uses hydrodynamic thrombolytic action occurring 
at the tip of the catheter via the Venturi effect from high-velocity saline jets. Thrombus is 
disrupted and directed down the second lumen of the device. A perforation of the venous 
sinus wall may occur rarely, at a rate that is unknown but reported in the existing small 
series. It may be avoided by removal of the AngioJet after partial recanalization of the 
thrombosis and follow-up with additional microcatheter thrombolysis. The Merci retrieval 
device (Concentric Medical, Mountain View, CA) has also been used to remove thrombus in 
the cerebral venous system. This technique also requires direct catheter access to the venous 
sinus. The small corkscrewshaped device is dispensed via the tip of the catheter, advanced 
into the thrombus, and then slowly pulled back into the catheter with the adherent 
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thrombus. Here again, the device may be used to perform partial recanalization, followed by 
thrombolysis to avoid damaging the wall or trabeculae of the dural sinus. As mentioned 
above, the evidence available at the present time is anecdotal. The Penumbra System 
(Penumbra, Inc, Alameda, CA) is a new-generation neuroembolectomy device that acts to 
debulk and aspirate acute clots. It uses a reperfusion catheter that aspirates thrombus while 
passing a wire-based separator within the catheter to break up the clot and facilitate 
aspiration. Only anecdotal evidence for its efficacy is available. The risks associated with use 
of the Penumbra System for cerebral venous thrombosis are likely similar to those seen with 
the Merci and AngioJet systems.  
As endovascular options for management of venous thrombosis have evolved, surgery has 
played an increasingly limited role. Surgical thrombectomy is needed uncommonly but may 
be considered if severe neurological or visual deterioration occurs despite maximal medical 
therapy. In a recent review, among 13 patients with severe CVST who underwent 
decompressive craniectomy, 11 (84.6%) achieved a favorable outcome (mRS score equal or 
less than 3). Decompressive craniotomy may be needed as a life-saving measure if a large 
venous infarction leads to a significant increase in intracranial pressure. Likewise, large 
hematomas rarely may need to be considered for surgical evacuation if associated with a 
progressive and severe neurological deficit. 
It is to note that, in summary, the use of these direct intrasinus thrombolytic techniques and 
mechanical therapies is only supported by case reports and small case series. If clinical 
deterioration occurs despite use of anticoagulation, or if the patient develops mass effect 
from a venous infarction or ICH that causes intracranial hypertension resistant to standard 
therapies, then these interventional techniques may be considered. Further, conservative 
parallel treatment with aspirin, steroids and antibiotics may be also discussed. In particular, 
there are no controlled trials or observational studies that directly assess the role of aspirin 
in management of CVST. The steroids may have a role in CVST by decreasing vasogenic 
edema, but may enhance hypercoagulability. In a matched case-control study among the 624 
patients in the ISCVST, 150 patients on steroids were compared with matched 150 patients 
without. Those treated with steroids thus had similar characteristics as control subjects, 
except they were more likely to have vasculitis. At 6 months, there was a trend toward a 
higher risk of death or dependence with steroid treatment (OR 1.7, 95%CI 0.9 to 3.3), and 
this did not differ after the exclusion of those with vasculitis, malignancy, inflammatory 
disease, and infection. Among those with parenchymal brain lesions on CT/MRI, results 
were striking, with 4.8-fold increased odds of death or dependence with steroid treatment 
(95%CI 1.2 to 19.8). Sensitivity analyses that used different analytic approaches yielded 
similar findings. Also, local (eg, otitis, mastoiditis) and systemic (meningitis, sepsis) 
infections can be complicated by thrombosis of the adjacent or distant venous sinuses. The 
management of patients with such suspected infection and CVST should include 
administration of the appropriate antibiotics and the surgical drainage of infectious sources 
(ie, subdural empyemas or purulent collections within the paranasal sinuses). 
3.3 Prognosis of the main clinical outcome and complications 
The understanding that CVST is a rare and severe disease with a poor prognosis had to be 
revised after more recent clinical studies reporting a much better outcome. Mortality rates 
range from 6–10% and independent survival is reported in 82–90% of patients (as cited in 
Masuhr et al, 2004). Besides severe underlying medical conditions (e. g. infectious and 
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malignant causes), coma on admission, clinical worsening after admission and ICH are the 
most important predictors of a poor outcome. In addition, the site of thrombosis is also a 
relevant factor and thrombosis of the internal and cerebellar veins carry the worst prognosis. 
A recently published follow-up study of 40 patients with CVST suggested also a correlation 
between the degree of recanalization and clinical outcome. Whereas the prevalence of 
persisting neurological deficits did not differ between patients with complete or partial 
recanalization, patients with no recanalization had significantly more neurological sequelae 
(Masuhr et al, 2004). 
3.3.1 Main outcome and prognosis 
There are several studies and reviews on the outcome and prognosis of CVST. The majority of 
such studies are mainly retrospective. Of the few prospective studies, some did not analyze 
prognostic factors or performed only a bivariate analysis of such predictors or analyzed 
specific subgroups of patients. There are only 5 cohort studies that analyzed prognostic factors 
for the short-term and the long-term outcome of CVST patients (Saposnik et al, 2011). 
Neurological and neuropsychiatric prognosis after the diagnosis of CVST. Neurological 
worsening may occur in 23% of patients, even several days after diagnosis. Neurological 
worsening can feature depressed consciousness, mental status disturbance, new seizure, 
worsening of or a new focal deficit, increase in headache intensity, or visual loss. About 30% 
of the patients with neurological deterioration will have new parenchymal lesions when 
neuroimaging is repeated. Patients with depressed consciousness on admission are more 
likely to deteriorate. In the view of the neuropsychiatric sequelae, the information on the long-
term outcome in CVST survivors is limited. Despite the apparent general good recovery in 
most patients with CVST, approximately one half of survivors feel depressed or anxious, 
and minor cognitive or language deficits may be observed. Risk factors for poor long-term 
prognosis in the ISCVST cohort were central nervous system infection, any malignancy, 
thrombosis of the deep venous system, intracranial hemorrhage on admission CT/MRI,  
Glasgow Coma Scale score <9, mental status disturbance, age>37 years, and male sex. Brain 
herniation leading to early death was more frequent in young patients, whereas late deaths 
due to malignancies and less favorable functional outcome were more frequent in elderly 
patients. A Glasgow Coma Scale score of 14 to 15 on admission, a complete or partial 
intracranial hypertension syndrome (including isolated headache) as the only manifestation 
of CVST, and absence of aphasia were variables associated with a favorable outcome. Below 
we provide separately a more extensive and detailed encounter of the cognition, 
behavioural changes and functional outcomes after CVST. 
Death. Approximately 3% to 15% of patients die in the acute phase of the disorder (early 
death). In the ISCVST (3.4%) of 624 patients died within 30 days from symptom onset; 
however, in a recent multicenter US study, the mortality (13%) was higher. The risk factors 
for 30-day mortality were depressed consciousness, altered mental status, and thrombosis of 
the deep venous system, right hemisphere hemorrhage, and posterior fossa lesions. The 
main cause of acute death with CVST is transtentorial herniation secondary to a large 
hemorrhagic lesion, followed by herniation due to multiple lesions or to diffuse brain 
edema. Status epilepticus, medical complications, and PE are among other causes of early 
death. The deaths after the acute phase (late death) are related mainly to the underlying 
conditions, in particular malignancies. In the ISCVST study, a complete recovery at last 
follow-up (median 16 months) was observed in 79% of the patients; however, the overall 
death rate was 8.3% and the dependency rate of 5.1% at the end of follow-up was observed. 
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In a systematic review that included both retrospective and prospective studies, overall 
mortality was 9.4%, and the proportion of dependency (mRS score ≥3 or Glasgow Outcome 
Scale score ≥3) was 9.7%. Two new studies were reported after this systematic review. In the 
Pakistan-Middle East registry,63 the dependency rate (mRS score≥3) was higher (11%), 
whereas in the US multicenter registry, 28% of patients were dependent at 12 months. Of note, 
some studies include patients transferred to tertiary care centers, whose strokes are usually 
more severe, with the potential for a referral bias. Among the 7 cohort studies (including the 
prospective part of retrospective/prospective studies in which information can be analyzed 
separately), the overall death and dependency rate was 15% (95%CI 13% to 18%). 
3.3.2 Ealry and late complications – Management and prevention 
Up to 40% of patients with CVST present with isolated intracranial hypertension. This is 
characterized by diffuse brain edema, sometimes seen as slit ventricles on CT scanning. 
Clinical features include progressive headache, papilledema, and third or sixth nerve 
palsies. Intracranial hypertension is primarily caused by venous outflow obstruction and 
tissue congestion compounded by CSF malabsorption. No randomized trials are available to 
clarify the optimal treatment; however, rational management of intracranial hypertension 
includes a combination of treatment approaches. First, measures to reduce the thrombotic 
occlusion of venous outflow, such as anticoagulation and possibly thrombolytic treatment, 
may result in resolution of intracranial hypertension. Second, reduction of increased 
intracranial pressure can be accomplished immediately by lumbar puncture with removal of 
CSF until a normal closing pressure is achieved. Unfortunately, lumbar puncture requires 
temporary cessation of anticoagulants, with an attendant risk of thrombus propagation. 
Despite the lack of randomized clinical trials, acetazolamide is a commonly used therapeutic 
alternative for the treatment of intracranial hypertension with CVST. It may have a limited 
role in the acute management of intracranial hypertension for patients with CVST. 
Acetazolamide, a carbonic anhydrase inhibitor, is a weak diuretic and decreases production 
of CSF. Serial lumbar punctures may be necessary when hypertension is persistent. In 
refractory cases, a lumboperitoneal shunt may be required. Because prolonged pressure on 
the optic nerves can result in permanent blindness, it is of paramount importance to closely 
monitor visual fields and the severity of papilledema during the period of increased 
pressure. Ophthalmologic consultation is helpful for this. Although rarely required, optic 
nerve fenestration is a treatment option to halt progressive visual loss. Decompressive 
craniectomy has been used in patients with malignant arterial stroke to treat elevated 
intracranial pressure unresponsive to conventional treatment. In a pooled analysis of 
randomized trials, surgical decompression within 48 hours of stroke onset reduced case 
fatality and improved functional outcome. Limited evidence is available on the role of 
decompressive craniectomy in CVST with either brain edema, venous infarction, 
neurological deterioration, or impending cerebral herniation. A disadvantage of 
craniectomy is that it precludes anticoagulation for the immediate postoperative period.  
Seizures are present in 37% of adults, 48% of children, and 71% of newborns who present 
with CVST. No clinical trials have studied either the optimal timing or medication choice for 
anticonvulsants in CVST. Whether to initiate anticonvulsants in all cases of CVST or await 
initial seizures before treatment is controversial. Because seizures increase the risk of anoxic 
damage, anticonvulsant treatment after even a single seizure is reasonable. In the absence of 
seizures, the prophylactic use of antiepileptic drugs may be harmful (the risk of side effects 
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malignant causes), coma on admission, clinical worsening after admission and ICH are the 
most important predictors of a poor outcome. In addition, the site of thrombosis is also a 
relevant factor and thrombosis of the internal and cerebellar veins carry the worst prognosis. 
A recently published follow-up study of 40 patients with CVST suggested also a correlation 
between the degree of recanalization and clinical outcome. Whereas the prevalence of 
persisting neurological deficits did not differ between patients with complete or partial 
recanalization, patients with no recanalization had significantly more neurological sequelae 
(Masuhr et al, 2004). 
3.3.1 Main outcome and prognosis 
There are several studies and reviews on the outcome and prognosis of CVST. The majority of 
such studies are mainly retrospective. Of the few prospective studies, some did not analyze 
prognostic factors or performed only a bivariate analysis of such predictors or analyzed 
specific subgroups of patients. There are only 5 cohort studies that analyzed prognostic factors 
for the short-term and the long-term outcome of CVST patients (Saposnik et al, 2011). 
Neurological and neuropsychiatric prognosis after the diagnosis of CVST. Neurological 
worsening may occur in 23% of patients, even several days after diagnosis. Neurological 
worsening can feature depressed consciousness, mental status disturbance, new seizure, 
worsening of or a new focal deficit, increase in headache intensity, or visual loss. About 30% 
of the patients with neurological deterioration will have new parenchymal lesions when 
neuroimaging is repeated. Patients with depressed consciousness on admission are more 
likely to deteriorate. In the view of the neuropsychiatric sequelae, the information on the long-
term outcome in CVST survivors is limited. Despite the apparent general good recovery in 
most patients with CVST, approximately one half of survivors feel depressed or anxious, 
and minor cognitive or language deficits may be observed. Risk factors for poor long-term 
prognosis in the ISCVST cohort were central nervous system infection, any malignancy, 
thrombosis of the deep venous system, intracranial hemorrhage on admission CT/MRI,  
Glasgow Coma Scale score <9, mental status disturbance, age>37 years, and male sex. Brain 
herniation leading to early death was more frequent in young patients, whereas late deaths 
due to malignancies and less favorable functional outcome were more frequent in elderly 
patients. A Glasgow Coma Scale score of 14 to 15 on admission, a complete or partial 
intracranial hypertension syndrome (including isolated headache) as the only manifestation 
of CVST, and absence of aphasia were variables associated with a favorable outcome. Below 
we provide separately a more extensive and detailed encounter of the cognition, 
behavioural changes and functional outcomes after CVST. 
Death. Approximately 3% to 15% of patients die in the acute phase of the disorder (early 
death). In the ISCVST (3.4%) of 624 patients died within 30 days from symptom onset; 
however, in a recent multicenter US study, the mortality (13%) was higher. The risk factors 
for 30-day mortality were depressed consciousness, altered mental status, and thrombosis of 
the deep venous system, right hemisphere hemorrhage, and posterior fossa lesions. The 
main cause of acute death with CVST is transtentorial herniation secondary to a large 
hemorrhagic lesion, followed by herniation due to multiple lesions or to diffuse brain 
edema. Status epilepticus, medical complications, and PE are among other causes of early 
death. The deaths after the acute phase (late death) are related mainly to the underlying 
conditions, in particular malignancies. In the ISCVST study, a complete recovery at last 
follow-up (median 16 months) was observed in 79% of the patients; however, the overall 
death rate was 8.3% and the dependency rate of 5.1% at the end of follow-up was observed. 
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In a systematic review that included both retrospective and prospective studies, overall 
mortality was 9.4%, and the proportion of dependency (mRS score ≥3 or Glasgow Outcome 
Scale score ≥3) was 9.7%. Two new studies were reported after this systematic review. In the 
Pakistan-Middle East registry,63 the dependency rate (mRS score≥3) was higher (11%), 
whereas in the US multicenter registry, 28% of patients were dependent at 12 months. Of note, 
some studies include patients transferred to tertiary care centers, whose strokes are usually 
more severe, with the potential for a referral bias. Among the 7 cohort studies (including the 
prospective part of retrospective/prospective studies in which information can be analyzed 
separately), the overall death and dependency rate was 15% (95%CI 13% to 18%). 
3.3.2 Ealry and late complications – Management and prevention 
Up to 40% of patients with CVST present with isolated intracranial hypertension. This is 
characterized by diffuse brain edema, sometimes seen as slit ventricles on CT scanning. 
Clinical features include progressive headache, papilledema, and third or sixth nerve 
palsies. Intracranial hypertension is primarily caused by venous outflow obstruction and 
tissue congestion compounded by CSF malabsorption. No randomized trials are available to 
clarify the optimal treatment; however, rational management of intracranial hypertension 
includes a combination of treatment approaches. First, measures to reduce the thrombotic 
occlusion of venous outflow, such as anticoagulation and possibly thrombolytic treatment, 
may result in resolution of intracranial hypertension. Second, reduction of increased 
intracranial pressure can be accomplished immediately by lumbar puncture with removal of 
CSF until a normal closing pressure is achieved. Unfortunately, lumbar puncture requires 
temporary cessation of anticoagulants, with an attendant risk of thrombus propagation. 
Despite the lack of randomized clinical trials, acetazolamide is a commonly used therapeutic 
alternative for the treatment of intracranial hypertension with CVST. It may have a limited 
role in the acute management of intracranial hypertension for patients with CVST. 
Acetazolamide, a carbonic anhydrase inhibitor, is a weak diuretic and decreases production 
of CSF. Serial lumbar punctures may be necessary when hypertension is persistent. In 
refractory cases, a lumboperitoneal shunt may be required. Because prolonged pressure on 
the optic nerves can result in permanent blindness, it is of paramount importance to closely 
monitor visual fields and the severity of papilledema during the period of increased 
pressure. Ophthalmologic consultation is helpful for this. Although rarely required, optic 
nerve fenestration is a treatment option to halt progressive visual loss. Decompressive 
craniectomy has been used in patients with malignant arterial stroke to treat elevated 
intracranial pressure unresponsive to conventional treatment. In a pooled analysis of 
randomized trials, surgical decompression within 48 hours of stroke onset reduced case 
fatality and improved functional outcome. Limited evidence is available on the role of 
decompressive craniectomy in CVST with either brain edema, venous infarction, 
neurological deterioration, or impending cerebral herniation. A disadvantage of 
craniectomy is that it precludes anticoagulation for the immediate postoperative period.  
Seizures are present in 37% of adults, 48% of children, and 71% of newborns who present 
with CVST. No clinical trials have studied either the optimal timing or medication choice for 
anticonvulsants in CVST. Whether to initiate anticonvulsants in all cases of CVST or await 
initial seizures before treatment is controversial. Because seizures increase the risk of anoxic 
damage, anticonvulsant treatment after even a single seizure is reasonable. In the absence of 
seizures, the prophylactic use of antiepileptic drugs may be harmful (the risk of side effects 
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may outweigh its benefits). A few studies have reported the occurrence and characteristics 
of patients with seizures accompanying CVST. One study reported that 32% out of 91 
patients presented with seizures and 2% developed them during hospitalization; only 9.5% 
developed late seizures, and seizures were not a predictor of prognosis at 12 months. Early 
seizures were 3.7-fold more likely (95%CI 1.4 to 9.4) in those with parenchymal lesions on 
CT/MRI at diagnosis and 7.8-fold more likely (95%CI 0.8 to 74.8) in those with sensory 
defects. A more recent report from the ISCVST showed 245 (39%) of 624 patients presented 
with seizures and 43 (6.9%) experienced early seizure within 2 weeks after diagnosis. 
Besides seizures on presentation, only a supratentorial parenchymal lesion on CT/MRI at 
diagnosis (present in 58%) was associated with occurrence of early seizures (OR 3.1, 95%CI 
1.6 to 9.6). Furthermore, among those with a supratentorial lesion and no presenting seizure, 
use of antiepileptic drugs was associated with a 70% lower risk of seizures within 2 weeks, 
although this was not statistically significant (OR 0.3, 95%CI 0.04 to 2.6). On the basis of 
these findings, the authors suggested the prescription of antiepileptic agents in acute CVST 
patients with supratentorial lesions who present with seizures. Hydrocephalus The superior 
sagittal and lateral dural sinuses are the principal sites for CSF absorption by the arachnoid 
granulations, highly vascular structures that protrude across the walls of the sinuses into the 
subarachnoid space and drain into the venous system. In CVST, the function of the 
arachnoid granulations may be impaired, potentially resulting in failure of CSF absorption 
and communicating hydrocephalus (6.6%).  
Obstructive hydrocephalus is a less common complication of CVST and results from 
hemorrhage into the ventricular system. This is typically associated with thrombosis that 
involves the internal cerebral veins and may be associated with thalamic hemorrhage. This 
syndrome is well described in term neonates but occurs at all ages. Neurosurgical 
evacuation of CSF with ventriculostomy, or in persistent cases, ventriculoperitoneal shunt, 
is necessary. The brain is under increased venous pressure, and tissue perfusion is at 
increased risk compared with other situations with obstructive hydrocephalus. Therefore, 
close monitoring and neurosurgical consultation are important, because intervention may be 
required at lesser severities of ventricular enlargement.  
Recurrence of CVST. The overall risk of recurrence of any thrombotic event (CVST or 
systemic) after a CVST is 6.5% per year. The risk of other manifestations of VTE after CVST 
ranges from 3.4% to 4.3% on the basis of the largest studies of this medical condition (Ferro 
et al, 2004; Saposnik et al, 2011). Patients with severe thrombophilia have an increased risk 
of VTE. The secondary Prevention of CVST and Other VTE Events DVT/PE and CVST share 
some similarities. The chronic and transient risk factors appear to be similar, although 
women are more likely to have CVST and selected thrombophilia subtypes may differ 
between CVST and DVT/PE. In the ISCVST cohort, the overall rate of recurrent CVST or 
other VTE recurrence was 4.1 per 100 person-years, with male sex and 
polycythemia/thrombocythemia being the only independent predictors found. The same 
study reported a steady increase in the cumulative risk of thrombotic recurrences not 
influenced by the duration of anticoagulation, which emphasizes the need for a clinical trial 
to assess the efficacy and safety of short versus extended anticoagulant therapy. Given that 
systemic VTE after CVST is more common than recurrent CVST, one may reasonably adopt 
the VTE guidelines for prevention of both new VTE and recurrent CVST. However, each 
individual patient should undergo risk assessment and the patient’s risk level and 
preferences regarding long-term anticoagulation treatment, the risk of bleeding, and the risk 
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of thrombosis without anticoagulation should then be considered. In particular, when 
considered in a more detail, the secondary prevention strategies focus on preventing 
recurrence of CVST or other VTE in those CVST patients at high risk of such outcomes. 
There are no available risk stratification schemes in CVST. There are no randomized clinical 
trials of long-term prevention of first or recurrent CVST. Because there are no secondary 
prevention trials of anticoagulation in adults with CVST, evaluation of prevention strategies 
can only be performed with observational studies that evaluate CVST or VTE recurrence. In 
a cohort of 154 patients treated at Mayo Clinic between 1978 and 2001, 56 patients initially 
received both heparin and warfarin, 12 received heparin only, and 21 received warfarin 
only. Seventy-seven (50%) were treated with warfarin for an average of 9 months, with 25 
committed to lifelong therapy. During 36 months of follow-up (464 patient-years), there 
were 23 recurrent VTEs in 20 patients (13%), the majority in the first year. Ten patients had 
recurrent CVST (2.2 per 100 patient-years), and 11 had DVT or PE (2.8 per 100 patient-years). 
Nine of the recurrent events occurred while the patients were taking warfarin. After 8 years 
of follow-up, there was no impact of warfarin on survival or recurrence-free survival. In a 
cohort of 54 CVST patients treated consecutively at University Hospital Gasthuisberg, 
Leuven, Belgium, 8 (14.8%) had a recurrence of VTE (7 with DVT or PE and one with CVST 
and mesenteric vein thrombosis) over a median of 2.5 years of follow-up (4.5 per 100 
patient-years). Median time to recurrence was 2.5 months (range 2 weeks to 4 years). Only 2 
of these 8 patients were taking anticoagulants at the time of recurrence, 1 with an 
international normalized ratio (INR) of 1.6 and the other with an INR of 2.1. Among the 6 
patients with recurrent VTE who were not taking anticoagulants, recurrence occurred 
between 2 weeks and 10 months after the index event. Those with recurrence more often 
had a thrombophilic disorder, had a history of DVT, and had not received oral 
anticoagulation because of perceived contraindications. In the ISCVST study, among 624 
patients with CVST, there were 14 (2.2%) recurrent CVSTs and 27 (4.3%) other thrombotic 
events (16 DVT, 3 PE, 2 ischemic stroke, 2 transient ischemic attack, and 4 acute limb 
ischemia) over a mean follow-up of 16 months. Seventeen (41.5%) of the 41 patients with 
recurrent or other thrombotic events were receiving anticoagulants, but the type of 
anticoagulation and the number who were receiving therapeutic doses of anticoagulation were 
unknown. It was not reported whether anticoagulation was given long-term and whether 
recurrent events differed based on its use. The Cerebral Venous Thrombosis Portuguese 
Collaborative Study Group (VENOPORT) evaluated outcomes for 142 CVST patients, of 
whom 51 were retrospectively enrolled and 91 were prospectively enrolled. There were 2 (2%) 
recurrent CVSTs and 10 (8%) other arterial or venous thrombotic events (maximum 16 years of 
follow-up for the retrospective cases and 12 months of follow-up for prospective cases). For the 
prospectively followed cases, the incident risk of a thrombotic event was 4% per year (5 
thrombotic events in 4 patients: 2 DVTs, 1 PE, 1 ischemic stroke, and 1 acute limb ischemia). 
Three of these events occurred with anticoagulation use, although the INR levels were 
unknown at the time of the event. In addition, all of these events occurred within 12 months of 
the index CVST. A cohort of 77 CVST patients diagnosed in France between 1975 and 1990 was 
followed up for 63 months. Nine (11.7%) had a recurrence of CVST, 8 during the first 12 
months, and none were receiving anticoagulation at the time of recurrence. Eleven patients 
(14.3%) had other thrombotic events, including retinal vein thrombosis, PE, and arterial 
thromboses. Use of anticoagulation at the time of recurrent thromboses that were not CVSTs 
was not reported. More recently, 145 patients with a first CVST were followed up for a median 
of 6 years after discontinuation of anticoagulation therapy. CVST recurred in 5 patients (3%), 
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may outweigh its benefits). A few studies have reported the occurrence and characteristics 
of patients with seizures accompanying CVST. One study reported that 32% out of 91 
patients presented with seizures and 2% developed them during hospitalization; only 9.5% 
developed late seizures, and seizures were not a predictor of prognosis at 12 months. Early 
seizures were 3.7-fold more likely (95%CI 1.4 to 9.4) in those with parenchymal lesions on 
CT/MRI at diagnosis and 7.8-fold more likely (95%CI 0.8 to 74.8) in those with sensory 
defects. A more recent report from the ISCVST showed 245 (39%) of 624 patients presented 
with seizures and 43 (6.9%) experienced early seizure within 2 weeks after diagnosis. 
Besides seizures on presentation, only a supratentorial parenchymal lesion on CT/MRI at 
diagnosis (present in 58%) was associated with occurrence of early seizures (OR 3.1, 95%CI 
1.6 to 9.6). Furthermore, among those with a supratentorial lesion and no presenting seizure, 
use of antiepileptic drugs was associated with a 70% lower risk of seizures within 2 weeks, 
although this was not statistically significant (OR 0.3, 95%CI 0.04 to 2.6). On the basis of 
these findings, the authors suggested the prescription of antiepileptic agents in acute CVST 
patients with supratentorial lesions who present with seizures. Hydrocephalus The superior 
sagittal and lateral dural sinuses are the principal sites for CSF absorption by the arachnoid 
granulations, highly vascular structures that protrude across the walls of the sinuses into the 
subarachnoid space and drain into the venous system. In CVST, the function of the 
arachnoid granulations may be impaired, potentially resulting in failure of CSF absorption 
and communicating hydrocephalus (6.6%).  
Obstructive hydrocephalus is a less common complication of CVST and results from 
hemorrhage into the ventricular system. This is typically associated with thrombosis that 
involves the internal cerebral veins and may be associated with thalamic hemorrhage. This 
syndrome is well described in term neonates but occurs at all ages. Neurosurgical 
evacuation of CSF with ventriculostomy, or in persistent cases, ventriculoperitoneal shunt, 
is necessary. The brain is under increased venous pressure, and tissue perfusion is at 
increased risk compared with other situations with obstructive hydrocephalus. Therefore, 
close monitoring and neurosurgical consultation are important, because intervention may be 
required at lesser severities of ventricular enlargement.  
Recurrence of CVST. The overall risk of recurrence of any thrombotic event (CVST or 
systemic) after a CVST is 6.5% per year. The risk of other manifestations of VTE after CVST 
ranges from 3.4% to 4.3% on the basis of the largest studies of this medical condition (Ferro 
et al, 2004; Saposnik et al, 2011). Patients with severe thrombophilia have an increased risk 
of VTE. The secondary Prevention of CVST and Other VTE Events DVT/PE and CVST share 
some similarities. The chronic and transient risk factors appear to be similar, although 
women are more likely to have CVST and selected thrombophilia subtypes may differ 
between CVST and DVT/PE. In the ISCVST cohort, the overall rate of recurrent CVST or 
other VTE recurrence was 4.1 per 100 person-years, with male sex and 
polycythemia/thrombocythemia being the only independent predictors found. The same 
study reported a steady increase in the cumulative risk of thrombotic recurrences not 
influenced by the duration of anticoagulation, which emphasizes the need for a clinical trial 
to assess the efficacy and safety of short versus extended anticoagulant therapy. Given that 
systemic VTE after CVST is more common than recurrent CVST, one may reasonably adopt 
the VTE guidelines for prevention of both new VTE and recurrent CVST. However, each 
individual patient should undergo risk assessment and the patient’s risk level and 
preferences regarding long-term anticoagulation treatment, the risk of bleeding, and the risk 
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of thrombosis without anticoagulation should then be considered. In particular, when 
considered in a more detail, the secondary prevention strategies focus on preventing 
recurrence of CVST or other VTE in those CVST patients at high risk of such outcomes. 
There are no available risk stratification schemes in CVST. There are no randomized clinical 
trials of long-term prevention of first or recurrent CVST. Because there are no secondary 
prevention trials of anticoagulation in adults with CVST, evaluation of prevention strategies 
can only be performed with observational studies that evaluate CVST or VTE recurrence. In 
a cohort of 154 patients treated at Mayo Clinic between 1978 and 2001, 56 patients initially 
received both heparin and warfarin, 12 received heparin only, and 21 received warfarin 
only. Seventy-seven (50%) were treated with warfarin for an average of 9 months, with 25 
committed to lifelong therapy. During 36 months of follow-up (464 patient-years), there 
were 23 recurrent VTEs in 20 patients (13%), the majority in the first year. Ten patients had 
recurrent CVST (2.2 per 100 patient-years), and 11 had DVT or PE (2.8 per 100 patient-years). 
Nine of the recurrent events occurred while the patients were taking warfarin. After 8 years 
of follow-up, there was no impact of warfarin on survival or recurrence-free survival. In a 
cohort of 54 CVST patients treated consecutively at University Hospital Gasthuisberg, 
Leuven, Belgium, 8 (14.8%) had a recurrence of VTE (7 with DVT or PE and one with CVST 
and mesenteric vein thrombosis) over a median of 2.5 years of follow-up (4.5 per 100 
patient-years). Median time to recurrence was 2.5 months (range 2 weeks to 4 years). Only 2 
of these 8 patients were taking anticoagulants at the time of recurrence, 1 with an 
international normalized ratio (INR) of 1.6 and the other with an INR of 2.1. Among the 6 
patients with recurrent VTE who were not taking anticoagulants, recurrence occurred 
between 2 weeks and 10 months after the index event. Those with recurrence more often 
had a thrombophilic disorder, had a history of DVT, and had not received oral 
anticoagulation because of perceived contraindications. In the ISCVST study, among 624 
patients with CVST, there were 14 (2.2%) recurrent CVSTs and 27 (4.3%) other thrombotic 
events (16 DVT, 3 PE, 2 ischemic stroke, 2 transient ischemic attack, and 4 acute limb 
ischemia) over a mean follow-up of 16 months. Seventeen (41.5%) of the 41 patients with 
recurrent or other thrombotic events were receiving anticoagulants, but the type of 
anticoagulation and the number who were receiving therapeutic doses of anticoagulation were 
unknown. It was not reported whether anticoagulation was given long-term and whether 
recurrent events differed based on its use. The Cerebral Venous Thrombosis Portuguese 
Collaborative Study Group (VENOPORT) evaluated outcomes for 142 CVST patients, of 
whom 51 were retrospectively enrolled and 91 were prospectively enrolled. There were 2 (2%) 
recurrent CVSTs and 10 (8%) other arterial or venous thrombotic events (maximum 16 years of 
follow-up for the retrospective cases and 12 months of follow-up for prospective cases). For the 
prospectively followed cases, the incident risk of a thrombotic event was 4% per year (5 
thrombotic events in 4 patients: 2 DVTs, 1 PE, 1 ischemic stroke, and 1 acute limb ischemia). 
Three of these events occurred with anticoagulation use, although the INR levels were 
unknown at the time of the event. In addition, all of these events occurred within 12 months of 
the index CVST. A cohort of 77 CVST patients diagnosed in France between 1975 and 1990 was 
followed up for 63 months. Nine (11.7%) had a recurrence of CVST, 8 during the first 12 
months, and none were receiving anticoagulation at the time of recurrence. Eleven patients 
(14.3%) had other thrombotic events, including retinal vein thrombosis, PE, and arterial 
thromboses. Use of anticoagulation at the time of recurrent thromboses that were not CVSTs 
was not reported. More recently, 145 patients with a first CVST were followed up for a median 
of 6 years after discontinuation of anticoagulation therapy. CVST recurred in 5 patients (3%), 
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and other manifestations of VTE (defined as DVT of the lower limbs or PE) were seen in 10 
additional patients (7%). The recurrence rate accounted for 3.4% of all VTEs in the first 16 
months (or 2.03 per 100 person-years; 95%CI 1.16 to 3.14) and 1.3% of CVSTs in the first 16 
months (or 0.53 per 100 person-years; 95%CI 0.16 to 1.10). Approximately half of the 
recurrences occurred 20 within the first year after discontinuation of anticoagulant therapy. 
Mild thrombophilia abnormalities were not associated with recurrent CVST, but severe 
thrombophilia showed an increased risk of DVT or PE. In summary, the prevalence of CVST 
recurrence was similar in the Italian and ISCVST studies (1.3% and 2.2%, respectively) at the 
16-month follow-up.   
In patients with DVT or PE, increasing evidence suggests there is clinical utility to D-dimer 
measurement when used to define risk of recurrent VTE. For example, in a randomized 
controlled trial (n_608), patients with an abnormal D-dimer level 1 month after the 
discontinuation of   21  anticoagulation had a significant incidence of recurrent VTE (15% 
versus 2.9%), which was reduced by the resumption of anticoagulation (compared with 
those not receiving vitamin K antagonists). During 1.4 years of follow-up, 120 subjects with 
an abnormal D-dimer level were randomized to no anticoagulation and 15% in this group 
developed a recurrent VTE. Of 103 patients with abnormal D-dimer randomized to resume 
anticoagulation, only 2.9% had a recurrent VTE. Although the study was randomized, it was 
unblinded, and D-dimer levels were only obtained once. In addition, there were no subjects 
with CVST and no similar studies in CVST patients. Although the clinical utility of D-dimer 
for longer-term anticoagulation for VTE secondary prevention appears promising, the lack 
of standardization of D-dimer assays may limit their clinical applicability and reliability.  
In particular, thrombophilias may be hereditary or acquired, and hereditary thrombophilias 
have been stratified as mild or severe on the basis of the risk of recurrence in very large 
family cohorts. Among VTE patients, the hereditary thrombophilias with the highest 
cumulative recurrence rates for VTE in the absence of ongoing anticoagulation have been 
deficiencies of antithrombin, protein C, and protein S, with a 19% recurrence at 2 years, 40% 
at 5 years, and 55% at 10 years. Homozygous prothrombin G20210A, homozygous factor V 
Leiden, deficiencies of protein C, protein S, or antithrombin, combined thrombophilia 
defects and antiphospholipid syndrome are categorized as severe. Interestingly, the more 
common hereditary thrombophilias, such as heterozygous factor V Leiden and prothrombin 
G20210A or elevated factor VIII, have a much lower risk of recurrence (7% at 2 years, 11% at 
5 years, and 25% at 10 years) and could be categorized as mild. Hyperhomocysteinemia, a 
common hereditary or acquired risk factor for VTE, was not significantly associated with a 
high risk of recurrence. In addition, the annual incidence and the risk of recurrence 
increased markedly in those with combined thrombophilic defects, described as double 
heterozygous/homozygous. There are several important points regarding the hereditary 
thrombophilia data described above. First, the familial nature of these deficiencies of protein 
C, S, or antithrombin was clearly established, which distinguishes these patients from those 
with sporadic or acquired abnormalities. Second, testing for deficiencies of protein C, S, and 
antithrombin must be performed at least 6 weeks after a thrombotic event and then 
confirmed with repeat testing and family studies. In addition, protein C and S functional 
activity and antithrombin levels are difficult to interpret during treatment with warfarin. 
Therefore, testing for these conditions is generally indicated 2 to 4 weeks after completion of 
anticoagulation. Lastly, clearly established deficiencies of proteins C, S, and antithrombin 
are relatively uncommon. Antiphospholipid antibody syndrome (Atanassova, 2007) is an 
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acquired thrombophilia associated with specific laboratory criteria (lupus anticoagulant, 
anticardiolipin antibody, and anti-_2-glycoprotein I) and a history of a venous or arterial 
event or fetal loss. Caution must be taken when the results of antiphospholipid antibody 
testing are interpreted. A normal result may occur at the time of the clinical presentation, 
which rules out antiphospholipid antibody syndrome. On the other hand, abnormal tests may 
occur transiently due to the disease process, infection, certain medications (antibiotics, cocaine, 
hydralazine, procainamide, quinine, and others), or unknown causes. Approximately 5% of 
the general population at any given time has evidence of abnormal tests, and these mainly 
have no clinical consequence. A diagnosis of antiphospholipid syndrome requires abnormal 
laboratory testing on 2 or more occasions at least 12 weeks apart. Patients diagnosed with 
antiphospholipid syndrome have an increased risk of recurrent thrombotic events; however, 
test results cannot predict the likelihood of complications, their type, or their severity in a 
particular patient. Although there are no prospective studies that report recurrence rates for 
CVST specifically, the high risk of recurrent VTE with this disorder meets the definition of 
severe thrombophilia. The Duration of Anticoagulation Study Group reported a 29% 
recurrence of VTE in patients with anticardiolipin antibodies versus 14% in those without over 
4 years and the risk increased with the titer of the antibodies. In a randomized controlled trial 
of warfarin for 3 months versus extended treatment for 24 months after first-ever idiopathic 
DVT or PE, the presence of antiphospholipid antibodies was associated with a 4-fold increased 
risk of recurrence (hazard ratio [HR] 4.0, 95%CI 1.2 to 13), and the presence of a lupus 
anticoagulant was associated with a 7-fold increased risk (HR 6.8, 95%CI 1.5 to 31) in the 
placebo group. Further recommendations, with associated class and level of evidence, are 
provided in the recent guidelines by Saposnik et al (2011). In particular, a testing for 
prothrombotic conditions, including protein C, protein S, antithrombin deficiency, 
antiphospholipid syndrome, prothrombin G20210A mutation, and factor V Leiden, can be 
beneficial for the management of CVST patients.  
Other late complications. Headache is common and occurs in about half of the patients 
during the follow-up. In general, headaches are primary and not related to CVST. In the 
Lille study, 53% of patients had residual headache, 29% fulfilled criteria for migraine, and 
27% had headache of the tension type. In VENOPORT, 55% of patients reported headaches 
during the follow-up, and these were mild to moderate in 45%. At follow-up, severe 
headaches that required bed rest or hospital admission were reported in 14% of patients in 
the ISCVST and 11% in VENOPORT. In patients with persistent or severe headaches, 
appropriate investigations should be completed to rule out recurrent CVST. Occasionally, 
MRV may show stenosis of a previously occluded sinus, but the clinical significance of this 
is unclear. Headache during follow-up is more common among patients who present 
acutely as having isolated intracranial hypertension. In these patients, if headache persists 
and MRI is normal, lumbar puncture may be needed to exclude elevated intracranial 
pressure. Focal or generalized post-CVST seizures can be divided into early or remote (2 weeks 
after diagnosis) seizures. On the basis of case series, remote seizures affect 5% to 32% of 
patients. Most of these seizures occur in the first year of follow-up. In ISCVST, 11% of the 
patients experienced remote seizures (36 patients by 6 months, 55 by 1 year, and 66 by 2 
years). Risk factors for remote seizures were hemorrhagic lesion on admission CT/MRI (HR 
2.62, 95%CI 1.52 to 4.52), early seizure (HR 2.42, 95%CI 1.38 to 4.22), and paresis (HR 2.22, 
95%CI 1.33 to 3.69). Five percent of the patients had post-CVST epilepsy. Post-CVST 
epilepsy was also associated with hemorrhagic lesion on admission CT/MRI (OR 6.76, 
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and other manifestations of VTE (defined as DVT of the lower limbs or PE) were seen in 10 
additional patients (7%). The recurrence rate accounted for 3.4% of all VTEs in the first 16 
months (or 2.03 per 100 person-years; 95%CI 1.16 to 3.14) and 1.3% of CVSTs in the first 16 
months (or 0.53 per 100 person-years; 95%CI 0.16 to 1.10). Approximately half of the 
recurrences occurred 20 within the first year after discontinuation of anticoagulant therapy. 
Mild thrombophilia abnormalities were not associated with recurrent CVST, but severe 
thrombophilia showed an increased risk of DVT or PE. In summary, the prevalence of CVST 
recurrence was similar in the Italian and ISCVST studies (1.3% and 2.2%, respectively) at the 
16-month follow-up.   
In patients with DVT or PE, increasing evidence suggests there is clinical utility to D-dimer 
measurement when used to define risk of recurrent VTE. For example, in a randomized 
controlled trial (n_608), patients with an abnormal D-dimer level 1 month after the 
discontinuation of   21  anticoagulation had a significant incidence of recurrent VTE (15% 
versus 2.9%), which was reduced by the resumption of anticoagulation (compared with 
those not receiving vitamin K antagonists). During 1.4 years of follow-up, 120 subjects with 
an abnormal D-dimer level were randomized to no anticoagulation and 15% in this group 
developed a recurrent VTE. Of 103 patients with abnormal D-dimer randomized to resume 
anticoagulation, only 2.9% had a recurrent VTE. Although the study was randomized, it was 
unblinded, and D-dimer levels were only obtained once. In addition, there were no subjects 
with CVST and no similar studies in CVST patients. Although the clinical utility of D-dimer 
for longer-term anticoagulation for VTE secondary prevention appears promising, the lack 
of standardization of D-dimer assays may limit their clinical applicability and reliability.  
In particular, thrombophilias may be hereditary or acquired, and hereditary thrombophilias 
have been stratified as mild or severe on the basis of the risk of recurrence in very large 
family cohorts. Among VTE patients, the hereditary thrombophilias with the highest 
cumulative recurrence rates for VTE in the absence of ongoing anticoagulation have been 
deficiencies of antithrombin, protein C, and protein S, with a 19% recurrence at 2 years, 40% 
at 5 years, and 55% at 10 years. Homozygous prothrombin G20210A, homozygous factor V 
Leiden, deficiencies of protein C, protein S, or antithrombin, combined thrombophilia 
defects and antiphospholipid syndrome are categorized as severe. Interestingly, the more 
common hereditary thrombophilias, such as heterozygous factor V Leiden and prothrombin 
G20210A or elevated factor VIII, have a much lower risk of recurrence (7% at 2 years, 11% at 
5 years, and 25% at 10 years) and could be categorized as mild. Hyperhomocysteinemia, a 
common hereditary or acquired risk factor for VTE, was not significantly associated with a 
high risk of recurrence. In addition, the annual incidence and the risk of recurrence 
increased markedly in those with combined thrombophilic defects, described as double 
heterozygous/homozygous. There are several important points regarding the hereditary 
thrombophilia data described above. First, the familial nature of these deficiencies of protein 
C, S, or antithrombin was clearly established, which distinguishes these patients from those 
with sporadic or acquired abnormalities. Second, testing for deficiencies of protein C, S, and 
antithrombin must be performed at least 6 weeks after a thrombotic event and then 
confirmed with repeat testing and family studies. In addition, protein C and S functional 
activity and antithrombin levels are difficult to interpret during treatment with warfarin. 
Therefore, testing for these conditions is generally indicated 2 to 4 weeks after completion of 
anticoagulation. Lastly, clearly established deficiencies of proteins C, S, and antithrombin 
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acquired thrombophilia associated with specific laboratory criteria (lupus anticoagulant, 
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particular patient. Although there are no prospective studies that report recurrence rates for 
CVST specifically, the high risk of recurrent VTE with this disorder meets the definition of 
severe thrombophilia. The Duration of Anticoagulation Study Group reported a 29% 
recurrence of VTE in patients with anticardiolipin antibodies versus 14% in those without over 
4 years and the risk increased with the titer of the antibodies. In a randomized controlled trial 
of warfarin for 3 months versus extended treatment for 24 months after first-ever idiopathic 
DVT or PE, the presence of antiphospholipid antibodies was associated with a 4-fold increased 
risk of recurrence (hazard ratio [HR] 4.0, 95%CI 1.2 to 13), and the presence of a lupus 
anticoagulant was associated with a 7-fold increased risk (HR 6.8, 95%CI 1.5 to 31) in the 
placebo group. Further recommendations, with associated class and level of evidence, are 
provided in the recent guidelines by Saposnik et al (2011). In particular, a testing for 
prothrombotic conditions, including protein C, protein S, antithrombin deficiency, 
antiphospholipid syndrome, prothrombin G20210A mutation, and factor V Leiden, can be 
beneficial for the management of CVST patients.  
Other late complications. Headache is common and occurs in about half of the patients 
during the follow-up. In general, headaches are primary and not related to CVST. In the 
Lille study, 53% of patients had residual headache, 29% fulfilled criteria for migraine, and 
27% had headache of the tension type. In VENOPORT, 55% of patients reported headaches 
during the follow-up, and these were mild to moderate in 45%. At follow-up, severe 
headaches that required bed rest or hospital admission were reported in 14% of patients in 
the ISCVST and 11% in VENOPORT. In patients with persistent or severe headaches, 
appropriate investigations should be completed to rule out recurrent CVST. Occasionally, 
MRV may show stenosis of a previously occluded sinus, but the clinical significance of this 
is unclear. Headache during follow-up is more common among patients who present 
acutely as having isolated intracranial hypertension. In these patients, if headache persists 
and MRI is normal, lumbar puncture may be needed to exclude elevated intracranial 
pressure. Focal or generalized post-CVST seizures can be divided into early or remote (2 weeks 
after diagnosis) seizures. On the basis of case series, remote seizures affect 5% to 32% of 
patients. Most of these seizures occur in the first year of follow-up. In ISCVST, 11% of the 
patients experienced remote seizures (36 patients by 6 months, 55 by 1 year, and 66 by 2 
years). Risk factors for remote seizures were hemorrhagic lesion on admission CT/MRI (HR 
2.62, 95%CI 1.52 to 4.52), early seizure (HR 2.42, 95%CI 1.38 to 4.22), and paresis (HR 2.22, 
95%CI 1.33 to 3.69). Five percent of the patients had post-CVST epilepsy. Post-CVST 
epilepsy was also associated with hemorrhagic lesion on admission CT/MRI (OR 6.76, 
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95%CI 2.26 to 20.41), early seizure (OR 3.99, 95%CI 1.16 to 11.0), and paresis (OR 2.75, 95%CI 
1.33 to 6.54). Initiation of antiepileptic drugs for a defined duration is recommended to 
prevent further seizures in patients with CVST and parenchymal lesions who present with a 
single seizure. Severe visual loss due to CVST is rare (2% to 4%). Papilledema can cause 
transient visual impairment, and if prolonged, optic atrophy and blindness may ensue. 
Visual loss is often insidious, with progressive constriction of the visual fields and relative 
sparing of central visual acuity. Visual deficits are more common in patients with 
papilledema and those who present with increased intracranial pressure. Delayed diagnosis 
is associated with an increased risk of later visual deficit. Patients with papilledema or 
visual complaints should have a complete neuroophthalmological study, including visual 
acuity and formal visual field testing. Further, a thrombosis of the cavernous, lateral, or 
sagittal sinus can later induce a dural arteriovenous fistula. A pial fistula can also follow a 
cortical vein thrombosis. The relationship between the 2 entities is rather complex, because 
(1) dural fistulas can be a late complication of persistent dural sinus occlusion with 
increased venous pressure, (2) the fistula can close and cure if the sinus recanalizes, and (3) a 
preexisting fistula can be the underlying cause of CVST. The exact frequency of dural fistula 
after CVST is not known because there are no cohort studies with 22 long-term angiographic 
investigation. The incidence of dural arteriovenous fistula was low in cohort studies without 
systematic angiographic follow-up (1% to 3%). A cerebral angiogram may help identify the 
presence of a dural arteriovenous fistula.  
Specific recommendations for management of CVST and its complications can be 
summarised as follows (Saposnik et al, 2011): 
 Patients with CVST and a suspected bacterial infection should receive appropriate 
antibiotics and surgical drainage of purulent collections of infectious sources associated 
with CVST when appropriate;  
 In patients with CVST and increased intracranial pressure, monitoring for progressive 
visual loss is recommended, and when this is observed, increased intracranial pressure 
should be treated urgently;  
 In patients with CVST and a single seizure with parenchymal lesions, early initiation of 
antiepileptic drugs for a defined duration is recommended to prevent further seizures;  
 In patients with CVST and a single seizure without parenchymal lesions, early initiation 
of antiepileptic drugs for a defined duration is probably recommended to prevent 
further seizures;  
 In the absence of seizures, the routine use of antiepileptic drugs in patients with CVST 
is not recommended;  
 For patients with CVST, initial anticoagulation with adjusted-dose UFH or weight-
based LMWH in full anticoagulant doses is reasonable, followed by vitamin K 
antagonists, regardless of the presence of ICH;  
 Admission to a stroke unit is reasonable for treatment and prevention of complications 
of patients with CVST;  
 In CVST patients with increased intracranial pressure, it is reasonable to initiate 
treatment with acetazolamide. Other therapies (lumbar puncture, optic nerve 
decompression, or shunts) can be effective if there is progressive visual loss;  
 Endovascular intervention may be considered if deterioration occurs despite intensive 
anticoagulation treatment;  
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 In patients with neurological deterioration due to severe mass effect or intracranial 
hemorrhage causing intractable intracranial hypertension, decompressive 
hemicraniectomy may be considered;  
 For patients with CVST, steroid medications are not recommended, even in the 
presence of parenchymal brain lesions on CT/MRI, unless needed for another 
underlying disease; 
 The current recommendations for VTE patients call for indefinite anticoagulation 
(adjusted-dose warfarin INR 2.0 to 3.0 or heparin) for patients with antiphospholipid 
syndrome; 
 In patients with a history of CVST who complain of new, persisting, or severe headache, 
evaluation for CVST recurrence and intracranial hypertension should be considered. 
3.3.3 Clinical prediction rules (CPRs) or risk score models in CVST 
Although the overall outcome of CVST is favourable, about 15% of the patients become 
dependent or die. Clinical prediction rules (CPRs) or risk stratification models and scores 
(McGinn et al, 2000; McNally et al, 2010) might improve the ability to inform doctors about 
the individual prognosis of different disease conditions, including CVST. There are specific 
methodological standards that are applied to CPRs before their use in the clinical practice 
can be recommended. Ideally, a rule or scale undergoes three steps: derivation, narrow and 
broad validation, and impact analysis (randomised controlled trial assessing its effectiveness 
and cost-effectiveness) (McGinn et al, 2000). In this way, if a rule is applied, it is possible to 
further identify those CVST patients who could benefit from more intensive monitoring 
and/or invasive interventions at most. For instance, Barinagarrementeria et al (1992) proposed 
a prognostic scale based on clinical, CT and cerebrospinal fluid (CSF) analysis. The presence of 
coma or bilateral pyramidal signs was rated at 3, that of generalized seizures at 2 and that of 
meningeal signs, bilateral lesions on CT scan and haemorrhagic CSF all at 2 points. The 
prognosis was found to be 100% good when total score was <3, usually good (85%) with a 
score of 4-5, usually bad (90%) with a score of 6-8 and 100% bad with a score of >9. This scale, 
however, has not been consistently validated further in other CVST datasets. Another risk 
score model to predict a poor outcome has also been derived and validated. The score ranged 
from 0 (lowest risk) to 9 (highest risk), and a cut-off value equal or higher than 3 indicated a 
higher risk of death or dependency at 6 months. One point was assigned for male sex, 
presence of decreased level of consciousness, or ICH while 2 points indicated the presence of 
malignancy, coma, or thrombosis of the deep venous system. The discrimination performance, 
or area under the receiver operating characteristics (ROC) curve (AUC or c-statistics) in the 
derivation cohort was 85.4%, 84.4%, and 90.1% in the validation cohorts samples (Ferro et al, 
2004; Dentali et al, 2006). Another study incorporated the age above 37 years and central 
nervous system infection as additional risk factors into the latter model. The authors validated 
the score in 90 patients and obtained AUCROC=81% to predict mortality (with sensitivity of 
88% and specificity of 70% at a cut-off value equal or above 14) (Koopman et al, 2009). Notably, 
further validation studies are needed to better quantify and estimate the discrimination and 
calibration performance and overall generalisability of the above clinical prediction rule in 
other populations and settings. 
3.4 Cognition, behavioural changes and functional outcomes after CVST 
For many years CVST has been considered rare and lethal disease, diagnosed postmortem. 
The use of neuroimaging techniques as computer tomography, the magnetic resonance 
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95%CI 2.26 to 20.41), early seizure (OR 3.99, 95%CI 1.16 to 11.0), and paresis (OR 2.75, 95%CI 
1.33 to 6.54). Initiation of antiepileptic drugs for a defined duration is recommended to 
prevent further seizures in patients with CVST and parenchymal lesions who present with a 
single seizure. Severe visual loss due to CVST is rare (2% to 4%). Papilledema can cause 
transient visual impairment, and if prolonged, optic atrophy and blindness may ensue. 
Visual loss is often insidious, with progressive constriction of the visual fields and relative 
sparing of central visual acuity. Visual deficits are more common in patients with 
papilledema and those who present with increased intracranial pressure. Delayed diagnosis 
is associated with an increased risk of later visual deficit. Patients with papilledema or 
visual complaints should have a complete neuroophthalmological study, including visual 
acuity and formal visual field testing. Further, a thrombosis of the cavernous, lateral, or 
sagittal sinus can later induce a dural arteriovenous fistula. A pial fistula can also follow a 
cortical vein thrombosis. The relationship between the 2 entities is rather complex, because 
(1) dural fistulas can be a late complication of persistent dural sinus occlusion with 
increased venous pressure, (2) the fistula can close and cure if the sinus recanalizes, and (3) a 
preexisting fistula can be the underlying cause of CVST. The exact frequency of dural fistula 
after CVST is not known because there are no cohort studies with 22 long-term angiographic 
investigation. The incidence of dural arteriovenous fistula was low in cohort studies without 
systematic angiographic follow-up (1% to 3%). A cerebral angiogram may help identify the 
presence of a dural arteriovenous fistula.  
Specific recommendations for management of CVST and its complications can be 
summarised as follows (Saposnik et al, 2011): 
 Patients with CVST and a suspected bacterial infection should receive appropriate 
antibiotics and surgical drainage of purulent collections of infectious sources associated 
with CVST when appropriate;  
 In patients with CVST and increased intracranial pressure, monitoring for progressive 
visual loss is recommended, and when this is observed, increased intracranial pressure 
should be treated urgently;  
 In patients with CVST and a single seizure with parenchymal lesions, early initiation of 
antiepileptic drugs for a defined duration is recommended to prevent further seizures;  
 In patients with CVST and a single seizure without parenchymal lesions, early initiation 
of antiepileptic drugs for a defined duration is probably recommended to prevent 
further seizures;  
 In the absence of seizures, the routine use of antiepileptic drugs in patients with CVST 
is not recommended;  
 For patients with CVST, initial anticoagulation with adjusted-dose UFH or weight-
based LMWH in full anticoagulant doses is reasonable, followed by vitamin K 
antagonists, regardless of the presence of ICH;  
 Admission to a stroke unit is reasonable for treatment and prevention of complications 
of patients with CVST;  
 In CVST patients with increased intracranial pressure, it is reasonable to initiate 
treatment with acetazolamide. Other therapies (lumbar puncture, optic nerve 
decompression, or shunts) can be effective if there is progressive visual loss;  
 Endovascular intervention may be considered if deterioration occurs despite intensive 
anticoagulation treatment;  
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 In patients with neurological deterioration due to severe mass effect or intracranial 
hemorrhage causing intractable intracranial hypertension, decompressive 
hemicraniectomy may be considered;  
 For patients with CVST, steroid medications are not recommended, even in the 
presence of parenchymal brain lesions on CT/MRI, unless needed for another 
underlying disease; 
 The current recommendations for VTE patients call for indefinite anticoagulation 
(adjusted-dose warfarin INR 2.0 to 3.0 or heparin) for patients with antiphospholipid 
syndrome; 
 In patients with a history of CVST who complain of new, persisting, or severe headache, 
evaluation for CVST recurrence and intracranial hypertension should be considered. 
3.3.3 Clinical prediction rules (CPRs) or risk score models in CVST 
Although the overall outcome of CVST is favourable, about 15% of the patients become 
dependent or die. Clinical prediction rules (CPRs) or risk stratification models and scores 
(McGinn et al, 2000; McNally et al, 2010) might improve the ability to inform doctors about 
the individual prognosis of different disease conditions, including CVST. There are specific 
methodological standards that are applied to CPRs before their use in the clinical practice 
can be recommended. Ideally, a rule or scale undergoes three steps: derivation, narrow and 
broad validation, and impact analysis (randomised controlled trial assessing its effectiveness 
and cost-effectiveness) (McGinn et al, 2000). In this way, if a rule is applied, it is possible to 
further identify those CVST patients who could benefit from more intensive monitoring 
and/or invasive interventions at most. For instance, Barinagarrementeria et al (1992) proposed 
a prognostic scale based on clinical, CT and cerebrospinal fluid (CSF) analysis. The presence of 
coma or bilateral pyramidal signs was rated at 3, that of generalized seizures at 2 and that of 
meningeal signs, bilateral lesions on CT scan and haemorrhagic CSF all at 2 points. The 
prognosis was found to be 100% good when total score was <3, usually good (85%) with a 
score of 4-5, usually bad (90%) with a score of 6-8 and 100% bad with a score of >9. This scale, 
however, has not been consistently validated further in other CVST datasets. Another risk 
score model to predict a poor outcome has also been derived and validated. The score ranged 
from 0 (lowest risk) to 9 (highest risk), and a cut-off value equal or higher than 3 indicated a 
higher risk of death or dependency at 6 months. One point was assigned for male sex, 
presence of decreased level of consciousness, or ICH while 2 points indicated the presence of 
malignancy, coma, or thrombosis of the deep venous system. The discrimination performance, 
or area under the receiver operating characteristics (ROC) curve (AUC or c-statistics) in the 
derivation cohort was 85.4%, 84.4%, and 90.1% in the validation cohorts samples (Ferro et al, 
2004; Dentali et al, 2006). Another study incorporated the age above 37 years and central 
nervous system infection as additional risk factors into the latter model. The authors validated 
the score in 90 patients and obtained AUCROC=81% to predict mortality (with sensitivity of 
88% and specificity of 70% at a cut-off value equal or above 14) (Koopman et al, 2009). Notably, 
further validation studies are needed to better quantify and estimate the discrimination and 
calibration performance and overall generalisability of the above clinical prediction rule in 
other populations and settings. 
3.4 Cognition, behavioural changes and functional outcomes after CVST 
For many years CVST has been considered rare and lethal disease, diagnosed postmortem. 
The use of neuroimaging techniques as computer tomography, the magnetic resonance 
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imaging and the cerebral angiography has made possible the early diagnoses and has 
changed the knowledge about this condition (Bousser et al., 2007; Breteau et al.,2003; Preter 
et al., 1996). The increase of the data about it in the scientific literature enlarges the aspects 
studied and poses new questions. One of these questions is related to the functional 
outcome after CVST and the impact of cognitive impairments and behavioural changes on 
it. Due to the heterogeneity of study methodology and design, it is very difficult to compare 
the obtained results. Another important obstacle is due to the differences in the diagnostic 
process, in the extent of control for the underlying causes for CVST, for the clinical 
presentations and the treatment strategy.  
Most of the authors reported good functional outcome after CVST (Cakmak et al.,2003; de 
Bruijn et al., 2001; Ferro et al., 2001; Ferro et al., 2002; Hameed et al.,2006; Kirmani et al., 
2005). In a 77 months follow-up 86% of the patients recovered without neurological sequelae 
(Preter et al., 1996). The conclusions from the largest, for the time being, international study 
- ISCVST (Ferro et al., 2004) and from a large systematic review of 19 papers on CVST 
(Dentali et al., 2006) were for a better prognosis than reported previously.  Most of the 
patients examined by Stolz et al. (2004) showed significant improvement on hospital 
discharge and 89% of them had significant functional improvement 12 months after the 
discharge. A review of long-term follow-up studies found that from 1943 patients examined, 
only 180 had poor recovery with permanent neurological deficit (Dentali et al.,2006). At the 
same time Bender et al. (2006) found that the severe CVST cases had not been studied in 
details and that cognitive impairments could influence negatively the quality of life of 
survived patients. De Bruijn et al. (2000) reported less favorable CVST outcome than 
reported previously. 
CVST is a condition that requires a prompt diagnose and treatment. The mode of onset of 
CVST is acute in 37,2% and sub-acute in 55,5% of the participants in ISCVST.  Probably this is 
the reason for the lack of data about the cognitive functioning of the patients.  But it is difficult 
to explain the absence of neuropsychological techniques from the set of methods, assessing the 
long-term recovery of surviving patients. Most of the outcome studies of CVST do not include 
testing of cognition and assessment of behavioural changes (Breteau et al., 2003; Cakmak et 
al.,2003; de Bruijn et al., 2001; Ferro et al., 2001; Ferro et al., 2002; Stolz et al., 2004). 
The assessment of the extent of functional recovery after CVST  is limited. The outcome after 
CVST is traditionally described by modified Rankin Scale score, that gives information only 
about the patient motor activity and the capacity for carrying out previous activities. Some 
of the studies report data received by mail or by phone. 
Abulia, executive deficits, and amnesia may result from thrombosis of the deep venous 
system, with bilateral panthalamic infarcts. Memory deficits, behavioral problems, or 
executive deficits may persist. The importance of more detailed examination and 
neuropsychological testing could be confirmed by a paper, reporting the results of 
functionally independent patients, having long-term symptoms with negative impact on 
their everyday functioning: 75% of patients, included in this 63 months follow-up, reported 
concentration impairments (Koopman et al.,2009). 
Aphasia was a clinical feature of CVST, found in 19% of the participants from 21 countries in 
ISCVST study (Ferro et al., 2004). Aphasia, in general of the fluent type, results from left 
lateral sinus thrombosis with temporal infarct or hemorrhage. Recovery is usually favorable, 
but minor troubles in spontaneous speech and naming might persist.  Cognitive assessment 
for aphasia, apraxia and working memory found aphasia in 3 patients and working memory 
deficit in 6 out of 34 patients in a follow-up study (Buccino et al., 2003). Preter et al. (1996) 
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report 1 patient with aphasia and 3 patients with memory loss and dementia in a 78 months’ 
follow-up of 77 patients with CVST. A detailed neuropsychological testing of participants in 
a long-term CVST outcome study showed that 35% of patients had abnormal performance 
on two or more cognitive tests, 33% - had impairments in two or more cognitive functions. 
Prevalence was found for visuospatial, constructive and language impairments (de Bruijn et 
al.,2000). Another interesting finding is the presence of cognitive impairments in patients 
with low scores for functional health. This report warrants for more detailed long-term 
assessment of CVST patients, including cognitive testing, because cognition is an important 
factor for everyday functioning and for the level of quality of life. The data about 
behavioural changes and the quality of life are even scarcer than these, related to cognitive 
domains. Psychiatric symptoms are rarely described during the diagnostic phase (Bousser et 
al., 2007). Behavioural changes are mentioned in the study of Preter et al., (1996). Data exist 
about depression and fatigue as long-term sequelae after CVST (Koopman et al.,2009; 
Buccino et al., 2003). Assessment with questionnaires for quality of life and for well-being 
after CVST is very rare as well (Bender et al.,2007).  
4. Conclusions 
The main findings of this review were that all age groups can be affected by CVST and the 
large sinuses such as the superior sagittal sinus are most frequently involved. Extensive 
collateral circulation within the cerebral venous system allows for a significant degree of 
compensation in the early stages of thrombus formation. Systemic inflammatory diseases 
and inherited as well as acquired coagulation disorders are frequent causes, although in up 
to 30% of cases no underlying cause can be identified. The diagnosis is usually made by 
venographic studies with computer tomography (CT or CTV) or magnetic resonance 
imaging (MRI or MRIV) to demonstrate obstruction of the venous sinuses or cerebral veins 
by a thrombus. The MRI with venography (MRIV) is the investigation of choice; computed 
tomography alone will miss a significant number of cases. Additionally, the use of such 
precise neuro-imaging techniques gives the possibility for early diagnosis and treatment of 
emerging neuropsychological impairments in the set of the clinical symptoms in CVST; for 
instance, a cognitive deficit as part of the long-term outcome; a range of psychiatric 
complications and, last but not least, to collect data and explore the various aspects of the 
health-related quality of life or HRQOL) in such patients. It should be noted that the 
neuropsychological impairments that could be present during CVST are not well known, 
including various aspects of the assessment of the eventually impaired mental status. For 
instance, various data exist about disorientation, lack of coordination, incapacity to follow 
commands, neglect, apraxia, recent memory impairments and language impairments, 
among others. In the same time, very little is known about the long term outcome of CVST – 
for instance, it has been observed that many patients experience some persistent neurologic 
and cognitive deficits, but data are scarce and difficult to collect and summarise. The 
management of CVST includes treatment of the underlying condition; symptomatic 
treatment; the prevention or treatment of complications of increased intracranial pressure, 
ICH, or venous infarction; and typically, anticoagulation therapy. It has now been 
conclusively shown that intravenous heparin is the first-line treatment for cerebral venous 
sinus thrombosis because of its efficacy, safety and feasibility. Local thrombolysis may be 
indicated in cases of deterioration, despite adequate heparinisation. This should be followed 
by oral anticoagulation for 3-6 months. The prognosis of cerebral venous sinus thrombosis is 
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imaging and the cerebral angiography has made possible the early diagnoses and has 
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report 1 patient with aphasia and 3 patients with memory loss and dementia in a 78 months’ 
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among others. In the same time, very little is known about the long term outcome of CVST – 
for instance, it has been observed that many patients experience some persistent neurologic 
and cognitive deficits, but data are scarce and difficult to collect and summarise. The 
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treatment; the prevention or treatment of complications of increased intracranial pressure, 
ICH, or venous infarction; and typically, anticoagulation therapy. It has now been 
conclusively shown that intravenous heparin is the first-line treatment for cerebral venous 
sinus thrombosis because of its efficacy, safety and feasibility. Local thrombolysis may be 
indicated in cases of deterioration, despite adequate heparinisation. This should be followed 
by oral anticoagulation for 3-6 months. The prognosis of cerebral venous sinus thrombosis is 
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generally favourable. A high index of clinical suspicion is needed to diagnose this 
uncommon condition so that appropriate treatment can be initiated. Complications, in a 
short- and a long-term, include but are not limited to cognition and behavioural changes. 
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1. Introduction 
Venous thrombosis is associated with Virchow’s triad. This involves the combination of 
hypercoagulability, damage to the vessel endothelium and haemodynamic changes in the 
form of stasis or turbulence. These features ultimately contribute to thrombosis formation 
(Heit 2008). 
Venous thrombosis can affect the eyes, resulting in serious ocular symptoms and is a 
significant cause of vision loss worldwide (Rogers, McIntosh et al. 2010). In the eye, venous 
thrombosis can result in a branch or a central retinal vein occlusion. The eye can also be 
affected by systemic venous thrombosis such as that which occurs in cerebral venous sinus 
thrombosis presenting with papilloedema, or in anti-phospholipid syndrome resulting in 
retinal arteriole occlusion, ischemic optic or cranial neuropathies. 
In this chapter, we will discuss the ocular features of venous thrombosis, the presentation of 
retinal vein occlusion, and its ocular and systemic management. We will then examine the 
ophthalmic manifestations of systemic venous thrombosis. 
2. Retinal vein occlusion 
2.1 Pathogenesis 
Retinal venous obstruction occurs as a result of Virchow’s triad in the retinal vessels with 
stasis, hypercoagulability and endothelial change. In the retina, disruption of venous return 
results in elevated intravascular pressure and culminates in retinal haemorrhage and 
oedema. Retinal ischaemia then follows, leading to non-perfusion of the capillary beds. 
Retinal vein occlusion RVO can be classified as either a branch retinal vein occlusion 
(BRVO) (Figure 1) or a central retinal vein occlusion (CRVO) (Figure 2) depending upon the 
location of the obstruction (Hayreh 2005). Each of BRVO and CRVO can be further sub-
classified into ischaemic and non-ischaemic categories. 
Ischaemic RVO is characterised by retinal capillary non-perfusion and results in more severe 
signs and symptoms including significant decrease in visual acuity, cotton wool spots 
(indicating retinal ischaemia) and a relative afferent pupil defect. An ischemic RVO is 
usually associated with ocular complications such as intraocular neovascularisation. 
In non-ischaemic RVO stasis of the retinal veins occurs. There is leakage from the 
capillary bed but capillary perfusion is still present. A non-ischaemic RVO is associated 
with decreased visual acuity as a result of leaking retinal capillaries that cause macular 
oedema. 
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Fig. 1. Fundus photograph of a superior-temporal branch retinal vein occlusion in the right 
eye (a) with the corresponding fluorescein angiogram (b). The retina shows a sectoral area of 
retinal haemorrhages (H) and cotton wool spots (C) in the area distal to the vein occlusion 
(black arrow). 
 








Fig. 2. Fundus photograph of a central retinal vein occlusion in the right eye (a) with normal 
left eye (b) of the same patient. In central retinal vein occlusion, there are scattered 
haemorrhages (H) in all four quadrants of the retina, cotton wool spots (C), and optic nerve 
swelling (ON), which is characterised by indistinct disc margins (black arrows). 
2.2 Prevalence 
The prevalence of RVO is approximately 1 in 200 people, with an estimated 16.4 million 
people being affected worldwide (Rogers, McIntosh et al. 2010). Prevalence appears to 
increase with age (Rogers, McIntosh et al. 2010), whereas gender or ethnicity does not 
appear to affect prevalence (Rogers, McIntosh et al. 2010). Retinal vein occlusion is usually 
unilateral and very rarely bilateral. A BRVO is four times more common than a CRVO 
(Rogers, McIntosh et al. 2010), with its prevalence ranging from 0.3% (Wong, Larsen et al. 
2005) to 1.1% (Mitchell, Smith et al. 1996). 
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2.3 Risk factors 
The risk factors for RVO include systemic or local conditions which result in vascular stasis 
or endothelial damage. Systemic risk factors for RVO are often associated with 
atherosclerotic vessel changes, and these risk factors include age (Hayreh, Zimmerman et al. 
1994), hypertension (Mitchell, Smith et al. 1996; Hayreh, Zimmerman et al. 2001) and 
hyperlipidaemia (1993; 1996). Diabetes mellitus (Dodson, Kritzinger et al. 1992; Hayreh, 
Zimmerman et al. 2001), peripheral vascular disease and cerebrovascular disease also 
contribute to a higher likelihood of developing RVO.  
Less common systemic risk factors for RVO include those associated with 
hypercoagulability. These include myeloproliferative disorders (Fegan 2002) such as 
polycythaemia, myeloma and Waldenstrom macroglobulinaemia. These account for 1% of 
RVO cases. Acquired and inherited hypercoagulable states (Fegan 2002) may also 
predispose a patient to RVO. Acquired diseases that have been shown to contribute to RVO 
include hyperhomocysteinaemia (Chua, Kifley et al. 2005; Janssen, den Heijer et al. 2005), 
anti-cardiolipin antibodies (Janssen, den Heijer et al. 2005), lupus anticoagulant and anti-
phospholipid antibodies. Inherited hypercoagulable diseases that have been associated with 
RVO include factor V Leiden mutation, protein C or S deficiency (Greiner, Hafner et al. 
1999), anti-thrombin deficiency, prothrombin gene mutation (Incorvaia, Lamberti et al. 
1999)and factor XII deficiency (Incorvaia, Lamberti et al. 1999). Inflammatory diseases such 
as Behçet’s disease, sarcoidosis, Wegener’s granulomatosis and Goodpasture syndrome and 
chronic renal failure have also been proven to be risk factors for RVO. Oestrogen therapy 
may be a cause of RVO, although the evidence is inconclusive (Kirwan, Tsaloumas et al. 
1997). Hormone replacement therapy has not been shown to be a major risk factor for RVO, 
whereas the contraceptive pill does increase the risk of RVO and is contraindicated in those 
with RVO.  
A local risk factor for the development of a CRVO is primary open angle glaucoma (1996; 
Mitchell, Smith et al. 1996). This is due to stasis caused by the elevated intraocular pressure 
in glaucoma reducing arterial perfusion. The mean arterial perfusion pressure is the 
difference between the mean arterial pressure and the intraocular pressure. 
2.4 Investigations 
All investigations should be directed towards examining the systemic risk factors of RVO 
and assessing the ocular complications of neovascularization. 
Systemic investigations include screening for atherosclerotic disease and hypercoagulability. 
This involves measuring blood pressure, electrocardiogram, a full blood count, measuring 
erythrocyte sedimentation rate, fasting glucose and lipids, a vasculitic screen and a 
thrombophilia screen. A vasculitic screen involves measuring antinuclear antibodies, 
rheumatoid factor, anti-neutrophil cytoplasmic antibody, serum protein electrophoresis, 
complement 3 and 4. Whereas a thrombophilia screen would include measuring serum 
homocysteine, protein C and S, Factor V Leiden, antithrombin, anticardiolipin antibodies 
and lupus anticoagulant. 
It is important to remember that in patients with BRVO, cardiovascular risk factors are the 
predominant cause. In contrast, in patients with CRVO, especially when the patient’s age is 
less than 65, there should be a more extensive search for other risk factors such as oral 
contraceptive use, thrombophilia or inflammatory diseases. 
Ocular investigation with a fundus fluorescein angiography allows for visualisation of large 
retinal vessels and retinal capillary beds. This helps to differentiate between the ischemic 
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and non-ischemic types of RVO (Figure 3). Optical coherence tomography (OCT) is another 
investigation that is becoming increasingly important in assessing the changes in retinal 
architecture and measuring the thickness of the retinal layers. OCT can assist in detecting 





Fig. 3. Fluorescein angiogram of a non-ischaemic central retinal vein occlusion (a) compared 
to an ischaemic central retinal vein occlusion (b). In non-ischaemic central retinal vein 
occlusion, there is effective capillary perfusion and this is seen as white due to the 
fluorescein filling the vessels. In ischaemic central retinal vein occlusion, there are areas of 
capillary non-perfusion (I) and seen as black due to the absence of fluorescein filling the 
vessels. 
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Fig. 4. Optical coherence tomography scan of the macular in an eye with retinal vein 
occlusion. Nasal to temporal (N→T) cross-sectional image of the macula demonstrates the 
presence of significant macula oedema and associated intra-retinal cysts (white arrow). 
2.5 Clinical presentations 
2.5.1 Branch retinal artery occlusion 
In BRVO, only a branch of the retinal venous system is affected. Risk factors for BRVO are 
listed above. The occlusion in BRVO occurs most commonly at an arteriovenous junction, 
where the artery and vein share a common adventitial sheath. Venous thrombosis results 
from arterial wall thickening, which compresses the adjacent vein.  
Vision loss is the most common presentation in patients with BRVO. The vision loss is 
usually sudden, unilateral and painless. This loss can be variable and is dependent upon the 
amount of macular and retinal involvement. If there is macular involvement, vision is 
usually affected. Alternatively, if the BRVO is small or located in the peripheral retina, the 
patient may still have 6/6 vision. Metamorphopsia or distorted vision and a visual field 
defect may also occur. 
Ocular fundus examination often reveals a wedge shaped area of retinal abnormality. The 
superior temporal retinal arcade is affected in 60% of all cases of BRVO due to the higher 
number of arteriovenous crossings in this area. The veins distal to the occlusion may 
demonstrate dilatation and tortuosity, while there may be some venous attenuation 
proximal to the occlusion. Retinal haemorrhages are a notable feature of BRVO. Superficial 
retinal haemorrhages appear flame shaped, while deep haemorrhages are characteristically 
referred to as dot-blot haemorrhages (Figure 5). Very rarely, there may be subhyaloid or 
vitreous haemorrhages. Other ocular fundus features of BRVO include retinal oedema and 
cotton-wool spots, which is also a sign of retinal ischaemia. 
 




Fig. 5. Fundus photograph of an inferior branch retinal vein occlusion in the left eye 
showing different types of retinal haemorrhages. Superficial retinal haemorrhages (S) are 
flame shaped; deep retinal haemorrhages (D) are dot-blot. 
2.5.2 Central retinal vein occlusion 
Similar to BRVO, the most common presentation in patients with CRVO is vision loss. The 
vision loss is sudden, unilateral, painless and usually profound, in the range of counting 
fingers. 
Examination reveals a relative afferent Pupillary defect. While fundus examination 
demonstrates tortuosity and dilatation of all the branches of the central retinal vein as well 
as superficial (flame-shaped) and deep (dot-blot) intraretinal haemorrhages. Cotton wool 
spots and oedema of the optic disc or macular may be present. 
Fluorescein angiography is the ocular investigation of choice in patients with suspected 
CRVO. The general features of CRVO using fluorescein angiography include delayed 
arteriovenous transit time and blockage by retinal haemorrhages. Fluorescein angiography 
is vital in distinguishing between non-ischaemic and ischaemic CRVO (Figure 3). There is 
effective capillary perfusion in non-ischaemic CRVO and capillary non-perfusion in 
ischaemic CRVO. 
2.6 Treatment 
Treatment involves management of the systemic risk factors and local treatment for 
complications of RVO, such as macular oedema and neovascularisation. 
With regard to systemic treatment of RVO, there is no strong evidence in current literature 
for the use of anticoagulant, fibrinolytic agents or antiplatelet agents. Best practice 
management involves treating the atherosclerotic risk factors, such as hypertension and 
hyperlipidaemia. 
Local treatment for BRVO differs from the treatment of CRVO. For BRVO, the Branch Vein 
Occlusion Study (BVOS) suggested that retinal haemorrhages and any macular oedema 
should be observed for 3 months to allow for spontaneous resolution. After 3 months, if the 
macular oedema is still present, treatment may be warranted. The BVOS recommends grid 
laser photocoagulation for the treatment of macular oedema (1984). Use of intravitreal anti-
VEGF agents, such as ranibizumab, has been shown to be beneficial (Campochiaro, Heier et 
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VEGF agents, such as ranibizumab, has been shown to be beneficial (Campochiaro, Heier et 
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al. 2010). There has been some conflicting evidence regarding the use of triamcinolone 
acetonide in the treatment of macular oedema in BRVO. Jonas et al. found it to beneficial in 
the treatment of macular oedema (Jonas, Akkoyun et al. 2005), however Scott et al found 
intravitreal triamcinolone to be no more effective than grid laser photocoagulation and was 
even associated with a higher risk of adverse events (Scott, Ip et al. 2009). Dexamethasone 
has been shown to be beneficial, but there is also a risk that dexamethasone can increase 
intraocular pressure (Haller, Bandello et al. 2010). Optic disc or retinal neovascularisation 
requires treatment with pan-retinal (scatter) laser photocoagulation in the distribution of 
occluded vein (1986; Hayreh, Rubenstein et al. 1993). Prophylactic PRP is not indicated to 
prevent neovascularisation, as the harmful effects of PRP outweigh the benefits in 
prophylaxis (1984). 
Treatment of CRVO should initially involve determining the type of CRVO present. In 
patients with non-ischaemic CRVO, the macular oedema can be treated with intravitreal 
steroids such as triamcinolone acetonide (Ip, Scott et al. 2009) or dexamethasone (Haller, 
Bandello et al. 2010). Treatment with intravitreal anti-VEGF agents, such as Ranibizumab 
has been shown to be useful in a double-blinded randomized controlled trial (Brown, 
Campochiaro et al. 2010). Laser photocoagulation for the treatment of macular oedema in 
CRVO has not been found to be beneficial (1995). In ischaemic CRVO, the presence of 
anterior chamber angle neovascularisation or rubeosis iridis should immediately be treated 
with laser pan-retinal photocoagulation (1995). Prophylactic PRP is not warranted and PRP 
is only indicated once anterior segment neovascularisation becomes apparent. Unproven 
treatments include the use of Ticlopidine, Troxerutin and Epoprostenol. 
2.7 Prognosis 
Prognosis is dependent upon the type of RVO. 
BRVO tends to have a better prognosis, but it may take 6 to 12 months to resolve. The 
affected area is commonly replaced by hard exudates and venous sheathing. Collateral 
vessels can form between the affected and unaffected retina. If there are improvements in 
visual acuity and the development of efficient collaterals, the prognosis is often good. The 
prognosis is poor if there are complications associated with the BRVO such as the 
development of chronic macular oedema, which occurs in 57% of temporal branch 
occlusions. Another serious complication is neovascularisation, which can lead to recurrent 
vitreous and pre-retinal haemorrhages as well as retinal detachments and ultimately 
adversely affects the visual outcome. 
Similarly, the acute stage of CRVO takes approximately 6 to 12 months to resolve. Disc 
collaterals between the retinal and choroidal vascular network usually form during this 
time. The final visual acuity is dependent upon the initial visual acuity following RVO 
(1997), with better visual outcomes in those with good initial visual acuity. The 
complications and prognoses are different for the different types of CRVO. The 
complications of non-ischaemic CRVO include chronic macular oedema and conversion to 
ischaemic CRVO. The prognosis of non-ischaemic CRVO is often good, unless a conversion 
to ischaemic CRVO occurs. One-third of non-ischaemic CRVO convert to become ischemic 
by 3 years, with half of these conversions occurring within the first 4 months following the 
CRVO (1997). Ischaemic CRVO may be complicated by neovascularization, which occurs in 
5% of eyes. When rubeosis iridis develops, it results in neovascular glaucoma, due to the 
neovascular membrane occluding the trabecular meshwork where the aqueous fluid drains 
out of the eye. Neovascular glaucoma commonly occurs within 3 months of the onset of the 
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CRVO and is characterised by a sudden increase in pain due to a rise in intraocular 
pressure. The risk factors for its development include poor visual acuity, extensive retinal 
haemorrhage and significant retinal non-perfusion on fluorescein angiography (1997). In 
patients with less than 10 optic disc areas of retinal non-perfusion, less than 10% of eyes will 
develop rubeosis iridis. However, if there are more than 30 optic disc areas of retinal non-
perfusion, the risk of rubeosis iridis increases significantly. The prognosis of ischaemic 
CRVO is usually poor due to the development of macular ischaemia or neovascularization. 
RVO in one eye increases the risk for the development of a RVO in the contralateral eye. 
This occurs in 9-15% of patients within 5 years of the initial diagnosis of RVO (Hayreh, 
Zimmerman et al. 1994). Unfortunately, at present there is no treatment available to prevent 
the development of RVO in the contralateral eye or a recurrence of RVO in the same eye. 
RVO is also associated with an increased likelihood of death from cerebral vascular and 
cardiovascular causes (Tsaloumas, Kirwan et al. 2000; Cugati, Wang et al. 2007). 
3. Ophthalmic manifestations of systemic thrombosis 
Systemic venous thrombosis can cause significant ocular symptoms and signs. Evidence 
suggests that ocular manifestation in systemic thrombosis increases the risk of cerebral events 
(Asherson, Khamashta et al. 1989) and ultimately, this impacts the prognosis of the patient. 
It is, therefore, important to consider ocular features of systemic venous thrombosis, but, it 
is also equally important that clinicians are aware of the ophthalmic features of systemic 
conditions that predispose to a venous thrombosis, such as thrombophilias. 
It is clearly impossible to consider all systemic conditions that cause a predisposition to 
venous thrombosis in this chapter. Therefore, here we will consider two systemic conditions 
that have important ocular manifestations. Firstly, we will discuss cerebral venous sinus 
thrombosis and to highlight the ocular features of systemic thrombosis. Then we will 
examine anti-phospholipid syndrome to review the ocular features of a condition that is a 
risk factor for venous thrombosis. 
3.1 Ophthalmic manifestations of cerebral venous sinus thrombosis 
Cerebral venous sinus thrombosis (CVT) is a condition that results from thrombosis and 
occlusion of the cerebral veins or dural sinus. This thrombosis causes increased venous 
pressure and subsequently results in impairment of cerebrospinal fluid (CSF) absorption 
and increased intracranial pressure (ICP). Regardless of the site, all CVT can cause raised 
ICP. The common sites for CVT include the cavernous sinus, sigmoid sinus, transverse sinus 
and sagittal sinus.  Rarer sites of thrombosis include the lateral sinus, jugular vein, posterior 
fossa vein and the deep cerebral venous system (straight sinus). 
Impaired CSF absorption is associated with increased intracranial pressure, while increased 
capillary pressure disrupts the blood-brain barrier, decreases capillary perfusion and results 
in capillary damage. This increased capillary pressure ultimately causes vasogenic and 
cytotoxic oedema as well as cerebral parenchyma lesions (Gotoh, Ohmoto et al. 1993; 
Yoshikawa, Abe et al. 2002). 
3.1.1 Prevalence 
CVT is a rare thrombotic occurrence with an incidence of 3-4 per million (Stam 2005). It is 
more common in females compared to males with a ratio of 3:1 (Ferro, Canhao et al. 2004), 
and is also more common in children compared to adults (Agnelli and Verso 2008). 
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CRVO and is characterised by a sudden increase in pain due to a rise in intraocular 
pressure. The risk factors for its development include poor visual acuity, extensive retinal 
haemorrhage and significant retinal non-perfusion on fluorescein angiography (1997). In 
patients with less than 10 optic disc areas of retinal non-perfusion, less than 10% of eyes will 
develop rubeosis iridis. However, if there are more than 30 optic disc areas of retinal non-
perfusion, the risk of rubeosis iridis increases significantly. The prognosis of ischaemic 
CRVO is usually poor due to the development of macular ischaemia or neovascularization. 
RVO in one eye increases the risk for the development of a RVO in the contralateral eye. 
This occurs in 9-15% of patients within 5 years of the initial diagnosis of RVO (Hayreh, 
Zimmerman et al. 1994). Unfortunately, at present there is no treatment available to prevent 
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3.1.2 Clinical presentation 
The ophthalmic presentation of CVT can be quite variable and it may have an acute or 
chronic onset. The most common ocular feature is papilloedema due to raised intracranial 
pressure. Acute papilloedema appears as flame shaped haemorrhages and cotton wool 
spots, which are an indication of nerve fibre layer infarction (Figure 6); whereas chronic 
papilloedema may have a ‘champagne cork’ like appearance (Figure 7). Despite the presence 
of papilloedema, visual acuity is often initially unaffected and the first ocular symptom to 
occur is usually visual field constriction (Figure 7). Patients can also present with visual 
obscuration with bending or coughing; and there may be diplopia due to cranial nerve VI 
palsy (Figure 8). 
In cases of cavernous sinus thrombosis, ocular features are the predominant feature and can 
include ocular pain, chemosis, proptosis and cranial nerve palsies affecting the extraocular 
muscles. This is due to the close association between the oculomotor (cranial nerve III), 





Fig. 6. Fundus photograph showing acute papilloedema with haemorrhages (H) and cotton 
wool spots (C) in the right eye (a) and the left eye (b) of the same patient. 
 








Fig. 7. Fundus photograph showing a ‘champagne cork’ like appearance in chronic 
papilloedema in the right eye (a) and left eye (b) of the same patient. In the right eye, there is 
a Y shaped retinochoroidal shunt (S) due to the retinal vessels diverting towards the 
choroidal vessels and is another fundus feature of chronic papilloedema. Corresponding 
visual fields images shows significant field constriction in the right eye (c) and an enlarged 
blind spot in the left eye (d). 
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Fig. 8. Clinical photograph of all nine positions of gaze in a patient with a cranial nerve VI 
palsy associated with raised intracranial pressure. The patient complains of diplopia and 
there is weakness in the lateral rectus as indicated by the visibility of the sclera on lateral 
gaze (arrows). 
3.1.3 Investigations 
Magnetic resonance imaging (MRI) with magnetic resonance venography is the most 
sensitive method for diagnosing CVT and visualising brain parenchymal lesions. However, 
this sensitivity depends upon the location of the thrombosis (Ferro, Morgado et al. 2007). 
Given its wide availability, computed tomography (CT) is often used for investigation of 
CVT. The radiological findings of CVT on CT are often non-specific and the scan may be 
normal in 30% of cases with CVT. Signs that assist in the diagnosis of CVT include the dense 
triangle sign on non-contrast CT (hyperdensity in the posterior part of the superior sagittal 
sinus caused by venous thrombosis), the cord sign on contrast CT (linear hyperdensity over 
cerebral cortex caused by venous thrombosis) and the empty delta sign on contrast CT (area 
where there is absence of contrast enhancement in the posterior part of the superior sagittal 
sinus) (Boukobza, Crassard et al. 2007). These signs occur in one-third of patients with CVT. 
Ocular assessment in patients with CVT should involve serial visual acuity, visual field 
measurements and imaging of the optic nerve head with stereophotographs or other 
imaging modalities such as OCT in order to monitor progression. 
Once diagnosed, an investigation for the possible causes of CVT may be warranted. This 
involves blood tests to screen for thrombophilias, as well as a search for a malignancy. 
3.1.4 Treatment 
Treatment aims to recanalise the occlusion, prevent thrombus propagation, address the 
underlying cause, and then control the symptoms of the condition such as vision loss. 
The most important principle of treatment of CVT is anticoagulation (Coutinho and Stam 
2010) in patients who have no contraindications to anticoagulation. Treatment with either 
unfractionated heparin or low molecular weight heparin has been shown to reduce the risk 
of death and dependency (Stam, De Bruijn et al. 2002). Anticoagulation appears to be safe in 
CVT patients with intracranial haemorrhages (Einhaupl, Stam et al. 2010), as the 
haemorrhages in CVT are the result of venous occlusion. 
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Although controversial, failure in improvement with anticoagulation may require the use of 
direct endovascular thrombolysis (Einhaupl, Stam et al. 2010) which involves either 
mechanically (Scarrow, Williams et al. 1999) or chemically (Wasay, Bakshi et al. 2001) 
dissolving the clot. This is generally reserved for patients with poorer prognoses (Stam 
2005), as there is the potential that thrombolysis may cause death or dependency in up to 
40% of patients with CVT (Stam, Majoie et al. 2008). However, in critically ill patients, 
thrombolysis may reduce death compared to other treatments or no treatment at all 
(Canhao, Falcao et al. 2003). 
Aside from treatment of the CVT, it is important to manage any associated symptoms. In 
particular, control of elevated intracranial pressure is vital in patients with headaches, as 
well as preserving visual function. In cases of decreasing visual acuity associated with CVT, 
optic nerve sheath fenestrations may help to reduce pressure, thereby preventing optic 
nerve atrophy. Equally important in CVT treatment is the control of seizures. 
3.1.5 Prognosis 
The prognosis of CVT is generally good. At 16 months, approximately 57% of patients with 
CVT have no signs or symptoms, and a further 22% of patients with CVT have only minor 
residual symptoms (Ferro, Canhao et al. 2004). Characteristics that are associated with a 
poorer prognosis include age over 37, male , previously having a coma or mental status 
abnormality; haemorrhage noted on imaging; deep venous system thrombosis; central 
nervous system infection and CVT associated with malignancy (Ferro, Canhao et al. 2004). 
Approximately 3% of patients die in the acute phase of CVT and 8% of patients die within 
the first 30 days following initial symptoms of CVT (Canhao, Ferro et al. 2005). Death is 
often due to transtentorial herniation or due to diffuse oedema and multiple parenchymal 
lesions (Canhao, Ferro et al. 2005). 
Significant visual loss in CVT is rare (Purvin, Trobe et al. 1995), and if present, is often 
associated with prolonged elevated intracranial pressure. Visual prognosis depends upon 
the duration and severity of elevation in pressure. 
There is often recanalisation after CVT and this commonly occurs within the first four 
months. The likelihood of recanalisation occurring depends on the location of the CVT 
(Baumgartner, Studer et al. 2003). Following a CVT, approximately 3% develop a recurrent 
CVT and 6% develop another form of venous thromboembolism at 6 years (Martinelli, 
Bucciarelli et al. 2010). 
3.2 Ophthalmic manifestations of antiphospholipid syndrome 
Antiphospholipid syndrome (APS) is an autoimmune disease associated with both arterial 
and venous thrombosis. It is characterised by lupus anticoagulant, anticardiolipin antibody 
and anti-β2 glycoprotein-I antibody (Miyakis, Lockshin et al. 2006). 
3.2.1 Prevalence 
The prevalence of ocular involvement in APS is variable, with studies suggesting that ocular 
features can occur in 8% to 88% of patients with APS (Utz and Tang 2011). 
3.2.2 Clinical presentation 
Ocular manifestations of APS include occlusive vascular disease (Miserocchi, Baltatzis et al. 
2001; Suvajac, Stojanovich et al. 2007), vasculitis (Miserocchi, Baltatzis et al. 2001) and neuro-
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ophthalmic manifestations. Occlusive vascular disease may occur in the form of central and 
branch retinal artery or vein occlusion, and choroidal infarction (Ang, Yap et al. 2000) 
(Figure 9). Vasculitis may manifest as anterior uveitis, episcleritis (Figure 10), scleritis 
(Figure 11) or retinal vasculitis causing retinal artery occlusion (Figure 12). APS may also be 
associated with cranial nerve III (Genevay, Hayem et al. 2002) (Figure 13), cranial nerve IV 
(Shin and Lee 2006) and cranial nerve VI (Shin and Lee 2006) palsies, in addition to 
ischaemic optic neuropathy (Giorgi and Balacco Gabrieli 1999), and optic neuritis (Giorgi 





Fig. 9. Fundus photograph showing central retinal artery occlusion with associated 
choroidal infarction in the left eye (a) and the corresponding fluorescein angiogram (b). 
 





Fig. 10. External photograph showing episcleritis of both eyes of the same patient with 
antiphospholipid syndrome. The right eye (a) is clinically more severe than the left eye (b). 
 
  
Fig. 11. External photograph showing scleritis of both eyes with the right eye (a) less severe 




Fig. 12. Fundus photograph of a branch retinal artery occlusion in the right eye due to 
vasculitis (a). The superior retina is pale due to infarction and the occluded artery is clearly 
visible on the corresponding fluorescein angiogram (b). 
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Fig. 13. Clinical photograph of all nine positions of gaze in a patient with a right pupil 
involving cranial nerve III palsy with right ptosis and exotropia on primary gaze. 
Patients with retinal vaso-occlusion usually present with pain, unilateral or bilateral 
decreased visual acuity, visual field defect or amaurosis fugax. Bilateral amaurosis fugax is a 
very serious condition, and may indicate the presence of central nervous system ischaemia. 
Those with cranial neuropathy present with acute binocular diplopia.  
On examination, patients with APS may have dry eyes, conjunctival telangiectasia 
(Miserocchi, Baltatzis et al. 2001) and corneal infiltrates or keratitis. Ocular fundus 
examination may reveal tortuous and dilated retinal veins, intra-retinal haemorrhages, 
cotton-wool spots, optic disc and macular oedema or neovascularisation. 
3.2.3 Investigations 
Ocular imaging with fluorescein angiography directly visualizes the retinal vessels and 
occlusion. An MRI scan may be important if there is visual loss without ocular fundus 
changes, as it is important to investigate the possibility of CNS ischaemia. 
In addition to imaging, a full thrombophilia work-up may be necessary in the absence of 
traditional thrombophilia risk factors. This would include searching for antiphospholipid 
antibodies, including lupus anticoagulant, anticardiolipin antibody and anti-β2 glycoprotein-I 
antibody. Other screening tests should include homocysteine, protein C and S, plasminogen, 
anti-thrombin levels, activated protein C resistance and factor V Leiden mutation. 
3.2.4 Treatment 
Early detection of ocular manifestations of APS is important as it allows treatment and 
prevention of further systemic disease. This first involves determining the patient’s 
thrombotic risk. 
The treatment of the systemic disease is vital as it may reverse the retinal ischaemia 
(Srinivasan, Fern et al. 2001). This should include reducing modifiable risk factors such as 
hypertension, hyperlipidaemia, diabetes mellitus, oral contraceptive use, hormone 
replacement therapy and smoking. 
Treatment should also target the cause of the thrombosis. APS with venous thrombosis 
requires anticoagulation with warfarin while APS with arterial thrombosis requires anti-
platelet agents (Ruiz-Irastorza, Hunt et al. 2007). 
 




Ocular prognosis depends upon the presence of complications such as neovascularisation 
and therefore, regular ocular monitoring is required. 
In patients with antiphospholipid syndrome, the risk of further thromboembolic 
complications ranges from 22% to 29% (Ruiz-Irastorza, Hunt et al. 2007) 
4. Conclusion 
Similar to systemic venous thrombosis, venous thrombosis in the eye is a manifestation of 
Virchow’s triad. Ocular venous thrombosis presents as retinal vein occlusion. The eye can 
also be affected by systemic venous thrombosis. Accurate diagnosis of venous thrombosis is 
vital and early treatment should be implemented in order to preserve existing vision and to 
prevent serious visual, and life threatening complications. 
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1. Introduction 
Venous thromboembolism (VTE) manifesting as deep vein thrombosis(DVT) or 
pulmonary embolism (PE), is one of the most common complications of hospitalization 
and is associated with short and long-term morbidity, mortality and resource 
expenditure.  Routine use of thromboprophylaxis reduces adverse patient outcomes while 
at the same time decreasing overall costs. Almost all hospitalized patients have at least 




Trauma (major trauma or lower-extremity injury) 
Immobility, lower-extremity paresis 
Cancer (active or occult) 
Cancer therapy (hormonal, chemotherapy, angiogenesis inhibitors, radiotherapy) 
Venous compression (tumor, hematoma, arterial abnormality)  
Previous VTE  
Increasing age 
Pregnancy and the postpartum period  
Estrogen -containing oral contraceptives or hormone replacement therapy 
Selective estrogen receptor modulators  
Erythropoiesis-stimulating agents  
Acute medical illness  
Inflammatory bowel disease  
Nephrotic syndrome  
Myeloproliferative disorder  
Paroxysmal nocturnal hemoglobinuria 
Obesity 
Central venous catheterization  
Inherited or acquired thrombophilia 
Table 1. Risk Factors for VTE  
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Without thromboprophylaxis, the incidence of objectively confirmed, hospital-acquired 
DVT is approximately 10 to 40% among medical or general surgical patients and 40 to 60% 
following major orthopedic surgery (Table 2)(1-2). 
 
Patient Group  DVT Prevalence, % 
Medical patients 10-20 
General, surgery 15-40 
Major gynecologic surgery 15-40 
Major Urologic surgery 15-40 
Neurosurgery 15-40 
Stroke 20-50 
Flip or knee arthroplasty, HFS 40-60 
Major trauma 60-80 
SCI 60-80 
Critical care patients 10-80 
* Rates based on objective diagnostic: screening for asymptomatic DVT in patients not receiving 
thromboprophylaxis.  
Table 2. Approximate Risk of DVT in Hospitalized Patients  
Several hundred clinical trials of thromboprophylaxis, conducted over the past 50 years, 
have shown that the use of prophylaxis reduces the rates of deep vein thrombosis (DVT), 
proximal DVT, pulmonary embolism (PE), and fatal PE by more than 60% in a broad 
spectrum of hospitalized patients with a very low risk of adverse effects. Although effective 
strategies for the prevention of venous thromboembolism (VTE) are widely available and 
existence of several guidelines for individual risk assessments to determine thrombosis risk 
and prophylaxis, a significant number of patients still develop VTE because appropriate 
thromboprophylaxis is not correctly prescribed. Adapting evidence-based practice 
guidelines into existing local policies and protocols has been shown to significantly increase 
the proportion of at-risk patients receiving appropriate thromboprophylaxis. 
The American College of Chest Physicians (ACCP) sponsor and publish what are generally 
considered to be the most comprehensive and most commonly utilized of these 
guidelines(3). A summary of the 2008 ACCP Guidelines on the Prevention of VTE is 
presented in Table 3, (4). 
The type and duration of surgery clearly influence the risk of DVT. Numerous efforts have 
been made to identify the patients most at risk for DVT and PE. The studies of this problem 
categorize risk levels as low, medium, high, and very high.  
Patients at low risk are under 40 years of age contemplating minor surgery and with no 
associated risk factors. The incidence of DVT is less than 2%, proximal DVT 0.4%, PE at 0.2%, 
and fatal PE 0.02%. This group requires no special prophylaxis other than early ambulation.  
Patients at moderate risk are those aged 40–50 who are undergoing major surgery, have no 
associated risk factors, and expect a prompt recovery. The frequency of DVT is 10%–20% 
proximal DVT, 2%–4%, clinical PE 1%–2%, and fatal PE 0%– 1.4%. This group will benefit 
from prophylactic treatment with LMWH, or LDUH and ES. 
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Patient groups Recommended 
thromboprophylaxis 
options* 
Optimal duration of 
prophylaxis 
Low VTE Risk: 
•Medical - fully mobile, 
brief admission, no 
additional risk factors 
• Surgical - procedure < 
30 minutes, patient 
mobile, no additional risk 
factors 
 
Moderate VTE Risk: 
•Acute medical illness 
•Major general surgery 
•Major gynecologic 





High VTE Risk: 
•Hip or knee arthroplasty 





High VTE Risk: 
•Major trauma, (including 




High bleeding risk 
No prophylaxis 











Combinations of a 





Rivaroxaban or dabigatran 





heparin Combinations of a 
mechanical method and an 
anticoagulant 
 
Mechanical method of 
prophylaxis (GCS, PCD, VFP) 
Consider anticoagulant 












Continue until discharge 
for the majority of patients. 







Minimum of 10 days and 





Continue until discharge 
for the majority of patients. 
Prophylaxis should be 
continued for the inpatient 
rehabilitation period. 
 
Duration appropriate for 
the specific patient risk 
group. 
 
GCS indicates graduated compression stocking; PCD, pneumatic compression device, VFP, venous foot 
pump. 
Table 3. Risk stratification, recommended thromboprophylaxis and optimal duration of 
prophylaxis by patient group. 
The high-risk group are patients over 60, candidates for major surgery, with associated risk 
factors. The prevalence of DVT is 20%–40%; proximal DVT 4%–8%, clinical PE 2%–4% and 
fatal PE 0.4%–1%. Higher doses of LMWH or LDUH should be used, together with 1 PC 
devices and ES.  
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Patient groups Recommended 
thromboprophylaxis 
options* 
Optimal duration of 
prophylaxis 
Low VTE Risk: 
•Medical - fully mobile, 
brief admission, no 
additional risk factors 
• Surgical - procedure < 
30 minutes, patient 
mobile, no additional risk 
factors 
 
Moderate VTE Risk: 
•Acute medical illness 
•Major general surgery 
•Major gynecologic 





High VTE Risk: 
•Hip or knee arthroplasty 





High VTE Risk: 
•Major trauma, (including 




High bleeding risk 
No prophylaxis 











Combinations of a 





Rivaroxaban or dabigatran 





heparin Combinations of a 
mechanical method and an 
anticoagulant 
 
Mechanical method of 
prophylaxis (GCS, PCD, VFP) 
Consider anticoagulant 












Continue until discharge 
for the majority of patients. 







Minimum of 10 days and 





Continue until discharge 
for the majority of patients. 
Prophylaxis should be 
continued for the inpatient 
rehabilitation period. 
 
Duration appropriate for 
the specific patient risk 
group. 
 
GCS indicates graduated compression stocking; PCD, pneumatic compression device, VFP, venous foot 
pump. 
Table 3. Risk stratification, recommended thromboprophylaxis and optimal duration of 
prophylaxis by patient group. 
The high-risk group are patients over 60, candidates for major surgery, with associated risk 
factors. The prevalence of DVT is 20%–40%; proximal DVT 4%–8%, clinical PE 2%–4% and 
fatal PE 0.4%–1%. Higher doses of LMWH or LDUH should be used, together with 1 PC 
devices and ES.  
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In the very-high-risk group of patients with major trauma (multiorgan, spinal, pelvic, long 
bone fractures), intermittent compression devices and ES should be started as early as 
possible, and LMWH or LDUH initiated as soon as it is safe. In cases of major trauma, with 
absolute contraindications for anticoagulants, the prophylactic indication of an inferior vena 
cava (IVC) filter should be considered, especially in cases with duplex ultrasonography 
demonstration of DVT. 
2. Mechanical methods of thromboprophylaxis and the role of combined 
thromboprophylaxis modalities 
Early and frequent mobilizitation of hospitalized patients at risk for VTE is an important 
part of patient care. However, many patients cannot be fully ambulatory early after  
surgery. Furthermore, the majority of hospital-associated, symptomatic thromboembolic 
events occur after patients have started to ambulate, and mobilization alone does not 
provide adequate thromboprophylaxis for hospital patients. Specific mechanical methods of 
thromboprophylaxis, which include graduated compression stockings (GCS), intermittent 
pneumatic compression (IPC) devices, and the venous foot pump (VFP), increase venous 
outflow and/or reduce stasis within the leg veins. Use of mechanical thromboprophylaxis is 
the preferred option for patients at high risk for bleeding. If the high bleeding risk is 
temporary, consideration should be given to starting pharmacologic thromboprophylaxis 
once this risk has decreased. Mechanical thromboprophylaxis may also be considered in 
combination with anticoagulant thromboprophylaxis to improve efficacy in patient groups 
for which this additive effect has been demonstrated(3,5,6). However, since they are not 
associated with bleeding, and some methods have demonstrated efficacy as DVT prevention 
in clinical trials, the use of mechanical prophylaxis in combination with pharmacological 
prophylaxis may be helpful in certain situations. For example, in major trauma patients who 
have a high risk of bleeding at presentation (as after head injury), we use mechanical 
prophylaxis initially followed by anticoagulant prophylaxis with LMWH when safe (5,6). 
This strategy could be adopted in any postoperative situation in which the initial risk of 
bleeding is high.  
3. VTE in cancer patients 
The association of cancer with thrombosis has been known for more than 100 years. Since 
the beginning it was regarded as a 2-way association, first cancer increases the risk of 
thrombosis(as first observed by Armand Trousseau in 1865), and secondy clotting activation 
increases the progression of cancer(as postulated by Billroth in 1878). Patients with cancer 
have at least a sixfold-increased risk of VTE compared to those without cancer and active 
cancer accounts for almost 20% of all new VTE events occurring in the community. 
Furthermore, VTE is one of the most common and costly complications seen in cancer 
patients. Although the association between cancer and thrombosis has been known for 
years, there is now an increasing recognition among cancer providers of the impact of 
thrombotic complications on patients with cancer (7,8). Several factors have contributed to 
this heightened awareness. Firstly, cancer-associated VTE is increasingly prevalent. In a 
recent analysis of more than 1 million hospitalized patients with cancer, the rate of VTE 
increased by 28% from 1995 to 2003 (P < .0001)(9). Secondly, the consequences of VTE are 
better understood. Thrombosis is the second-leading cause of death in patients with cancer 
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and is associated with worsened mortality (10-12). In addition, patients with cancer who 
suffer VTE have an increased risk of recurrent VTE, bleeding complications, morbidity, and 
utilization of health care resources(13,14). Finally, newer anticancer agents particularly 
antiangiogenic drugs, appear to be more thrombogenic than conventional chemotherapy 
(15,16). Selected cancer patients with established VTE will need extended treatment to 
prevent its recurrence. In addition, a number of new cancer therapies have been associated 
with a further increase in the risk of VTE, warranting primary prophylaxis. Given the high 
mortality rate for VTE in cancer patients, it is imperative to ensure that all health-care 
professionals become familiar with and utilize the latest guidelines and tools for timely and 
evidence-based risk assessment, prevention, and treatment of VTE(17,18). 
A hypercoagulable state or low-grade DIC is common in patients with cancer. The results of 
laboratory tests indicate that a process of fibrin formation and removal is ongoing during 
the development of malignancy. Reported rates of venous thromboembolism (VTE) in 
patients with cancer range from 4% to 31%(19,23). Cancer alone elevates the risk of 
thrombosis 4-fold; chemotherapy increases the risk 6.5-fold(24,25). Patients who undergo 
cancer surgery have a higher risk of postoperative VTE than those who have surgery for a 
nonmalignant disease (26). VTE is the second leading cause of death in cancer patients, and 
the presence of VTE in patients with cancer has been reported to increase the likelihood of 
death by 2- to 8-fold (27-32). 
Results of the FRONTLINE (Fundamental Research in Oncology and Thrombosis) survey 
underscored the need for development of clinical guidelines focusing on VTE in cancer 
patients: surgeons and medical oncologists reported that they used VTE prophylaxis in only 
about 50% and 5% of their patients, respectively(33). Two sets of guidelines devoted 
specifically to oncology patients are available to help guide clinicians: recommendations by 
the American Society of Clinical Oncology (ASCO) and by the National Comprehensive 
Cancer Network (NCCN) (34-35). Both sets of recommendations direct that all adults 
hospitalized with cancer receive prophylactic anticoagulation therapy in the absence of 
contraindications. However, a recent review of more than 70,000 hospitalized patients with 
cancer in whom an indication for thromboprophylaxis had been identified showed that the 
rate of appropriate prophylaxis was only 27%(36). 
Alcalay et al. was found VTE as a significant predictor of death within 1 year of colorectal 
cancer diagnosis, among the patients with local or regional stage disease, but not among the 
patients with metastatic disease(37). 
Thromboembolic events are a major cause of morbidity and mortality in patients 
undergoing surgery. Cancer patients requiring curative abdominal surgery are considered 
to be at a particularly high risk for VTE, and thromboprophylaxis is strongly recommended 
(38). Studies of Western populations have shown that DVT rates range from 15% to 30% for 
cancer patients not receiving thromboembolic prophylaxis, and a meta-analysis by Colditz 
et al. estimated fatal PE rates of 0.1%–0.8% (39,40). Colorectal surgery is associated with a 
specific high risk of postoperative thromboembolic complications relative to other general 
surgery (41-43). The incidences of DVT and PE in colorectal cancer surgery patients who do 
not receive thromboembolic prophylaxis are approximately 40% and 5%, respectively (42-
43). Moreover, late VTE rates of 10%– 20% have been reported in patients who received 
LMWH thromboprophylaxis in the first postoperative week (44). 
The randomized double-blind ENOXACAN II study, and the multicenter randomized 
Denmark/Norway study found that thromboprophylaxis for 4 weeks after abdominal or 
pelvic cancer surgery reduced the incidence of venographically demonstrated asymptomatic 
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In the very-high-risk group of patients with major trauma (multiorgan, spinal, pelvic, long 
bone fractures), intermittent compression devices and ES should be started as early as 
possible, and LMWH or LDUH initiated as soon as it is safe. In cases of major trauma, with 
absolute contraindications for anticoagulants, the prophylactic indication of an inferior vena 
cava (IVC) filter should be considered, especially in cases with duplex ultrasonography 
demonstration of DVT. 
2. Mechanical methods of thromboprophylaxis and the role of combined 
thromboprophylaxis modalities 
Early and frequent mobilizitation of hospitalized patients at risk for VTE is an important 
part of patient care. However, many patients cannot be fully ambulatory early after  
surgery. Furthermore, the majority of hospital-associated, symptomatic thromboembolic 
events occur after patients have started to ambulate, and mobilization alone does not 
provide adequate thromboprophylaxis for hospital patients. Specific mechanical methods of 
thromboprophylaxis, which include graduated compression stockings (GCS), intermittent 
pneumatic compression (IPC) devices, and the venous foot pump (VFP), increase venous 
outflow and/or reduce stasis within the leg veins. Use of mechanical thromboprophylaxis is 
the preferred option for patients at high risk for bleeding. If the high bleeding risk is 
temporary, consideration should be given to starting pharmacologic thromboprophylaxis 
once this risk has decreased. Mechanical thromboprophylaxis may also be considered in 
combination with anticoagulant thromboprophylaxis to improve efficacy in patient groups 
for which this additive effect has been demonstrated(3,5,6). However, since they are not 
associated with bleeding, and some methods have demonstrated efficacy as DVT prevention 
in clinical trials, the use of mechanical prophylaxis in combination with pharmacological 
prophylaxis may be helpful in certain situations. For example, in major trauma patients who 
have a high risk of bleeding at presentation (as after head injury), we use mechanical 
prophylaxis initially followed by anticoagulant prophylaxis with LMWH when safe (5,6). 
This strategy could be adopted in any postoperative situation in which the initial risk of 
bleeding is high.  
3. VTE in cancer patients 
The association of cancer with thrombosis has been known for more than 100 years. Since 
the beginning it was regarded as a 2-way association, first cancer increases the risk of 
thrombosis(as first observed by Armand Trousseau in 1865), and secondy clotting activation 
increases the progression of cancer(as postulated by Billroth in 1878). Patients with cancer 
have at least a sixfold-increased risk of VTE compared to those without cancer and active 
cancer accounts for almost 20% of all new VTE events occurring in the community. 
Furthermore, VTE is one of the most common and costly complications seen in cancer 
patients. Although the association between cancer and thrombosis has been known for 
years, there is now an increasing recognition among cancer providers of the impact of 
thrombotic complications on patients with cancer (7,8). Several factors have contributed to 
this heightened awareness. Firstly, cancer-associated VTE is increasingly prevalent. In a 
recent analysis of more than 1 million hospitalized patients with cancer, the rate of VTE 
increased by 28% from 1995 to 2003 (P < .0001)(9). Secondly, the consequences of VTE are 
better understood. Thrombosis is the second-leading cause of death in patients with cancer 
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and is associated with worsened mortality (10-12). In addition, patients with cancer who 
suffer VTE have an increased risk of recurrent VTE, bleeding complications, morbidity, and 
utilization of health care resources(13,14). Finally, newer anticancer agents particularly 
antiangiogenic drugs, appear to be more thrombogenic than conventional chemotherapy 
(15,16). Selected cancer patients with established VTE will need extended treatment to 
prevent its recurrence. In addition, a number of new cancer therapies have been associated 
with a further increase in the risk of VTE, warranting primary prophylaxis. Given the high 
mortality rate for VTE in cancer patients, it is imperative to ensure that all health-care 
professionals become familiar with and utilize the latest guidelines and tools for timely and 
evidence-based risk assessment, prevention, and treatment of VTE(17,18). 
A hypercoagulable state or low-grade DIC is common in patients with cancer. The results of 
laboratory tests indicate that a process of fibrin formation and removal is ongoing during 
the development of malignancy. Reported rates of venous thromboembolism (VTE) in 
patients with cancer range from 4% to 31%(19,23). Cancer alone elevates the risk of 
thrombosis 4-fold; chemotherapy increases the risk 6.5-fold(24,25). Patients who undergo 
cancer surgery have a higher risk of postoperative VTE than those who have surgery for a 
nonmalignant disease (26). VTE is the second leading cause of death in cancer patients, and 
the presence of VTE in patients with cancer has been reported to increase the likelihood of 
death by 2- to 8-fold (27-32). 
Results of the FRONTLINE (Fundamental Research in Oncology and Thrombosis) survey 
underscored the need for development of clinical guidelines focusing on VTE in cancer 
patients: surgeons and medical oncologists reported that they used VTE prophylaxis in only 
about 50% and 5% of their patients, respectively(33). Two sets of guidelines devoted 
specifically to oncology patients are available to help guide clinicians: recommendations by 
the American Society of Clinical Oncology (ASCO) and by the National Comprehensive 
Cancer Network (NCCN) (34-35). Both sets of recommendations direct that all adults 
hospitalized with cancer receive prophylactic anticoagulation therapy in the absence of 
contraindications. However, a recent review of more than 70,000 hospitalized patients with 
cancer in whom an indication for thromboprophylaxis had been identified showed that the 
rate of appropriate prophylaxis was only 27%(36). 
Alcalay et al. was found VTE as a significant predictor of death within 1 year of colorectal 
cancer diagnosis, among the patients with local or regional stage disease, but not among the 
patients with metastatic disease(37). 
Thromboembolic events are a major cause of morbidity and mortality in patients 
undergoing surgery. Cancer patients requiring curative abdominal surgery are considered 
to be at a particularly high risk for VTE, and thromboprophylaxis is strongly recommended 
(38). Studies of Western populations have shown that DVT rates range from 15% to 30% for 
cancer patients not receiving thromboembolic prophylaxis, and a meta-analysis by Colditz 
et al. estimated fatal PE rates of 0.1%–0.8% (39,40). Colorectal surgery is associated with a 
specific high risk of postoperative thromboembolic complications relative to other general 
surgery (41-43). The incidences of DVT and PE in colorectal cancer surgery patients who do 
not receive thromboembolic prophylaxis are approximately 40% and 5%, respectively (42-
43). Moreover, late VTE rates of 10%– 20% have been reported in patients who received 
LMWH thromboprophylaxis in the first postoperative week (44). 
The randomized double-blind ENOXACAN II study, and the multicenter randomized 
Denmark/Norway study found that thromboprophylaxis for 4 weeks after abdominal or 
pelvic cancer surgery reduced the incidence of venographically demonstrated asymptomatic 
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thrombosis (45-46). In those studies, the rate of asymptomatic thrombosis was 5%–7% after 
prolonged prophylaxis. Although the majority of asymptomatic DVT is not clinically 
significant, there is an association between asymptomatic DVT and the subsequent 
development of symptomatic VTE (47). In most studies, the ratio of asymptomatic DVT to 
symptomatic VTE ranges from 5:1 to 10:1. If a ratio of 10:1 is applied, the incidence of 
symptomatic DVT is approximately 0.5%–0.7% after prolonged thromboprophylaxis (4 
weeks), similar to that found in the present study (0.63%). It shows the comparable 
incidence with that of Western countries, although in the present study thromboprophylaxis 
was administered only to high-risk patients and the treatment was of much shorter duration 
(median 3 days) and at a lower dose than that reported in those other studies. 
Venous thromboembolism is a common complication in cancer patients due to the 
hypercoagulable state induced by changes in the coagulation system (48). A prothrombotic 
state is present in many cancer patients as a result of an increase in procoagulants, such as 
tissue factor, cancer procoagulant, and factor VIIa, and hypercoaguability increases as the 
cancer progresses (49,50). Patients with metastatic cancers are at an increased risk of VTE. 
Several studies have shown a direct association between cancer stage and thrombosis risk. 
Recent studies showed that a higher initial cancer stage was a strong independent risk factor 
for developing VTE within the first year after diagnosis of cancer (51). In the Korean study, 
multivariate analysis showed metastatic colorectal cancer (stage IV) was found a predictor 
of VTE. Moreover, advanced colorectal cancer (stage III, IV) was also a predictor of VTE, 
and patients with advanced cancer were twice as likely to be diagnosed with VTE as 
patients with less-advanced cancer (52). 
4. Anticoagulant use in renal insufficiency 
Renal clearance is the primary mode of elimination for several anticoagulants, including 
LMWH, fondaparinux, and the new oral factor Xa and Ha inhibitors. Therefore, with 
reduced renal function, these drugs may accumulate and may increase the risk of bleeding, 
particularly in elderly patients and those at high risk for bleeding (53). The relationship 
between renal impairment and drug accumulation for the various LMWHs appears to be 
variable and may be related to the chain length distribution of the different LMWH 
preparations (54). Two recent studies in hospitalized patients, the majority of whom were 
critically ill and had creatinine clearances less than 30 mL/min, have shown no 
bioaccumulation of dalteparin 5000 U once daily based on serial anti-factor Xa levels (55,56). 
Therefore, we do not reduce the prophylaxis dose of dalteparin in patients with renal 
insufficiency. In patients receiving intermittent hemodialy-sis, we suggest that the LMWH 
be administered after the dialysis session. With enoxaparin thromboprophylaxis, we suggest 
that 30 mg once daily be used. We also suggest that fondaparinux, rivaroxaban and 
dabigatran be avoided unless future evidence demonstrates that these agents can be used 
safely in patients with severe renal insufficiency. 
5. Concomitant use of regional anesthesia techniques and anticoagulant 
prophylaxis  
Neuraxial blockade (spinal or epidural anesthesia and continuous epidural analgesia) 
results in a significant reduction in cardiopulmonary morbidity compared with general 
anesthesia and narcotic-based systemic analgesia, as well as better pain control and patient 
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satisfaction (57). However, concerns have been raised about a possible increased risk of 
epidural or spinal hematoma and spinal cord ischemia or paraplegia with use of 
concomitant anticoagulant prophylaxis (58,59).We believe that anticoagulant 
thromboprophylaxis with LMWH or LDH can safely be given along with neuraxial 
blockade with proper patient selection and timing of doses. Further details can be found in 
Section 1.5 of the 8th ACCP Prevention of VTE guidelines(3). In summary: 
1. Neuraxial blockade should be avoided in patients with systemic bleeding disorders and 
if hemostasis is impaired by an anticoagulant. The spinal needle or epidural catheter 
should be inserted at a time when there is minimal or no anticoagulant effect present. 
2. Anticoagulant prophylaxis should be delayed if a hemorrhagic aspirate ("bloody tap") is 
encountered during initial needle or catheter placement. 
3. Removal of an epidural catheter should be done when the anticoagulant effect is at a 
minimum (usually just before the next scheduled injection) and anticoagulant 
prophylaxis should be delayed for at least 2 hours after spinal needle or epidural 
catheter removal. 
4. In patients with an indwelling epidural catheter, we suggest that warfarin be avoided 
altogether or that the catheter be removed less than 48 hours after starting warfarin 
because of its unpredictable anticoagulant effect. 
5. The safety of continuous epidural analgesia with concomitant administration of 
fondaparinux or one of the new oral anticoagulants is not known and this combination 
is best avoided at this time. 
6. Patients with epidural catheters who are given anticoagulant thromboprophylaxis 
should be carefully monitored for symptoms and signs of spinal cord compression. If 
spinal hematoma is suspected, diagnostic imaging and surgical decompression should 
be performed rapidly to reduce the risk of permanent spinal cord damage. 
7. Every hospital using neuraxial blockade along with anticoagulant prophylaxis should 
develop a written protocol. 
8. For patients receiving deep peripheral nerve blocks along with anticoagulant 
prophylaxis, it is reasonable to use the same cautions described above. 
6. Trauma 
Deep venous thrombosis DVT and pulmonary embolism are among the most common 
preventable sources of mortality and morbidity in trauma patients treated in intensive care 
units. In various studies, DVT and PE have been demonstrated to range from 6%to 40% and 
from2%to 22%, respectively, in patients with serious spinal/head trauma (5, 6, 60-62). 
Knudson et al. and Geerts et al. reported that in trauma patients other than the ones with 
head trauma LMWH was better than unfractionated heparin for DVT prophylaxis (61,62). 
Vanek, with a metaanalysis, showed that intermittent pneumatic compression (IPC) 
decreased the relative risk of DVT by 62%, 47%, and 48% compared to placebo, high-
pressure stockings, and LMWH, respectively (63). Norwood et al. reported that enoxaparin 
for DVT prophylaxis in patients with acute brain injury having an Abbreviated Injury Score 
of >  3 did not increase the morbidity (64). Early use of LMWH for DVT prophylaxis in the 
presence of intraabdominal solid organ injury (liver, spleen, kidney) may also be safe (6, 61). 
A properly placed and managed intermittent pneumatic compression device could provide 
thromboprophylaxis of comparable efficacy to that of LMWH, in patients with moderate 
and severe injury (65). 
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prolonged prophylaxis. Although the majority of asymptomatic DVT is not clinically 
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symptomatic VTE ranges from 5:1 to 10:1. If a ratio of 10:1 is applied, the incidence of 
symptomatic DVT is approximately 0.5%–0.7% after prolonged thromboprophylaxis (4 
weeks), similar to that found in the present study (0.63%). It shows the comparable 
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state is present in many cancer patients as a result of an increase in procoagulants, such as 
tissue factor, cancer procoagulant, and factor VIIa, and hypercoaguability increases as the 
cancer progresses (49,50). Patients with metastatic cancers are at an increased risk of VTE. 
Several studies have shown a direct association between cancer stage and thrombosis risk. 
Recent studies showed that a higher initial cancer stage was a strong independent risk factor 
for developing VTE within the first year after diagnosis of cancer (51). In the Korean study, 
multivariate analysis showed metastatic colorectal cancer (stage IV) was found a predictor 
of VTE. Moreover, advanced colorectal cancer (stage III, IV) was also a predictor of VTE, 
and patients with advanced cancer were twice as likely to be diagnosed with VTE as 
patients with less-advanced cancer (52). 
4. Anticoagulant use in renal insufficiency 
Renal clearance is the primary mode of elimination for several anticoagulants, including 
LMWH, fondaparinux, and the new oral factor Xa and Ha inhibitors. Therefore, with 
reduced renal function, these drugs may accumulate and may increase the risk of bleeding, 
particularly in elderly patients and those at high risk for bleeding (53). The relationship 
between renal impairment and drug accumulation for the various LMWHs appears to be 
variable and may be related to the chain length distribution of the different LMWH 
preparations (54). Two recent studies in hospitalized patients, the majority of whom were 
critically ill and had creatinine clearances less than 30 mL/min, have shown no 
bioaccumulation of dalteparin 5000 U once daily based on serial anti-factor Xa levels (55,56). 
Therefore, we do not reduce the prophylaxis dose of dalteparin in patients with renal 
insufficiency. In patients receiving intermittent hemodialy-sis, we suggest that the LMWH 
be administered after the dialysis session. With enoxaparin thromboprophylaxis, we suggest 
that 30 mg once daily be used. We also suggest that fondaparinux, rivaroxaban and 
dabigatran be avoided unless future evidence demonstrates that these agents can be used 
safely in patients with severe renal insufficiency. 
5. Concomitant use of regional anesthesia techniques and anticoagulant 
prophylaxis  
Neuraxial blockade (spinal or epidural anesthesia and continuous epidural analgesia) 
results in a significant reduction in cardiopulmonary morbidity compared with general 
anesthesia and narcotic-based systemic analgesia, as well as better pain control and patient 
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satisfaction (57). However, concerns have been raised about a possible increased risk of 
epidural or spinal hematoma and spinal cord ischemia or paraplegia with use of 
concomitant anticoagulant prophylaxis (58,59).We believe that anticoagulant 
thromboprophylaxis with LMWH or LDH can safely be given along with neuraxial 
blockade with proper patient selection and timing of doses. Further details can be found in 
Section 1.5 of the 8th ACCP Prevention of VTE guidelines(3). In summary: 
1. Neuraxial blockade should be avoided in patients with systemic bleeding disorders and 
if hemostasis is impaired by an anticoagulant. The spinal needle or epidural catheter 
should be inserted at a time when there is minimal or no anticoagulant effect present. 
2. Anticoagulant prophylaxis should be delayed if a hemorrhagic aspirate ("bloody tap") is 
encountered during initial needle or catheter placement. 
3. Removal of an epidural catheter should be done when the anticoagulant effect is at a 
minimum (usually just before the next scheduled injection) and anticoagulant 
prophylaxis should be delayed for at least 2 hours after spinal needle or epidural 
catheter removal. 
4. In patients with an indwelling epidural catheter, we suggest that warfarin be avoided 
altogether or that the catheter be removed less than 48 hours after starting warfarin 
because of its unpredictable anticoagulant effect. 
5. The safety of continuous epidural analgesia with concomitant administration of 
fondaparinux or one of the new oral anticoagulants is not known and this combination 
is best avoided at this time. 
6. Patients with epidural catheters who are given anticoagulant thromboprophylaxis 
should be carefully monitored for symptoms and signs of spinal cord compression. If 
spinal hematoma is suspected, diagnostic imaging and surgical decompression should 
be performed rapidly to reduce the risk of permanent spinal cord damage. 
7. Every hospital using neuraxial blockade along with anticoagulant prophylaxis should 
develop a written protocol. 
8. For patients receiving deep peripheral nerve blocks along with anticoagulant 
prophylaxis, it is reasonable to use the same cautions described above. 
6. Trauma 
Deep venous thrombosis DVT and pulmonary embolism are among the most common 
preventable sources of mortality and morbidity in trauma patients treated in intensive care 
units. In various studies, DVT and PE have been demonstrated to range from 6%to 40% and 
from2%to 22%, respectively, in patients with serious spinal/head trauma (5, 6, 60-62). 
Knudson et al. and Geerts et al. reported that in trauma patients other than the ones with 
head trauma LMWH was better than unfractionated heparin for DVT prophylaxis (61,62). 
Vanek, with a metaanalysis, showed that intermittent pneumatic compression (IPC) 
decreased the relative risk of DVT by 62%, 47%, and 48% compared to placebo, high-
pressure stockings, and LMWH, respectively (63). Norwood et al. reported that enoxaparin 
for DVT prophylaxis in patients with acute brain injury having an Abbreviated Injury Score 
of >  3 did not increase the morbidity (64). Early use of LMWH for DVT prophylaxis in the 
presence of intraabdominal solid organ injury (liver, spleen, kidney) may also be safe (6, 61). 
A properly placed and managed intermittent pneumatic compression device could provide 
thromboprophylaxis of comparable efficacy to that of LMWH, in patients with moderate 
and severe injury (65). 
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7. Laparoscopic surgery 
The expanding use of laparoscopy last 3 decades has profoundly changed surgical diagnosis 
and therapy. However there is still some controversy over the best practice for prevention of 
deep vein thrombosis (DVT) during laparoscopic surgery. There is considerable uncertainty 
related to the thromboembolic risk after laparoscopic procedures, and the use of 
thromboprophylaxis is controversial. Surgical trauma is generally less with laparoscopic 
than with open abdominal surgery, but activation of the coagulation system is similar to or 
only slightly less with laparoscopic procedures. Laparoscopic operations may be associated 
with longer surgical times than comparable open procedures. Both pneumoperitoneum and 
the reverse Trendelenburg position reduce venous return from the legs, creating venous 
stasis. Patients undergoing laparoscopic procedures may have shorter hospital stays, but 
they may not mobilize more rapidly at home than those who have had open procedures. 
Despite the paucity of evidence, the European Association for Endoscopic Surgery has 
recom mended that intraoperative IPC be used for all prolonged laparoscopic procedures 
(66). In 2006, the Society of American Gastrointestinal Endoscopic Surgeons recommended 
the use of similar thromboprophylaxis options for laparoscopic procedures as for the 
equivalent open surgical procedures (67). However, available evidence does not support a 
recommendation for the routine use of thromboprophylaxis in these patients (68,69,70).  
Furthermore, with anticoagulant thromboprophylaxis, the risk of major bleeding may 
exceed the rate of thrombotic complications(71). Patients who are at particularly high 
thromboembolic risk can be considered for thromboprophylaxis with any of the modalities 
currently recommended for surgical patients (3,72). 
8. Treatment of VTE 
Treatment for VTE has been widely studied, and treatment guidelines have been published 
and frequently updated by the American College of Chest Physicians (ACCP), American 
College of Emergency Physicians, Eastern Association for the Surgery of Trauma, and 
Institute for Clinical Systems Improvement(1,3). Generally, acute treatment consists of low-
molecular-weight heparin (LMWH) or unfractionated heparin (UFH) for 4 to 5 days, with 
overlapping therapy to warfarin until an international normalized ratio (INR) of  >2 for two 
consecutive days is achieved. Anticoagulation should be continued for at least 3 to 12 
months, depending on the site of thrombosis and risk factors. Failure to provide adequate 
VTE treatment can result in patient morbidity and mortality, with a substantial economic 
burden(73). Although the evidence and consensus strongly favor LMWH treatment for up 
to 6 months in patients with cancer with established VTE, evidence is lacking to support 
continuing treatment beyond 6 months. It is likely that anticoagulation can be safely 
discontinued in certain patients (eg, patients who developed a VTE while on adjuvant 
chemotherapy and are in complete remission withnoplans for further treatment). 
Conversely, certain patients will continue to be at risk for recurrent VTE (eg, a patient with 
cancer with metastatic disease with plans for indefinite chemotherapy). Data from well-
designed randomized clinical trials are essential for clinicians to make evidencebased 
recommendations in these varied settings.  
Activation of the hemostatic system promotes tumor growth, angiogenesis, and metastasis. 
Antithrombotic agents could therefore potentially influence tumor biology and outcomes in 
patients with cancer.  Multiple recent studies have evaluated the effect of anticoagulants on 
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survival, with encouraging but inconclusive results (74). Given that anticoagulant 
prophylaxis could have dual benefits for patients with cancer reducing VTE and prolonging 
survival it is vital to pursue well-designed clinical trials of thromboprophylaxis focusing on 
survival(75). 
9. Appendix 
An informative summary from American College of Chest Physicians Evidence-Based 
Clinical Practice Prevention of Venous Thromboembolism Guidelines (8th Edition)(3). 
10. Guyatt grading(76) 
Grade 1 recommendations are strong and indicate that the benefits do or do not outweigh 
risks, burden, and costs. 
Grade 2 suggestions imply that individual patient values may lead to different choices  
11. General surgery 
- For low-risk general surgery patients who are undergoing minor procedures and have 
no additional thromboembolic risk factors, ACCP recommend against the use of 
specific thromboprophylaxis other than early and frequent ambulation (Grade 1A). 
- For moderate-risk general surgery patients who are undergoing a major procedure for 
benign disease, patients should receive thromboprophylaxis with LMWH, LDUH, or 
fondaparinux (each Grade 1A). 
- For higher-risk general surgery patients who are undergoing a major procedure for 
cancer, patient should receive thromboprophylaxis with LMWH, LDUH three times 
daily, or fondaparinux (each Grade 1A). 
- For general surgery patients with multiple risk factors for VTE who are thought to be at 
particularly high risk, AACP recommend that a pharmacologic method (ie,   LMWH,  
LDUH three times daily, or fondaparinux)  be combined with the optimal use of a 
mechanical method (te, graduated compression stockings [GCS] and/or IPC) [Grade 1C]. 
- For general surgery patients with a high risk of bleeding, optimal use of mechanical 
thromboprophylaxis with properly fitted GCS or IPC is best method (Grade 1A). When 
the high bleeding risk decreases, we recommend that pharmacologic 
thromboprophylaxis be substituted for or added to the mechanical thromboprophylaxis 
(Grade 1C). 
- For patients undergoing major general surgical procedures, we recommend  that 
thromboprophylaxis continue  until  discharge from hospital (Grade 1A). For selected 
high-risk general surgery patients, including some of those who have undergone major 
cancer surgery or have previously had VTE, ACCP suggest that continuing 
thromboprophylaxis after hospital discharge with LMWH for up to 28 days be 
considered (Grade 2A). 
12. Cancer patients 
- For cancer patients undergoing surgical procedures, ACCP recommend routine 
thromboprophylaxis that is appropriate for the type of surgery (Grade 1A). Refer to the 
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7. Laparoscopic surgery 
The expanding use of laparoscopy last 3 decades has profoundly changed surgical diagnosis 
and therapy. However there is still some controversy over the best practice for prevention of 
deep vein thrombosis (DVT) during laparoscopic surgery. There is considerable uncertainty 
related to the thromboembolic risk after laparoscopic procedures, and the use of 
thromboprophylaxis is controversial. Surgical trauma is generally less with laparoscopic 
than with open abdominal surgery, but activation of the coagulation system is similar to or 
only slightly less with laparoscopic procedures. Laparoscopic operations may be associated 
with longer surgical times than comparable open procedures. Both pneumoperitoneum and 
the reverse Trendelenburg position reduce venous return from the legs, creating venous 
stasis. Patients undergoing laparoscopic procedures may have shorter hospital stays, but 
they may not mobilize more rapidly at home than those who have had open procedures. 
Despite the paucity of evidence, the European Association for Endoscopic Surgery has 
recom mended that intraoperative IPC be used for all prolonged laparoscopic procedures 
(66). In 2006, the Society of American Gastrointestinal Endoscopic Surgeons recommended 
the use of similar thromboprophylaxis options for laparoscopic procedures as for the 
equivalent open surgical procedures (67). However, available evidence does not support a 
recommendation for the routine use of thromboprophylaxis in these patients (68,69,70).  
Furthermore, with anticoagulant thromboprophylaxis, the risk of major bleeding may 
exceed the rate of thrombotic complications(71). Patients who are at particularly high 
thromboembolic risk can be considered for thromboprophylaxis with any of the modalities 
currently recommended for surgical patients (3,72). 
8. Treatment of VTE 
Treatment for VTE has been widely studied, and treatment guidelines have been published 
and frequently updated by the American College of Chest Physicians (ACCP), American 
College of Emergency Physicians, Eastern Association for the Surgery of Trauma, and 
Institute for Clinical Systems Improvement(1,3). Generally, acute treatment consists of low-
molecular-weight heparin (LMWH) or unfractionated heparin (UFH) for 4 to 5 days, with 
overlapping therapy to warfarin until an international normalized ratio (INR) of  >2 for two 
consecutive days is achieved. Anticoagulation should be continued for at least 3 to 12 
months, depending on the site of thrombosis and risk factors. Failure to provide adequate 
VTE treatment can result in patient morbidity and mortality, with a substantial economic 
burden(73). Although the evidence and consensus strongly favor LMWH treatment for up 
to 6 months in patients with cancer with established VTE, evidence is lacking to support 
continuing treatment beyond 6 months. It is likely that anticoagulation can be safely 
discontinued in certain patients (eg, patients who developed a VTE while on adjuvant 
chemotherapy and are in complete remission withnoplans for further treatment). 
Conversely, certain patients will continue to be at risk for recurrent VTE (eg, a patient with 
cancer with metastatic disease with plans for indefinite chemotherapy). Data from well-
designed randomized clinical trials are essential for clinicians to make evidencebased 
recommendations in these varied settings.  
Activation of the hemostatic system promotes tumor growth, angiogenesis, and metastasis. 
Antithrombotic agents could therefore potentially influence tumor biology and outcomes in 
patients with cancer.  Multiple recent studies have evaluated the effect of anticoagulants on 
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survival, with encouraging but inconclusive results (74). Given that anticoagulant 
prophylaxis could have dual benefits for patients with cancer reducing VTE and prolonging 
survival it is vital to pursue well-designed clinical trials of thromboprophylaxis focusing on 
survival(75). 
9. Appendix 
An informative summary from American College of Chest Physicians Evidence-Based 
Clinical Practice Prevention of Venous Thromboembolism Guidelines (8th Edition)(3). 
10. Guyatt grading(76) 
Grade 1 recommendations are strong and indicate that the benefits do or do not outweigh 
risks, burden, and costs. 
Grade 2 suggestions imply that individual patient values may lead to different choices  
11. General surgery 
- For low-risk general surgery patients who are undergoing minor procedures and have 
no additional thromboembolic risk factors, ACCP recommend against the use of 
specific thromboprophylaxis other than early and frequent ambulation (Grade 1A). 
- For moderate-risk general surgery patients who are undergoing a major procedure for 
benign disease, patients should receive thromboprophylaxis with LMWH, LDUH, or 
fondaparinux (each Grade 1A). 
- For higher-risk general surgery patients who are undergoing a major procedure for 
cancer, patient should receive thromboprophylaxis with LMWH, LDUH three times 
daily, or fondaparinux (each Grade 1A). 
- For general surgery patients with multiple risk factors for VTE who are thought to be at 
particularly high risk, AACP recommend that a pharmacologic method (ie,   LMWH,  
LDUH three times daily, or fondaparinux)  be combined with the optimal use of a 
mechanical method (te, graduated compression stockings [GCS] and/or IPC) [Grade 1C]. 
- For general surgery patients with a high risk of bleeding, optimal use of mechanical 
thromboprophylaxis with properly fitted GCS or IPC is best method (Grade 1A). When 
the high bleeding risk decreases, we recommend that pharmacologic 
thromboprophylaxis be substituted for or added to the mechanical thromboprophylaxis 
(Grade 1C). 
- For patients undergoing major general surgical procedures, we recommend  that 
thromboprophylaxis continue  until  discharge from hospital (Grade 1A). For selected 
high-risk general surgery patients, including some of those who have undergone major 
cancer surgery or have previously had VTE, ACCP suggest that continuing 
thromboprophylaxis after hospital discharge with LMWH for up to 28 days be 
considered (Grade 2A). 
12. Cancer patients 
- For cancer patients undergoing surgical procedures, ACCP recommend routine 
thromboprophylaxis that is appropriate for the type of surgery (Grade 1A). Refer to the 
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recommendations in the relevant surgical subsections. 7.0.2. For cancer patients who are 
bedridden with an acute medical illness, ACCP recommend routine 
thromboprophylaxis as for other high-risk medical patients (Grade 1A). Refer to the 
recommendations in Section 6.0. 7.0.3. For cancer patients with indwelling central 
venous catheters, ACCP recommend that clinicians  not use  either prophylactic doses  
of LMWH (Grade IB), or minidose warfarin (Grade IB) to try to prevent catheter-related 
thrombosis. 
- For cancer patients receiving chemotherapy or hormonal therapy, ACCP recommend 
against the routine use of thromboprophylaxis for the primary prevention of VTE 
(Grade 1C). 7.0.5. For cancer patients, ACCP recommend against the routine use of 
primary thromboprophylaxis to try to improve survival (Grade IB). 
13. Laparoscopic surgery 
- For patients undergoing entirely laparoscopic procedures who do not have additional 
thromboembolic risk factors, routine use of thromboprophylaxis is unneccessary. Early 
and frequent ambulation should be forced (Grade 1B). 
- For patients undergoing laparoscopic procedures in whom additional VTE risk factors 
are present, ACCP recommend the use of thromboprophylaxis with one or more of 
LMWH, LDUH, fondaparinux, IPC, or GCS (all Grade 1C). 
14. Trauma 
- For all major trauma patients, ACCP recommend routine thromboprophylaxis if 
possible (Grade 1A). 
- For major trauma patients, in the absence of a major contraindication, ACCP 
recommend that clinicians use LMWH thromboprophylaxis starting as soon as it is 
considered safe to do so (Grade 1A). An acceptable alternative is the combination of 
LMWH and the optimal use of a mechanical  method of thromboprophylaxis (Grade 
IB). 
- For major trauma patients, if LMWH thromboprophylaxis is contraindicated due to 
active bleeding or high risk for clinically important bleeding, we recommend that 
mechanical thromboprophylaxis with IPC or possibly with GCS alone be used (Grade 
IB). When the high bleeding risk decreases, we recommend that pharmacologic 
thromboprophylaxis be substituted for or added to the mechanical thromboprophylaxis 
(Grade 1C). 
- In trauma patients, ACCP recommend against routine DUS screening for asymptomatic 
deep vein thrombosis (DVT) (Grade IB). We do recommend DUS screening in patients 
who are at high risk for VTE (eg, in the presence of a spinal cord injury [SCI], lower-
extremity or pelvic fracture, or major head injury), and who have received suboptimal 
thromboprophylaxis or no thromboprophylaxis (Grade 1C). 
- For trauma patients, ACCP recommend against the use of an inferior vena cava (IVC) 
filter as thromboprophylaxis (Grade 1C). 
- For major trauma patients, ACCP recommend the continuation of thromboprophylaxis 
until hospital discharge  (Grade 1C). For trauma patients with impaired mobility who 
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undergo inpatient rehabilitation, ACCP suggest continuing thromboprophylaxis with 
LMWH or a VKA (target INK, 2.5; range, 2.0 to 3.0) (Grade 2C). 
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recommendations in the relevant surgical subsections. 7.0.2. For cancer patients who are 
bedridden with an acute medical illness, ACCP recommend routine 
thromboprophylaxis as for other high-risk medical patients (Grade 1A). Refer to the 
recommendations in Section 6.0. 7.0.3. For cancer patients with indwelling central 
venous catheters, ACCP recommend that clinicians  not use  either prophylactic doses  
of LMWH (Grade IB), or minidose warfarin (Grade IB) to try to prevent catheter-related 
thrombosis. 
- For cancer patients receiving chemotherapy or hormonal therapy, ACCP recommend 
against the routine use of thromboprophylaxis for the primary prevention of VTE 
(Grade 1C). 7.0.5. For cancer patients, ACCP recommend against the routine use of 
primary thromboprophylaxis to try to improve survival (Grade IB). 
13. Laparoscopic surgery 
- For patients undergoing entirely laparoscopic procedures who do not have additional 
thromboembolic risk factors, routine use of thromboprophylaxis is unneccessary. Early 
and frequent ambulation should be forced (Grade 1B). 
- For patients undergoing laparoscopic procedures in whom additional VTE risk factors 
are present, ACCP recommend the use of thromboprophylaxis with one or more of 
LMWH, LDUH, fondaparinux, IPC, or GCS (all Grade 1C). 
14. Trauma 
- For all major trauma patients, ACCP recommend routine thromboprophylaxis if 
possible (Grade 1A). 
- For major trauma patients, in the absence of a major contraindication, ACCP 
recommend that clinicians use LMWH thromboprophylaxis starting as soon as it is 
considered safe to do so (Grade 1A). An acceptable alternative is the combination of 
LMWH and the optimal use of a mechanical  method of thromboprophylaxis (Grade 
IB). 
- For major trauma patients, if LMWH thromboprophylaxis is contraindicated due to 
active bleeding or high risk for clinically important bleeding, we recommend that 
mechanical thromboprophylaxis with IPC or possibly with GCS alone be used (Grade 
IB). When the high bleeding risk decreases, we recommend that pharmacologic 
thromboprophylaxis be substituted for or added to the mechanical thromboprophylaxis 
(Grade 1C). 
- In trauma patients, ACCP recommend against routine DUS screening for asymptomatic 
deep vein thrombosis (DVT) (Grade IB). We do recommend DUS screening in patients 
who are at high risk for VTE (eg, in the presence of a spinal cord injury [SCI], lower-
extremity or pelvic fracture, or major head injury), and who have received suboptimal 
thromboprophylaxis or no thromboprophylaxis (Grade 1C). 
- For trauma patients, ACCP recommend against the use of an inferior vena cava (IVC) 
filter as thromboprophylaxis (Grade 1C). 
- For major trauma patients, ACCP recommend the continuation of thromboprophylaxis 
until hospital discharge  (Grade 1C). For trauma patients with impaired mobility who 
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undergo inpatient rehabilitation, ACCP suggest continuing thromboprophylaxis with 
LMWH or a VKA (target INK, 2.5; range, 2.0 to 3.0) (Grade 2C). 
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1. Introduction  
Heparin-induced thrombocytopenia (HIT) is an immune-mediated response to heparin 
administration that causes thrombocytopenia and a prothrombotic state. Heparin is the 
most commonly used anticoagulant drug for the prevention and treatment of 
thromboembolic diseases in hospitalized patients. Heparin exists in two main forms, pure 
unfractionated heparin (UFH) and low molecular weight heparin (LMWH), which is 
derived from UFH. Though HIT is relatively rare, occurring in less than 5% of patients 
receiving UFH and less than 1% of patients receiving LMWH, it has the potential to cause 
significant morbidity and mortality. The main complication of HIT is thrombosis, most 
commonly deep vein thrombosis (DVT) or pulmonary embolism (PE). More rarely HIT can 
manifest as occlusion of a limb artery, acute myocardial infarct, stroke, a systemic reaction 
or skin necrosis.  In the current chapter the topic of HIT will be reviewed in terms of its 
pathophysiology, diagnosis, and treatment.  
1.1 Clinical Vignette: Patient S-B 
S-B is a 48-year-old male who was admitted to the orthopedics service for surgical repair of a right 
acetabular fracture resulting from a fall. He had no significant past medical history. His course was 
complicated by an ileus. He was given enoxaparin for thromboprophylaxis starting on day 2 of 
admission.  During his hospital stay, he developed a pulmonary embolus and atrial fibrillation and 
the dose of enoxaparin was increased. An IVC filter was also placed. His platelet count dropped from 
278K/uL on admission to a low of 88K/uL on hospital day 10. HIT antibody was positive. Enoxaparin 
was discontinued and lepirudin was started. Platelet count began improving by the next day and was 
190K/uL two days after starting lepirudin. He was transitioned to warfarin. A PICC line was placed 
for parenteral nutrition as his ileus had not resolved.  
Several days later, the patient suddenly developed shortness of breath, chest pain, nausea and fever of 
102°F. His heart rate increased to 130; he was normotensive. An arterial blood gas revealed metabolic 
acidosis and hypoxemia; his lactate level was elevated. Chest x-ray showed no infiltrates and a CT 
pulmonary angiogram (CTPA) was negative for infiltrates, pulmonary emboli and other pathology. 
EKG showed sinus tachycardia. Antibiotics were begun for possible sepsis. Platelet count was found 
to be 114K/uL compared to 231K/uL the previous day. Review of his chart revealed that the patient 
had received heparin flushes of his PICC line as part of a standing protocol. Heparin flushes were 
discontinued and lepirudin was restarted. Over the next several hours his fever, tachycardia, and 
hypoxemia improved. His lactate level normalized and platelets rose to 160K/uL by the following 
morning. All cultures were negative and antibiotics were discontinued.  
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Heparin is a negatively-charged, highly sulfated glycosaminoglycan that occurs naturally in 
the body. It was discovered nearly one century ago (Howell & Holt, 1918) and shortly 
thereafter was used in the medical profession for thromboprophylaxis in post-operative 
patients (Crafoord, 1936). Amongst the qualities that made it an attractive option for 
physicians were its immediate onset of action and its short half-life. During the first three 
decades of its use in the medical field, case reports and series of patients developing 
thrombosis while on heparin began to emerge in the literature, a phenomenon known as 
HIT (e.g. Weismann & Tobin, 1958; Roberts et al., 1963). Over the last several decades much 
has been learned about heparin and the mechanisms that are responsible for this disorder. 
Physiologically, two types of thrombocytopenia due to heparin exposure have been 
described. Non-immune heparin-associated thrombocytopenia, historically referred to as 
HIT type I, describes a response that is self-limiting and rarely causes major complications. 
Non-immune HIT occurs in 10% to 30% of patients who receive heparin and typically 
emerges within 4 days of exposure (Jang & Hursting, 2005). Platelet counts do not normally 
fall below 100K/uL. Heparin use does not need to be discontinued and no treatment is 
needed (Chong, 2003). 
Currently the term HIT is used to denote what has been historically called HIT type 2. HIT 
occurs when, following heparin administration, platelet factor 4 (PF4) binds to heparin to 
form heparin/PF4 complexes. The body identifies these complexes as abnormal and, in 
response, develops antibodies. Specifically immunoglobulin G (IgG), M (IgM) and/or A 
(IgA) antibodies are formed. IgG is pathogenic, and binding of the IgG antibodies to the 
heparin/PF4 complexes results in platelet activation and aggregation. This causes thrombin 
generation, resulting in thrombotic events. Activated platelet aggregates are removed 
prematurely from circulation, which leads to development of thrombocytopenia, the main 
criteria for diagnosis of HIT (Warkentin et al., 1994a; Untch et al., 2002). The heparin/PF4 
antibodies (also known as chemokine CXCL4) are typically activated within 5-14 days of 
heparin exposure, though delayed-onset cases have been reported (Warkentin & Kelton, 
2001a). In patients who have a recent history of heparin use, however, significant platelet 
activation can occur more rapidly after reintroducing a heparin-containing product 
(Warkentin & Kelton, 2001b). This may be because HIT antibodies are transient and can 
remain in the body for up to four months after withdrawal of heparin (Lubenow et al., 
2002). 
Though the exact mechanisms of action are unclear, endothelial cells and monocytes also 
seem to play a role in the procoagulant state associated with HIT (Blank et al., 2002; 
Pouplard et al., 2001; Rauova et al., 2010; Arepally & Mayer, 2001). Many processes still 
remain unexplained in HIT, including the inability of some anti-heparin/PF4 IgG molecules 
to cause platelet activation (Warkentin, 2005) and the role of individual biological 
differences in predisposing to development of the disease. There is evidence that the length 
of the heparin molecule chain may positively correlate with the potential for HIT. Since 
LMWH’s are formed from smaller molecules, this could explain why there is less 
immunogenic potential in these derived forms of heparin (Gruel et al., 2003). Furthermore, 
there may be a role of other glycosaminoglycans that are found on the surface of platelets, 
which may cross-react with heparin/PF4 antibodies and more directly cause thrombus 





3. Clinical features 
3.1 Epidemiology 
Several factors have been identified as being associated with an increased risk of HIT. At the 
patient level, HIT has been more frequently reported in females (Warkentin et al., 2006) and 
in patients over 40 years of age (Stein et al., 2009). Patients on UFH have a higher likelihood 
of developing HIT than those on LMWH (Martel et al., 2005). Dosage is also an important 
factor; patients receiving therapeutic doses may be more likely to develop clinical 
manifestations of HIT than those receiving prophylactic doses (Dager & White, 2003). 
Patients receiving thromboprophylaxis with UFH for six or more days have a higher 
incidence of HIT than those receiving it for shorter periods (Martel et al., 2005; Smythe et al., 
2007). Furthermore, the preparation type seems to influence risk; bovine UFH is more likely 
to cause HIT than porcine UFH (Green et al., 1984; Bailey et al., 1986; Francis et al., 2003).  
In general, surgical patients are at a higher risk of developing HIT than medical patients 
(Warkentin et al., 2006), but there is variation in incidence between surgical types. Since HIT 
develops secondary to the formation of heparin/PF4 complexes, it would be logical to 
assume that patients with higher concentrations of circulating PF4 would be at greater risk, 
including patients undergoing cardiac surgery on cardiopulmonary bypass (Yoon & Jang, 
2011). However, the incidence of HIT in these cardiac surgery patients is less than 3% 
(Warkentin et al,. 2000), whereas those who undergo orthopedic surgery, which is 
associated with less PF4 production, has incidence rates of HIT around 5% (Warkentin et al., 
2003). The mechanism underlying this difference is not clearly understood, but evidence 
from data collected in trauma patients suggests a role of inflammatory processes in the 
development of heparin/PF4 complexes (Lubenow et al., 2010).  
3.2 Timing 
Thrombocytopenia secondary to HIT commonly occurs between 5 and 14 days after the 
onset of heparin therapy. Patients with recent heparin exposure (e.g. within 30 to 100 days) 
may develop a significant fall in platelets related to HIT more quickly, even within minutes 
of re-exposure (i.e. rapid-onset HIT) (Warkentin, 2004; Warkentin and Kelton, 2001b). This is 
likely due to the continued presence of antibodies from previous exposure (Warkentin and 
Kelton, 2001b; Lubenow et al., 2002). Conversely, there have been cases of HIT where 
symptoms do not manifest until 10-14 days or more after heparin withdrawal, a 
phenomenon known as delayed-onset HIT (Warkentin and Kelton, 2001a).  This 
phenomenon is not completely understood. It is known that the anti-heparin/PF4 
antibodies can remain in the system for 100 days or more following discontinuation of 
heparin therapy and that the antibody titers in patients who develop delayed-onset HIT are 
very high (Rice et al., 2002; Warkentin & Kelton, 2001a). There may be a role of cross-
reactivity with other glycosaminoglycans residing on the surface of platelets, thus inducing 
platelet activation in the absence of heparin (Rauova et al., 2006). 
3.3 Degree of thrombocytopenia 
In the majority of patients with HIT the platelet count drops below 150K/uL, or falls to less 
than 50% of baseline. HIT may be overlooked when the platelet count remains above 
100K/uL if prior values are not reviewed. The nadir platelet count in HIT typically does not 
fall below 20K/uL; if such an extensive drop is seen, alternate or additional diagnoses must 
be seriously considered (Warkentin, 1998). Generally the nadir platelet count in HIT is 
between 40 and 80K/uL (Greinacher et al., 2005). 
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Thrombosis occurs in 30% to 70% of cases of HIT, depending on the population, and can occur 
without the presence of significant thrombocytopenia (Warkentin, 2007). Thrombotic events 
may occur days prior to the onset of thrombocytopenia (Greinacher et al., 2005). In patients 
who develop a thrombotic event who are either on or have recently completed heparin 
therapy, the possibility of HIT should be considered (Levine et al., 2006). In addition, it is 
important to realize that small amounts of heparin, such as those used to perform heparin 
flushes, can also cause significant manifestations of HIT (Refaai et al., 2007).  
When HIT is associated with thrombosis approximately 20-30% of cases are fatal and an 
additional 20-30% result in permanent disability (Greinacher, 1995). DVT (50%) and PE 
(25%) are the most common thrombotic events related to HIT. Arterial thrombosis, 
infrarenal aortic thrombosis (Karkos et al., 2011), acute myocardial infarct (Iqbal et al., 
2007), cerebral ischemia (Meyer-Lindenberg et al., 1997), limb ischemia (Kreidy & Hatem, 
2004), acute adrenal insufficiency (Poulain et al., 2008) and bilateral adrenal hemorrhage 
(Ernest & Fisher, 1991; Rosenberg et al., 2011) are less common.  Skin lesions, which may 
or may not be necrotic, can be seen at the heparin injection site in 10% to 20% of patients 
who develop HIT (Jang et al., 2005). Skin lesions appear to be more common in patients 
with higher levels of platelet-activating IgG (Warkentin, 1996). Despite the presence of 
thrombocytopenia, bleeding complications related to HIT are uncommon (Selleng et al., 
2007). 
Systemic or anaphylactoid reactions can rapidly occur after an IV bolus of UFH. In addition 
to a marked decline in platelet count, patients may develop fever, chills, respiratory 
symptoms that may simulate a pulmonary embolus (Hartman et al., 2006; Popov et al., 
1997), cardiac arrest, gastrointestinal symptoms such as nausea, vomiting and diarrhea, or 
even neurologic symptoms such as ischemia or transient global amnesia (Warkentin et al., 
1994b; Warkentin & Greinacher, 2009). It is important to note that these reactions are due to 
the immune-mediated response to heparin therapy (Warkentin & Greinacher, 2009); 
additional cases of anaphylactic reactions due to contaminated or over-sulfated heparins 
also exist (Liu et al., 2009). This type of systemic reaction is illustrated in the clinical vignette 
at the beginning of the chapter.  
In hemodialysis patients, a unique set of complications may emerge as a result of HIT. For 
example, there may be clotting of the extracorporeal circuit or failed arteriovenous fistulae. 
If an IV bolus of UFH or LMWH is given prior to hemodialysis and systemic reactions 
occur, it is important to consider HIT as a cause (Syed and Reilly, 2009). Increased circuit 
pressures, formation of a clot in the drip chambers, clotted dialyzer fibers, or an acute 
thrombocytopenia with at least a 20% decrease in platelet counts may also be suggestive of 
HIT (Yamamoto et al., 1996). 
3.5 Alternative causes 
Thrombocytopenia is frequently encountered in critically ill patients and can have a variety 
of etiologies. ICU patients often receive UFH or LMWH for either prophylaxis or treatment 
of venous thromboembolic disease or for treatment of a variety of other conditions, such as 
cardiac ischemia or atrial fibrillation. The question of HIT is therefore frequently raised 
(Sakr, 2011). However, HIT is actually an uncommon cause of thrombocytopenia in this 
patient population with an incidence of less than 1% (Crowther et al., 2010; Verma et al., 





sepsis and infection, non-heparin drugs, disseminated intravascular coagulation (DIC), 
chronic liver disease, immune disorders, and pseudo-thrombocytopenia (Sakr, 2011; Rice et 
al., 2009). A list of drugs to consider when determining the cause of thrombocytopenia can 
be found in Table 1 Note that the Table does not include chemotherapeutic agents since 
most drugs in this class are well-known to cause thrombocytopenia. Serologic confirmation 
is often delayed for several days and physicians are forced to make decisions based on 
clinical judgment alone. Therefore, especially in very ill patients, close attention must be 
given to all possible causes of thrombocytopenia.  
4. Diagnosis 
Recent data from the CATCH (Complications After Thrombocytopenia Caused by Heparin) 
registry suggests that less than 10% of patients who develop thrombocytopenia receive a 
diagnostic evaluation for HIT (Oliveira et al., 2008). Furthermore, many do not receive 
diagnostic attention for possible HIT until after a thromboembolic event has occurred 
(Crespo et al., 2009). Given the potential for significant morbidity and mortality, timely 
diagnosis is of utmost importance. Diagnosis of HIT should be based on both clinical 
judgment and laboratory assessment. The patient’s presentation and history provide the 
most important information for initial determination of likelihood of HIT, but verification of 
anti-heparin/PF4 antibodies through serum or plasma analysis is a significant step for 
guiding treatment and follow-up.  
4.1 Clinical diagnosis  
The Four T’s (4T) score can be used to calculate the pre-test probability of HIT in patients 
experiencing signs or symptoms of the disorder (Warkentin & Heddle, 2003). The 4T score 
takes into account four domains and generates a score of 0–8 points depending on the 
patients’ signs and symptoms; a total score of 0 to 3 indicates that HIT is unlikely; 4 to 5 
indicates an intermediate probability; 6 to 8 indicates high likelihood of HIT. In addition to 
the severity of thrombocytopenia, the score also takes into account the timing of the fall in 
platelet count, the occurrence of thrombosis or other sequelae, and the presence of other 
potential causes of the thrombocytopenia. In general, studies have found that the 4T score 
has high sensitivity for diagnosis (>95%), but specificity is low, especially in ICU patients 
(Lo et al., 2006; Pouplard et al., 2007). Most authors suggest that those patients with a high 
likelihood of HIT based on 4T score should be immediately withdrawn from heparin 
therapy, be treated with an alternative, and be monitored closely while laboratory tests for 
HIT antibodies are performed. Withdrawal of heparin should not wait until laboratory 
results are obtained in any patient where HIT is being strongly considered. 
Several other sets of criteria and scoring systems have been developed for determining pre-
test probability of HIT in both general and specific populations (e.g. Messmore et al., 2011). 
The HIT Expert Probability Score has recently been developed based on a panel of expert 
opinions (Cuker et al., 2010), but data regarding its psychometric properties are still lacking. 
Scoring systems for patients on hemodialysis (Yamamoto et al., 1996) have been created 
owing to the unique factors associated with HIT in this population. It has also been noted 
that the use of some scoring systems, such as the 4T score, should be modified in the setting 
of a critically ill patient; in such cases more emphasis should be placed on ruling out other 
causes of thrombocytopenia (Hall et al., 2010).  
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 Vancomycin  Penicillins 
 Cephalosporins  Ciprofloxacin 
 Clarithromycin  Pentamidine 
 Daptomycin  Meropenem 
 Rifampin  Linezolid 
 Nitrofurantoin  Ganciclovir 
 Fluconazole  Valganciclovir hydrochloride 
 Trimethoprim/sulfamethoxazole 
 
Glycoprotein IIb/IIIa inhibitors    
 Abciximab  Eptifibatide 
 Tirofiban 
 
Thienopyridines    
 Clopidogrel  Ticlopidine 
 
Antiepileptics    
 Phenytoin  Carbamazepine 
 Valproate 
 
Antiarrhythmics    
 Procainamide  Amiodarone 
 Quinidines 
 
Anti-Inflammatory Drugs    
 Salicylates  Acetaminophen 
 Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) 
 
Diuretics    
 Furosemide  Thiazides 
 Spironolactone  Acetazolamide 
 
Histamine 2 Receptor Blockers    
 Ranitidine  Cimetidine 
 
Sulfonylurea Drugs    
Captopril    
Digoxin    
Morphine    
Haloperidol 
Table 1. Non-Chemotherapeutic Agents other than Heparin and Low Molecular Weight 
Heparin that may cause Thrombocytopenia in the Hospitalized Patient 
4.2 Laboratory diagnosis 
Both functional and immunologic assay tests are available for the detection of HIT 
antibodies. Functional tests work by detecting antibodies that induce heparin-dependant 





antibodies, regardless of their ability to activate platelets. Immunologic assays, such as 
polytypic ELISA, IgG-specific ELISA, and particle gel immunoassay (PGI) have a sensitivity 
of over 95%, but the specificity is sub-optimal and true positive diagnosis is identified in as 
few as half of all cases. Due to the pathogenicity of IgG, assays that are specific to this 
antibody are more likely to yield a true positive diagnosis than the general ELISA assays. 
Immunologic tests are relatively rapid, producing results within hours. Because of the high 
sensitivity and the fast turn-around, they are often used to rule-out HIT, but a positive test 
needs to be interpreted in conjunction with clinical data (Amiral, 1999; Amiral & Vissac, 
1999). Mistakenly diagnosing and treating for HIT based on positive assay in the setting of a 
low pre-test probability score could result in serious consequences, such as venous limb 
gangrene or fatal hemorrhage (Smythe et al., 2011).  
Functional assay tests, such as serotonin release assay (SRA), flow cytometric detection and 
heparin-induced platelet aggregation (HIPA) assay, have a slightly lower sensitivity 
(approximately 90%), but a much better specificity (>90%) than the immunologic assays. 
Therefore, the overall accuracy of the test for correctly identifying HIT is high (Warkentin, 
2002). However, these tests are technically more demanding and are only offered at a 
minority of laboratories. Therefore, they are not relevant in most clinical settings.  
The HemosIL AcuStar HIT-IgG (specific for IgG anti-PF4/heparin antibodies) and the 
HemosIL AcuStar HIT-Ab (for detecting IgG, IgA and IgM anti-PF4/heparin antibodies) are 
newer laboratory tests available for diagnosing HIT. These two semi-quantitative 
chemiluminescent immunoassays provide results in 30 minutes and can be run for single 
sample testing. Legnani and colleagues (2010) reported on initial data showing a 100% 
sensitivity and negative predictive value for these tests, making them ideal for ruling out 
HIT. Specificity for the HIT-IgG test was 96.5% and for the HIT-Ab test was 81.2%. These 
tests, especially the IgG specific test, may gain more use in the future depending on results 
of further studies.  
A recent article advocates the use of a colorimetric test to detect HIT (Prechel et al., 2011). 
The test uses a tetrazolium-based indicator dye that reacts to the activity of platelets. When 
contact is made with inactivated or mildly activated platelets, the dye metabolizes to a dark 
color. When the platelets are highly activated (e.g. due to the presence of HIT antibodies) the 
dye is unable to metabolize and remains light in color.  Preliminary analyses have shown 
this platelet activation assay test to have between 96% and 100% agreement with the 
functional assay C-SRA for HIT diagnosis.  
In general, pairing the findings of a clinical diagnostic score with the results of a laboratory 
test significantly increases the sensitivity and specificity of the diagnostic yield (Demma et 
al., 2011; Ruf et al., 2011; Kim et al., 2011).  
5. Treatment 
When HIT is suspected or proven, all heparin and LMWH should be discontinued. A careful 
investigation for heparin exposure from sources such as catheter flushes and hemodialysis is 
necessary. Even the low doses used to flush a catheter can lead to worsening 
thrombocytopenia and a systemic reaction in patients with HIT, as in the case presented 
above. Once heparin therapy is discontinued, platelet count should begin to rise within 
three days, though this is dependent on the amount of antibodies present in the system 
(Seleng et al., 2007; Kelton, 2002).  
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When HIT is suspected or proven, all heparin and LMWH should be discontinued. A careful 
investigation for heparin exposure from sources such as catheter flushes and hemodialysis is 
necessary. Even the low doses used to flush a catheter can lead to worsening 
thrombocytopenia and a systemic reaction in patients with HIT, as in the case presented 
above. Once heparin therapy is discontinued, platelet count should begin to rise within 
three days, though this is dependent on the amount of antibodies present in the system 
(Seleng et al., 2007; Kelton, 2002).  
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There are several important principles in the management of HIT. The American College of 
Chest Physicians published evidenced-based clinical practice guidelines for the treatment 
and prevention of HIT in 2008 (Warkentin et al., 2008). Given the prothrombotic nature of 
the disorder, alternate, non-heparin anticoagulants should be administered. Just 
discontinuing UFH or LMWH or substituting warfarin (Coumadin®) is associated with a 
significant risk of thrombosis (Warkentin et al., 1998). As test results may take days to come 
back, treatment cannot wait until final confirmation of the diagnosis is made and should be 
instituted if the diagnosis is highly suspected. 
For patients who develop a thrombotic event while on heparin or soon after discontinuing 
heparin, the platelet count should be checked and alternate non-heparin anticoagulants 
should be used until HIT is excluded. 
Low molecular weight heparins, such as enoxaparin (Lovenox®) and dalteparin (Fragmin®) 
cannot be used in patients who develop HIT due to UFH as there may be cross-reactivity. 
The use of vitamin K antagonists such as warfarin is contraindicated during the acute phase 
of the illness when the patient is thrombocytopenic to avoid complications such as venous 
limb gangrene (Srinivasin, 2004; Warkentin et al., 1997) and multicentric skin necrosis 
(Warkentin et al., 1999). If the patient is on warfarin at the time HIT is diagnosed, Vitamin K 
should be administered. Platelet transfusions should generally be avoided, although there 
have been reports of their use without complication (Hopkins & Goldfinger, 2008; Refaai et 
al., 2010). IVC filters are not recommended during acute HIT (Warkentin et al., 2008). 
Ultrasound of the lower extremity can be considered as presence of DVT will affect the 
duration of anticoagulation (Tardy et al., 1999).  
Choice of alternative, nonheparin anticoagulants include direct thrombin inhibitors (DTIs), 
such as argatroban and lepirudin (Refludan®), the heparinoid danaparoid (Orgaran®), and 
possibly the Xa inhibitor, fondaparinux (Arixtra®). Argatroban and lepirudin are approved 
for treatment of HIT in the United States. Danaproid has not been available in the United 
States since 2002. Choice of agent depends on a number of factors including availability and 
the presence of renal or hepatic dysfunction. An important difference between the DTIs is 
that argatroban is primarily hepatically eliminated, while lepirudin is primarily renally 
eliminated. The dose of argatroban should be reduced in the setting of liver dysfunction, 
congestive heart failure, anasarca, and after cardiac surgery. Lepirudin needs be adjusted for 
patients with renal insufficiency. Adjustments in the doses of these medications should be 
based on the aPTT. DTIs can elevate the INR and this can complicate the transition to 
warfarin when the thrombocytopenia has resolved.  
Other DTI’s have been utilized for the treatment of HIT. Bivalrudin is approved for patients 
with HIT or at risk for HIT undergoing percutaneous coronary intervention. It has also been 
used successfully in cardiac surgery. This agent undergoes enzymatic proteolysis and a 
minority is excreted renally. Desirudin, another DTI, showed promise as a more economical 
alternative to argatroban in a recent, small pilot study (Boyce et al., 2011). In addition, 
observational studies examining the role of desirudin in HIT in patients undergoing 
orthopedic and cardiac surgery have shown some positive results (Duncan et al., 2011; Levy 
& Koster, 2011). Desirudin is given subcutaneously every 12 hours as opposed to the other 
DTI’s mentioned above, which are given as continuous intravenous infusions.   
Factor Xa inhibitors make an attractive option for use in HIT. Fondaparinux can be given 
once a day subcutaneously. It costs less and requires less monitoring than the DTIs 
(monitoring of coagulation parameters to adjust dosing is not required). However, large 





used to successfully treat HIT (Lobo et al., 2008), though there have been case reports of 
worsening thrombocytopenia in patients with HIT or a history of HIT treated with 
fondaparinux (Pistulli et al., 2011; Warkentin et al., 2007; Modi et al., 2009; Rota et al., 2008). 
Newer Xa inhibitors such as Rivaroxiban that can be taken orally are becoming available, 
however their role in the treatment of HIT is not yet known. 
For patients requiring longer term anticoagulation once the HIT has resolved, a transition to 
warfarin can be made. It should not be done until the platelet count has improved to at least 
150K/uL and there should be an overlap of at least 5 days of warfarin and the non-heparin 
anticoagulant (Warkentin et al., 2008). 
For patients who require anticoagulation with heparin and have a remote history of HIT, 
heparin can be used for a short duration when antibody assays are negative. Anti-
heparin/PF4 antibodies are usually undetected by 100 days after discontinuation of heparin 
therapy (Warkentin & Kelton, 2001b). For those who are antibody positive, or those who 
need prolonged anticoagulation, a non-heparin alternative should be considered (Warkentin 
et al., 2008).  
6. Conclusion 
HIT is an important clinical entity to recognize as it creates a prothrombotic state that can 
lead to a variety of thromboembolic and systemic consequences. These most commonly 
include DVT and PE, though arterial thrombosis, acute myocardial infarction, stroke, acute 
adrenal insufficiency, and other serious complications can occur. Patients with HIT given an 
IV bolus of heparin may experience acute systemic reactions that can simulate pulmonary 
embolus or sepsis and even lead to cardiac arrest. Treatment includes discontinuation of all 
UFH and LMWH. A thorough search for surreptitious sources of heparin exposure should 
be performed. An alternative, non-heparin anticoagulant, such as a DTI should be started. 
HIT should be considered in patients who develop DVT or PE who are either receiving or 
have recently discontinued heparin. Intravenous heparin or LMWH should not be utilized 
to treat thrombosis in these situations. In the future, newer DTI’s and possibly factor Xa 
inhibitors may simplify treatment and reduce cost in managing this condition.  
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1. Introduction 
Pulmonary infarction is localized destruction (necrosis) of lung tissue by blocking 
(obstruction of) the arterial blood supply. It  follows an embolic event in ~10% of cases. 
Blockage of pulmonary artery by a clot or air bubble or other particle (called pulmonary 
embolism) leads to localized damage of lung tissue which results in pulmonary infarction (1, 
2). The reasons for this low incidence of pulmonary infarct are the dual blood supply 
systems, as well as oxygenation of the lung tissues via ventilation (3).    
The predisposing factors for pulmonary infarct include congestive heart failure, pleural 
effusion, pulmonary infection, atelectasis, hypotension, positive-pressure ventilation, 
chronic lung disease, central venous catheterization and an immunocompromised state. It is 
more common in people with chronic heart and lung diseases. Infarction condition may be 
mild and can be rapidly fatal (4). 
Common symptoms include chest pain which may be because of difficulty in breathing, 
high pulse rate, mild fever, developing of fluid in the lungs, a productive cough (sputum 
may be blood-tinged). Blockage may also result into circulatory breakdown, like low blood 
pressure, presence of very little oxygen in the blood. Also, swelling of neck vein and leg, 
weakness, restlessness, and fainting. In the case of infection as developing complication, 
there is worsening of the clinical status, persistent  fever, malaise, sweating, increasing pulse 
rate and leukocytosis (usually more than 20 x 109/l) (5).  
Diseases that should be listed in the differential diagnosis include bacterial pneumonia, 
aspergillosis, tuberculosis, norcardia, actinomycosis, and granulomatous vasculitis. Other 
unusual etiologies that should be listed in the differential diagnosis include primary or 
metastatic angiosarcoma or leomyosarcoma and lung cancer invading the main pulmonary 
arteries (6,7).  
2. Clinical presentation  
Bacterial pneumonia and pulmonary infarction frequently mimic each other clinically, 
indicates that most methods for distinguishing between these illnesses are unsatisfactory. Both 
diseases may give rise to dyspnea, pleuritic pain, tachypnoea, fever, cyanosis, hypotension, 
cough, hemopthysis, jaundice, leukocytosis and similar radiographic abnormalities (8).  
Shaking chills point strongly to bacterial pneumonia. Additional hints are a preceding upper 
respiratory tract infection followed by gradually increasing malaise and then cough, usually 
 
Venous Thrombosis – Principles and Practice 
 
214 
Warkentin, T.E., Sikov, W.., & Lillicrap, D.P. (1999). Multicentric warfarin-induced skin 
necrosis complicating heparin-induced thrombocytopenia. American Journal of 
Hematology, vol.62, no.1, (September 1999), pp.44-48. 
Weismann, R.E. & Tobin, R.W. (1958). Arterial embolism occurring during systemic heparin 
therapy. AMA Archives of Surgery, vol.76, no.2, (February 1958), pp.219–225. 
Yamamoto, S., Koide, M., Matsuo, M. Suzuki, S., Ohtaka, M., Saika, S., & Matsuo, T. (1996). 
Heparin-induced thrombocytopenia in haemodialysis patients. American Journal of 
Kidney Diseases, vol.28, no.1, (July 1996), pp.82-85. 
Yoon, J.H. & Jang, I.K. (2011). Heparin-induced thrombocytopenia in cardiovascular 
patients: Pathophysiology, diagnosis, and treatment. Cardiology in Review, vol.19, 
no.3, (May-June 2011), pp.143-153.  
12 
Cavitary Pulmonary Infarct: The Differential 
Diagnostic Dilemma – A Case Report 
Ivanka Djordjevic and Tatjana Pejcic 
Clinic for lung diseases; Clinical Center – Nis,  
Serbia 
1. Introduction 
Pulmonary infarction is localized destruction (necrosis) of lung tissue by blocking 
(obstruction of) the arterial blood supply. It  follows an embolic event in ~10% of cases. 
Blockage of pulmonary artery by a clot or air bubble or other particle (called pulmonary 
embolism) leads to localized damage of lung tissue which results in pulmonary infarction (1, 
2). The reasons for this low incidence of pulmonary infarct are the dual blood supply 
systems, as well as oxygenation of the lung tissues via ventilation (3).    
The predisposing factors for pulmonary infarct include congestive heart failure, pleural 
effusion, pulmonary infection, atelectasis, hypotension, positive-pressure ventilation, 
chronic lung disease, central venous catheterization and an immunocompromised state. It is 
more common in people with chronic heart and lung diseases. Infarction condition may be 
mild and can be rapidly fatal (4). 
Common symptoms include chest pain which may be because of difficulty in breathing, 
high pulse rate, mild fever, developing of fluid in the lungs, a productive cough (sputum 
may be blood-tinged). Blockage may also result into circulatory breakdown, like low blood 
pressure, presence of very little oxygen in the blood. Also, swelling of neck vein and leg, 
weakness, restlessness, and fainting. In the case of infection as developing complication, 
there is worsening of the clinical status, persistent  fever, malaise, sweating, increasing pulse 
rate and leukocytosis (usually more than 20 x 109/l) (5).  
Diseases that should be listed in the differential diagnosis include bacterial pneumonia, 
aspergillosis, tuberculosis, norcardia, actinomycosis, and granulomatous vasculitis. Other 
unusual etiologies that should be listed in the differential diagnosis include primary or 
metastatic angiosarcoma or leomyosarcoma and lung cancer invading the main pulmonary 
arteries (6,7).  
2. Clinical presentation  
Bacterial pneumonia and pulmonary infarction frequently mimic each other clinically, 
indicates that most methods for distinguishing between these illnesses are unsatisfactory. Both 
diseases may give rise to dyspnea, pleuritic pain, tachypnoea, fever, cyanosis, hypotension, 
cough, hemopthysis, jaundice, leukocytosis and similar radiographic abnormalities (8).  
Shaking chills point strongly to bacterial pneumonia. Additional hints are a preceding upper 
respiratory tract infection followed by gradually increasing malaise and then cough, usually 
 
Venous Thrombosis – Principles and Practice 
 
216 
productive of purulent sputum. Patients with pulmonary infarction more often become ill 
with dramatic suddenness, seldom have a cough and experience shaking chills only if the 
emboli are septic or the infarct become infected (8).  
Physical signs are not specific for either diseases. Although high fever is more typical of 
bacterial pneumonia, it is occurs with sufficient frequency in pulmonary infarction to be 
unreliable as differential diagnostic sign. Patients with pulmonary infarction, as compared 
to those with bacterial pneumonia, generally are more dyspnoic and tachypnoic in relation 
to the extent of their physical and radiographic abnormalities and rarely exhibit classic signs 
of consolidation. They more often manifest hypotension, either transient or recurrent, and 
more commonly show signs suggesting pulmonary hypertension and right-sided congestive 
heart failure, e.g. a loud pulmonis component of the second heart sound and elevation of the 
jugular venous pressure (8).  
A pleural friction rub helps in differentiation only when chest radiography shows no 
parenchymal disease. Then, infarction is more often do not cause radiographic changes early 
in the course of the illness (8). 
3. Laboratory and other diagnostic tests  
Sputum examination is one of the best ways of differentiating bacterial pneumonia from 
pulmonary infarction. In bacterial pneumonia the sputum classically is purulent, 
occasionally foul smelling and may contain bright red fleck of blood. Gram’s stain typically 
shows many bacteria and polymorphonuclear leukocytes. In pulmonary infarction, sputum, 
when present, usually is frankly blood with few bacteria or inflammatory cells. If the infarct 
becomes infected the sputum may be indistinguishable from that in bacterial pneumonia. 
Blood cultures often reveal the causative microorganism in the patients with bacterial 
pneumonia but show no growth in cases of bland pulmonary infarction (8).  
Cavitation after bland pulmonary infarcts may result from either aseptic necrosis of the 
infracted lung or from secondary bacterial infection with subsequent abscess formation. It is 
infective almost as often as it is aseptic (9).  
Two types of infected pulmonary infarct have been proposed based on the mode by which 
infection sets in (10). One is called “primary” because the infection is from a septic embolus. 
The other is called “secondary” because the infection is bronchigenic origin. Some authors 
suggest that the development of fever and/or purulent sputum following a pulmonary 
infarct is highly suspicious for secondary infection. The spectrum of causative agents for 
infected pulmonary infarct is similar to that of nosocomial pneumonia (3).  
Total leukocyte count has limited discriminatory value. It usually is normal or slightly 
elevated in pulmonary infarction, but there is reports of leukocytes count higher than 40 000 
per mm3 in patients with  massive, bland necrosis of pulmonary tissue. Elevated serum 
lactic dehydrogenase (LDH) activity, normal aspartate aminotranspherase activity (AST) 
and increased serum bilirubin concentration forms a triad once considered a sensitive 
indicators of pulmonary embolism and infarction. However, subsequent studies have 
shown that these tests fail to differentiate pulmonary infarction from pneumonia and host of 
other disorders (8). 
Electrocardiographic abnormalities that may appear are right ventricular conduction 
disturbances; right axis deviation; inverted T-waves with S-T segment deviation in the right 
precordial leads; peaked T-waves in leads II, III and AVF; various types of supraventricular 
and raraly ventricular arrhythmias and S1, Q3 or S1,S2, S3 patterns. Heart ultrasound may 
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reveals right ventricular dilatation, septal deviation of left ventricle, tricuspidal 
regurgitation or right ventricle hypokinesis with wall thinning (8, 11).  
Pulmonary function test and arterial blood gas studies provide data that are too variable 
and nonspecific to differentiate bacterial pneumonia from pulmonary infarction (8).  
4. Imaging studies  
Radiographic similarities of bacterial pneumonia and pulmonary infarction are the chief 
source of diagnostic confusion between the two entities. Each is responsible for 
parenchymal infiltrates of varied size and shape, with or without pleural effusion, 
atelectasis or cavitation. In contrast to bacterial pneumonia, pulmonary infarcts always abut 
a pleural surface and predominate in lower lobes, especially the right. They also may appear 
in concert with dilatation of one or both main pulmonary arteries, decreased peripheral 
vascular markins in the affected portion of lung (oligemia) or engorged vassels in the non 
affected areas (pleonemia). Further radiographic clues to pulmonary infarction are infiltrates 
appearing first in one lung and then the other or “pneumonia” unresponsive to 
chemotherapy (8).  
Spiral computed tomography and magnetic resonance angiography are helpful in 
establishing the difference between pneumonia and pulmonary infarct. Also, this imaging 
techniques could help tracking the resolution of the thrombo emboli, but they are expensive 
and unavailable in many hospitals (6,7).  
Pulmonary arteriography is the most specific means of differentiating  bacterial pneumonia 
from pulmonary infarction. In bacterial pneumonia the pulmonary arteries proximal to the 
subsegmental level show neither filling defect nor obstructive lesions, where in pulmonary 
infarction they contain filling defect, appear obstructed, or both (8).  
The grater the size of infarct, more likely its centre will be hypoxic and nectrotic. Pulmonary 
infarct larger than 4 x 4 cm in size have a great tendency for cavitation (12).  
The median time from the first detection of consolidation to cavity formation is 14 days (12).  
Doppler sonography is a noninvasive and convenient tool for diagnosing pulmonary 
embolism and follow-up reperfusion of the lung. Dynamic changes in blood flow in 
consolidated areas provides information about the status of reperfusion (6).  
Despite use of the aforementioned techniques, the question of infected versus infracted lung 
sometimes will persist. To minimize error, the physicians should think of both diseases 
when he considers either, particularly if the process involves the lower lobes, especially the 
right. Dangers of delaying treatment for pulmonary infarction rival the hazards of 
withholding specific chemotherapy in bacterial pneumonia. Thus, as long as the diagnosis 
remains in doubt, treatment for both disorders seems well advised (8). 
Multiple complications have been associated with pulmonary infarct, including pneumonia, 
empyema, pneumothorax, lung abscess, bronchopleural fistulae and lethal haemorrhage. 
Large series of autopsies reveald cavitation in 4-5% of all pulmonary infarcts (5).  
The mortality rate is as high as 41% and 73% for nonifected and infected cavitary pulmonary 
infarcts, respectively. Anticoagulants and antibiotics are the mainstay of therapy. Massive 
haemopthysis may persist even after discontinuation of anticoagulants. Possible explanation 
for this phenomenon are an overdose of anticoagulants and reperfusion of necrotic lung 
tissue. Anticoagulants use in cavitary pulmonary infarction, therefore, must be very 
carefully monitored and causation should be exercised in monitoring clinical conditions and 
the status of coagulation (10).  
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5. Case presentation 
Patient was admitted to our clinic with a three week history of dyspnea, tachycardia, cough, 
expectoration of yellow colored sputum, fever, exhaustion and lower legs edema. Few days 
before admission to clinic he presented altered level of consciousness (mental confusion), 
caused by alcohol withdrawal. The patient suffered from congestive heart failure and 
chronic obstructive pulmonary disease for several years. There was no past medical history 
of predisposition factors for embolism or episodes of venous thrombo-embolism. 
On examination he presented normal mental status, body temperature was within normal 
range, blood pressure 130/80 mmHg, pulse rate 90 beats/min; respiratory rate 26 
breath/min; with signs of peripheral cyanosis. The chest expanded symmetrically and 
breathing sounds were clear. There were heart rhythm disorder (absolute arrhythmia) but 
no heart murmurs were detected. The liver and spleen were not palpable. Lower leg edema 
was noticed. 
The initial laboratory blood test revealed elevated inflammatory parameters: white blood 
cells:15.7 x 109/L; with 87.6% neutrophils; 3.4% monocytes and 9.0% lymphocytes; C-
reactive protein: 73 mg/L; D-dimer: 759 ηg/ml. The prothrombin time, activated partial 
thromboplastin time (PTT) and platelets  were within normal range. There were elevated 
activity of aspartate aminotranspherase (160.6 U/L); alanin aminotransferase (128.0 U/L); 
lactic dehydrogenase (745 U/L); serum bilirubin concentration (45 μmol/L);blood urea 
nitrogen (16.3 mmol/L) and creatinine (120.4 μmol/L). But, all this test has limited 
discriminatory value. 
The arterial gas blood analysis showed the following: pH 7,5; carbon dioxide tension in 
arterial blood (PCO2) 31 mmHg; oxygen tension in arterial blood (PO2) 71 mmHg; HCO3 24 
mmol/L; BE 1 mmol/L and oxygen saturation (SaO2) 95%. 
Lung functional test shown severe restrictive ventilation disorder (FEV1: 8%; FVC: 44% - 
1.67 L; FEV1/FVC: 72%) which is nonspecific to differentiate bacterial pneumonia from 
pulmonary infarction as well as the arterial gas blood analysis too.  
The electrocardiography (ECG) revealed atrial fibrillation only. The initial chest radiograph 
was showed enlarged cardiac shadow without pulmonary opacities (Figure 1) because  
infarction is more often do not cause radiographic changes early in the course of the illness. 
Congestive heart failure was diagnosed and the patient was treated with diuretics and 
inotropes.  
However, a ten days later the intensity of dyspnea, fatique, weakness and exhaustion has 
increased. He was febrile (38.30 C). A contribution to literature data, in our case, clinical 
condition has got worsening suddenly. Chest radiography was significant since it showed 
round pulmonary consolidation with central cavitation on the apical segment of the right 
lower lobe (Figure 2). The patient was placed on antibiotic therapy (intravenous ceftazidine 
and ertapenem) for a presumptive diagnosis of bacterial pneumonia.  
However, one week later, the treatment with antibiotics was not satisfactory and there were 
no clinical recovery. Also, there were no microbiologic confirmation of causative 
microorganism which made definitive diagnosis difficult. The clinical symptoms of 
congestive heart failure was dominant and the patient underwent a cardiac ultrasound 
which revealed tricuspidal regurgitation and elevated right ventricular pressure (systolic 
blood pressure of right ventricule - SPRV: 46 mmHg). The increased intensity of dyspnoea, 
fatique, weakness and exhaustion, despite the treatment with diuretics and inotropes was 
due to unconfirmed hemodynamic disorder.  
 




Fig. 1. Initial chest PA (postero-anterior) radiography showing enlarged cardiac shadow 
without pulmonary  opacities 
 
 
Fig. 2. PA (postero-anterior) chest radiography ten days from admission showing round 
pulmonary consolidation with central cavitation on the apical segment of the right lower lobe 
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Fig. 1. Initial chest PA (postero-anterior) radiography showing enlarged cardiac shadow 
without pulmonary  opacities 
 
 
Fig. 2. PA (postero-anterior) chest radiography ten days from admission showing round 
pulmonary consolidation with central cavitation on the apical segment of the right lower lobe 
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The most striking and unexpected findings was contrast-enhanced computed tomography 
(CT) scan of blood vessels and identification of filling defect in the main pulmonary arteries 
which presumptive diagnosis of pneumonia excluded. There were pulmonary consolidation 
with central cavitation on the right lower and left upper lobes too. The diameter of  right  
and left  consolidation was 63 x 75 mm and 85 x 70 mm respectively (Figure 3a and 3b). The 
size of pulmonary infarct , in our case, is grater than 40 x 40 mm which explain the 
appearance of cavitation. Also, the velocity of cavity formation presented in our case is 
significantly lower than literature data pointed out. Venous duplex ultrasound of lower 
extremitas was negative for deep-vein thrombosis. Low-molecular heparin were 





Fig. 3a. and 3b. Contrast - enhanced computed tomography scan of blood vessels showing 
filling defect in the main pulmonary arteries with central cavitation on the right  lower and 
left upper lobes too 
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The follow-up chest radiograph (three weeks later) showed regression of mentioned 
pulmonary opacities (Figure 4). Due to anticoagulant therapy was administered 
immediately after the findings of the CT scans were obtained, the patient was clinicaly 
recovered and he was discharged with follow-up recommended. 
 
 
Fig. 4. Follow-up chest radiograph (three weeks later) showing regression of mentioned 
pulmonary opacities. 
6. Conclusion  
Cavitary pulmonary infarct is a rare but frequently misdiagnosed disease entity. 
Differentation between cavitary pulmonary infarct and multiple complications or other 
diseases can be a real challenge because of the similar radiographic abnormalities and 
clinical presentation of all this  conditions. In the cases with clinical suspicion to 
“pneumonia” unresponsive to chemotherapy images studies are of great help. The best 
evidence of infarction is the angiographic demonstration of pulmonary thromboemboli. 
Anticoagulant and antibiotic treatment in the cases of infected cavitary pulmonary infarct 
must be started immediately after the diagnosis is established. 
7. Acknowledgement 
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1. Introduction 
Dural ateriovenous fistula (DAVF) is the acquired and progressive arteriovenous (AV) 
shunt disease on or between the dura matter, and its etiology is still controversial1-4. This 
disorder occurs not in the whole dura but at very specific locations. DAVF can be divided 
into two types based on the intervention of the drainage route and affected sinus; sinus 
type and non-sinus type. The sinus type has the shunt at the sinus wall or dural vein, and 
includes DAVF at the cavernous sinus (CS), transverse-sigmoid sinus (TS-SS), anterior 
condylor confluence (ACC), and superior sagittal sinus (SSS). The non-sinus DAVF has 
the shunt on the dura and directly drains into the pial veins, and includes tentorial, 
ethmoidal, craniocervical and spinal DAVF. However, even the sinus type DAVF 
ultimately changes to the isolated sinus with cortical reflux due to progressive sinus 
occlusion, similar to the non-sinus type. Such seemingly separated and complex 
pathogeneses of DAVF remain elusive.  
2. Previous theory about DAVF etiology 
Previous recognition of the etiology of DAVF has been directed to sinus hypertension1,4 and 
thrombosis5, 8. It is true that such abnormal situations may create the experimental AV 
shunt1-4. However, if one considers that the sinus hypertension is the initial trigger, it should 
be caused secondary to the thrombosis or outlet stenosis. It is unreasonable to adopt this 
theory into non-sinus type, because this type has no correspondence with the sinus. In other 
hand AV shunt formation can easily create the condition of sinus hypertension. Thus, the 
conventional discussion over the etiology of AV shunt formation between sinus occlusion 
and sinus hypertension is just a chicken-or-egg question. We consider that sinus 
hypertension concerning sinus wall hypertrophy may not be the cause, but rather one factor 
in the development of DAVF. Our theory based on inflammatory initiation affecting EV can 
explain both types of DAVF and subsequent development with pathological changes of the 
drainage route is not contradictory to the previous sinus-oriented theory. 
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Etiologically, DAVF is revealed secondary to causes such as trauma, inflammation, or sinus 
thrombosis5-8. However, most causes are idiopathic and independent of the preceding 
hematological and immunological impairments. Therefore, comprehensive factors concerning 
the initiation of DAVF that covers all of the pathological features should be considered. From 
this perspective, we focused on the location of emissary veins (EV) and discovered that the 
distribution of EV definitely corresponds to those of the location of DAVF (Fig. 1). According 
to this previous consensus and to new information, we propose following hypothesis 
concerning the development of DAVF which focuses on the emissary vein. 
 
        
A     B 
A Postero–anterior view 
B Lateral view 1. parietal (parasagittal ) emissary vein (EV), 2. occipital (torcular) EV, 3. mastoid EV, 4. 
condylar (condyloid) EV, 5. hypogroassal EV, 6. frontal (ethmoidal) emissary vein (EV), 7. 
petrosquamosal EV, 8. foramen ovale EV, 9. foramen spinosum EV, 10. foramen lacerum EV, 11. Basilar 
plexus EV and Trolard’s inferior petrooccipital vein (venous plexus of Raktzik) 
Fig. 1. Distribution of emissary veins 
Emissary veins connecting the intracranial and extracranial venous system through the bone 
are distributed in specific parts of the vault or base of the skull9. They are usually 
accompanied by and penetrate together through the same foramen with emissary arteries 
(transosseous perforating arteries) (Fig. 2A). Fig. 2 shows the scheme of this process in the 
DAVF at SSS (a representative of sinus type DAVF). First, some inflammatory reaction 
occurs at the penetrating site of EV. It may be reasonable to consider the cause of 
inflammation to the infection of adjacent tissue such as sinusitis and mechanical 
inflammation after trauma (including catheter intervention). Sinus thrombosis is 
occasionally observed before the occurrence of DAVF7, however, such thrombosis might be 
the result of focal inflammation. In most cases with DAVF, inflammation will develop 
undetected or as an autoimmune allergic reaction. Local inflammation may expand with 
expression of various cytokines, cause vessel dilatation, and open the physiological AV 
shunt at the level of capillary vessels (Fig. 2B). 
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E 
A Normal site. Emissary vein (EV) and artery (a) is penetrating through a foramen of the parasagittal 
skull. EV is connected with the venous lacunae (b). Meningeal arteries (c) have no connection with SSS 
(d) and cortical vein (e). 
B Neovascularization (arrow) and vessel dilatation induced by dural inflammation 
C AV shunt formation at the level of dural arteriole and penetration into the sinus (initial stage of 
DAVF). Note the shunt flow draining into the sinus as well as EV (double arrow). 
D. Shunt development with thrombosis of an emissary vein (asterisk) and recruitment of distal arteries 
from anterior falx artery (f) and posterior meningeal arteries (g). 
E. Maturation of DAVF with the reflux to cortical veins (red arrow) due to sinus occlusion (white 
arrow). Note the further recruitment of feeders from the other side or transosseous branches (h). 
Fig. 2. Mechanism of development of the DAVF at the superior sagittal sinus (SSS) as a 
representative of the sinus type DAVF. 
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In sinus type DAVF, a micro AV shunt between the emissary artery and vein will enlarge to 
the adjacent sinus wall. The increase in shunt flow triggers drainage into the sinus, and 
subsequently changes the main drainage route from the EV to the sinus. As a result, the 
sinus will be occupied by the shunt flow more than the normal intracranial venous outflow 
pathway (Fig. 2C). While this shift in shunt flow direction decreases the role of EV as the 
drainage pathway, the developed and swollen emissary artery compresses the accompanied 
EV and impairs the drainage flow. This results in occlusion of the EV (Fig. 2D). 
This degeneration of the EV is an important process in the formation of a well-known style 
of sinus type of DAVF. However, in some cases of DAVF at CS and SSS the EV may remain 
patent and serve as a drainage route to the pterygoid plexus or parietal vault. Also an EV 
that connects with diploic veins can form an enlarged intraosseus venous lake, and appear 
as a new channel of sinus or duplication. The shunt recruits other dural feeders from the 
distant and contralateral parts due to angiogenetic and hemodynamic factors, and forms the 
extended vascular network as a new DAVF10. Extracranial arteries on the skull or under the 
skull base are often mobilized through the bone. Such active recruitment of feeders is 
considered to be due to angiogenesis enhanced by the expression of vasculogenetic factors 
at the affected dura (including vascular endothelial growth factor (VEGF)) 11-16. 
The next key process in maturation of the DAVF is the occlusive change of the draining 
system. Although draining pathway may finally occlude due to intrasinus thrombosis 
associated with hypercoagulopathy, the essence of the occlusive mechanism should be 
hypertrophy of the sinus wall12. This occlusive process is typical in the DAVF at CS17. Its 
drainage route gradually occludes from the inferior petrosal sinus and superior ophthalmic 
vein11, and occasionally causes a paradoxical worsening of visual acuity and chemosis with 
ocular hypertension following occlusion of the anterior drainage route. During this 
progression, the thrombophilic abnormalities characteristic of DAVF are also reported18-22. 
In some cases such thrombotic change of drainage route may occur in the initial stage 
preceding the development of the shunt.  
Next, the same process progresses in the upstream side because the remaining upstream 
drainage with more hemodynamic stress may yield the hypertrophic change of sinus wall12, 
23. As a result, the meeting point of the shunt flow will be isolated, and shunt flow without 
exit to the sinus may reflux into cortical veins (Fig. 2E). Such a matured and aggressive type 
of DAVF with an affected isolated sinus or dural vein 24 (Fig. 3), may be the final expression 
 
   
A    B 
A. DAVF at cavernous sinus, B. DAVF at transvers-sigmoid sinus 
Fig. 3. Examples of matured sinus type DAVF 
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of this process. However, this final isolated part of the DAVF will not be always consistent 
with the first trigger point of a micro AV shunt, because the inflammatory extension and 
recruitment of many dural arteries will easily cause the movement of the main shunt point. 
It is quite easy to adopt this mechanistic hypothesis to non-sinus type DAVF. Fig. 4 
demonstrates the scheme of the development of ethmoidal (anterior skull base) DAVF as a 
representative of non-sinus type DAVF.  
 
  
A     B 
  
C    D 
A. Normal state. a; frontal cortex, b; frontal emissary vein, c; dural branches from anterior  
ethmoidal artery  
B. Neovascularization and dilatation induced with dural inflammation (#)  
C. AV shunt formation at the level of dural arteriole and reflux into an EV (initial stage of DAVF)  
D. Shunt development and increased reflux into the varicose cortical vein (white arrow) following the 
occlusion of an emissary vein 
Fig. 4. Mechanism of development of the DAVF: an ethmoidal (anterior skull base) DAVF as 
a representative of the non-sinus type DAVF. 
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of this process. However, this final isolated part of the DAVF will not be always consistent 
with the first trigger point of a micro AV shunt, because the inflammatory extension and 
recruitment of many dural arteries will easily cause the movement of the main shunt point. 
It is quite easy to adopt this mechanistic hypothesis to non-sinus type DAVF. Fig. 4 
demonstrates the scheme of the development of ethmoidal (anterior skull base) DAVF as a 
representative of non-sinus type DAVF.  
 
  
A     B 
  
C    D 
A. Normal state. a; frontal cortex, b; frontal emissary vein, c; dural branches from anterior  
ethmoidal artery  
B. Neovascularization and dilatation induced with dural inflammation (#)  
C. AV shunt formation at the level of dural arteriole and reflux into an EV (initial stage of DAVF)  
D. Shunt development and increased reflux into the varicose cortical vein (white arrow) following the 
occlusion of an emissary vein 
Fig. 4. Mechanism of development of the DAVF: an ethmoidal (anterior skull base) DAVF as 
a representative of the non-sinus type DAVF. 
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EV at the anterior skull base (Fig. 4A) connecting with the cortical vein will create, secondary 
to the ethmoidal inflammation, a micro AV shunt at the skull base dura (Fig. 4B). Subsequently 
the EV will occlude according to the same process as described above (Fig. 4C, D). As a result, 
all the shunt flow supplied from ethmoidal arteries drains into the cortical veins, which is the 
common style encountered in the clinical setting. The pathological process at the spine or 
craniocervical junction DAVF can be explained by the same mechanism. 
4. Atypical DAVF 
1. Tentorial DAVF It is true that there is no EV on the tent. The name of this type of DAVF 
may come from the participation of tentorial artery, however the main shunt point is 
not on the tent but at the clival dura (Fig. 5). The tentorial artery as the feeder usually 
creates the AV shunt just posterior to its origin, and the shunt flow immediately drains 
into the subtentorial venous complex. Although there are some classifications of various 
type of tentorial DAVF25, the most common type of tentorial DAVF at the clivus may be 
caused by the pathological process of a concerned EV, petrosal bridging vein 26, that 
connects between the ventral venous system in the posterior fossa and the basilar 
plexus. The exceptional tentorial DAVFs affecting the posterior tentorial sinus or the 
confluence are considered to be variants of TS-DAVF with the influence of EV at the 
petrous and occipital skull. 
 
  
Fig. 5. Tentorial DAVF. The lateral view of the left carotid angiogram showing the dilated 
feeder from the tentorial artery (arrow) and AV shunt at the clival portion (asterisk) 
immediately draining into the prepontine venous network. 
2. DAVF at the anterior condylor confluence DAVF at the anterior condylor confluence has 
been newly defined as the generic clinical entity24, and includes DAVF of the inferior 
petrosal sinus, DAVF of the marginal sinus, hypoglossal DAVF, DAVF of the anterior 
condylor vein within the hypoglossal canal, and jugular foramen DAVF27. Anterior 
condylor confluence (ACC) is extracranially located, and is a major venous crossroad at 
the posterior base of the skull. Tributaries from the hypoglossal canal, petroclival fissure, 
and the vertebral venous plexus meet together at the ACC and drain into the jugular bulb 
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through multiple channels28. As seen in previous nomenclature, one of the important 
drainage routes is the anterior condylor vein is the EV passing though the hypoglossal 
canal. However, in most cases, the anterior condylor vein has been already occluded, and 
other venous systems (including the lateral condylor vein, inferior petroclival vein, and 
inferior petrosal sinus) may function as a drainage route via ACC. Specific characteristics 
of this type of DAVF include patients suffering from strong tinnitus just when the DAVF 
is initially formed. Hypoglossal palsy develops in some cases. DAVF at the ACC tends to 
be diagnosed in the early stages. Therefore, as the original drainage route, the anterior 
condylor vein occasionally remains one of the draining veins. 
3. Vault DAVF This rare type of DAVF is located at the temporal or occipital convexity, 
and is a non-sinus type DAVF. An aggressive feature of this type of DAVF is that it 
directly drains into cerebral cortical veins. According to our theory, it may be caused by 
the focal inflammation around the atypically located EV, or due to the congenital focal 
connection between pial and dural veins. 
4. Multiple, de novo, recurrent DAVF. These clinical features cannot be explained with the 
single inflammation theory, and spreading or multifocal inflammation should be 
considered (Fig. 6). Although recurrence of the same lesion can be due to incomplete 
occlusion of the shunt29, de novo creation of DAVF independent from the previous 




Fig. 6. Mulitple DAVF Multiple DAVF at superior sagittal, tranevers and sigmoid sinus 
(arrows) 
5. Supporting clinical situation 
This hypothesis is supported by some familiar features encountered in clinical cases. First, in 
the case of mature SSS-DAVF, shunt flow usually drains into the cortical vein through an 
isolated sinus with the particular congestion of pial veins. However, in spite of such an 
aggressive type with reflux to the cortical vein, SSS is still patent in some particular cases. 
This unusual situation suggests the influence of EV at the initial location of the micro AV 
shunt. As seen in Fig. 7, the parasagittal (parietal) EV has no direct connection with SSS itself 
and drains from venous lacunae. The abnormal state mentioned above can be interpreted as 
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follows; the occlusive change of drainage site might occur at the channel between venous 
lacunae and SSS after the formation of AV shunt, therefore SSS as the normal cortical 
drainage route is independent from DAVF and can be preserved. It may suggest that the 
shunt point is located not the sinus wall of SSS but venous lacunae, exit of EV. In the early 
stage of CS-DAVF without ocular symptoms there are various drainage routes into the 
pterygoid plexus as well as the superior ophthalmic vein and inferior petrosal sinus. 
Similarly, the anterior condylor vein is patent in the initial stage of ACC-DAVF. In such 
young DAVF, EV of the foramen ovale or foramen lacerum and hypoglossal EV still remain 
as the original drainage pathway. This fact suggests the possibility that the EV plays an 
important role in the initial stages of newly developed DAVF. 
One often encounters a multiplicity about the location or TS-SS-DAVF. This fact is also 
explainable using the present hypothesis. At the confluence, the lateral side and the sigmoid 
junction, the initially affected EVs: may be torcular, petrosquamosal and mastoid EVs, 
respectively. 
Unfortunately, our hypothesis has not yet been proven in a pathological specimen of clinical 
cases as well as from the animal experiments. Further, it is difficult to explain the etiology of 
DAVF in locations without emissary veins or those without arterial supply coming from 
emissary arteries with the exception of osteodural AV shunts. Although our theory was not 
based on the anatomical, physiopathological or clinical observational convincing 
background, if the very early stage of DAVF is incidentally found, inflammatory 
investigation into the inflammation and meticulous observation of the flow change will be 
helpful to predict the development of DAVF and also to support this theory. 
6. Conclusion 
According to previous theories concerning the mechanism of DAVF, it is very important to 
consider the occlusive pathway and hypertension of the affected sinus. However, previous 
theories did not indicate an initiation of this pathological situation which can explain both 
sinus and non-sinus type DAVF and the promoting factors to develop the extension of DAVF. 
We propose a new theory: the inflammatory vascular network at the penetration site of 
emissary veins may induce local shunt formation. Subsequent occlusion of the affected EV 
completes the usual figure of DAVF, and, the sinus (venous) occlusive pathway and arterial 
recruitment are important steps in the maturation of the DAVF. Previous mechanistic 
hypotheses focusing on sinus hypertension and sinus thromboses cannot explain the 
pathogenesis of non-sinus type of DAVF. Although the etiology of DAVF may be concerned 
by the thrombo-occlusive change of sinus, and our theory is only a speculation without the 
base of experimental study, it may enable to understanding the common etiology of the two 
(sinus & non-sinus) types of DAVF, and is not contradictory to the previous sinus-oriented 
theory. Pathological proof of the initial stage of DAVF will be mandatory. 
Abbreviations: DAVF: dural arteriovenous fistula, EV: emissary vein, CS: cavernous sinus, 
SSS: superior sagittal sinus, TS: transvers sinus, SS: sigmoid sinus, ACC: anterior condylor 
confluence, CCJ: craniocervical junction 
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According to Virchow’s triad, venous thrombosis can occur as a result of one or 
more of three factors: changes in the dynamics of the blood flow, endothelial injury/
dysfunction of the blood vessel and hypercoagulability. The blood in the veins is 
constantly forming microscopic thrombi that are routinely broken down by the body, 
and significant clotting can occur only when the balance of thrombus formation and 
resolution is altered. This book is a fresh synthesis of venous thromboembolism care 
and considers the opinions and studies from different fields of medicine. As venous 
thrombosis spectrum is wide and can affect many organ systems, from deep veins 
of the leg to the cerebral venous system, our intent is for this to be a comprehensive, 
up-to-date and readable book. We tried to present a synthesis of existing material 
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